SPECIAL REPORT DECEMBER 2011

DRUG DELIVERY REVIEW AND OUTLOOK

INDUSTRY GROWTH TO CONTINUE THROUGH NEW TECHNOLOGIES

The worldwide drug-delivery arena is growing each year as the increasing aging population is in need of improved methods of administration for products and therapies. Drug-delivery industry growth is being led by the United States as well as emerging markets.

Oral forms remain the preferred method of drug-delivery administration. Gaining in popularity are parenteral, inhalation and implantable systems. Elements impacting the development of drug-delivery systems include reimbursement, environmental factors, and regulatory processes.

Product developers are coming up with better ways to improve therapy performance and safety as patients become more involved in their treatments in an effort to cut down on costs. New electronic technologies for reusable systems and disposable devices are leading to improved sales of auto-injectors. Microneedle technology is on the rise so that medicine can be precisely delivered to areas in need of treatment.



UBM CANON DATA PRODUCTS

828B Newtown-Yardley Road, Suite B Newtown, PA 18940 United States Phone: +1.215.944.9800 Fax: +1.215.867.0053 Website: PharmaLive.com

Steve Corrick VP and Executive Director UBM Canon Publishing steve.corrick@ubm.com

Roger Burg VP, Operations Publications Division roger.burg@ubm.com +1.310.445.4221

Glenn Glasberg Circulation and Marketing Director glenn.glasberg@ubm.com +1.215.944.9810

Sandra Baker Data Products Manager sandra.baker@ubm.com +1.215.944.9836

Amanda Wells Assistant Marketing Manager amanda.wells@ubm.com +1.215.944.9840

Brandon Materazzi Marketing Assistant brandon.materazzi@ubm.com +1.215.944.9809

Andrew Humphreys Editor In Chief, Data Products andrew.humphreys@ubm.com +1.215.944.9812

Stefanie Fedder Manager, Data and Content stefanie.fedder@ubm.com +1.215.944.9807

John King Market Analyst/Editor john.king@ubm.com +1.215.944.9820

Silvia Arriola Data Specialist silvia.arriola@ubm.com +1.215.944.9803

Diane Strohm Data Specialist diane.strohm@ubm.com +1.215.944.9828

Andrew Ellison Data Specialist andrew.ellison@ubm.com +1.215.944.9826

Stacey Miller Contributing editor

Kim Stannard Production assistant

UBM Ltd. Corporate Head Office

Ludgate House 245 Blackfriars Road London, SE1 9UY, United Kingdom Phone: +44 (0) 20 7921 5000 Website: ubm.com

UBM Canon Headquarters

11444 W. Olympic Blvd. Los Angeles, CA 90064 United States Phone: +1.310.445.4200 Fax: +1.310.445.4299 Website: ubmcanon.com

TABLE OF CONTENTS

Drug-Delivery Industry Overview Page 3
Drug-Delivery Company Overview
Drug-Delivery Prescription Products
Awaiting Approval
Phase III
Phase II/III
Phase II
Phase I/II
Phase I
Preclinical Development
Companies
Drug-Delivery Medical Devices
Class I Devices - General Controls - 510(k) Exempt
Class II Devices - General Controls and Special Controls - 510(k)
Class III Devices – General Controls and Special Controls – 510(k)
Unclassified Devices – 510(k)
Companies

Review the most recent Special Reports at: www.PharmaLive.com/SpecialReports

See these and other topics:

POM Quarterly Top 50 Specialty Companies Global Contract Manufacturing Companies: Pharmaceutical and Biotechnology Nutraceuticals and Vitamins Review and Outlook Top 50 Pharmaceutical Companies and Their Pipelines

eKnowledgeBase - searchable pipeline and business-information database for the world's pharma & biotech companies. **Request a trial at:** www.PharmaLive.com/newEKB

MDRWeb.com - searchable database of global medical device companies and their products. Learn more at: www.MDRWeb.com - enter promo code SRTRIAL for free two-week trial access.

For more information on these products contact: Sandra.Baker@ubm.com or call: +1-215-944-9836

EDITORIAL ADVISORS FOR SPECIAL REPORTS

Jay Carter, SVP Director of Strategy Services, AbelsonTaylor
Sander Flaum, President, Flaum Partners
Mark Havenhand, MBA, Ph.D., Novartis Pharma AG, Global Head, Business Strategy & Planning Clinical Medical Services
Boaz Mendzelevski, VP of Cardiology & Chief Medical Officer, Medifacts International
Steven Michaelson, Managing Partner, RosettaWishbone
Mike Myers, President, Palio
David M. Oakley, R.Ph., Ph.D., Director of Technical Development, AAIPharma
Deborah Schnell, President, Sales and Strategic Planning, Healthy Advice Networks
Marc Weiner, Managing Partner, Ogilvy CommonHealth Worldwide

DRUG DELIVERY REVIEW AND OUTLOOK

The global drug-delivery market is experiencing annual growth in the mid-tohigh single digits. The rising global population and the need for more convenient drug-administration methods have created more opportunities for manufacturers to produce additional drug-delivery systems and therapies.

The U.S. drug-delivery market is anticipated to generate 10 percent yearly growth during 2011 and 2012, according to industry experts.

The worldwide pharma market was projected to grow about 5-7% during 2011 compared to 4-5% growth generated in 2010. U.S. pharma sales were predicted to be up slightly during 2011 compared to 2010.

The industry will continue to grow through more sophisticated drug-delivery systems, says Graham Reynolds, VP of Marketing/Innovation, Pharmaceutical Delivery Systems, **West Pharmaceutical Services** Inc. "There will be an increase in self-administration of therapies," he shares. "For novel devices, look for continued trends toward safety and a strong focus on the needs of the patient."

West Pharmaceutical has developed innovative delivery systems such as the **ConfiDose** auto-injector system and the **SmartDose** electronic patch injector. These systems offer a range of options for dose volume, injection time and electronic control/feedback. They are designed to meet the challenges of innovative drug products.

Oral forms are expected to remain the largest drug-delivery category. Parenteral, inhalation and implantable systems are on the quickest growth pace. Industry analysts expect parenteral formulations will eventually surpass oral dosages as the largest segment.

Influencing drug-delivery systems development will be reimbursement, environmental factors and regulatory pathways, Mr. Reynolds says. "In addition, understanding the importance of the drug container as it relates to the integration into the overall drug-delivery system will continue to be a key factor."

Manufacturers are also accounting for patients' ability and desire to care for themselves, or have a family member care for them, in the comfort of their own home, Mr. Reynolds notes. "There can be a cost benefit when transitioning health-care provision from the hospital environment to the home environment or other health-care facilities," he states. "Effective drug-delivery devices and systems that enable a patient to self-inject can aid this transition. For example, it is now possible to transition from hospital IV to home-administered subcutaneous injection through the use of an electronic patch injector or autoinjector."

Auto-injectors are becoming more commonly used to deliver medications that treat a variety of therapeutic areas such as rheumatoid arthritis, oncology, diabetes, and multiple sclerosis. As a result, mass production will be required to support the demand for auto-injectors and in turn stimulate various industrial activities to support the manufacturing processes required for development.

Worldwide sales of advanced drug-delivery systems – inhalers, injections and infusion pumps – are projected to grow from a value of \$139 billion in 2009 to \$197 billion in 2014, according to **Cambridge Design Partnership** LLP experts. Cambridge Design Partnership is a consulting company that develops drug-delivery devices in the United Kingdom.

Matt Schuman, senior partner at Cambridge Design Partnership, advises manufacturers to learn from other industries that focus on creating differentiation and gaining competitive advantage through innovations in branding, usability and shelf appeal.

"We think, in the future, patients are going to be much more involved in their own treatments to reduce costs and smart drug-delivery technologies are part of what is going to enable this change safely," says Tom Oakley, Head of Drug Delivery at Cambridge Design Partnership. "As device developers, we are going to have to think of new ways to increase the performance and safety of therapies at lower cost.

"We expect healthcare systems increasingly to make drug choices based on calculations of the total cost of a patient's disease, and devices that can contribute to reducing overall costs could have significant commercial value. This means looking at system-level solutions integrating drug delivery, diagnostics and health informatics in new patient-centered systems," he adds.

In the field of auto-injectors, sophisticated use of electronics in reusable systems and disposable devices is causing growth, Mr. Reynolds says.

"There are also trends toward enhanced manual systems, including ergonomic features designed to improve an impaired patient's ability to deliver a dose from a prefilled syringe," he states. "There are several well-established companies in this space offering device technologies, and increasing emphasis on new and merging players offering improved patient convenience, and integration between the device and the container."

MICRONEEDLE TECHNOLOGY

In the realm of new technologies, a small band of device-development companies have been attempting to commercialize drug-delivery products based on arrays of microneedles. By establishing channels in the outer most layer of the epidermis, these devices were expected to deliver therapeutic drugs across the skin and into the dermal layers, according to **Grevstone Research Associates**.

Greystone analysts say after years of prototyping unique array designs, a few development programs have migrated toward improving the performance of existing delivery methods. The market availability of microneedle drug-delivery devices such as the **Sanofi Pasteur's Intanza** influenza vaccine, which is based on **Becton**, **Dickinson** and Co.'s (BD) **Soluvia** syringe-mounted microneedle array device, is considered a milestone in the transition of microneedle drug delivery from development to market.

Microneedle technology is anticipated to affect healthcare by enabling precise injection of therapeutic agents to prescribed areas below the skin. Microneedle technology is generating commercial viability at a time when drug developers are dealing with new challenges as they assess ways to admi1nister a new class of compounds with important therapeutic potential, according to Greystone.

Radius Health Inc. of Cambridge, Mass., and 3M Drug Delivery Systems of St. Paul, Minn., during 2011 agreed to collaborate together in the microneedle realm to deliver osteoporosis therapy. The BA058 Microneedle Patch will use 3M's patented Microstructured Transdermal System microneedle technology to administer BA058 through the skin, as an alternative to subcutaneous injection. The patch is expected to combine the ease, convenience, and self-administration attributes of a transdermal patch with the speed and efficiency of a traditional injection. Terms of the agreement were not disclosed.

Radius' BA058 Microneedle Patch product is undergoing Phase 1 clinical studies. The company's concluded Phase 2 human testing of an injectable form of BA058 showed that BA058 significantly increased bone mineral density (BMD) after six months of therapy.

TRANSDERMAL SYSTEMS

Transdermal patches - medicated adhesive pads placed on the skin that release drugs gradually for up to a week - have been available in the United States for more than 20 years.

The first transdermal patch, approved by the U.S. Food and Drug Administration in 1979, delivered scopolamine to treat motion sickness. Since then, more

than 35 transdermal patch products have been approved for marketing. Examples include the nicotine patch that helps people quit smoking, the lidocaine patch for relieving pain, and a patch containing hormone derivatives for preventing pregnancy.

LTS Lohmann Therapie-Systeme is one of the world's leading suppliers of transdermal and oral systems for the international pharmaceutical industry. Using the company's advanced oral medical wafers, LTS provides flat, film or waferlike medication for application in the oral cavity. This oral wafer medication systems uses the mouth as a site of both application and drug action.

The Andernach, Germany-based company offers three different oral wafer medication systems to provide the ideal solution for patients' specific requirements. Depending on the type of oral medical wafer, it is possible to generate different pharmacokinetic profiles, and avoid undesirable side effects in the gastrointestinal tract.


There are three types of LTS oral medical wafers: flash-release wafer; mucoadhesive melt-away wafer; and mucoadhesive sustained-release wafer.

According to LTS, oral medication wafer systems offer many advantages including: therapy restriction of local effects in the oral cavity (for example those indicated by local lesions); effects in the entire oral cavity, such as mouth refreshment or disinfection; swift systemic effects after absorption via the oral mucosae; discreet and easy application (no additional water needed); buccal absorption that bypasses hepatic first path metabolism; and improved bioavailability, enabling lower doses.

3M continues to be a major player in transdermal drug-delivery technology. For decades, the company has pioneered several advancements, including drug-in-adhesive (DIA) technology that has become the industry standard for passive delivery.

The 3M DIA system is a versatile platform that provides compatibility with a wide variety of drugs. This type of patch is less likely to deliver too much medication. Continued advancements allow this system to deliver more than one drug in a single patch, resulting in added patient convenience.

Because the adhesive layer not only serves to adhere the patch layers together and to the skin, but also contains the drug, DIA systems offer advantages in reduced size and thickness as well as improved conformability to the appli-



cation site. This process helps drive patient preference.

Delivery of drugs through skin has become a popular mechanism for delivering long-term, controlled dosages of various compounds. A drug is mixed with an adhesive and cast into a patch, which is then applied to the skin.

Acrux Ltd. of Melbourne, Australia has developed a revolutionary Metered Dose Transdermal System (MDTS) that enables transdermal delivery of smallmolecule drugs without the use of skin patches. The technology is based upon absorption enhancers used for more than 20 years in sunscreens, which the company has applied to treatments that are in clinical testing. These include estrogen, testosterone and a pain-management compound.

Acrux's business strategy involves taking off-patent or soon to be off-patent drugs and developing them for transdermal delivery. Acrux has entered into collaborations with major pharmaceutical companies such as **Pharmacia** (now part of **Pfizer** Inc.). Acrux agreed to partner in March 2002 for the development of transdermal applications for Pharmacia compounds.

One innovative way to deliver drugs transdermally comes from a partnership between the **California Institute of Technology** (Caltech) of Pasadena, Calif., in partnership with **Zcube** Srl, a research venture of the Italian pharmaceutical company **Zambon**. The two entities inked an exclusive research and option agreement to develop and commercialize skin patches that contain embedded carbon nanotubes for delivering drugs. The patches will first be developed to painlessly administer drugs through the skin; other applications are envisioned for future use.

A key aspect of the new skin patches is an innovative technique that partially embeds the nanotubes into the flexible materials in which they are grown. This embedding technique allows one end of each nanotube to be anchored to the patch. The other end protrudes from the patch to deliver drugs to the skin. This technique, which allows for the anchoring and alignment of the nanotubes, neatly overcomes a previous technological shortcoming and will enable new methods of drug delivery. This approach is anticipated to help these therapeutic nanotubes make their way to patient bedsides in a variety of medical applications.

Researchers report an important benefit of the new patches is that they are painless – the nanotubes' diameter is too small for nerves in the skin to detect. Industry experts believe that drugs can be delivered more effectively via nanotubes than through current microneedle or traditional patch technologies because the sea of nanotubes in the skin patches can be dosed and designed for optimal effectiveness, efficiently delivering drugs across the densest layers of the skin.

MATERIAL ISSUES

There has been a great deal of innovation in terms of drug-container materials used within devices.

"Although glass has been the traditional material of choice for drug containment, it has significant limitations including breakage, glass particulate, visual quality and functional performance," Mr. Reynolds said. "Many glass systems require siliconization to enable mechanical performance, and this material can interact with drug products."

FDA is becoming increasingly aware of glass-related quality issues, including breakage, cracks, contamination and particulates (often formed over time due to interaction between the glass and the drug) and there has been a tremendous increase in the number of recalls related to glass issues, Mr. Reynolds reports.

"High-profile recalls have been initiated for drugs that have had issues between the container closure system and the device," he explains. "For example, if a glass prefilled syringe is used in an auto-injector, there is a possibility of breakage due to the force used to activate the system. It has also been demonstrated that glass syringes within an auto-injector may fracture or break if subjected to a sudden force, and this may not be visually detectable. Other issues, such as uneven siliconization, may result in incomplete injections, and there have been recalls for potential loss of sterility due to cracks in glass syringes."

Recent developments around the use of polymeric materials for drug containment have allowed delivery-system companies to work closely with drug manufacturers to develop novel systems designed specifically to meet patient needs, Mr. Reynolds says. "The design and manufacturing flexibility of a polymeric drug container, combined with the ability to create patientfriendly devices designed with human factors engineering, enables the design of more innovative overall delivery systems that may aid in patient compliance through ease of use and enhanced technology," he explains.

Cyclic olefin polymers such as the **Daikyo Crystal Zenith** polymer provide a transparent, break-resistant alternative to glass that is also silicone-oil free.

Another trend expanding in the drugdelivery device industry is the increase of combination products, and drug-device combinations in particular.

"Many pharmaceutical companies are gaining interest in drug-delivery device technologies and the accompanying containment materials at a very early stage of drug development," Mr. Reynolds says. "Companies are finding that incorporating the overall drug-delivery system earlier in their development process enables a potentially faster route through the compliance process and thus to market. This creates increased interest in devices at an early stage.

However, Mr. Reynolds warns, the FDA is placing extra scrutiny on the area of combination products.

"There is uncertainty about how this may impact the drug-development process," he says. "Clearly, regulatory factors will continue to have a key impact on the future development of delivery systems."

Any automated process runs the risk that the system does not function effectively, which in this case means the dose cannot be delivered. Risks include failure of the device and failure of the device-container combination.

"In either case, the system would not be able to deliver the drug effectively to the patient," Mr. Reynolds says. "Understanding how the device and container integrate and interact to ensure effective operation is a critical part of ensuring that the overall drug delivery is effective and safe for the end user."

3M'S NOVEL DRY-POWDER INHALER TECHNOLOGY

3M Drug Delivery Systems provides efficient delivery systems for pharmaceutical companies that develop inhalation therapy. In a clinical study, 3M Drug Delivery Systems found its Conix Dry Powder Inhaler (DPI) achieved bronchodilator efficacy comparable to Glaxo-SmithKline Ple.'s blockbuster brand Advair Diskus (fluticasone propionate and salmeterol inhalation powder) while patients with asthma use less drug.

The study compared Conix DPI with Advair Diskus 100/50 in the delivery of a combination therapy (fluticasone propionate and salmeterol xinafoate). Seventeen patients with mild-to-moderate asthma received two treatments separated by 7 to 16 days, according to a randomized, two-period crossover design.

Results of the study showed that Conix DPI achieved a similar improvement in pulmonary function as compared with Advair Diskus. Additionally, the study demonstrated pulmonary delivery of a combination formulation from the Conix DPI device was safe and well tolerated. Patients reported that the Conix DPI device was easy to use.

Conix DPI is designed to deliver a higher respirable (more efficient) dose and a smaller non-respirable (less swallowed) dose to patients. The dry powder inhaler works by using an innovative reverse-flow cyclone technology to deagglomerate and aerosolize drug partieles. The inhaler's design allows formulation flexibility and protection from moisture ingress. The design is engineered to increase the effectiveness of energy transfer from patients' inspiration to the drug formulation.

Conix DPI is available for use with marketed molecules as well as new chemical entities.

ANATARES GAINS LONG-TERM PATENT PROTECTION

Antares Pharma Inc. is a leading U.S. developer of novel and advanced self-injection products, including needle-free



Antares' proprietary injection technologies include VIBEX, a pressureassisted, mini-needle jet-injector that offers comfort and versatility.

injectors and pen devices. The Ewing, N.J.-based company received patent protection in 2011 for one of its devices to deliver treatment for rheumatoid arthritis. The **VIBEX** platform of needle-assisted jet injection devices was granted patent protection until 2027.

The VIBEX platform is the basis for several products in development by Antares, including **VIBEX MTX**. This is the first auto-injector in development to potentially enable rheumatoid arthritis patients to comfortably and safely self-inject **methotrexate** at home.

Antares CEO Paul Wooton, Ph.D., says, "Independent market research commissioned by Antares with 200 rheumatologists has confirmed that physicians, if offered a reliable and patient-friendly method for self-injection, would like to switch many patients to an injectable form of methotrexate, potentially providing reproducible absorption, reduced side effects and a better therapeutic response. Since rheumatoid arthritis patients are often already prescribed methotrexate in combination with injectable biological products, VIBEX MTX may represent a significant revenue opportunity for Antares, potentially as early as in 2013, as we continue to focus on our product based strategy."

FUTURE GROWTH ANTICIPATED FOR DRUG-DELIVERY MARKET

The marketplace for drug-delivery systems and their manufacturers is expected to continue growing for many years to come.

"Growth trends in key areas, specifically diabetes, will continue," Mr. Reynolds says. "Watch for growth in areas such as auto-immune disease as well as sophisticated vaccines. Novel systems to enable the effective treatment of chronic conditions such as high cholesterol and allergies will also grow.

"Pharmaceutical and biotech companies are working closely with drug-delivery device manufacturers at an early stage to ensure that there is efficient development of an overall system to enable cost-effective drug delivery. Cost factors may include the ability to move the product to market as quickly and effectively as possible; reducing in-process rejects due to breakage or lack of function; and the overall cost of quality, which has to be built into a system from the start."

DIABETES DRUG DELIVERY

Among the various drug-delivery segments that will continue on a growth trajectory for years to come is diabetes.

Since the early 1920s, injectable insulin has saved the lives of millions of people living with diabetes worldwide. With more people being diagnosed with diabetes each year – in 2011, the CDC reported 25.8 million Americans are now living with the disease – the market for insulin is steadily growing.

Worldwide insulin sales have quadrupled in the past decade, exceeding \$15 billion. The Danish drug company Novo Nordisk A/S, the world's largest insulin maker, sold \$7.1 billion of insulin in 2010. Those sales could climb by a double-digit percentage annually in 2011 and beyond.

Additionally, spending for therapies to treat diabetes could account for up to 7% of all pharma expenditure in 2015.

A current treatment for diabetic retinopathy is laser therapy, which has side effects such as laser burns and the loss of peripheral or night vision. Anti-cancer drugs may also be used to treat the disease. However, these compounds clear quickly from the bloodstream so high dosages are required, thus exposing other tissues to toxicity.

One novel device in the works is a device that can be implanted behind the eye for controlled and on-demand release of drugs to treat retinal damage caused by diabetes.

Key to the innovation, developed at the University of British Columbia in Canada, is the ability to trigger the drug-delivery system through an external magnetic field. The research team accomplished this by sealing the reservoir of the implantable device – no larger than the head of a pin – with an elastic magnetic polydimethylsiloxane (silicone) membrane. A magnetic field causes the membrane to deform and discharge a specific amount of the drug, similar to squeezing water out of a flexible bottle.

In a series of lab tests, the UBC researchers loaded the implantable device with the drug **docetaxel** and triggered the drug release at a dosage suitable for treating diabetic retinopathy. The researchers found the implantable device kept its integrity with negligible leakage for 35 days.

Researchers also monitored the drug's

biological effectiveness over a given period, testing it against two types of cultured cancer cells, including those found in the prostate. They found that they were able to achieve reliable release rates.

The device offers improvements upon existing implantable devices for drug delivery, says Mu Chiao, Ph.D. "Technologies available now are either battery operated and are too large for treating the eye, or they rely on diffusion, which means drug release rates cannot be stopped once the device is implanted – a problem when patients' conditions change."

The UBC device will not be ready for patient use for several years. Team members are working to pinpoint all the possible medical applications for their device so that they can tailor the mechanical design to particular diseases.

After nearly a decade-long partnership, San Diego-based **Amylin Pharmaceuticals** Inc. and **Eli Lilly** and Co. of Indianapolis ended their relationship in 2011 to deliver **Byetta** to people living with diabetes. Amylin agreed to pay Lilly \$250 million to assume responsibility to develop and market the drug to control low blood sugar.

Under the alliance, Byetta (exenatide) was launched in 2005 and has been used by nearly 1.8 million patients worldwide. During October 2011, the U.S. Food and Drug Administration approved Byetta as an add-on therapy to insulin **glargine**, with or without **metformin** and/or a **thiazolidinedione** (TZD), in conjunction with diet and exercise for adults with type 2 diabetes who are not achieving adequate glycemic control on insulin glargine alone.

According to John Buse, M.D., Ph.D., professor of medicine and director of the **Diabetes Care Center** and chief of the Division of Endocrinology at the **University of North Carolina School of Medicine** in Chapel Hill, "Byetta is well-suited for use with insulin glargine, offering a simple fixed-dose regimen that can help improve control of blood sugar overall and after meals. In a clinical trial, patients using Byetta with insulin glargine achieved better glycemic control, without weight gain or an increased risk of hypoglycemia, compared to patients using insulin glargine alone."

Amylin is awaiting word from the FDA on whether the regulatory agency will approve **Bydureon** (exenatide extended-release for injectable suspension). A regulatory decision is set for early 2012. If approved, the drug will be the first onceweekly treatment for diabetes.

Becton Dickinson, a leading global medical technology company based in Franklin Lakes, N.J., made great strides in 2011 with the development of **BD Nano**, the world's smallest pen needle.

"BD is committed to helping improve the injection experience for the millions of people who live with diabetes, as demonstrated by our long history of innovative firsts – the first insulin syringe in 1924, the first 5 mm pen needle in 1999 and the now the world's first 4 mm pen needle, the BD Nano," said Linda Tharby, president of BD Medical - Diabetes Care. "We are confident this tiny needle can have a big impact by easing diabetes patients' transition and ongoing adherence to injectable drug therapy regimens a key element in helping to reduce the disease's deadly, debilitating and costly complications."

Animas Corp. and LifeScan Inc., both of West Chester, Pa., and members of the Johnson & Johnson Family of Diabetes Companies, continues to build upon their existing collaborative efforts to co-develop and market innovative new products and tools for people living with diabetes.

The two companies joined forces to co-develop the **OneTouch Ping Glucose Management System**. This is the first full-feature insulin pump that wirelessly communicates with a blood glucose meter remote.

Other products include the **OneTouch Verio Meter and Test Strip** platform, which received FDA clearance, paving the way for a new portfolio of self-monitoring of blood glucose products in the United States.

Continuous glucose monitoring (CGM) is one of the latest advancements in diabetes management, Animas is partnering with **DexCom** Inc. to develop a continuous glucose monitoring-enabled insulin pump and CGM system. This integrates a DexCom continuous glucose monitoring sensor with an Animas insulin pump. The system has been filed for CE Mark approval in Europe.

Johnson & Johnson expanded its realm of diabetes care by developing the **Diabetes Institute**. David L. Horwitz, M.D., Ph.D., FACP, chief medical officer of the Johnson & Johnson Diabetes Institute, feels confident that this program can make a positive impact to help improve patient outcomes.

When asked why J&J became involved in diabetes education, Dr. Horwitz responded, "People traditionally didn't think of J&J as a diabetes company, although we are among the global leaders in our glucose monitoring and pump products. We decided we wanted to make a difference 'in the trenches,' using the best practices of adult education to train diabetes educators how to change behaviors and motivate their patients."

Indianapolis-based Roche Diagnostics U.S., with its business unit Roche Diabetes Care, continues its tradition as a leader in blood glucose monitoring and insulin delivery systems by partnering with DexCom. The two companies signed a research and development agreement in 2011 to integrate DexCom's next-generation CGM system with the next generation of Accu-Chek insulin delivery systems targeted at the U.S. market.

In the future, users of an Accu-Chek insulin pump in the U.S. will not only be able to view their blood glucose data and insulin information on their wireless handheld, but also continuous glucose monitoring readings and trends. This would enable the user to make therapy adjustments from the palm of his hand while operating the pump.

Beyond the traditional leading pharma regions, Russia is growing into a significant diabetes market. During the next few years, the Russian diabetes market is projected to grow more than 7% annually during the next few years. This growth will result from the market launch of several premium-priced diabetes medicines and the rising use of glucagon-like peptide 1 (GLP-1) analogs, dipeptidyl peptidase (DPP-IV) inhibitors and insulin analog mixes.

Two pipeline products belonging to a novel class of sodium glucose cotransporter (SGLT)-2 inhibitors are anticipated to have a strong market impact: **Bristol-Myers Squibb** Co./**AstraZeneca** Plc.'s **dapagliflozin** and J&J's **canagliflozin**.

The government reimbursement policy in Russia, which encompasses treatment with most insulins – including the premium-priced long-acting insulin analogs – is expected to increase use of rapid-acting and long-acting branded insulin analogs.

DRUG DELIVERY COMPANIES REVIEW

THIS SECTION OF THE REPORT PROFILES SOME OF THE WORLD'S LEADING COMPANIES AS WELL AS UP-AND-COMERS IN THE AREA OF DRUG DELIVERY; SOME COMPANIES WERE ALREADY DETAILED WITHIN THE PRECEDING PAGES OF THIS REPORT.

HOSPIRA INC.

Hospira is a global specialty pharmaceutical and medication delivery company located in Lake Forest, Ill. Behind proven leadership and experience, Hospira provides solutions to help improve the productivity, safety and effectiveness of patient care.

As a result of the lower-than-expected third-quarter results for 2011, the company projected net sales for full-year 2011 to increase 1% to 2% on a constant-currency basis. On a reported basis, the company expected full-year 2011 net sales growth of 2% to 3%.

For full-year 2010, net sales were \$3.9 billion. Projections for eash flow in 2011 were between \$650 million and \$700 million.

As the world's leading provider of injectable drugs and infusion technologies, Hospira in 2011 launched **imipenem-cilastatin** for injection I.V. This is the first generic version of this key antibiotic to become available in the United States. The medication – a carbapenem that belongs to the beta-lactam class of antibiotics – is a generic version of **Merck** & Co.'s **Primaxin**, which generated 2010 U.S. sales of \$140 million. Hospira also sells imipenem-cilastatin in Europe, Japan and several other countries.

During 2010, Hospira launched meropenem, the first generic carbapenem on the U.S. market. Carbapenem antibiotics have a U.S. market value of about \$600 million.

Hospira's specialty injectable pharmaceuticals (SIP) offering includes roughly 200 generic injectable drugs in many dosages and formulations. Many of the company's products are available in popular differentiated presentations, several of which are proprietary, such as the **ADD-Vantage** drug-delivery system and **iSecure** prefilled syringes. Therapeutic areas include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, emergency and other areas. Hospira also has robust pipelines of generic and biosimilar drugs.

ENDO PHARMACEUTICALS HOLDINGS INC.

Endo is expanding to bring new therapies

HOSPIRA Global Portfolio Expansion: Four-Point Strategy 1. Portfolio Expansion • Focus investment to expand our global presence - introduce our on-market products to additional markets - focus on growing targeted markets - explore opportunities in select emerging markets - continue biosimilar launches • Continue biosimilar launches • Redouble efforts on differentiated delivery systems - bringing existing delivery systems to new geographies 3. Strengthen Global Franchise

• Strengthen global franchise by enhancing low-cost global leadership position, e.g., India expansion

4. M&A

 Pursue focused M&A strategy to enhance / accelerate expansion strategies

Source: Hospira

to patients, new treatment approaches to physicians and better outcomes to managed-care providers.

In 2011 the Pennsylvania-based company relocated headquarters from Chadds Ford to Malvern and acquired **American Medical Systems**. AMS is a diversified supplier of medical devices and procedures to treat incontinence, erectile dysfunction, benign prostatic hyperplasia (BPH), pelvic floor prolapse and other pelvic disorders in men and women. American Medical Systems' products were used to treat 340,000 patients in 2010.

Endo's total revenue during the third quarter of 2011 increased 71% to \$759.1 million, compared with \$444.1 million in the same quarter of 2010. Net income for the three-month period ended Sept. 30, 2011, was \$40.6 million, versus \$54.2 million in the comparable 2010 period.

Endo's devices and services sales, driven by the acquisition of AMS, totaled \$185.6 million for the third quarter of 2011, an increase of 259% over the prior year's same period. Men's Health, led by strong sales of the AMS 800 Artificial Urinary Sphincter, grew 21% on a pro-forma basis in the third quarter of 2011 year over year.

In early September 2011, an FDA advisory panel met to discuss the use of surgical mesh products in the repair of pelvic organ prolapse and stress urinary incontinence, which Endo believes led to reduced procedural volumes during the third quarter. However, the company believes that the advisory panel addressed the questions raised and that a recovery in procedural volumes will emerge in the near term.

Endo Pharmaceuticals is evaluating new drug-delivery technologies to create innovative new medicines. During December 2011, Endo received FDA marketing approval for a new formulation of **Opana ER** designed to be crushresistant.

Endo is dedicated to executing a seamless transition during 2012 from the original formulation to the new formulation of Opana ER, which uses the proprietary **INTAC** technology owned by **Grunenthal**, a partner in the development of the product. The new formulation will remain named Opana ER with the same dosage strengths, color and packaging and similar tablet size and shape. The FDA clearance signifies that there is no significant difference in the rate and extent of absorption of the therapeutic ingredient between this new formulation and the original version of Opana ER.

HISAMITSU PHARMACEUTICAL CO. INC.

Japan's Hisamitsu has organized effective research & development systems, with four major centers that enable prompt facilitation of R&D activities. Three of the centers are based in Japan: **Tosu Laboratories**, **Tsukuba Laboratories**, and the Tokyo headquarters. The fourth center is Miami-based **Noven Pharmaceuticals** Inc., which serves as Hisamitsu's U.S. growth platform for prescription pharmaceuticals. Aiming to convey "the benefits of transdermal patches" to patients worldwide, the centers work together to engage in R&D of transdermal drug delivery system (TDDS) products in a wide range of the therapeutic fields.

Among Hisamitsu's leading products is **Salonpas** brand patches, which were first introduced in 1934, According to the company, their outright efficacy propelled Hisamitsu to the position of market leadership currently held. Salonpas was developed through the application of Asahi Mankinko, the prototype therapeutic patch launched during 1903. Since then, Hisamitsu has striven to develop and refine therapeutic patches that are safe and easy to use.


For Hisamitsu's fiscal 2012 second quarter ended Sept. 30, 2011, the company reported net sales of 69,160 million yen, down 2% year over year. R&D spending for 2Q fiscal 2012 advanced 28% to 7,487 million yen compared to second-period fiscal 2011.


IPSEN GROUP

Paris-based Ipsen is a global specialtydriven pharma company with total sales exceeding 1.1 billion euros in 2010 and nearly 4,500 employees. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. The company's development strategy is supported by four franchises: neurology/**Dysport**, endocrinology/**Somatuline**, uro-oncology/**Decapeptyl** and hemophilia.

The Ipsen Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient-driven platforms, peptides and toxins. During 2010, R&D expenditure totaled more than 220 million euros, representing more than 20% of group sales.

For the company's first nine months of 2011, consolidated group sales reached 864 million euros, up 2.6% year over year. Discounting a stocking effect in





Russia during 2010, Ipsen's consolidated sales improved 3.9% versus January-September 2010. The 2011 sales improvement was led by the endocrinology franchise and in particular Somatuline, which generated a 12.6% year-on-year sales increase (12.8% excluding foreign exchange impacts).

Based on Ipsen's solid performance during the first three quarters of 2011, for the full year management expected e to deliver on:

- Specialty Care drug sales growth close to 8.0% year-on-year

- Primary Care drug sales decrease of 3.0% to 5.0% year-on-year

- A recurring adjusted operating income in the upper range of 190 million euros to 200 million euros.

CONSORT MEDICAL PLC.

Consort Medical is a healthcare company in the United Kingdom focused on medical device technologies for drug delivery and hospital products for the management of patient airways.

After a challenging three years of re-

structuring the company, Consort Medical is optimistic for the future with expectations to see benefits in its investment in research and development through the economic downturn with a range of product launches during the next few years.

"Our strategy of diversification reduces the risk of being exposed to any single market and in the past two years we



Bespak - three new development programmes in period

have positioned ourselves to benefit from higher growth markets such as biologic drug delivery by autoinjector and Pointof-Care diagnostics," says Toby Woolrych, group finance director. "We have been pleased in the past year also to take advantage of low interest rate swap rates and to fix substantially the whole of the Group's borrowings until the end of 2013 at a rate of between 1.48% and 1.78% plus bank margin."

Production milestones for 2011 included manufacturing of the 500 millionth Diskus and 1 billionth HFA valve manufactured and development of the of **OTS Autoinjector**.

Consort Medical's **Bespak** unit has comprehensive scientific capabilities, regulatory expertise as well as worldclass facilities to support the development and production of metered-dose inhaler valves, actuators and dose-counters. Bespak offers complete device development services, with the design and engineering expertise to manage medical device development programs from concept to full-scale manufacturing.

For Consort Medical's six-month financial period ended Oct. 31, 2011, revenue from products and services increased 5% to £68.8 million (May-October 2010: £65.6 million). During the 2011 period ended in October, two new nasal development contracts were inked that diversify Bespak into new drug delivery markets. Also, Consort Medical signed a new medicinal nicotine delivery device development contract (please see the visual on page 10 for more details).

"We are pleased to report a record set of results in what can only be described as a challenging and uncertain global economic environment," noted CEO Jon Glenn. "Our strategy to deliver sustainable organic growth is now delivering ahead of expectations and we are confident for the outlook for the rest of the year and beyond."

AUXILIUM PHARMACEUTICALS INC.

Auxilium was founded in 1999 to devel-

op and market pharmaceutical products that focus on urology and sexual health. The company is based in Malvern, Pa.


For the third quarter of 2011, Auxilium reported net revenue of \$66.7 million compared to \$53.6 million during thirdquarter 2010. The net loss for July-September 2011 was \$4.1 million or 8 cents per share, versus a net loss of \$12.8 million or 27 cents per share for 3Q 2010.

Driving the company's growth are two medications: **Testim**, a gel used to treat adult men who have low or no testosterone, and **XIAFLEX**, the only FDA-approved nonsurgical treatment for adults with Dupuytren's Contracture with a palpable cord.

Worldwide net revenue for XIAFLEX amounted to \$13.1 million for the third quarter of 2011, up 130% versus sametime 2010. Global revenue for Testim totaled \$53.6 million, advancing 12% over the third quarter of 2010, with \$52.9 million of revenue generated in the United States.

"We believe that the progress we

Gels Continue to Drive Significant Growth in TRT Marketplace



made in the third quarter of 2011 will drive long term shareholder value. XIAF-LEX revenues showed sequential growth over the second quarter of 2011, despite a slight decrease in overall Dupuytren's procedure volumes, and new XIAFLEX data were well received by physicians attending the American Society for Surgery of the Hand meeting. We remain encouraged by the physician and patient success stories and believe that XIAF-LEX will become the standard of care for Dupuytren's contracture," commented Armando Anido, CEO and president of Auxilium. "Testim continued to perform well, despite continuing competition in the testosterone replacement market, with prescriptions posting growth over the third quarter of 2010 and over the second quarter 2011."

ACINO HOLDING LTD.

Acino is a Basel, Switzerland-based company that develops and manufactures generic and innovative pharmaceuticals using advanced drug-delivery technologies. Acino is concentrated on sophisticated oral dosage forms with modified release of active ingredients, transdermal therapeutic patches and biodegradable subcutaneous implants. Acino supplies leading pharmaceutical companies worldwide. The company offers the pharma arena a comprehensive array of services ranging from product development and registration to sourcing, contract manufacturing, packaging and logistics.

The Acino Group generated annual net revenues of 128 million euros in 2010. For first-half 2011, the group reported top-line growth of 6% to EUR 65.2 million.

The company is in the process of a transition in 2011 and 2012 via building on its established business-to-business (B2B) with pharma specialties and generics.

Acino intends to strengthen its technology competence and aims at intensifying company partnerships with the research-driven pharma industry. On this basis, Acino expects to further enlarge its pipeline of own and original customer products.

The group intends to take its product portfolio under the Acino brand into new selected emerging markets that have a demand for high quality Swiss/Germanmade pharmaceuticals.


Acino anticipates delivering a steady revenue growth and EBITDA-margin during full-year 2011 similar to the company's results during the first six months of the year. According to the company, with no euro currency recovery on the horizon the CHF/EUR exchange rate will in all likelihood leave its marks on Acino's full-year 2011 result, primarily by limiting operational margin improvements.

Assuming a continued strength of the CHF at current levels, Acino expects a positive full-year 2011 net result slightly above the year's half-year level.

SKYEPHARMA PLC.

SkyePharma is a specialist drug-delivery company developing oral and inhalation products. The SkyePharma portfolio includes a wide range of patented and proven technologies to improve medicines.

The European-based company's R&D facilities are located in Switzerland and manufacturing operations are based in France. SkyePharma partners with a wide range of companies from Big Pharma (GlaxoSmithKline, Novartis AG, Sanofi SA, AstraZeneca and F. Hoffmann-La Roche Ltd.) to a range of smaller speciality pharmaceutical entities. SkyePharma's proprietary drug-delivery technologies enable the development of new formulations of existing products as



well as new chemical entities to provide a clinical benefit to patients.

SkyePharma's Geomatrix and Geoclock technologies allow for controlled-release or timed-release versions of immediate-release products to be developed providing advantages to both partner companies and patients.

The group's inhalation technologies include formulation as well as device technologies. They encompass metereddose inhalers and dry-powder inhalers.

SkyePharma revenue in the first half of 2011 totaled \$22.1 million, down 25% compared with the first half of 2010 (\$29.3 million). This decrease was primarily due to substantial manufacturing revenues in the first half of 2010 related to non-recurring volumes to support regulatory and commercial activities, the company reports.

DEPOMED INC.

Depomed is a specialty pharmaceutical company located in Menlo Park, Calif. Depomed has two approved and marketed products. **Gralise** (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). **Glumetza** (metformin hydrochloride extended-release tablets) is approved for use in adults with type 2 diabetes and promoted by **Santarus** Inc. in the United States.

The company's third-quarter 2011 results reflect a new commercialization agreement for Glumetza entered into with Santarus in August 2011. Under terms of the agreement, Santarus began booking Glumetza product sales in September 2011 while paying Depomed a royalty on net sales of 26.5% for the remainder of 2011 with the rate increasing to 29.5% during 2012, 32% in 2013 and 2014, and 34.5% in 2015 and beyond.

Total revenue for the 2011 third quarter amounted to \$16.5 million compared to \$20.1 million for July-September 2010. Revenue for 3Q 2011 included two months of Glumetza product sales and one month of royalties on Glumetza product sales made by Santarus. Thirdperiod 2011 revenue included the onetime recognition of \$6 million in milestone payments under development and license arrangements with **Janssen** Pharmaceutica and **Covidien**. Net loss for the quarter was \$8.6 million, or \$0.15 per share, compared to net income of \$1.9 million, or \$0.04 per share, during the third quarter of 2010.

"Today, Depomed is a growing commercial business and has a strong balance sheet with over \$150 million in cash that can facilitate transactions to accelerate our growth," noted Jim Schoeneck, Depomed's president and CEO, upon the announcement of the company's 3Q 2011 performance. "I believe Depomed's future as an integrated specialty pharma company is very bright, and that we are well-positioned to execute our strategies,"

VECTURA GROUP PLC.

Vectura is a Chippenham, UK–based company that specializes in developing inhaled therapies, principally for the treatment of respiratory diseases.

For the first half of 2011, company revenue was recorded ahead of expectations at \$21.1 million, down from \$26.3 million during same-time 2010.

Vectura experienced several operational highlights in 2011. **NVA237** for the treatment of COPD is on track for European launch in 2012. The company successfully filed a European Marketing Authorization Application, triggering a \$5 million milestone receipt from Novartis.

Phase III data presented at the European Respiratory Symposium (ERS) found the drug increased lung function with fast onset of action; improved exercise endurance; delay to onset of first moderate/severe COPD exacerbation; and reduced incidence of hospitalizations. Further clinical data is under way.

Another drug to treat COPD, **QVA149**, is on track for a European launch in 2013.

According to Chief Executive Chris Blackwell regarding Vectura's six-month results ended Sept. 30, 2011, "Vectura's results demonstrate continued financial strength, with a profit after tax and cash in excess of \$80m. This strong financial performance was underpinned by two important new collaboration agreements concerning **VR315** and the filing of NVA237 in Europe. We look forward to the launch of NVA237 in Europe in 2012 as well as additional Phase III clinical data for both NVA237 and QVA149.

"Looking ahead, we will focus on building our pipeline whilst looking for new partnering opportunities to maintain the growth prospects of the Company."

COLUMBIA LABORATORIES INC.

Livingston, N.J.-located Columbia Laboratories develops drugs that improve treatment options for women's reproductive healthcare. This is done by using Columbia's novel bioadhesive delivery technologies, which optimize drug delivery in a controlled, sustained manner.

Total net revenue for Columbia for the third quarter of 2011 totaled \$4.9 million, compared to \$14.2 million for the third quarter of 2010. The 2010 quarter



included \$8.5 million of the amortization of the \$34 million gain on the sale of the progesterone assets in July 2010 to Watson Pharmaceuticals Inc.

Third-quarter 2011 net revenue from Merck Serono for international sales of CRINONE (progesterone gel) increased 56% on a 60% volume increase year over year. Net revenue from Watson for domestic CRINONE grew 92% on a 41% volume increase compared to third-period 2010 levels. The higher dollar increase in Watson net product revenue over volumes represents a pass-through of costs due to higher exchange rates.

The PREGNANT study, Columbia's pivotal clinical trial of **progesterone vaginal gel 8%** to reduce the risk of preterm birth in women with premature cervical shortening, was published in the July 2011 issue of *Ultrasound in Obstetrics and Gynecology*.

"We are very pleased with the strong growth of CRINONE by Watson in the U.S. and Merck Serono internationally," commented Frank Condella, Columbia's president and CEO. "We look forward to further revenue growth from our partners going forward.

"During the third quarter of 2011, we continued to work closely with the U.S. Food and Drug Administration (FDA) to ensure a thorough review of the New Drug Application (NDA) for progesterone vaginal gel 8% to reduce the risk of preterm birth in women with premature cervical shortening. Our PDUFA date is February 26, 2012. If the FDA approves this product for the preterm birth indication, we plan to supply sufficient quantities to Watson for a timely commercial launch."

Columbia Laboratories expected to be operating at a slight loss in the fourth quarter of 2011, but still maintain a net profit for the full year.

ANTARES PHARMA INC.

Antares develops jet-injectors, auto-injectors and pen injectors to accommodate patients' increasing use of self-injectable medicines.

The Ewing, N.J.-based company recorded revenue of \$3.9 million for the third quarter of 2011 and \$11.0 million for the year-to-date period, with increased quarter and YTD product revenue of 33% and 41% compared to the same periods in 2010. In 2011, Antares received patent approval from the U.S. Patent and Trademark Office covering technology used in the company's VIBEX platform of needleassisted jet injection devices. The patent provides protection for the VIBEX technology until 2027.

"During the third quarter, Antares continued to make significant progress across all of our key development programs," says Paul K. Wotton, PhD, president and Chief Executive Officer. "In addition to generating strong and growing revenues, we continued to make substantial headway on our wholly-owned VIBEX MTX auto injector product, a potentially significant opportunity in the large rheumatoid arthritis market. We also received development revenues from our marketing partner Watson Pharmaceuticals, triggered by our advances towards commercial manufacturing readiness for Anturol."

LOHMANN THERAPIE-SYSTEME AG

LTS of Germany is a global leader in the development and manufacturing of transdermal systems and oral thin films. The products developed by LTS comprise a multitude of innovations, including the world's first nicotine patch as well as the only patch against Parkinson's and Restless-Legs-Syndrome.

The innovation capability of LTS led the way for oral thin film products on the market with the introduction of **Listerine Pocketpaks**, which dominate the North American market. West Caldwell, N.J.-based **LTS Corp.** has produced more than one billion strips in the first three years after market launch.

More than 5,000 patents reinforce LTS' top position in development of transdermal technologies. Since the end of the 1990s, LTS has been the principal shareholder of **CRS Clinical Research Servic**es, which conducts Phase I through IV clinical trials. LTS offers the entire service spectrum: starting with development, continuing to clinical trials and production, up to final packaging.

PSIVIDA INC.

pSivida is a leader in the development of miniaturized, injectable drug-delivery systems. Small in size, the company's devices are FDA-approved to be administered into the eye. Once administered, the devices release their drug for months and years.

pSivida has a worldwide collaborative R&D agreement with Pfizer to develop a long-term sustained-release implant to deliver **latanoprost** for patients with ocular hypertension and glaucoma. This collaboration is focused on developing a bioerodible version of pSivida's proprietary **Durasert** technology, designed to be injected into the subconjunctival space of the eye.

Revenue for the company's first quarter of 2011 ended Sept. 30 totaled \$1.7 million compared to \$476,000 one year earlier. This result primarily reflected recognition of deferred collaborative research and development revenue from the amended and restated Pfizer agreement in June 2011 and the termination of a 2008 field-of-use license by Intrinsiq in July 2011.

pSivida reported a net loss of \$2.4 million, or \$0.12 per share, for its first quarter ended Sept. 30, 2011, compared to a net loss of \$3.1 million, or \$0.17 per share, for July-September 2010.

"We have a very full plate with three clinical-stage product candidates for the treatment of back-of-the-eye diseases," noted Dr. Paul Ashton, pSivida president and CEO. "Most advanced is ILUVIEN for diabetic macular edema (DME) being developed by our licensee Alimera Sciences, for which Alimera has resubmitted a New Drug Application and is awaiting a response from the FDA. We are also independently developing a product to treat uveitis affecting the posterior segment of the eye (posterior uveitis) and a product to treat glaucoma and ocular hypertension in collaboration with Pfizer."

The product pSivida is developing for treating posterior uveitis uses the same micro insert (with a different inserter) as ILUVIEN for DME. The company's collaboration agreement with Alimera allows pSivida to reference the ILUVIEN for DME regulatory filings, which provides the potential for an abbreviated clinical development and regulatory approval process for the posterior uveitis product.

Posterior uveitis is an inflammatory condition that can be extremely serious. In the United States, this disease has been estimated to affect 175,000 people and is responsible for 30,000 cases of blindness. An investigator-sponsored trial in posterior uveitis opened during September 2011.

pSivida's proposed product to treat glaucoma is an injectable, bioerodible sustained-release insert delivering latanoprost. The product is undergoing a dose-ranging study. pSivida granted Pfizer an exclusive option under various circumstances to license the development and commercialization globally of this insert for human ophthalmic disease other than uveitis.

pSivida is continuing to advance its **Tethadur** system (based on **BioSilicon** technology), which is designed to deliver large biologic molecules – including peptides and proteins – on a sustained basis.

SHL GROUP

SHL (Scandinavian Health Ltd.) is the world's largest privately owned designer, developer and manufacturer of advanced drug-delivery systems. Based in Sweden, SHL manufactures devices including pen injectors, auto injectors and inhaler systems.

In 2011, SHL Group expanded operations with an expansion to its plant in Taiwan. Frank Isaksson, GM for Taiwan, commented, "Demand for auto injectors continues to rise as the number of biologics coming to market steadily increases. The simple fact is that SHL will continue to expand our production capabilities over the next few years and will also find new ways to enhance our utilization of current machinery, people and resources. Several of our biotechnology and pharmaceutical customers are now working with us on multiple projects.

"With continued expansion in Taiwan, our new facility in the USA and future expansion in Europe we will have the depth of capabilities and resources needed to maintain our leadership position in the auto injector market, including production of other drug delivery devices such as pen injectors and inhalers systems," he says.

During 2011 SHL Group received certification for the Good Design Award for its revolutionary auto injector **Molly**. This award recognizes outstanding designs that can further advance lifestyle and industrial activity, both of which are embraced by Molly's innovative design and related business model.

Officially introduced to biopharma

customers during late 2010, Molly features compact size, permanently hidden needle, locking needle shield as well as a two-step operation with integrated safety features.

According to the company, although the commercial applications of the Molly auto injector will depend on the corresponding biopharmaceutical customer, it is likely to be intended for therapeutic areas that require frequent injections either at home or in a clinical environment. This will result in high-volume demands.

OWEN MUMFORD LTD.

Owen Mumford designs and manufactures a range of medical devices and disposables that are used by healthcare professionals and consumers worldwide. The Oxford, England, company focuses on manufacturing devices for drug delivery, sexual health, capillary blood sampling and neuropathy screening.

The company's advanced automatic injection devices and pen needles offer maximum comfort. The product range includes Autopen, Unifine Pentips, Autoject 2, Autodrop, and Autosqueeze.

YPSOMED HOLDING AG

Ypsomed is a worldwide leading independent developer and manufacturer of injection systems for custom-made self-administration as well as supplier of pen needles for treating diabetes, growth disorders or infertility, and other therapeutic areas. Ypsomed is based in Burgdorf, Switzerland.

Ypsomed has well-established partnerships with numerous leading pharmaceutical and biotech companies such as Sanofi, Eli Lilly, Pfizer, Roche, Genentech Inc., Merck Serono, Amylin, and NPS.

In November 2011 Ypsomed acquired ICU Medical Inc., one of few independent manufacturers of diabetes infusion sets operating in the very competitive and patent-protected market for insulin-pump accessories. Through this acquisition, Ypsomed secures ownership of ICU's diabetes infusion set patents. Previously, Ypsomed had been acting as a trading partner for ICU Medical, selling its **Orbit** infusion set under the name of **mylife Roto**.

In the first half of Ypsomed's 2011/2012 business year ended Sept. 30, 2011, the company generated sales of goods and services totaling CHF 122.8 million. The 6.6% year-over-year decrease from CHF 131.5 million was due to the currency effect and lower levels of remuneration for R&D services. Company reps say the strong Swiss franc had a negative impact on sales of goods totaling to CHF 6.9 million. After adjustments for currency effects, sales represented an increase in the current reporting year of about CHF 1.5 million (+1.3 %) year-on-year.

According to the company, in Germany as many as one in three new patients or patients moving to a new pump system are opting for **mylife OmniPod** insulin patch pump. The tubing-free insulin pump is especially popular with women (55%) and patients aged between 30 and 50 (39%), Ypsomed officials noted.

In 2012, Ypsomed will be launching a new, second-generation pod that has undergone further development. According to Ypsomed, the new pod is not only significantly smaller and flatter, but also consumes less energy.

For the second half of the company's fiscal year ending March 31, 2012, Ypsomed expects turnover and operational profit margin to be slightly higher compared to the first half of the year based on current exchange rates.

NEKTAR THERAPEUTICS

Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with top biopharmaceutical companies to bring new products to market. Nektar's technology and drug-development expertise have resulted in seven approved products for partners, including leading biopharmaceutical players.

The San Francisco-based company reported a drop in revenue for the third quarter of 2011 to \$27.1 million compared to \$37.9 million during the third quarter of 2010. The 3Q 2010 revenue, however, was partially the result of the completion as of December 31, 2010, of the amortization of a \$125.0 million upfront payment received in 2009 from AstraZeneca for the **NKTR-118** and **NKTR-119** license agreement.

"Nektar is highly focused on continuing to advance our important proprietary drug candidates in pain and cancer," said

Nektar's Advancing and Diversified R&D Pipeline

Product / Partner / Indication		Research & Preclinical	Phase 1	Phase 2	Phase 3
Oral NKTR-118 - KODIAC Phase 3 Program Treatment of Opioid-Induced Constipation	AstraZeneca				
NKTR-061/BAY41-6551 (Amikacin Inhale)/Gram-negative Pneumonias	Bayer				
NKTR-102 – BEACON Phase 3 Program Metastatic Breast Cancer					
NKTR-102 Platinum-Resistant /Refractory Ovarian Cancer					
NKTR-102 Metastatic Colorectal Cancer Patients with KRAS mutati	on				
NKTR-181 Oral long-acting opioid for chronic pain					
NKTR-119 (Opioid Combos) Oral analgesic	AstraZeneca				
NKTR-192 Oral short-acting opioid for acute pain					
NKTR-107 Cytotoxic solid tumors					
4+ Additional Anti-cancer Programs					
NKTR-171 Neuropathic Pain					
NKTR-140 (Protease Inhibitor) HIV					
NKTR-125 Antihistamine					
10+ Additional Preclinical Programs					

Howard W. Robin, president and CEO of Nektar. "AstraZeneca's Phase 3 KO-DIAC program for NKTR-118 for opioidinduced constipation is continuing ontrack with AZ targeting regulatory filing in 2013. We are targeting the start of the Phase 3 BEACON study for NKTR-102 in metastatic breast cancer before yearend. NKTR-181, our novel opioid candidate to treat chronic pain, is moving rapidly through Phase 1 clinical development and we plan to announce top-line data before year-end. Finally, we plan to file an IND for NKTR-192, our new clinical candidate to treat acute pain, in the first quarter of 2012."

Total operating costs and expenses in the third quarter of 2011 were \$48.4 million, an increase compared to \$44.2 million in the third quarter of 2010. The increase is primarily a result of higher development expenses related to the advancement of multiple programs in clinical development. Research and development expense increased to \$31.0 million in the third quarter of 2011 as compared to \$27.7 million for the same period in 2010. General and administrative expense totaled \$12.4 million in the third quarter of 2011 as compared to \$10.2 million for the third quarter of 2010.

ARADIGM CORP.

Aradigm is an emerging specialty pharmaceutical company developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory disease.

Bolstered by its depth of expertise in pulmonary drug delivery and an extensive intellectual property portfolio, the company is uniquely positioned to fulfill unmet needs in pulmonary medicine.

Total revenue for the Hayward, Calif., company was \$0.2 million for the third quarter of 2011, compared with the same amount for the third quarter of 2010. Revenue for both periods reflects the quarterly royalty payment from **Zogenix** Inc. for product sales of **SUMAV-EL DosePro** needle-free delivery system for the treatment of acute migraine and cluster headaches.

The company's net loss for the third quarter of 2011 was \$2.4 million, or \$0.01 per share, compared with net income of \$1.3 million, or \$0.01 per share, for the third quarter of 2010. Net income for the third period of 2010 was derived from the non-cash gain on the extinguishment of debt from the Novo Nordisk equity for debt transaction.

Total operating expenses for the third quarter of 2011 were \$2.3 million, compared with total operating expenses of \$3.3 million for the third quarter of 2010. The decrease in operating expenses was primarily due to expense-reduction efforts and lower clinical and manufacturing costs for the inhaled ciprofloxacin program versus the prior-year period.

3M DRUG DELIVERY SYSTEMS

3M, based in St. Paul, Minn., is a diversified technology company serving customers and communities with innovative products and services. According to 3M, the company captures a culture of creative collaboration that inspires a never-ending stream of powerful technologies that make life better. 3M says it is the innovation company that never stops inventing. With \$27 billion in sales, 3M employs about 80,000 people worldwide and has operations in more than 65 countries.

Third-quarter sales for 2011 were came in at about \$7.5 billion, up 9.6 percent year-on-year. The company reported third-quarter worldwide sales growth of 9.6 percent, of which 3.7 percent came from acquisitions, 3.1 percent stemmed from foreign exchange impacts, 1.9 percent derived from organic volume growth and 0.9 percent came from higher yearon-year selling prices. Organic volume growth was below recent trend levels, reflecting weakness across the electronics market along with generally slowing economic growth in the developed world. 3M also noted that a number of its customers reduced inventories during the quarter in anticipation of slowing demand.

Excluding the positive impact of currency, five of the company's six business segments expanded sales in the third quarter of 2011. One of the segments was Health Care, which improved 10.9 percent.

The company reported year-on-year sales increases in all geographic regions. Sales in local currencies grew 11.2 percent in Latin America/Canada, 9.2 percent in the United States, 5.9 percent in Europe and 2.1 percent in Asia Pacific. Excluding optical, Asia-Pacific sales increased 11.3 percent in local currencies.

Taking into account the third-quarter performance, 3M updated its 2011 full-year performance expectations. The company expected earnings to be in the range of \$5.85 to \$5.95 per share versus a prior expected range of \$6.10 to \$6.25.

Along with innovation, 3M Drug Delivery Systems welcomed new leadership in 2011. New Vice President and General Manager James Ingebrand replaced the retiring James Vaughan in October.

Mr. Ingebrand has a 27-year career at 3M, giving him significant insight into the pharmaceutical and health-care industries.


As VP and general manager, Mr. Ingebrand assumed responsibility for the strategic direction of 3M Drug Delivery Systems' inhalation, transdermal, topical and oral drug delivery devices and components, which are manufactured and sold in more than 60 countries and six continents.

"We are pleased to have Jim step into this new role within 3M," commented Brad Sauer, executive VP of 3M Health Care Business. "Jim's depth of knowledge and understanding of the pharmaceutical industry equip him with outstanding tools to cultivate the innovation that 3M Drug Delivery Systems is known for.

Mr. Ingebrand's previous positions within the 3M Drug Delivery Systems Division include roles as a key account manager in the United Kingdom, an inhalation program manager and a Six Sigma Black Belt. Mr. Ingebrand most recently served as the global business director for **3M Dental**. He has worked in several other health-care divisions of 3M, including **3M Infection Prevention** and **3M Health Care Specialties**.

APTALIS PHARMA INC.

On February 11, 2011, Axcan completed the acquisition of **Eurand** N.V., a global specialty pharmaceutical company with operating units in the United States and Europe. The new company began its combined operations on February 14,



2011, and took on the new name Aptalis as of May 4, 2011. Headquarters is based in Bridgewater, N.J. Other offices are located in Alabama, Ohio and Pennsylvania.

Aptalis is a leading international specialty pharmaceutical company that develops, manufactures, markets and distributes cystic fibrosis and gastroenterology products and therapeutic treatments.

Another major milestone during 2011 came with the Food and Drug Administration's decision to approve a new strength of **ZENPEP** (pancrelipase) Delayed-Release Capsules.

The new formulation is offered in 25,000 units of lipase, the highest strength approved by the Food and Drug Administration. The 25,000-unit strength gives physicians another option in dosing patients with exocrine pancreatic insufficiency (EPI) caused by cystic fibrosis or other conditions, and could potentially reduce pill burden.

"Added to the recent FDA approval of the 3,000-unit dose, ZENPEP offers physicians and their patients the broadest range of dosing options, including the lowest and highest doses available, of any FDA-approved pancreatic enzyme product," said Frank Verwiel, M.D., president and CEO of Aptalis Pharma. He noted ZENPEP is the only pancreatic enzyme offered in six dosage strengths -3,000, 5,000, 10,000, 15,000, 20,000and 25,000 units of lipase - reflecting the company's strong emphasis on research and development. "We believe the broad range of ZENPEP strengths can provide added convenience by helping patients reduce the number of capsules they take with every meal, while the precise dosing can aid in the management of their EPI."

FLAMEL TECHNOLOGIES S.A.

Flamel Technologies is a leading drugdelivery company. Flamel is focused on the goal of developing safer, more efficacious formulations of drugs to tackle unmet medical needs. The company's development pipeline includes biological and chemical drugs formulated with its proprietary platforms **Medusa** and **Micropump**.

The Lyon, France-based company reported financial gains in 2011. Thirdquarter 2011 revenue gains were reported at \$10.4 million, versus \$8.0 million in the previous year's period. License and research revenues amounted to \$2.7 million compared to \$4.1 million during the third quarter of 2010. Product sales and services during 3Q 2011 were \$5.2 million, and included the impact of the supply agreement with an effective date of January 1, 2011, versus \$1.8 million in the third quarter 2010. Other revenues during the third quarter of 2011, composed primarily of royalties on the sale of **Coreg CR** to GlaxoSmithKline, were \$2.5 million versus \$2.1 million in the prior-year period.

Stephen H. Willard, Flamel's chief executive officer, commented, "We are very pleased to have come to an agreement with GSK on a new Coreg CR microparticle supply contract. While the negotiations were lengthy, we believe we achieved an excellent result for both parties. This agreement was a primary driver of our profitability this past quarter and increases our expectations for the continued sales of this product."

CATALENT PHARMA SOLUTIONS INC.

Catalent Pharma Solutions serves thousands of large and small innovators in more than 100 markets, including 36 of the top 50 biotech companies and 49 of the leading 50 pharma companies. Its intellectual property in oral, injectable, and respiratory dosage forms and advanced drug packaging includes more than 1,200 patents and patent applications.

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has 75 years of experience in the industry. Catalent helps clients get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions.

For its fiscal-year 2011 the company generated more than \$1.6 billion in revenue. Also during 2011, Somerset, N.J.based Flamel became a new member of the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS). This is the industry's leading scientific consortium for the development of standards and regulations to enhance the availability of quality, safe and efficacious drug products for patients.

Dean McKinney, Catalent's VP of Pul-

monary and Nasal Development, stated, "We have a strong history in inhalation built around our talented team of scientists, who have experience gained from supporting numerous inhaled products and dosage forms available on the market today. It is this talent and experience we hope to share with the industry at large for the advancement of patient treatments through active participation in IPAC-RS."

CIMA LABS INC.

CIMA specializes in orally disintegrating tablet, oral transmucosal and oral powder drug-delivery technologies. In addition, CIMA has expertise in taste-masking and customized release profiles.

CIMA has functioned as an independent business unit of **Cephalon** Inc. Cephalon is an international biopharmaceutical company dedicated to the discovery, development, and marketing of innovative products to treat human diseases. Cephalon focuses on four core therapeutic areas: central nervous system disorders, pain, cancer, and addiction. During 2011, Cephalon was acquired by **Teva Pharmaceutical Industries** Ltd.

CIMA has commercialized more than 20 products in 70-plus countries around the world. The company is based in Brooklyn Park, Minn.

SAGENT PHARMACEUTICALS INC.

Sagent Pharmaceuticals of Schaumburg, Ill., experienced a productive 2011. In the third quarter, the company launched six new products including generic **levofloxacin** in pre-mixed bags, **gemcitabine** at patent expiration and **paclitaxel**, a critical oncology product on the FDA drug shortage list.

Such product launches increased revenue 94% to \$41.3 million. Gross profit increased to \$6.9 million.

Sagent received the 2011 North American Frost & Sullivan Award for Product Quality Leadership for Sagent's **PreventIV Measures** (SM) packaging and labeling system used in the heparin product line.

"I am very pleased with the growth we achieved during the quarter, nearly doubling our gross margin percentage from the second quarter," said Jeffrey M. Yordon, CEO, founder, and chairman of the board of Sagent. "We expect to continue our revenue and gross margin momentum in the fourth quarter, while focusing on the launch of 40 additional products, which are represented by 75 ANDAs that have been recently approved or are pending approval by the FDA."

NOVAGALI PHARMA SA

Founded in 2000, Novagali of Evry, France, is a pharmaceutical company that develops ophthalmic innovative products for all segments of the eye. Due to Novagali's three proprietary technology platforms, the company has an advanced portfolio of highly innovative products. One of them is on the market and two are undergoing Phase III clinical trials.

For the 3rd quarter of 2011, Novagali Pharma's earnings – reflecting sales of **Cationorm** – totaled 199,000 euros, up more than 24% compared to the 3rd quarter of 2010. This pursuance in sales growth is associated with the upramping of sales in countries where the product was already marketed. Total revenue was 636,000 euros over the prior-year same quarter, an increase of 3.8%.

In October Japanese pharmaceutical

leader Santen Pharmaceutical Co. Ltd. and Novagali Pharma announced Santen's acquisition of 50.55% of Novagali Pharma's capital. As a result of this acquisition, Santen will table a mandatory takeover bid with the AMF for the remaining shares and securities it does not yet hold. This offer would be followed by the delisting of the remaining Novagali Pharma shares, assuming that Santen holds at least 95% of Novagali Pharma's capital and voting rights after the takeover offer.

PEARL THERAPEUTICS INC.

Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease. Pearl's current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers.


The privately held company based in Redwood City, Calif., is finding positive results with its Phase IIb study (NCT01085045) demonstrating that the dual bronchodilator combination product **PT003** (GFF MDI) provides superior inspiratory capacity (IC) compared to **Spiriva HandiHaler**.

PT003 is an inhaled, fixed-dose combination bronchodilator product comprising a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) delivered via a metereddose inhaler (HFA MDI). The company additionally is developing a triple-combination product that combines the LAMA and LABA components of PT003 with an inhaled corticosteroid (ICS) for twicedaily administration from an HFA MDI for the treatment of severe COPD.

Both products are being developed using Pearl's proprietary porous particle cosuspension technology. This technology allows the formulation of multiple products in the MDI format, with highly stable, robust and aerodynamically efficient drug delivery.

ACURA PHARMACEUTICALS INC.

Palatine, Ill.-based Acura is a specialty pharma company focused on the R&D and commercialization of product candidates meant to address medication use and misuse via its **AVERSION** and **IM-PEDE** technologies. During June 211, FDA cleared for marketing the first prod-



uct using the AVERSION technology. Acura also has a development pipeline of other AVERSION technology products such as additional opioids, stimulants, and benzodiazepines along with the IM-PEDE technology for pseudoephedrine hydrochloride products.

The company reported a net loss of \$2.1 million for the third quarter of 2011, compared to a net loss of \$2.6 million the previous year's third quarter. The company generated \$20.5 million in revenue for the first nine months of 2011, an increase from the first nine months in 2010. Acura attributes the gains to a \$20 million payment from Pfizer as a result of the FDA's approval of a new drug application for **OXECTA**.

"We are making progress in our strategy to leverage Acura's proprietary technology platforms to develop products intended to address medication abuse and misuse," says Bob Jones, president and CEO. "The abuse and misuse of opioids and other medications is a serious public health and safety issue and we believe that the products developed through our AVERSION and IMPEDE technology platforms can be part of the solution."

BIODELIVERY SCIENCES INTERNATIONAL INC.

BioDelivery Sciences is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drugdelivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.

In 2011, BDSI completed a Phase III clinical study of **BEMA Buprenorphine** for the treatment of moderate-to-severe chronic pain in a mixed opioid naive and opioid experienced population.

"We witnessed a high placebo response in the opioid naive segment of our patient population, particularly at our starting dose, which accounted for the overall lack of efficacy that was observed in this trial," explains Andrew Finn, Ph.D., executive vice president of product development at BDSI. "This group of patients, who are not accustomed to taking opioids and prone to higher placebo effects, accounted for nearly two-thirds of the total study population. When we eliminate the BEMA Buprenorphine starting dose from the analysis, where the greatest placebo response occurred, particularly in the opioid naive group, we achieved a pain score difference between BEMA Buprenorphine and placebo that approached statistical significance (p=0.066). This starting dose 'phenomenon' is not dissimilar to what has been observed with other approved opioids."

"While there is disappointment over missing the primary efficacy endpoint of this study, the many positive findings we observed gives us great confidence in our ability to ultimately bring this product to market for the treatment of chronic pain in a variety of patient types," adds Dr. Mark A. Sirgo, president and chief executive officer of Raleigh, N.C.-based BDSI.

BDSI's **ONSOLIS** (fentanyl buccal soluble film) is approved in the United States, Canada, and the European Union (where the product is marketed as **BREAKYL**) for the management of breakthrough pain in opioid-tolerant adult patients with cancer.



BEMA Products	Formulation Development	Phase I	Phase II	Phase III	NDA Submission*	Marketed
ONSOLIS^{®**} fentanyl buccal soluble film) Breakthrough Cancer Pain				•		
BEMA® Buprenorphine/ Naloxone Treatment of Opioid Dependence				Pivotal Bioequivalence Study 1Q 2012	Target: 1Q 2013	
BEMA [®] Buprenorphine Moderate to Severe Chronic Pain					Target : 1H 2013	
BEMA [®] Granisetron						
BEMA [®] "Triptan"						
Anticipated submission date. Marketed in the U.S. by Meda Pharmaceuticals	: :					BioDeliver Sciences Internatio

20

DUSA PHARMACEUTICALS INC.

Dusa is a dermatology company that is developing and marketing **Levulan Photodynamic Therapy** (PDT) and other products focused on patients with common skin conditions. Dusa is based in Wilmington, Mass.

Total product revenues for the company's nine-month period ended September 30, 2011, were \$30.3 million, an increase of \$4.9 million, or 19%, from \$25.4 million in the comparable prior-year period. PDT revenues totaled \$30.0 million, an increase of \$5.5 million, or 22%, from \$24.5 million for the comparable 2010 period. The increase in PDT revenues was attributable to a \$5.3 million increase in **Kerastick** revenues.

Levulan Kerastick for topical solution plus Dusa's **BLU-U Blue Light Photodynamic Therapy Illuminator** is approved for the treatment of minimally to moderately thick actinic keratoses of the face or scalp. Dusa also sells other dermatology products, including **ClindaReach**.

During the third quarter of 2011, the company terminated its agreement with Daewoong Pharmaceutical Co. Ltd. and DNC Daewoong Derma & Plastic Surgery Network Co. for the Levulan Kerastick in Korea and other Asia-Pacific countries. The termination resulted in the recognition of \$1.4 million of deferred revenues and \$1.3 million in income from operations, which positively impacted both the company's GAAP and non-GAAP results for the third quarter of 2011.

ACCESS PHARMACEUTICALS INC.

Access Pharmaceuticals is a biopharmaceutical company based in Dallas leveraging its proprietary drug-delivery platforms to develop treatments in the areas of oncology, cancer supportive care and diabetes.

Access' products include **MuGard**, which received FDA marketing clearance for the management of patients with mucositis; **ProLindac**, a second-generation DACH Platinum in Phase II clinical testing of patients with ovarian cancer; and **Thiarabine**, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers. Thiarabine is undergoing a Phase I/IIa clinical trial in hematological malignancies at the **M.D. Anderson Cancer Center** in Houston.

Throughout the third quarter of 2011,


Access made significant progress in increasing reimbursement for MuGard. MuGard continued receiving reimbursement from many networks of leading insurance companies and pharmacy benefit managers, including **Group Health** Inc. (GHI), **TRICARE**, **Harvard Pilgrim**, **Humana** and **Express Scripts**. Reimbursement has more than doubled and now includes several more payers.

Clinicians prescribing MuGard continue to provide feedback and anecdotal evidence of positive clinical experiences. More than 700 clinicians have prescribed MuGard for their patients and over 75% of these doctors are recurring prescribers.

ACRUX LTD.

Acrux is an Australian drug-delivery company developing and commercializing a range of patient-preferred, patented pharmaceutical products for global markets. The company uses its innovative technology to administer drugs through the skin.

For Acrux's fiscal year ended June 30, 2011, the company recorded a profit of \$57 million, resulting in earnings of 35 cents per share, up from 29 cents in the



prior year. The result was driven by revenue of \$93 million, including a milestone payment of \$87 million from Eli Lilly after the FDA issued a marketing authorization for **Axiron** in November 2010.

In April 2011, Acrux paid a special dividend to shareholders of 60 cents per share, or approximately \$100 million. After distributing surplus cash in the special dividend, Acrux retained cash reserves of \$33 million as of June 30, 2011. The testosterone therapy market in the United States continues to grow strongly, with sales in 2010 up 29% versus the prior year to \$1.3 billion.

Axiron was launched into the market by Lilly in April 2011. Uptake by patients has been strong; four months after launch, Axiron's share had grown to 22.3% of New to Brand Prescriptions and 6.1% of Total Prescriptions.

"Acrux is pleased to have delivered a profit of \$57 million and a first dividend of 60 cents per share," commented Acrux CEO Richard Treagus. "We are encouraged by the uptake of Axiron so far in the United States and look forward to continuing to deliver shareholder value."

ACUSPHERE INC.

Acusphere is a specialty pharmaceutical company primarily focused on the development of **Imagify**, a cardiovascular drug for the detection of coronary artery disease. Acusphere is in the process of seeking regulatory approval of Imagify in Europe, and negotiating a Special Protocol Assessment with FDA for an additional clinical trial required for U.S. approval.

In 2010, the Lexington, Mass.-based company secured \$10 million in financing to develop Imagify. In 2011, Acusphere worked with the FDA on a design for its Phase III clinical study of the drug. The study will compare stress ultrasound with Imagify to stress ultrasound without Imagify for the detection of coronary artery disease.

The company expects the study to cost \$15 million and take two years to complete, based upon enrollment of 900 patients.

AKELA PHARMA INC.

Akela Pharma is a drug-development company with its lead product **Fentanyl TAIFUN** being developed for the treatment of breakthrough cancer pain. Fentanyl TAIFUN is a fast-acting fentanyl formulation delivered using the company's TAIFUN multi-dose dry-powder inhaler platform. Akela's pipeline also includes a growth hormone releasing hormone (GHRH), which is being developed for frailty and wasting in chronic renal disease.

Its pharmaceutical contract manufacturing business, **PharmaForm**, has accounted for much of the company's success in the past year. PharmaForm enabled Akela to become profitable in 2010 and has continued to grow profitably, quarter over quarter, generating nearly \$1 million in net income during the first quarter of 2011.

Akela intends to focus on Pharma-Form's business through business-development initiatives, the addition of specialty commercial manufacturing services, expansion of capacity and – as opportunities arise – expansion through targeted acquisitions of niche, formulation and manufacturing businesses.

In 2011, Akela also regained the product rights to Fentanyl TAIFUN in Japan from **Teikoku Seiyaku** Co. Akela will no longer invest in the Fentanyl TAIFUN program and is actively seeking buyers for the project.

ALKERMES INC.

Alkermes is a leader in innovative medicines that address the unmet needs and challenges of people living with debilitating diseases. The company is designing innovative treatments for major clinical conditions specifically focused on central nervous system (CNS) disorders such as schizophrenia, addiction and depression.

The Dublin, Ireland-based company boasts a product portfolio that includes more than 20 products on the market; five key commercial products to treat MS, schizophrenia, bipolar disorder, opioid dependence, and type 2 diabetes; and a substantial and growing pipeline of product candidates in clinical development.

In September 2011, Alkermes merged with **Elan Drug Technologies**. As of Sept. 30, 2011, Alkermes had \$1.5 billion in total assets – reflecting the combination of Alkermes and Elan – compared with total assets of Alkermes Inc. on March 31, 2011, of \$452.4 million.

For the company's fiscal-year 2012, which ends in March 2012, Alkermes expects total revenues to range from \$350 million to \$380 million, up from a previous range of \$205 million to \$229 million.

"This quarter marks the beginning of a new phase of growth for Alkermes, as we begin to realize the financially transformative effects of the EDT transaction," comments Richard Pops, CEO of Alkermes. "We are now fully executing on our strategy to build Alkermes for growth in both the near- and long-term. In the near-term, we will see the growth in revenues from the expansion of our portfolio of commercial products. Over the long-term, we will realize the value of our advancing pipeline of new drug candidates.

AlphaRx In Brief

- A small publicly traded specialty pharma focusing on difficult to treat indications.
- Drug delivery: reformulating well known and marketed drugs using site specific drug delivery technology. Changing biodistribution of drug in human body, as a result, better efficacy, less side effects, shorter development time.
- 1 topical NSAID completed Phase II Proof of Concept study targeting Osteoarthritis of the knee. 4 product candidates in preclinical stage with major market opportunities.
- Revenues generated from royalties, licensing fees and R&D income.

Source: AlphaRx

"We are committed to our vision of building Alkermes ple as a global leader in the development of innovative products for a broad range of CNS diseases for the benefit of patients and healthcare systems around the world."

ALPHARX INC.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating marketed drugs. Through application of the company's proprietary site-specific nano drugdelivery technology, the reformulated products offer improved medical benefits and a potential for significant commercial product development.

AlphaRx of Hong Kong, China, is developing and commercializing **Indaflex** and **ARX8203** internally for the pain market. With Indaflex, the company takes in royalties of \$10,000 monthly, which is increasing to \$15,000. The company is reviewing options to make the product available in Europe, which it projects will bring in an additional \$12 million.

ARX8203 is a therapy for gout. The company is looking to conduct an efficacy and safety trial on 90 gout patients.


Another potential blockbuster is GAI-122 for the Chinese market. China reportedly has more patients with stroke than anywhere else in the world. The total market potential for GAI-122 in China is \$1.68 billion. GAI-122 is being developed by AlphaRx's partner, Gaia BioPharma, under a licensing agreement.

BIOJECT MEDICAL TECHNOLOGIES INC.

Bioject Medical Technologies is a developer of needle-free drug-delivery systems based out of Portland, Ore.

Bioject reported third-quarter 2011 revenue of \$3.1 million, compared to revenue of \$1.5 million in the comparable 2010 period. For the nine-month period ended September 30, 2011, Bioject reported revenue of \$7.3 million compared to revenue of \$3.9 million in the comparable period of 2010. However, projected revenues for the company were not optimistic, according to management.

"Unfortunately we have to report a mixed message," stated Ralph Makar, Bioject's president and CEO. "Third quarter 2011 revenue increased 107%



over the same prior year-ago time period. Our significant revenue growth resulted from the shipment of the remaining additional one-time orders to Merck Serono and increased sales to **Merial**. In addition, both operating and net income were positive for the third quarter of 2011 as compared to the negative results of the prior year-ago time period."

"However, these positive results are only temporary. There are no additional Serono orders to fill. The increased Merial orders for their launch have been met, and Merial's order forecast is dramatically lower."

QLT INC.

QLT is an ocular-focused company. QLT is dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide.

For the third quarter, total revenue of \$9.6 million was up 11.6% from the third quarter of 2010, primarily because the quarter included \$2 million related to a shipment of **Visudyne** for the treatment of wet age-related macular degeneration to Novartis.

QLT expected annual U.S. Visudyne sales to be in the range of \$20 million to \$22 million, compared with the original 2011 guidance of \$23 million to \$26 million. Visudyne sales in the United States through the first nine months of 2011 were \$15.6 million.

The Vancouver, Canada-based company is working on drug-delivery systems for glaucoma, age-related retinal diseases and hereditary blindness as well as other conditions.

NOVO NORDISK A/S


Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. With headquarters in Denmark, Novo Nordisk markets products in 179 countries.

The company's sales growth of 11% during January-September 2011 was attributed to the diabetes drugs **Victoza**, **NovoRapid** and **Levemir**. Sales in North America increased 17% in the first nine months of 2011. Sales in International Operations grew 16%.

Novo Nordisk expects to end 2011 with sales growth of 10-11% (previously projected at 9-11%), and operating profit growth measured in local currencies was anticipated to be 17-19% (previously fore-casted at 15-19%).

The preliminary outlook for 2012 indicates high single-digit sales growth and operating profit growth of close to 10%. The outlook is associated with unusual uncertainty given the challenging financial situation in major countries around the world. The outlook for operating profit furthermore reflects costs

Diversified and Mature Development Pipeline Multiple Products and Partnerships to Drive Value



related to the expected market launch of **Degludec**.

Lars Rebien Sørensen, president and CEO of Novo Nordisk, stated, "We are pleased to see our key products, NovoRapid, Levemir and Victoza, continue to drive strong underlying sales growth. The filing of our new-generation insulins, ultra-long-acting Degludec and **DegludecPlus**, in the US and Europe is a major milestone in the expansion of our leadership in diabetes care."

DURECT CORP.

Durect is a drug-delivery technology company focused on developing proprietary products in chronic care areas. Durect's approach minimizes development risk and maximizes speed to market to expand technology platforms through internal work and acquisitions, and optimizes and enables the development of biotech products.

Durect's injectable, implantable and micro-catheter-based technologies allow for site-specific delivery of drugs while reducing drug degradation, a current obstacle with the delivery of protein and peptides. Additionally, Durect has acquired technologies to expand the breadth of its drug-delivery capabilities into injectable, transdermal and oral dosage forms. Durect believes that its technologies have the potential to make significant impacts in the treatment of chronic debilitating diseases and may in the future enable biotechnology drugs to reach the marketplace in a superior dosage form.

As of September 30, 2011, the Cupertino, Calif.-based company had cash and investments of \$35.1 million, compared to cash and investments of \$37.5 million as of June 30, 2011, and \$49.6 million at December 31, 2010.

"We completed enrollment in our pivotal Phase III trial for **POSIDUR** (BESST) in the third quarter, expect to have topline data in the fourth quarter of this year and, assuming positive data, we expect to submit the New Drug Application in the first half of 2012," according to James E. Brown, D.V.M., president and CEO of Durect. "In July, as a culmination of a multi-year feasibility effort with Zogenix, DURECT added an antipsychotic development program to our pipeline. In addition, we continue to support an experienced team at Pfizer in resolving the remaining issues related to **REMOXY**."

NOVADEL PHARMA INC.

NovaDel is a specialty pharmaceutical company that is developing oral spray formulations for a broad range of marketed therapeutics. The company's **NovaMist** technology enables rapid delivery of drugs into the bloodstream, which results in faster onset of action and potential patient benefits in compliance, convenience and safety. NovaDel's most advanced candidates target angina, insomnia and nausea.

The Bridgewater, N.J., company recorded total revenue of \$0.4 million for the first nine months of 2011, compared to \$0.3 million for the first nine months of 2010.

NovaDel Pharma expects current and anticipated cash and cash equivalents to fund operations through December 31, 2011. The company is actively seeking additional funding through equity financing, strategic alternatives or similar transactions. However, the company cannot assure it will be able to obtain additional funding.

A.P. Pharma Highlights

- Lead product candidate, APF530, is long-acting, injectable product for chemotherapy-induced nausea and vomiting (CINV)
 - Incorporates widely used 5HT3 antagonist granisetron (Kytril[®])
 - 5-day delivery profile
 - Reduces both acute- and delayed-onset CINV with single injection
- APF530 shown to be non-inferior to market leader Aloxi[®]
 - 1,341-patient, randomized, controlled, Phase 3 study
 - Presented at ASCO 2009
- Company is addressing issues raised in Complete Response Letter
 - End-of-review meetings held in 1Q 2011
 - Resubmission planned for 1H 2012
- APF530 targets a \$900 million market opportunity in US alone
 Could be second, long-acting, injectable product on market
- A.P. Pharma has pipeline of additional products based on its Biochronomer[™] drug delivery technology

Source: A.P. Pharma



A.P. PHARMA INC.

A.P. Pharma is a specialty pharmaceutical company that is developing products using its proprietary **Biochronomer** polymer-based drug-delivery technology. The company's primary focus is on A.P. Pharma's lead product candidate **APF530**, which is intended for the prevention of chemotherapy-induced nausea and vomiting (CINV).

The Redwood City, Calif., company reported a net loss for the second quarter of 2011 at \$1.9 million, compared with a net loss of \$3.6 million for the second quarter of 2010. The net loss was lower in the fiscal third quarter primarily due to expenses related to the resignation of the company's former chief executive officer during the second quarter of 2010 and \$0.6 million of lower spending in the fiscal third quarter related to the New Drug Application (NDA) resubmission.

In May 2011, A.P. Pharma received notice of termination from Merial Ltd. related to an agreement covering a product under development in the animal health care market. As a result, all remaining deferred revenues under this agreement were substantially recognized in the current fiscal quarter.

A.P. Pharma has additional clinical and preclinical stage programs in the area of pain management, all of which Oral Protein Delivery
• Absorption enhancers (carriers) are the predominant delivery systems used in the industry
Intestinal Lumen

A: Passive Transcellular Pathway
B: Passive Paracellular Pathway (through tight junctions)
C: Active Transport

use its bioerodible injectable and implantable delivery systems.

EMISPHERE TECHNOLOGIES INC.

Emisphere Technologies develops oral forms of injectable drugs or poorly absorbed compounds.

For the first nine months of 2011, Emisphere of Cedar Knolls, N.J., reported a net loss of \$4.8 million. For the third quarter of the year, Emisphere reported a net loss of \$17.6 million.

Promising marquee products in the pipeline include an improved formulation of oral Vitamin B12, oral calcitonin for osteoarthritis and osteoporosis (in Phase III development with **Novartis** **Pharma** AG), and oral GLP-1 and GLP-1 analogs for Type 2 diabetes (with partner Novo Nordisk).

Emisphere is developing an oral formulation of Eligen B12 (1,000 mcg) for use by B12-deficient individuals. On August 5, 2011, Emisphere received notice from the U.S. Patent Office that the U.S. patent application directed to the oral Eligen B12 formulation was allowed. This new patent provides intellectual property protection for Eligen B12 in the United States through 2029.

Results of the product's clinical trials and market research are being evaluated and the company is exploring alternative development and commercialization options.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Abstral	Sublingual fentanyl	Abstral is intended for the treatment of breakthrough cancer pain.	Narcotic analgesic	Africa	NewBridge Pharmaceuticals
Afrezza	Insulin	Afrezza is intended for the treatment of type 1 diabetes.	Insulin	United States	MannKind Corp.
Afrezza	Insulin	Afrezza is intended for the treatment of type 2 diabetes.	Insulin	United States	MannKind Corp.
Androderm 2nd Generation	Testosterone	Androderm 2nd Generation is intended for testosterone replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone, such as primary hypogonadism and secondary hypogonadism.	Hormone therapy	United States	Watson Pharmaceuticals Inc.
Anturol	Oxybutynin	Anturol is intended for the treatment of overactive bladder.	—	United States	Watson Pharmaceuticals Inc.
APF530	Granisetron	APF530 is intended for the prevention of acute and delayed chemotherapy- induced vomiting.	5-HT3 receptor antagonist	United States	A.P. Pharma Inc.
Bio-T-Gel	-	Bio-T-Gel is intended for the treatment of hypogonadism in men.	Hormone therapy	United States	BioSante Pharmaceuticals Inc.
Bonalfa (TV-02H)	Tacalcitol monohydrate	Bonalfa (TV-02H) is intended for the treatment of psoriasis vulgaris.	Active vitamin D3	Japan	Teijin Ltd.
Bronchitol	Mannitol	Bronchitol is intended for the treatment of cystic fibrosis in adults aged 18 years old or older as an add-on therapy to best standard of care.	Osmotic diuretic	European Union	Pharmaxis Ltd.
Bydureon	Exenatide	Bydureon is intended for the treatment of type 2 diabetes.	Glucagon-like peptide-1 receptor agonist	United States	Developer: Amylin Pharmaceuticals Inc., Eli Lilly and Co., and Alkermes plc.; Marketer: Amylin Pharmaceuticals Inc. and Eli Lilly and Co.
Ciclesonide Nasal Aerosol HFA	Ciclesonide	Ciclesonide Nasal Aerosol HFA is intended for the treatment of perennial allergic rhinitis in adult and adolescent patients 12 years old or older.	Glucocorticosteroid	United States	Sunovion Pharmaceuticals Inc.
Ciclesonide Nasal Aerosol HFA	Ciclesonide	Ciclesonide Nasal Aerosol HFA is intended for the treatment of seasonal allergic rhinitis in adult and adolescent patients 12 years old or older.	Glucocorticosteroid	United States	Sunovion Pharmaceuticals Inc.
Concerta	Methylphenidate hydrochloride	Concerta is intended for the treatment of attention deficit hyperactivity disorder in adults.	Central nervous system stimulant	European Union	Developer: Johnson & Johnson Pharmaceutical Research & Development; Marketer: McNeil Pediatrics
Contrave	Bupropion and nattrexone	Contrave is intended for the treatment of obesity.	Dopamine and norepinephrine reuptake inhibitor and opioid antagonist	United States	Developer/Marketer: Orexigen Therapeutics Inc. and Takeda Pharmaceuticals North America Inc.
Duac Low Dose	Clindamycin phosphate and benzoyl peroxide	Duac Low Dose is intended for the topical treatment of acne vulgaris.	Oxidizing agent	United States	Stiefel
Dulera	Momestasone furoate and formoterol fumarate	Dulera is intended for the treatment of chronic obstructive pulmonary disease.	Beta 2 adrenergic agonist and corticosteroid	United States	Merck & Co.
Excellarate	-	Excellarate is intended for the treatment of non-healing, neuropathic diabetic foot ulcers.	-	United States	Tissue Repair Co.
Extended Release Carbinoxamine Oral Suspension	Carbinoxamine	Extended Release Carbinoxamine Oral Suspension is intended for the treatment of allergies in children 2 years old or older.	Antihistamine	United States	Tris Pharma

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Eylea	Aflibercept	Eylea is intended for the treatment of wet age-related macular degeneration.	Vascular endothelial growth factor	United States	Developer: Regeneron Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc.; Marketer: Regeneron Pharmaceuticals Inc.
Eylea	Aflibercept	Eylea is intended for the treatment of wet age-related macular degeneration.	Vascular endothelial growth factor	European Union	Developer: Regeneron Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals; Marketer: Bayer HealthCare Pharmaceuticals
Eylea	Aflibercept	Eylea is intended for the treatment of wet age-related macular degeneration	Vascular endothelial growth factor	Japan	Developer: Regeneron Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals; Marketer: Bayer HealthCare Pharmaceuticals
Fentanyl SL Spray	Fentanyl	Fentanyl SL Spray is intended for the treatment of breakthrough cancer pain.	_	United States	Insys Therapeutics Inc.
Fluenz	Live attenuated influenza vaccine	Fluenz is intended for the prevention of seasonal influenza in children 24 months to less that 18 years old.	Preventive vaccine	European Union	AstraZeneca Pic.
Flutiform	Formoterol and fluticasone	Flutiform is intended for the treatment of asthma in patients 12 years old or older.	_	United States	SkyePharma Plc.
Flutiform	Formoterol and fluticasone	Flutiform is intended for the treatment of asthma.	—	European Union	Mundipharma International Ltd.
Horizant	Gabapentin enacarbil	Horizant is intended for the management of post-herpetic neuralgia in adults.	Voltage-gated calcium channel modulator	United States	GlaxoSmithKline Inc.
lluvien	Fluocinolone acetonide	lluvien is intended for the treatment of diabetic macular edema.	Corticosteroid	United States	Developer/Marketer: Alimera Sciences Inc. and pSivida Ltd.
lluvien	Fluocinolone acetonide	lluvien is intended for the treatment of diabetic macular edema.	Corticosteroid	European Union	Developer/Marketer: Alimera Sciences Inc. and pSivida Ltd.
Imiquimod	Imiquimod	Imiquimod is intended for the treatment of actinic keratosis.	—	Japan	Mochida Pharmaceutical Co.
Immediate Release Oxycodone with Aversion Technology (with Niacin)	Oxycodone hydrochloride	Immediate Release Oxycodone with Aversion Technology (with Niacin) is intended for the treatment of moderate to severe pain.	Mu-type opioid receptor (MOR-1) agonist	United States	Pfizer Inc.
Intermezzo	Zolpidem tartrate	Intermezzo is intended for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep.	Imidazopyridine	United States	Developer: Transcept Pharmaceuticals Inc.; Marketer: Purdue Pharma LP
Ivermectin	Ivermectin	Ivermectin is intended for the treatment of head lice.	Pediculicide	United States	Topaz Pharmaceuticals LLC
Janumet XR	Sitagliptin phosphate and metformin hydrochloride	Janumet XR is intended for the treatment of type 2 diabetes.	Dipeptidyl peptidase-4 inhibitor and biguanide	United States	Merck & Co.
Komboglyze	Saxagliptin hydrochloride and metformin	Komboglyze is intended as an adjunct to diet and exercise, for the treatment of type 2 diabetes in adults who are not adequately controlled on metformin or those already being treated with the combination of saxagliptin and metformin as separate tablets.	Dipeptidyl peptidase IV inhibitor and biguanide	European Union	Developer/Marketer: Bristol-Myers Squilob Co. and AstraZeneca Plc.
KW-0761	Mogamulizumab	KW-0761 is intended for the treatment of adult T-cell leukemia-lymphoma.	Anti-CCR4 humanized monoclonal antibody	Japan	Kyowa Hakko Kirin Pharma Inc.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Levadex	Dihydroergotamine mesylate	Levadex is intended for the treatment of acute migraine headaches.	_	United States	Developer: MAP Pharmaceuticals Inc.; Marketer: MAP Pharmaceuticals Inc. and Allergan Inc.
Lodotra	Prednisone	Lodotra is intended for the treatment of rheumatoid arthritis.	Circadian cytokine modulator	United States	Horizon Pharma Inc.
Long-Acting Oxymorphone HCI	Oxymorphone hydrochloride	Long-Acting Oxymorphone HCl is intended for the relief of chronic pain.	Narcotic analgesic	United States	Endo Pharmaceuticals Inc.
Lucentis	Ranibizumab	Lucentis is intended for the treatment of retinal vein occlusion.	Human antibody fragment	European Union	Novartis Ophthalmics Inc.
Mechlorethamine	Mechlorethamine	Mechlorethamine is intended for the treatment of early-stage cutaneous T-cell lymphoma.	_	United States	Yaupon Therapeutics Inc.
MoxDuoIR	Morphine and oxycodone	MoxDuolR is intended for the treatment of moderate to severe acute pain.	Opioid analgesic	United States	QRxPharma Pty Ltd.
MQX-503	Nitroglycerin	MQX-503 is intended for the treatment and prevention of Raynaud phenomenon disease.	Vasodilator	United States	MediQuest Therapeutics Inc.
MuGard	_	MuGard is intended for the treatment of oral mucositis in cancer patients.	_	China	Developer: Access Pharmaceuticals Inc.; Marketer: Milestone Biosciences LLC
Neupro	Rotigotine	Neupro is intended as adjunctive therapy with levodopa for the treatment of adults with advanced Parkinson's disease.	Dopamine D2 receptor agonist	United States	UCB Inc.
Neupro	Rotigotine	Neupro is intended for the treatment of moderate-to- severe restless legs syndrome.	Dopamine D2 receptor agonist	United States	UCB Inc.
NVA237	Glycopyrronium bromide	NVA237 is intended for the treatment of chronic obstructive pulmonary disease.	Long acting muscarinic antagonist	European Union	Novartis Pharma AG
Ocriplasmin	Microplasmin	Ocriplasmin is intended for the non-surgical treatment of vitreomacular adhesion.	Thrombolytic agent	European Union	ThromboGenics Ltd.
Ondansetron RapidFilm	Ondansetron	Ondansetron RapidFilm is intended for the prevention of nausea and vomiting caused by chemotherapy, radiotherapy and surgery.	Serotonin 5-HT3 receptor antagonist	China	SciClone Pharmaceuticals Inc.
Ondansetron RapidFilm	Ondansetron	Ondansetron RapidFilm is intended for the prevention of nausea and vomiting caused by chemotherapy, radiotherapy and surgery.	Serotonin 5-HT3 receptor antagonist	Vietnam	SciClone Pharmaceuticals Inc.
Pancrecarb	Pancrelipase	Pancrecarb is intended for the treatment of exocrine pancreatic insufficiency.	Enzyme	United States	Digestive Care Inc.
Prochieve	Progesterone	Prochieve is intended to reduce the risk of preterm birth in women with a cervical length between 10 and 20 mm as measured by transvaginal ultrasound at mid- pregnancy.	Progestin	United States	Watson Pharmaceuticals Inc.
QNASL	Beclomethasone diproprionate hydrofluroalkane	QNASL is intended for the treatment of perennial allergic rhinitis.	Corticosteroid	United States	Teva Pharmaceutical Industries Ltd.
QNASL	Beclomethasone diproprionate hydrofluroalkane	QNASL is intended for the treatment of seasonal allergic rhinitis.	Corticosteroid	United States	Teva Pharmaceutical Industries Ltd.
Qnexa	Phentermine and topiramate	Qnexa is intended for the treatment of obesity.	_	United States	Vivus Inc.
Qnexa	Phentermine and	Qnexa is intended for the treatment of obesity.	_	European Union	Vivus Inc.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Remoxy	Oxycodone	Remoxy is intended for the treatment of moderate-to-severe chronic pain.	Mu-type opioid receptor (MOR-1) agonist	United States	Pfizer Inc.
Sancuso	Granisetron	Sancuso is intended for the prevention of side-effects of nausea and vomiting in patients undergoing chemotherapy.	5-HT3 receptor antagonist	European Union	ProStrakan Group Plc.
Sitavir	Acyclovir	Sitavir is intended for the treatment of oral herpes (labial herpes).	-	European Union	BioAlliance Pharma SA
Sublivac	-	Sublivac is intended for the treatment of allergic asthma.	Therapeutic vaccine	Germany	HAL Allergy Group
Sublivac	-	Sublivac is intended for the treatment of allergic conjunctivitis.	Therapeutic vaccine	Germany	HAL Allergy Group
Sublivac	—	Sublivac is intended for the treatment of allergic rhinitis.	Therapeutic vaccine	Germany	HAL Allergy Group
Tazarotene	Tazarotene	Tazarotene is intended for the treatment of acne vulgaris in patients 12 years old or older.	Retinoid	United States	Developer: Stiefel; Marketer: Allergan Inc. and Stiefel
Tobi Podhaler	Tobramycin	Tobi Podhaler is intended for the treatment of pseudomonas aeruginosa infections in patients with cystic fibrosis 6 years old or older.	Aminoglycoside antibiotic	European Union	Novartis Pharma AG
Vitaros	Alprostadil	Vitaros is intended for the treatment of erectile dysfunction.	Prostaglandin E1 vasodilator	United States	Apricus Biosciences Inc.
Vitaros	Alprostadil	Vitaros is intended for the treatment of erectile dysfunction.	Prostaglandin E1 vasodilator	European Union	Apricus Biosciences Inc.
Xerclear	Chlorhexidine	Xerclear is intended for the treatment of labial herpes (cold sores).	Antiviral	South Korea	Developer: Medivir AB; Marketer: Daewoong Pharmaceutical Co.
Zelrix	Sumatriptan	Zelrix is intended for the treatment of acute migraine.	—	United States	NuPathe Inc.
Zyclara	Imiquimod	Zyclara is intended for the treatment of actinic keratosis.	Toll-like receptor 7 agonist	European Union	Meda AB

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Aeroquin	Levofloxacin	Aeroquin is intended for the treatment of treatment of pulmonary infections due to Pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis.	Fluoroquinolone antibiotic	United States	Mpex Pharmaceuticals Inc.
AG200-15	Levonorgestrel and ethinyl estradiol	AG200-15 is intended for the prevention of pregnancy.	Contraceptives	United States	Agile Therapeutics Inc.
AG0178	Agomelatine	AGO178 is intended for the treatment of major depressive disorder.	Melatonin receptor (M1 and M2) agonist and 5-HT2C antagonist	United States	Novartis Pharmaceuticals Corp.
AN2690	-	AN2690 is intended for the treatment of onychomycosis infection.	Antifungal	United States	Anacor Pharmaceuticals Inc.
Arikace	Liposomal amikacin	Arikace is intended for the treatment of Pseudomonas aeruginsa lung infections in children from birth to 18 years of age with cystic fibrosis.	Antibiotic	European Union	Insmed Inc.
Aza Acid Foam	_	Aza Acid Foam is intended for the treatment of rosacea.	_	European Union	Intendis GmbH
Aztreonam	Aztreonam	Aztreonam is intended for the treatment of Burkholdemia cepacia infection in patients with cystic fibrosis.	Monobactam antibiotic	United States	Gilead Sciences Inc.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
BEMA Buprenorphine	Buprenorphine	BEMA Buprenorphine is intended for the treatment of moderate to severe chronic pain.	Partial mu-opiate receptor agonist	United States	BioDelivery Sciences International Inc.
BromSite	_	BromSite is intended for the treatment of pain and swelling associated with ocular surgery.	_	United States	InSite Vision Inc.
Bronchitol	Mannitol	Bronchitol is intended for facilitating mucus clearance in patients with cystic fibrosis.	Osmotic diuretic	United States	Pharmaxis Ltd.
Bronchitol	Mannitol	Bronchitol is intended for the treatment of bronchiectasis.	Osmotic diuretic	United States	Pharmaxis Ltd.
Bronchitol	Mannitol	Bronchitol is intended for the treatment of bronchiectasis.	Osmotic diuretic	European Union	Pharmaxis Ltd.
CD07805/47	—	CD07805/47 is intended for the treatment of rosacea.	—	United States	Galderma Laboratories LP
Ciclesonide HFA	Ciclesonide	Ciclesonide HFA is intended for the treatment of allergic rhinitis.	Glucocorticosteroid	European Union	Nycomed Group
Cogenzia	Gentamicin	Cogenzia is intended for the prevention of infection in diabetic foot ulcers.	-	United States	Innocoll Inc.
Cogenzia	Gentamicin	Cogenzia is intended for the treatment of infection in diabetic foot ulcers.	-	United States	Innocoll Inc.
COL-003	Oxycodone	COL-003 is intended for the treatment of chronic low back pain.	Opioid analgesic	United States	Collegium Pharmaceutical Inc.
CollaRx Gentamicin Surgical Implant	Gentamicin	CollaRx Gentamicin Surgical Implant is intended for the prevention of surgical site infections in patients who are at higher risk of infections.	Aminoglycoside antibiotic	United States	Developer: Innocoll Inc.; Marketer: Baxter Healthcare Corp.
Crinone	Progesterone	Crinone is intended for the prevention of preterm birth.	Progestin	United States	Watson Pharmaceuticals Inc.
CVBT-141B	_	CVBT-141B is intended for the treatment of ischemic diabetic wounds.	Human fibroblast growth factor-1 (FGF-1)	United States	CardioVascular BioTherapeutics Inc.
Cyclokat	Cyclosporine A	Cyclokat is intended for the treatment of moderate to severe dry eye syndrome.	-	United States	Novagali Pharma
Cyclokat	Cyclosporine A	Cyclokat is intended for the treatment of moderate to severe dry eye syndrome.	_	European Union	Novagali Pharma
Cymbalta	Duloxetine hydrochloride	Cymbalta is intended for the treatment of prediatric depression.	Serotonin and norepinephrine reuptake inhibitor	United States	Eli Lilly and Co.
Duodopa	Levodopa and carbidopa	Duodopa is intended for the treatment of advanced Parkinson's disease.	DOPA decarboxylase inhibitor and dopamine prodrug	United States	Abbott Laboratories
E6014	Glutamine	E6014 is intended for the treatment of oral mucositis in patients receiving mucotoxic cancer therapy.	_	United States	Eisai Inc.
EGP-437	Dexamethasone phosphate	EGP-437 is intended for the treatment of dry eye.	Corticosteroid	United States	EyeGate Pharmaceuticals Inc.
ELI-154	Oxycodone	ELI-154 is intended for the treatment of pain.	Narcotic analgesic	United States	Elite Pharmaceuticals Inc.
ELI-216	Oxycodone hydrochloride	ELI-216 is intended for the treatment of opioid abuse.	-	United States	Elite Pharmaceuticals Inc.
Elidel	Pimecrolimus	Elidel is intended for the treatment of atopic dermatitis in infants under 2 years old.	Calcineurin inhibitor	United States	Developer: Novartis Pharmaceuticals Corp.; Marketer: Valeant Pharmaceuticals International Inc.
Eralese	Ingenol mebutate	Eralese is intended for the topical treatment of actinic keratosis.	—	United States	Leo Pharma Inc.
			*		·

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Eylea	Afilbercept	Eylea is intended for the treatment of central retinal vein occlusion.	Vascular endothelial growth factor	United States	Developer: Regeneron Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc.; Marketer: Regeneron Pharmaceuticals Inc.
Eylea	Aflibercept	Eylea is intended for the treatment of central retinal vein occlusion.	Vascular endothelial growth factor	European Union	Developer: Regeneron Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals; Marketer: Bayer HealthCare Pharmaceuticals
Eylea	Aflibercept	Eylea is intended for the treatment of diabetic macular edema.	Vascular endothelial growth factor	European Union	Developer: Regeneron Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals; Marketer: Bayer HealthCare Pharmaceuticals
Eylea	Aflibercept	Eylea is intended for the treatment of diabetic macular edema.	Vascular endothelial growth factor	Japan	Developer: Regeneron Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals; Marketer: Bayer HealthCare Pharmaceuticals
Eylea	Aflibercept	Eylea is intended for the treatment of diabetic macular edema.	Vascular endothelial growth factor	Australia	Developer: Regeneron Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals; Marketer: Bayer HealthCare Pharmaceuticals
Eylea	Aflibercept	Eylea is intended for the treatment of myopic choroidal neovascularization.	Vascular endothelial growth factor	European Union	Developer: Regeneron Pharmaceuticals Inc. and Bayer HeolthCare Pharmaceuticals; Marketer: Bayer HealthCare Pharmaceuticals
Eylea	Aflibercept	Eylea is intended for the treatment of patients with choroidal neovascularisation of the retina as a result of pathologic myopia.	Vascular endothelial growth factor	Japan	Developer: Regeneron Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals; Marketer: Bayer HealthCare Pharmaceuticals
Eylea	Aflibercept	Eylea is intended for the treatment of patients with choroidal neovascularisation of the retina as a result of pathologic myopia.	Vascular endothelial growth factor	China	Developer: Regeneron Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals; Marketer: Bayer HealthCare Pharmaceuticals
Eylea	Aflibercept	Eylea is intended for the treatment of patients with choroidal neovascularisation of the retina as a result of pathologic myopia.	Vascular endothelial growth factor	Taiwan	Developer: Regeneron Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals; Marketer: Bayer HealthCare Pharmaceuticals
FC Patch Low	Ethinyl estradiol and gestodene	FC Patch Low is intended for the prevention of pregnancy.	Contraceptives	United States	Bayer HealthCare Pharmaceuticals Inc.
FC Patch Low	Ethinyl estradiol and gestodene	FC Patch Low is intended for the prevention of pregnancy.	Contraceptives	European Union	Bayer HealthCare Pharmaceuticals
Femprox	Alprostadii	Femprox is intended for the treatment of female sexual arousal disorder.	Prostaglandin E1 vasodilator	United States	Apricus Biosciences Inc.
Fentanyl Taifun	Fentanyl	Fentanyl Taifun is intended for the treatment of breakthrough cancer pain.	Narcotic analgesic	United States	Akela Pharma Inc.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Fentos Tape	Fentanyl citrate	Fentos Tape is intended for the relief of non-malignant chronic pain.	Narcotic analgesic	Japan	Developer: Kyowa Hakko Kirin Co.; Marketer: Kyowa Hakko Kirin Co. and Hisamitsu Pharmaceutical Inc.
Flagyl	Metronidazole	Flagyl 375 is intended for the treatment of bacteria vaginosis.	Antiprotozoal	Japan	Shionogi & Co.
FP 1097	_	FP 1097 is intended for the treatment of women suffering from overactive bladder.	_	United States	FemmePharma Global Healthcare Inc.
FP 1097	-	FP 1097 is intended for the treatment of women suffering from urinary incontinence.	-	United States	FemmePharma Global Healthcare Inc.
HOB-294	Oxybutynin hydrochloride	HOB-294 is intended for the treatment of overactive bladder.	-	Japan	Hisamitsu Pharmaceutical Inc.
HTU-520	Terbinafine hydrochloride	HTU-520 is intended for the treatment of onychomycosis.	-	Japan	Hisamitsu Pharmaceutical Inc.
IDP 108	_	IDP 108 is intended for the treatment of fungal infection.	-	United States	Valeant Pharmaceuticals International Inc.
Intuniv	Guanfacine hydrochloride	Intuniv is intended for the treatment of attention deficit hyperactivity disorder.	Selective alpha-2A- adrenergic receptor agonist	European Union	Shire Plc.
Invega	Paliperidone palmitate	Invega is intended for the treatment of schizophrenia in adolescent.	Benzisoxazole derivative	European Union	Developer: Johnson & Johnson Pharmaceutical Research & Development; Marketer: Janssen Pharmaceuticals Inc.
IPX066	Carbidopa and levodopa	IPX066 is intended for the treatment of Parkinson's disease.	-	United States	Impax Laboratories Inc.
IPX066	Carbidopa and levodopa	IPX066 is intended for the treatment of Parkinson's disease.	_	European Union	Developer: GlaxoSmithKline Plc. and Impax Laboratories Inc.; Marketer: GlaxoSmithKline Plc.
ITM-014	Lanreotide acetate	ITM-014 is intended for the treatment of acromegaly.	Somatostatin analog	Japan	Teijin Ltd.
Ketotransdel	Ketoprofen	Ketotransdel is intended for the treatment of acute pain.	Non-steroidal anti- inflammatory drug	United States	Transdel Pharmaceuticals Inc.
KRP-108	-	KRP-108 is intended for the treatment of asthma.	Beta-3 agonist	Japan	Kyorin Pharmaceutical Co.
KW-2246	Fentanyl citrate	KW-2246 is intended for the treatment of cancer pain.	Opioid receptor agonist	Japan	Kyowa Hakko Kirin Co.
LCS	-	LCS is intended for prevention of pregnancy.	Contraceptives	European Union	Bayer HealthCare Pharmaceuticals
Levomilnacipran	Levomilnacipran	Levomilnacipran is intended for the treatment of depression.	Norepinephrine and serotonin reuptake inhibitor	United States	Forest Laboratories Inc.
Levomilnacipran	Levomilnacipran	Levomilnacipran is intended for the treatment of major depressive disorder.	Norepinephrine and serotonin reuptake inhibitor	Canada	Forest Laboratories Inc.
Lialda	Mesalamine	Lialda is intended for the treatment of diverticulitis.	Aminosalicylate	United States	Shire US Inc.
LibiGel	Testosterone	LibiGel is intended for the treatment of female sexual dysfunction, specifically hypoactive sexual desire disorder in naturally menopausal women and surgically menopausal women.	Hormone therapy	United States	BioSante Pharmaceuticals Inc.
LibiGel	Testosterone	LibiGel is intended for the treatment of myocardial infarction and stroke in women with female sexual dysfunction 50 years of age or older.	Hormone therapy	United States	BioSante Pharmaceuticals Inc.
Liraglutide	Liraglutide	Liraglutide is intended for the treatment of obesity in non- diabetic patients.	Glucagon-like peptide-1	European Union	Novo Nordisk AS

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Livatag	Doxorubicin	Livatag is intended for the treatment of hepatocellular carcinoma.	-	European Union	BioAlliance Pharma SA
Lixiana	Edoxaban	Lixiana is intended for the prevention of stroke in atrial fibrillation.	Factor Xa inhibitor	United States	Daiichi Sankyo Inc.
Lixiana	Edoxaban	Lixiana is intended for the prevention of stroke in atrial fibrillation.	Factor Xa inhibitor	European Union	Daiichi Sankyo Co.
Lixiana	Edoxaban	Lixiana is intended for the treatment and prevention of recurrent venous thromboembolism.	Factor Xa inhibitor	European Union	Daiichi Sankyo Co.
Lixiana	Edoxaban	Lixiana is intended for the treatment and prevention of recurrent venous thromboembolism.	Factor Xa inhibitor	Japan	Daiichi Sankyo Co.
Locilex	Pexiganan acetate	Locilex is intended for the treatment of diabetic foot ulcers.	Antimicrobial peptide	United States	Dipexium Pharmaceuticals LLC
Marqibo	Vincristine sulfate	Marqibo is intended for the treatment of adult patients in relapsed Philadelphia chromosome negative acute lymphoblastic leukemia.	Vinca alkaloid	United States	Talon Therapeutics Inc.
MEDI-3250	Live, attenuated, influenza virus vaccine (quadrivalent)	MEDI-3250 is intended for the prevention of seasonal influenza.	Preventive vaccine	United States	MedImmune Inc.
Melphalan	Melphalan	Melphalan is intended for the treatment of cutaneous melanoma.	Alkylating agent	United States	Delcath Systems Inc.
Melphalan	Melphalan	Melphalan is intended for the treatment of ocular melanoma metastatic to the liver.	Alkylating agent	United States	Delcath Systems Inc.
Mezavant	Mesalazine	Mezavant is intended for the treatment of diverticulitis.	5-aminosalicylic acid	European Union	Shire Plc.
Midazolam	Midazolam	Midazolam is intended for the treatment of epileptic patients who experience episodic seizure clusters, sometimes referred to as acute repetitive seizures.	Benzodiazepine	United States	Upsher-Smith Laboratories Inc.
Misodel	Misoprostol	Misodel is intended for the induction of labor.	—	United States	Cytokine PharmaSciences Inc.
MK-0524A	Niacin and laropiprant	MK-0524A is intended for treatment of atherosclerosis.	Niacin combined with a novel flushing pathway inhibitor	United States	Merck & Co.
MK-3641	-	MK-3641 is intended for the treatment of ragweed allergies.	Therapeutic vaccine	United States	Merck & Co.
MK-7243	Lyophilisate	MK-7243 is intended for the treatment of grass pollen allergies in children and adolescents aged 5 to 17 years old.	Therapeutic vaccine	United States	Merck & Co.
MoxDuoIR	Morphine and oxycodone	MoxDuolR is intended for the treatment of moderate to severe pain.	Opioid analgesic	European Union	QRxPharma Pty Ltd.
MoxDuoIR	Morphine and oxycodone	MoxDuoIR is intended for the treatment of moderate to severe postoperative pain in patients following total knee replacement surgery.	Opioid analgesic	United States	QRxPharma Pty Ltd.
Neupro	Rotigotine	Neupro is intended for the treatment of Parkinson disease.	Dopamine D2 receptor agonist	Japan	Otsuka Pharmaceutical Co.
Neupro	Rotigotine	Neupro is intended for the treatment of restless legs syndrome.	Dopamine D2 receptor agonist	Japan	Otsuka Pharmaceutical Co.
Nucynta ER	Tapentadol hydrochloride	Nucynta ER is intended for the treatment of diabetic peripheral neuropathy.	Mu-opioid receptor agonism and norepinephrine reuptake inhibitor	United States	Developer: Johnson & Johnson Pharmaceutical Research & Development and Grunenthal GMBH; Marketer: Janssen Pharmaceuticals Inc.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
NVA237	Glycopyrronium bromide	NVA237 is intended for the treatment of chronic obstructive pulmonary disease.	Long acting muscarinic antagonist	United States	Novartis Pharmaceuticals Corp.
NX-1207	_	NX-1207 is intended for the treatment of benign prostatic hyperplasia.	_	United States	Nymox Pharmaceutical Corp.
NX-1207	-	NX-1207 is intended for the treatment of benign prostatic hyperplasia.	-	European Union	Recordati SpA
Ocriplasmin	Microplasmin	Ocriplasmin is intended for the non-surgical treatment of vitreomacular adhesion.	Thrombolytic agent	United States	ThromboGenics Ltd.
Octreotide Implant	Octreotide	Octreotide Implant is intended for the treatment of acromegaly.	Synthetic peptide	United States	Endo Pharmaceuticals Inc.
Octreotide Implant	Octreotide	Octreotide Implant is intended for the treatment of acromegaly.	Synthetic peptide	European Union	Endo Pharmaceuticals Inc.
Oral Treprostinil	Treprostinil sodium	Oral Treprostinil is intended for the treatment of pulmonary arterial hypertension	Prostacyclin analog	United States	United Therapeutics Corp.
Oralair Grasses	-	Oralair Grasses is intended for the treatment of grass pollen allergies.	Therapeutic vaccine	United States	Stallergenes
Oral-lyn	Insulin	Oral-lyn is intended for the treatment of type 1 diabetes mellitus.	Insulin	United States	Generex Biotechnology Corp.
Oral-lyn	Insulin	Oral-lyn is intended for the treatment of type 1 diabetes mellitus.	Insulin	European Union	Generex Biotechnology Corp.
Oral-lyn	Insulin	Oral-lyn is intended for the treatment of type 1 diabetes mellitus.	Insulin	Canada	Generex Biotechnology Corp.
Oral-lyn	Insulin	Oral-lyn is intended for the treatment of type 2 diabetes.	Insulin	Canada	Generex Biotechnology Corp.
Ozurdex	Dexamethasone	Ozurdex is intended for the treatment of diabetic macular edema.	Synthetic adrenocortical steroid	United States	Allergan Inc.
PA32540	Aspirin and omeprazole	PA32540 is intended for secondary CV/stroke prevention.	_	United States	Pozen Inc.
PA32540	Aspirin and omeprazole	PA32540 is intended to reduce gastrointestinal side effects and complications compared to a nonsteroidal anti-inflammatory drug or enteric coated aspirin taken alone.	_	United States	Pozen Inc.
Probuphine	Buprenorphine and ethylene vinyl acetate	Probuphine is intended for the treatment of opioid dependence.	_	United States	Titan Pharmaceuticals Inc.
Progestin Only Patch	-	Progestin Only Patch is intended for the prevention of pregnancy.	Contraceptives	United States	Watson Pharmaceuticals Inc.
Provecta	_	Provecta is intended for the treatment of metastatic melanoma.	_	Australia	Provectus Pharmaceuticals Inc.
PSD502	Lidocaine and prilocaine	PSD502 is intended for the treatment of premature ejaculation.	_	United States	Developer: Shionogi Inc. and Plethora Solutions Holding Plc.; Marketer: Shionogi Inc.
PSD502	Lidocaine and prilocaine	PSD502 is intended for the treatment of premature ejaculation.	_	European Union	Developer: Shionogi Inc. and Plethora Solutions Holdings Plc.; Marketer: Shionogi Inc.
Qnaze	Beclomethasone dipropionate	Qnaze is intended for the treatment of seasonal allergic rhinitis.	Corticosteroid	United States	Teva Pharmaceuticals USA Inc.
Qutenza	Capsaicin	Qutenza is intended for the treatment of HIV-associated distal sensory polyneuropathy.	TRVR-1 channel agonist	United States	NeurogesX Inc.
QVA149	Indacaterol and glycopyrronium bromide	QVA149 is intended for the treatment of chronic obstructive pulmonary disease.	Long-acting beta 2 agonist and long-acting muscarinic antagonist	United States	Novartis Pharmaceuticals Corp.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Relovair	Fluticasone furoate and vilanterol trifenatate	Relovair is intended for the treatment of chronic obstructive pulmonary disease.	Glucocotticoid agonist and long acting beta2 agonist	United States	Developer: GlaxoSmithKline Inc. and Theravance Inc.; Marketer: GlaxoSmithKline Inc.
Relovair	Fluticasone furoate and vilanterol trifenatate	Relovair is intended for the treatment of chronic obstructive pulmonary disease.	Glucocorticoid agonist and long acting beta2 agonist	European Union	Developer: GlaxoSmithKline Plc. and Theravance Inc.; Marketer: GlaxoSmithKline Plc.
Remura	Bromfenac	Remura is intended for the treatment of dry eye disease.	Non-steroidal anti- inflammatory drug	United States	Ista Pharmaceuticals Inc.
RP103	Cysteamine bitartrate	RP103 is intended for the treatment of nephropathic cystinosis.	-	United States	Raptor Pharmaceutical Corp.
RP103	Cysteamine bitartrate	RP103 is intended for the treatment of nephropathic cystinosis.	_	European Union	Raptor Pharmaceutical Corp.
SAR1118	_	SAR1118 is intended for the treatment of dry eye.	Leukocyte function- associated antigen-1 inhibitor	United States	SARcode Corp.
Scenesse	Afamelanotide	Scenesse is intended for the treatment of erythropoietic protoporphyria.	Alpha-melanocyte stimulating hormone	European Union	Clinuvel Pharmaceuticals Ltd.
Scenesse	Afamelanotide	Scenesse is intended for the treatment of erythropoietic protoporphyria.	Alpha-melanocyte stimulating hormone	Australia	Clinuvel Pharmaceuticals Ltd.
Ser-120	-	Ser-120 intended for the treatment of nocturia.	_	United States	Allergan Inc.
Serada	Gabapentin	Serada is intended for the treatment of moderate to severe menopausal hot flashes.	-	United States	DepoMed Inc.
Sitavir	Acyclovir	Sitavir is intended for the treatment of oral herpes (labial herpes).	_	United States	BioAlliance Pharma SA
SMC021	Salmon calcitonin	SMC021 is intended for the treatment of osteoporosis.	Osteoclast activity inhibitor	United States	Novartis Pharmaceuticals Corp.
Somatuline Autogel	Lanreotide acetate	Somatuline Autogel is intended for the treatment of neuroendocrine tumors.	Somatostatin analog	United States	Developer: Ipsen Inc.; Marketer: Tercica Inc.
Somatuline Autogel	Lanreotide acetate	Somatuline Autogel is intended for the treatment of neuroendocrine tumors.	Somatostatin analog	European Union	Developer: Ipsen Inc.; Marketer: Tercica Inc.
SR-rhGH	-	SR-rhGH is intended for the treatment of growth hormone deficiency in children and adults.	_	United States	Developer: Biopartners GmbH and LG Life Sciences Ltd.; Marketer: Biopartners GmbH
SR-rhGH	-	SR-rhGH is intended for the treatment of growth hormone deficiency in children and adults.	_	European Union	Developer: Biopartners GmbH and LG Life Sciences Ltd.; Marketer: Biopartners GmbH
Stimuvax	_	Stimuvax is intended for the treatment of non-small cell lung cancer.	Therapeutic vaccine	United States	EMD Serono Inc.
Stimuvax	-	Stimuvax is intended for the treatment of non-small cell lung cancer.	Therapeutic vaccine	European Union	Merck Serono SA
TDT-067	Terbinafine	TDT-067 is intended for the treatment of onychomycosis.	Antifungal	United States	Celtic Pharmaceutical Holdings L.P.
TDT-067	Terbinafine	TDT-067 is intended for the treatment of onychomycosis.	Antifungal	European Union	Celtic Pharmaceutical Holdings L.P.
ThermoDox	Doxorubicin	ThermoDox, in combination with radio-frequency ablation, is intended for the treatment of liver cancer.	_	Japan	Yakult Honsha Co.
ThermoDox	Doxorubicin	ThermoDox, in combination with radio-frequency ablation, is intended for the treatment of non-resectable liver cancer.	_	United States	Celsion Corp.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Tiotropium/Olodaterol Combination	Tiotropium bromide and olodaterol	Tiotropium/Olodaterol Combination is intended for the treatment of chronic obstructive pulmonary disease.	Long-acting muscarinic antagonist and Long- acting beta-2 agonist	Germany	Boehringer Ingelheim GmbH
Tobi Podhaler	Tobramycin	Tobi Podhaler is intended for the treatment of Pseudomonas aeruginosa infections infection in cystic fibrosis patients.	Aminoglycoside antibiotic	United States	Novartis Pharmaceuticals Corp.
Tofacitinib Topical	Tofacitinib	Tofacitinib is intended for the treatment of psoriasis.	Janus kinase 3 inhibitor	United States	Pfizer Inc.
Topiramate	Topiramate	Topiramate is intended as adjunctive treatment of patients 18 to 75 years old with refractory partial-onset seizures with or without secondary generalized seizures.			
	-	United States	Upsher-Smith Laboratories Inc.		
Urocidin	Mycobacterial cell wall- DNA complex	Urocidin is intended for the treatment of refractory non- muscle invasive bladder cancer.	Biological response modifier	United States	Endo Pharmaceuticals Inc.
Urocidin	Mycobacterial cell wall- DNA complex	Urocidin is intended for the treatment of refractory non- muscle invasive bladder cancer.	Biological response modifier	Canada	Endo Pharmaceuticals Inc.
Vaginorm	Dehydroepiandrosterone	Vaginorm is intended for the treatment of female sexual dysfunction in postmenopausal women.	_	European Union	Bayer HealthCare Pharmaceuticals
Vaginorm	Dehydroepiandrosterone	Vaginorm is intended for the treatment of female sexual dysfunction in postmenopausal women.	_	European Union	Bayer HealthCare Pharmaceuticals
Varisolve	-	Varisolve is intended for the treatment of vericose veins.	—	United States	BTG International Inc.
Varisolve	_	Varisolve is intended for the treatment of vericose veins.	—	European Union	BTG International Inc.
Vekacia	Cyclosporine A	Vekacia is intended for the treatment of vernal keratoconjunctivitis.	Cyclosporine A cationic emulsion	United States	Novagali Pharma
Zattrap	Aflibercept	Zaltrap, in combination with 5-fluorouracil, leucovorin and irinotecan, is intended as second- line treatment for metastatic colorectal cancer.	Vascular endothelial growth factor	United States	Developer/ Marketer: Regeneron Pharmaceuticals Inc. and Sanofi
Zaltrap	Aflibercept	Zaltrap, in combination with 5-fluorouracil, leucovorin and irinotecan, is intended as second- line treatment for metastatic colorectal cancer.	Vascular endothelial growth factor	European Union	Developer/ Marketer: Regeneron Pharmaceuticals Inc. and Sanofi
Zenhale	Momestasone furoate and formoterol fumarate	Zenhale is intended for the treatment of chronic obstructive pulmonary disease.	Beta 2 adrenergic agonist and corticosteroid	European Union	Merck & Co.
ZX002	Hydrocodone	ZX002 is intended for the treatment of chronic pain.	Narcotic analgesic	United States	Zogenix Inc.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
ADS-5102	Amantadine hydrochloride	ADS-5102 is intended for the treatment of levodopa induced dyskinesia in patients with Parkinson's disease.	_	United States	Adamas Pharmaceuticals Inc.
Aerosolized AAT	Alpha-1antitrypsin	Aerosolized AAT is intended for the treatment of patients with alpha-1 antitrypsin deficiency .	Alpha 1 proteinase inhibitor	European Union	Kamada Ltd.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
DE-102	Betamethasone	DE-102 is intended for the treatment of diabetic macular edema.	_	Japan	Developer: Santen Pharmaceutical Co. and Oakwood Laboratories LLC; Marketer: Santen Pharmaceutical Co.
Livatag	Doxorubicin	Livatag is intended for the treatment of hepatocellular carcinoma.	_	United States	BioAlliance Pharma SA
NVD-201	Sumatriptan succinate	Sumatriptan Oral Spray is intended for the treatment of migraine headaches.	5-HT receptor agonist	United States	NovaDel Pharma Inc.
Sufentanil Transdermal Patch	Sufentanil	Sufentanil Transdermal Patch is intended to provide extended chronic pain relief for several days.	_	European Union	Developer: Labtec GmbH and Hameln rds GmbH; Marketer: Labtec GmbH

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
256066	-	256066 is intended for the treatment of chronic obstructive pulmonary disease.	Phosphodiesterase type 4 inhibitor	United States	GlaxoSmithKline Inc.
705498	_	705498 is intended for the treatment of non-allergic rhinitis.	Transient receptor potential vanilloid (TRPV1) antagonist	United States	GlaxoSmithKline Inc.
870086	-	870086 is intended for the treatment of asthma.	Novel glucocorticoid agonist	United States	GlaxoSmithKline Inc.
870086	-	870086 is intended for the treatment of atopic dermatitis.	Novel glucocorticoid agonist	United States	GlaxoSmithKline Inc.
961081	-	961081 is intended for the treatment of moderate to severe chronic obstructive pulmonary disease.	Muscarinic antagonist and beta2 agonist	South Africa	GlaxoSmithKline Inc.
AEN-100	Zinc	AEN-100, in combination with AEN-200, is intended for the treatment of amyotrophic lateral sclerosis.	_	United States	Adeona Pharmaceuticals Inc.
Aerosolized AAT	Alpha-1antitrypsin	Aerosolized AAT is intended for the treatment of bronchiectasis.	Alpha 1 proteinase inhibitor	Israel	Kamada Ltd.
Aerosolized AAT	Alpha-1antitrypsin	Aerosolized AAT is intended for the treatment of cystic fibrosis.	Alpha 1 proteinase inhibitor	European Union	Kamada Ltd.
Aerovant	_	Aerovant is intended for the treatment of asthma.	Recombinant human IL-4 variant	United States	Aerovance Inc.
Aerovant	-	Aerovant is intended for the treatment of asthma.	Recombinant human IL-4 variant	European Union	Aerovance Inc.
Afimoxifene	Afimoxifene	Afimoxifene is intended for the treatment of cyclic breast pain, also known as cyclical mastalgia.	-	United States	Developer: BHR Pharma LLC; Marketer: Ascend Therapeutics Inc.
AG900	Progestin	AG900 is intended for the prevention of pregnancy in women desiring contraception who are breast-feeding.	Contraceptives	United States	Agile Therapeutics Inc.
AG900	Progestin	AG900 is intended for the prevention of pregnancy in women where estrogen containing contraceptives are contraindicated, inappropriate or unwanted.	Contraceptives	United States	Agile Therapeutics Inc.
ALN-RSV01	_	ALN-RSV01 is intended for the treatment of adult lung- transplant patients naturally infected with respiratory syncytial virus.	_	United States	Developer/Marketer: Anylam Pharmaceuticals Inc. and Cubist Pharmaceuticals Inc.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Amikacin Inhale	Amikacin	Amikacin Inhale is intended as adjunctive treatment of Gram-negative pneumonia in intubated and mechanically- ventilated patients.	_	United States	Developer/Marketer: Nektar Therapeutics and Bayer HealthCare Pharmaceuticals Inc.
Amikacin Inhale	Amikacin	Amikacin Inhale is intended as adjunctive treatment of Gram-negative pneumonia in intubated and mechanically- ventilated patients.	_	European Union	Developer: Nektar Therapeutics and Bayer HealthCare Pharmaceuticals; Marketer: Bayer HealthCare Pharmaceuticals
AmiKet	Amitriptyline and ketamine	AmiKet is intended for the relief of pain associated with diabetic peripheral neuropathy.	Tricyclic antidepressant and dissociative		
anesthetic	United States	EpiCept Corp.			
AmiKet	Amitriptyline and ketamine	Amiket is intended for the relief of pain associated with neuralgia due to of chemotherapy.	Tricyclic antidepressant and dissociative		
anesthetic	United States	EpiCept Corp.			
AmiKet	Amitriptyline and ketamine	Amiket is intended for the relief of pain associated with post- herpetic neuralgia.	Tricyclic antidepressant and dissociative		
anesthetic	United States	EpiCept Corp.			
AN2728	-	AN2728 is intended for the treatment of mild to moderate plaque type psoriasis.	Phosphodiesterase 4 enzyme inhibitor	United States	Anacor Pharmaceuticals Inc.
APF112	Mepivacaine	APF 112 is intended for the relief of postsurgical pain.	Local anesthetic	United States	A.P. Pharma Inc.
Arbaclofen placarbil	Arbaclofen placarbil	Arbaclofen placarbil is intended for the adjunctive treatment of gastroesophageal reflux disease.	_	United States	XenoPort Inc.
ARC-4558	Clonidine hydrochloride	ARC-4558 is intended for the treatment of pain associated with painful diabetic neuropathy.	_	United States	Arcion Therapeutics Inc.
Arikace	Liposomal amikacin	Arikace is intended for the treatment of pseudomonas aeruginosa lung infections in cystic fibrosis patients.	Antibiotic	European Union	Insmed Inc.
Arikace	Liposomal amikacin	Arikace is intended for the treatment of Pseudomonas aeruginsa lung infections in non-cystic fibrosis patients with bronchiectasis.	Antibiotic	United States	Insmed Inc.
ARX-01	_	ARX-01 is intended for the treatment of moderate-to-severe inpatient acute pain following knee replacement surgery.	Analgesic	United States	AcelRx Pharmaceuticals Inc.
ARX-02	Sufentanil	ARX-02 is intended for the treatment of breakthrough cancer pain.	Narcotic analgesic	United States	AcelRx Pharmaceuticals Inc.
ARX-03	Sufentanil and triazolam	ARX-03 is intended to provide sedation and analgesia for the treatment of procedural pain and anxiety.	_	United States	AcelRx Pharmaceuticals Inc.
Asacol	Mesalamine	Asacol is intended for the treatment of Crohn's disease.	-	Japan	Developer/Marketer: Zeria Pharmaceutical Co. and Kyowa Hakko Kirin Co.
ASC-J9	_	ASC-J9 is intended for the treatment of acne vulgaris.	Antiandrogen	United States	Developer: AndroScience Corp. and Orient Europharma Co.; Marketer: AndroScience Corp.
ASC-J9	_	ASC-J9 is intended for the treatment of acne vulgaris.	Antiandrogen	Taiwan	Developer: AndroScience Corp. and Orient Europharma Co.; Marketer: Orient Europharma Co.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
ASM-024	—	ASM-024 is intended for the treatment of asthma.	—	Canada	Asmacure Ltee
ASM8	-	ASM8 is intended for the treatment of asthma.	Inhaled anti-inflammatory drug	Canada	Pharmaxis Ltd.
AZD3199	—	AZD3199 is intended for the treatment of asthma.	Inhaled long-acting beta2 agonist	United States	AstraZeneca Pharmaceuticals LP
AZD3199	—	AZD3199 is intended for the treatment of asthma.	Inhaled long-acting beta2 agonist	European Union	AstraZeneca Pharmaceuticals LP
AZD3199	-	AZD3199 is intended for the treatment of chronic obstructive pulmonary disease.	Inhaled long-acting beta2 agonist	United States	AstraZeneca Pharmaceuticals LP
AZD3199	_	AZD3199 is intended for the treatment of chronic obstructive pulmonary disease.	Inhaled long-acting beta2 agonist	European Union	AstraZeneca Pharmaceuticals LP
AZD5423	-	AZD5423 is intended for the treatment of chronic obstructive pulmonary disease.	ISEGRA	United States	AstraZeneca Pharmaceuticals LP
AZD5423	_	AZD5423 is intended for the treatment of chronic obstructive pulmonary disease.	isegra	European Union	AstraZeneca Pharmaceuticals LP
Aztreonam	Aztreonam	Aztreonam is intended for the treatment of bronchiectasis	Monobactam antibiotic	United States	Gilead Sciences Inc.
BC-819	_	BC-819 is intended for the treatment of pancreatic cancer.		United States	BioCancell Therapeutics Inc.
BC-819	-	BC-819 is intended for the treatment of superficial bladder carcinoma.	-	United States	BioCancell Therapeutics Inc.
BC-819	-	BC-819 is intended for the treatment of superficial bladder carcinoma.	-	Israel	BioCancell Therapeutics Inc.
Bepotastine Besilate	Bepotastine Besilate	Bepotastine Besilate is intended for the treatment of symptoms associated with seasonal allergic rhinitis.	Histamine H1 receptor antagonist	United States	Ista Pharmaceuticals Inc.
Beraprost-MR	Beraprost	Beraprost-MR is intended for the treatment of pulmonary arterial hypertension	Prostacyclin receptor stimulator	United States	United Therapeutics Corp.
Bimosiamose	Bimosiamose	Bimosiamose is intended for the treatment of asthma.	Selectin antagonist	European Union	Revotar Biopharmaceuticals AG
Bimosiamose	Bimosiamose	Bimosiamose is intended for the treatment of chronic obstructive pulmonary disease.	Selectin antagonist	European Union	Revotar Biopharmaceuticals AG
BIQ-11006	-	BIO-11006 is intended for the treatment of chronic obstructive pulmonary disease.	-	United States	BioMarck Pharmaceuticals Ltd.
Bremelanotide	Bremelanotide	Bremelanotide is intended for the treatment of premenopausal women with female sexual dysfunction.	Melanocortin receptor agonist	United States	Palatin Technologies Inc.
Catioprost	Latanoprost	Catioprost is intended for the treatment of glaucoma.	—	United States	Novagali Pharma
CB-03-01	-	CB-03-01 is intended for the treatment of acne.	Androgen receptor antagonist	United States	Cosmo Pharmaceuticals SpA
CB-03-01	-	CB-03-01 is intended for the treatment of alopecia.	Androgen receptor antagonist	United States	Cosmo Pharmaceuticals SpA
Cevira	_	Cevira is intended for the non- surgical treatment of cervical HPV infection and precancerous lesions of the cervix.	_	United States	PhotoCure ASA
Cevira	_	Cevira is intended for the non- surgical treatment of cervical HPV infection and precancerous lesions of the cervix.	_	European Union	PhotoCure ASA
Cipro Inhaler	Ciprofloxacin	Cipro Inhaler is intended for the			

Chemical	Indication	Class of drug	Region	Developer/Marketer
Quinolone antibiotic	United States	Developer: Bayer HealthCare Pharmaceuticals Inc. and Nektar Therapeutics; Marketer: Merck & Co.		
Irinotecan and floxuridine	CPX-1 is intended for the treatment of colorectal cancer.	—	United States	Celator Pharmaceuticals Inc.
Cytarabine and danorubicin	CPX-351 is intended for the treatment of newly diagnosed acute myeloid leukemia in patients between 60 and 75 years old.	_	United States	Celator Pharmaceuticals Inc.
Cytarabine and danorubicin	CPX-351 is intended for the treatment of patients up to 60 years old with acute myeloid leukemia in first relapse.	_	United States	Celator Pharmaceuticals Inc.
Camptothecin	CRLX101 is intended for the treatment of advanced cancer.	_	United States	Cerulean Pharma Inc.
Camptothecin	CRLX101 is intended for the treatment of non-small cell lung cancer.	-	United States	Cerulean Pharma Inc.
Camptothecin	CRLX101 is intended for the treatment of solid tumors.	_	United States	Cerulean Pharma Inc.
_	CT327 is intended for the treatment of atopic dermatitis.	TrkA inhibitor	Switzerland	Creabilis SA
—	CT327 is intended for the treatment of neuropathic pain.	TrkA inhibitor	Denmark	Creabilis SA
_	CT327 is intended for the treatment of psoriasis.	TrkA inhibitor	United States	Creabilis SA
-	CT327 is intended for the treatment of psoriasis.	TrkA inhibitor	European Union	Creabilis SA
Davunetide	Davunetide is intended for the treatment of Alzheimer's disease.	_	United States	Allon Therapeutics Inc.
Davunetide	Davunetide is intended for the treatment of schizophrenia.	—	United States	Allon Therapeutics Inc.
_	Deovo is intended for the treatment of head lice.	_	United States	Hatchtech Pty Ltd
-	Diabecell is intended for the treatment of type 1 diabetes.	Insulin secretion enhancer	New Zealand	Living Cell Technologies Ltd
Dipraglurant	Dipraglurant is intended for the treatment of Parkinson's disease levadopa induced dyskinesia.	Metabotropic glutamate receptor 5 negative allosteric modulator	European Union	Addex Pharmaceuticals SA
—	E6005 is intended for the treatment of atopic dermatitis.	Phosphodiesterase 4 inhibitor	European Union	Eisai Co.
Dexamethasone phosphate	EGP-437 is intended for the treatment of anterior uveitis.	_	United States	EyeGate Pharmaceuticals Inc.
-	EISO is intended for the treatment of human papilloma virus skin warts.	-	United States	ViroXis Corp.
Bupivacaine	Eladur is intended for the treatment of chronic lower back pain.	_	United States	Pfizer Inc.
Zonisamide	Empatic SR is intended for the treatment of obesity.	—	United States	Orexigen Therapeutics Inc.
-	EndoTAG-1 is intended for the treatment of pancreatic cancer.	—	United States	MediGene AG
—	EndoTAG-1 is intended for the treatment of pancreatic cancer.	—	European Union	MediGene AG
_	EndoTAG-1 is intended for the treatment of triple receptor negative breast cancer.	_	European Union	MediGene AG
Enkephalin	NP2 is intended for the treatment of cancer pain.	Gene therapy	United States	Diamyd Inc.
Ingenol mebutate	Eralese is intended for the treatment of non-melanoma skin cancer.	_	United States	Leo Pharma Inc.
	Quinolone antibiotic Irinotecan and floxuridine Cytarabine and Ganorubicin Camptothecin Camptothecin Camptothecin Camptothecin Davunetide Davunetide Dipraglurant Dipraglurant Dipraglurant Dipraglurant Conisamide Eupivacaine Rupivacaine Eupivacaine Eupivacaine Eupivacaine Dipraglurant Dexamethasone phosphote Conisamide Conisamide Dipraglurant Dexamethasone phosphote Conisamide Conisamide	Quinolone antibiotic United States Itinotecan and floxuidine CPX-1 is intended for the treatment of colorectal cancer. Cytarabine and danorubicin CPX-351 is intended for the treatment of nowly diagnosed acute myeloid leukemia in patients between 60 and 75 years old. Cytarabine and danorubicin CPX-351 is intended for the treatment of patients up to 60 years old. Cytarabine and danorubicin CPX.351 is intended for the treatment of patients up to 60 years old. Camptothecin CPX.101 is intended for the treatment of advanced cancer. Camptothecin CRIX101 is intended for the treatment of advanced cancer. Camptothecin CRIX101 is intended for the treatment of alcid tumors. - CT327 is intended for the treatment of aclos tumors. - CT327 is intended for the treatment of pacidas. - CT327 is intended for the treatment of pacidas. Davunetide Davunetide is intended for the treatment of solical tumors. - CT327 is intended for the treatment of solical tumors. - CT327 is intended for the treatment of pacidas. Davunetide Davunetide is intended for the treatment of solical tumors. - CT327 is intended for the treatment of solical tumors. - Diabeccelis intended for	Quinolone antibiotic United States Developer Bayer HeatThCase Phormaceutical inc. and Netran Therapeutics Marketer March & Co. Inforecon and flowuiding CPK-1 is intended for the treatment of newly diagnosed domoublin - Cytarabline and danoublin CPK-351 is intended for the treatment of newly diagnosed domoublin - Cytarabline and danoublin CPK-351 is intended for the treatment of patients up to 00 years old with acute myelid leukemia in first neicose. - Camptothecin CRX101 is intended for the treatment of advanced cancer. - Camptothecin CRX101 is intended for the treatment of advanced cancer. - Camptothecin CRX101 is intended for the treatment of solid humos. - Camptothecin CRX101 is intended for the treatment of solid humos. - - C1322 is intended for the treatment of solid humos. - - C1322 is intended for the treatment of solid humos. - - C1322 is intended for the treatment of solid humos. - - C1322 is intended for the treatment of solid humos. - - C1322 is intended for the treatment of solid humos. - - C1322 is intended for the treatment of solid humos. -	Quinciple ontblocic United States Developer Burry and Maker Theopartics (Marketer: Merck & Co. Innotecon and flow/idea CPK-35 is intended for the technerel of code grances — United States Cytorabine and danotubion CPK-35 is intended for the technerel of code grances — United States Cytorabine and danotubion CPK-35 is intended for the technerel of pod grances — United States Cytorabine and danotubion CPK-35 is intended for the technerel of advanced conce — United States Cytorabine and danotubion CPK-35 is intended for the technerel of advanced conce — United States Comptothecin CRX-35 is intended for the technerel of advanced conce — United States Comptothecin CRX-35 is intended for the technerel of advanced conce — United States Comptothecin CRX-35 is intended for the technerel of advanced conce If A Inhibitor Switzerand T CRX-15 is intended for the technerel of advanced conce If A Inhibitor European Union Comptothecin CRX-15 is intended for the technerel of advanced is entrode for the technerel of advanced is entrode for the technerel of advanced is entrode for the techorenel of advanced is entrode for the technerel of advanced is ent

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Eylea	Aflibercept	Eylea is intended for the treatment of diabetic macular edema.	Vascular endothelial growth factor	United States	Developer: Regeneron Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc.; Marketer: Regeneron Pharmaceuticals Inc.
FOV1101	Prednisolone and cyclosporine	FOV1101 is intended for the treatment of allergic conjunctivitis.	_	United States	Sanofi
FOV1101	Prednisolone and cyclosporine	FOV1101 is intended for the treatment of allergic conjunctivitis.	-	European Union	Sanofi SA
FOV2302	_	FOV2302 is intended for the treatment of retinal vein occlusion induced macular edema.	Plasma kallikrein inhibitor	European Union	Developer: Sanofi SA and Dyax Corp.; Marketer: Sanofi SA
HIV Vaccine	-	HIV Vaccine is intended for the treatment of HIV infection.	Therapeutic vaccine	United States	Vical Inc.
HP-3000	-	HP-3000 is intended for the treatment of Parkinson's disease.	_	Japan	Hisamitsu Pharmaceutical Inc.
HP802-247	-	HP802-247 is intended for the treatment of venous leg ulcers.	_	United States	Healthpoint Ltd.
HTU-520	Terbinafine hydrochloride	HTU-520 is intended for the treatment of onychomycosis.	_	United States	Hisamitsu Pharmaceutical Inc.
lluvien	Fluocinolone acetonide	lluvien is intended for the treatment of dry age-related macular degeneration.	Corticosteroid	United States	Developer/Marketer: Alimera Sciences Inc. and pSivida Ltd.
lluvien	Fluocinolone acetonide	lluvien is intended for the treatment of retinal vein occlusion.	Corticosteroid	United States	Developer/Marketer: Alimera Sciences Inc. and pSivida Ltd.
lluvien	Fluocinolone acetonide	lluvien is intended for the treatment of wet age-related macular degeneration.	Corticosteroid	United States	Developer/Marketer: Alimera Sciences Inc. and pSivida Ltd.
INO-8875	—	INO-8875 is intended for the treatment of glaucoma.	Adenosine A1 receptor antagonist	United States	Inotek Pharmaceuticals Corp.
IOP Lowering SR	-	IOP Lowering SR is intended for the treatment of glaucoma.	-	United States	Allergan Inc.
ITCA 650	Exenatide	ITCA 650 is intended for the treatment of type 2 diabetes.	Glucagon-like peptide-1 receptor agonist	United States	Developer: Intarcia Therapeutics Inc. and Quintiles Laboratories Ltd.; Marketer: Intarcia Therapeutics Inc.
Jakafi	Ruxolitinib	Jakafi is intended for the treatment of psoriasis.	JAK1/JAK2 inhibitor	United States	Incyte Corp.
LAS100977	-	LAS100977 is intended for the treatment of asthma.	Long acting beta2 agonist	European Union	Laboratorios Almirall S.A.
LAS100977 (LABA)	_	LAS100977 (LABA) is intended for the treatment of asthma.	Long acting beta2 agonist	United States	Developer: Forest Laboratories Inc. and Laboratorios Almirall S.A.; Marketer: Forest Laboratories Inc.
LAS100977 (LABA)	_	LAS100977 is intended for the treatment of chronic obstructive pulmonary disease.	Long acting beta2 agonist	United States	Developer: Forest Laboratories Inc. and Laboratorios Almirall S.A.; Marketer: Forest Laboratories Inc.
Lipoquin	Ciprofloxacin	Lipoquin is intended for the treatment of cystic fibrosis.	-	United States	Aradigm Corp.
Lipoquin	Ciprofloxacin	Lipoquin is intended for the treatment of cystic fibrosis.	-	European Union	Aradigm Corp.
Lipoquin	Ciprofloxacin	Lipoquin is intended for the treatment of patients with non- cystic fibrosis bronchiectasis.	-	United States	Aradigm Corp.
Locteron	Alfa interferon	Locteron is intended for the treatment of chronic hepatitis C virus.	-	United States	Biolex Therapeutics Inc.
Locteron	Alfa interferon	Locteron is intended for the treatment of previously untreated chronic hepatitis C .	-	European Union	Biolex Therapeutics Inc.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Lodotra	Prednisone	Lodotra is intended for the treatment of polymyalgia rheumatica.	Circadian cytokine modulator	United States	Horizon Pharma Inc.
LT-02	Phosphatidylcholine	LT-02 is intended for the treatment of mesalazine- refractory ulcerative colitis.	_	Germany	Lipid Therapeutics GmbH
Luliconazole	Luliconazole	Luliconazole is intended for the treatment of onychomycosis.	Imidiazole antifungal	United States	Topica Pharmaceuticals Inc.
MAP0005	-	MAP0005 is intended for the treatment of asthma.	Corticosteroid and long- acting beta 2 agonist	United States	MAP Pharmaceuticals Inc.
MAP0005	_	MAP0005 is intended for the treatment of chronic obstructive pulmonary disease.	Corticosteroid and long- acting beta 2 agonist	United States	MAP Pharmaceuticals Inc.
Marqibo	Vincristine sulfate	Marqibo is intended as front-line for the treatment of elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia.	Vinca alkaloid	United States	Talon Therapeutics Inc.
Marqibo	Vincristine sulfate	Marqibo is intended for the first-line treatment of aggressive non-Hodgkin's lymphoma.	Vinca alkaloid	United States	Talon Therapeutics Inc.
Melphalan	Melphalan	Melphalan is intended for the treatment of unresectable liver cancer.	Alkylating agent	United States	Delcath Systems Inc.
MG01CI	Metadoxine	MG01Cl is intended for the treatment of adults with attention deficit hyperactivity disorder.	_	Israel	Developer: Teva Pharmaceutical Industries Ltd. and Alcobra Ltd.; Marketer: Teva Pharmaceutical Industries Ltd.
MQX-5902	Methotrexane	MQX-5902 is intended for the treatment nail psoriasis.	_	United Kingdom	MediQuest Therapeutics Inc.
MRX-4	—	MRX-4 is intended for the treatment of allergic rhinitis.	Anti-inflammatory	European Union	Morria Biopharmaceuticals Plc.
MRX6	-	MRX6 is intended for the treatment of contact dermatitis.	Anti-inflammatory	Israel	Morria Biopharmaceuticals Plc.
Multaq	Dronedarone	Multaq is intended for the treatment of patients with permanent atrial fibrillation.	Calcium channel blocker	Japan	Sanofi SA
Naloxone	Naloxone	Naloxone is intended for the treatment of binge eating in obese patients.	Short-lasting opioid antagonist	Finland	Lightlake Therapeutics Inc.
Naloxone	Naloxone	Naloxone is intended for the treatment of bulimia nervosa.	Short-lasting opioid antagonist	United Kingdom	Lightlake Therapeutics Inc.
NanoDOX	Doxycycline	NanoDOX is intended for the treatment of dermal ulcers.	_	United States	Nanotherapeutics Inc.
NB-002	_	NB-002 is intended for the treatment of onychomycosis.	_	United States	NanoBio Corp.
ND0801	_	ND0801 is intended for the treatment of attention deficit disorder in adults.	_	Israel	NeuroDerm Ltd.
ND0801	_	ND0801 is intended for the treatment of attention deficit hyperactivity disorder in adults.	_	Israel	NeuroDerm Ltd.
NestraGel	Nestorone	NestraGel, in combination with estradiol, is intended for the prevention of pregnancy.	Contraceptives	United States	Antares Pharma Inc.
Nexagon	_	Nexagon is intended for the treatment of patients with chronic venous leg ulcers.	Oligonucleotide	United States	CoDa Therapeutics Inc.
NGX-1998	Capsaicin	NGX-1998 is intended for the treatment of post-herpetic neuralgia.	-	United States	NeurogesX Inc.
NH004	Tropicamide	NH004 is intended for the treatment of sialorrhea in patients with Parkinson disease.	Anticholinergic agent	United States	NeuroHealing Pharmaceuticals Inc.
NKQ-01	Phentanyl	NKQ-01 is intended for the relief	Narcotic analgesic	United States	Nippon Kayaku Co.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Norovirus VLP Vaccine Intranasal(Monovalent)	_	Norovirus VLP Vaccine Intranasal(Monovalent) is intended for the prevention of Norovirus infection(stomach flu).	Preventive vaccine	United States	LigoCyte Pharmaceuticals Inc.
Novexatin	-	Novexatin is intended for the treatment of nail fungus.	Antifungal	United Kingdom	NovaBiotics Ltd.
NST-141	_	NST-141 is intended for the treatment of pruritus associated with atopic dermatitis.	_	Japan	Developer/Marketer: Nippon Shinyaku Co. and Taiho Pharmaceutical Co.
NST-141	-	NST-141 is intended for the treatment of pruritus associated with atopic dermatitis.	-	Japan	Otsuka Pharmaceutical Co.
NT-501	Ciliary neurotrophic factor	NT-501 is intended for the treatment of retinitis pigmentosa.	Ciliary neurotrophic factor	United States	Neurotech USA Inc.
NT-501	Ciliary neurotrophic factor	NI-501 is intended for the treatment of visual loss associated with the dry form of age related macular degeneration.	Ciliary neurotrophic factor	United States	Neurotech USA Inc.
NVC-422	_	NVC-422 is intended for the prevention of urinary catheter blockage and encrustation which is often a contributing factor to urinary tract infections in chronically catheterized patients.	Aganocide antimicrobial	United States	NovaBay Pharmaceuticals Inc.
Ocriplasmin	Microplasmin	Ocriplasmin is intended for induction of posterior vitreous detachment.	Thrombolytic agent	United States	ThromboGenics Ltd.
Ocriplasmin	Microplasmin	Ocriplasmin is intended for the treatment of age-related macular degeneration.	_	European Union	ThromboGenics Ltd.
OncoGel	Paclitaxel	OncoGel is intended for the treatment of esophageal cancer.	Taxane	United States	BTG International Inc.
ONO-7165/ EMD531444	-	ONO-7165/ EMD531444 is intended for the treatment of non-small cell lung cancer.	Therapeutic vaccine	Japan	Developer/Marketer: Merck Serono SA and Ono Pharmaceutical Co.
Oral Treprostinil	Treprostinil sodium	Oral Treprostinil is intended for the treatment of digital ulcers.	Prostacyclin analog	United States	United Therapeutics Corp.
Oral Treprostinil	Treprostinil sodium	Oral Treprostinil is intended for the treatment of pulmonary arterial hypertension in idiopathic pulmonary fibrosis.	Prostacyclin analog	United States	United Therapeutics Corp.
Pandemic Flu Vaccine Patch	-	Pandemic Flu Vaccine Patch is intended for the prevention of pandemic influenza.	Preventive vaccine	United States	Developer/Marketer: Intercell AG and GlaxoSmithKline Inc.
Pennsaid	Diclofenac sodium	Pennsaid is intended for the treatment of pain, stiffness, and impaired physical function associated with osteoarthritis.	Nonsteroidal anti- inflammatory drug	United States	Mallinckrodt Pharmaceuticals
PEP02	Irinotecan hydrochloride	PEP02 is intended for second- line treatment of metastatic pancreatic cancer.	-	United States	PharmaEngine Inc.
PH94B	-	PH94B is intended for the treatment of social phobia.	Psychotropic vomeropherin	United States	Pherin Pharmaceuticals Inc.
ProLindac	-	ProLindac is intended for the treatment of ovarian cancer.	DACH platinum polymer	United States	Access Pharmaceuticals Inc.
ProLindac	_	ProLindac is intended for the treatment of platinum sensitive ovarian cancer.	DACH platinum polymer	European Union	Access Pharmaceuticals Inc.
ProLindac	-	ProLindac is intended for the treatment of relapsed ovarian cancer.	DACH platinum polymer	European Union	Access Pharmaceuticals Inc.
Provecta	_	Provecta is intended for the treatment of Stage III and IV metastatic melanoma.	-	United States	Provectus Pharmaceuticals Inc.
PT001	Glycopyrrolate hydrofluoroalkane	PT001 is intended for the treatment of chronic obstructive pulmonary disease.	Long acting muscarinic antagonist bronchodilator	United States	Pearl Therapeutics Inc.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
PT003	Glycopyrrolate and formoterol	PT003 is intended for the treatment of chronic obstructive pulmonary disease.	-	United States	Pearl Therapeutics Inc.
PT005	Formoterol fumarate	PT005 is intended for the treatment of mild to severe chronic obstructive pulmonary disease.	_	United States	Pearl Therapeutics Inc.
Pulmaquin	Ciprofloxacin	Ciprofloxacin is intended for the treatment of adult patients with non-cystic fibrosis bronchiectasis.	_	United States	Aradigm Corp.
Pulmaquin	Ciprofloxacin	Ciprofloxacin is intended for the treatment of adult patients with non-cystic fibrosis bronchiectasis.	-	Australia	Aradigm Corp.
PXL01	_	PXL01 is intended for the prevention of post-surgical adhesions in patients undergoing hand surgery.	-	Sweden	Pergamun AB
QMF149	Indacaterol and mometasone furoate	QMF149 is intended for the treatment of asthma.	Corticosteroid and long- acting beta 2 agonist	United States	Novartis Pharmaceuticals Corp.
QMF149	Indacaterol and mometasone furoate	QMF149 is intended for the treatment of chronic obstructive pulmonary disease.	Corticosteroid and long- acting beta 2 agonist	United States	Novartis Pharmaceuticals Corp.
Qnexa	Phentermine and Topiramate	Qnexa is intended for the treatment of type 2 diabetes.	-	United States	Vivus Inc.
Reolysin	_	Reolysin, in combination with paclitaxel and carboplatin, is intended for the treatment of non-small cell lung cancer with K-RAS or EGFR-activated tumours.	Therapeutic vaccine	United States	Oncolytics Biotech Inc.
RGN-137	Thymosin beta4	RGN-137 is intended for the treatment of chronic pressure ulcers.	Synthetic peptide	United States	RegeneRx Biopharmaceuticals Inc.
RGN-137	Thymosin beta4	RGN-137 is intended for the treatment of epidermolysis bullosa.	Synthetic peptide	United States	RegeneRx Biopharmaceuticals Inc.
RGN-137	Thymosin beta4	RGN-137 is intended for the treatment of venous stasis ulcers.	Synthetic peptide	United States	RegeneRx Biopharmaceuticals Inc.
RPL554	_	RPL554 is intended for the treatment of asthma.	phosphodiesterase 3 and phosphodiesterase 4 enzyme inhibitors	Netherlands	Verona Pharma Plc.
RT001	Botulinum toxin type A	RT001 is intended for the treatment of lateral canthal lines (crow's feet wrinkles).	-	United States	Revance Therapeutics Inc.
RX-10045	_	RX-10045 is intended for the treatment of moderate to severe dry eye syndrome.	Resolvin analog	United States	Celtic Therapeutics LLLC
Saber-Bupivacaine	Bupivacaine	Saber-Bupivacaine is intended for the treatment of pain and incisional pain.	Local anesthetic	European Union	Nycomed Group
Sativex	Tetrahydrocannabinol and cannabidiol	Sativex is intended for the treatment of pain in patients with advanced cancer that has not been adequately relieved by opioid medications.	Cannabinoid	United States	Otsuka America Pharmaceutical Inc.
Scenesse	Afamelanotide	Scenesse is intended for the treatment of erythropoietic protoporphyria.	Alpha-melanocyte stimulating hormone	United States	Clinuvel Pharmaceuticals Ltd.
Scenesse	Afamelanotide	Scenesse is intended for the treatment of nonsegmental vitiligo.	Alpha-melanocyte stimulating hormone	United States	Clinuvel Pharmaceuticals Ltd.
Scenesse	Afamelanotide	Scenesse is intended for the treatment of nonsegmental vitiligo.	Alpha-melanocyte stimulating hormone	Europen Union	Clinuvel Pharmaceuticals Ltd.
SKP-1041	_	SKP-1041 is intended for the treatment of sleep disorders.	Non benzodiazepine agent	United States	Somnus Therapeutics Inc.
Synavive	Dipyridamole and prednisolone	Synavive is intended for the treatment of hand osteoarthritis.	Dissociated glucocorticoid	United States	Zalicus Inc.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Synavive	Dipyridamole and prednisolone	Synavive is intended for the treatment of knee osteoarthritis.	Dissociated glucocorticoid	United States	Zalicus Inc.
Synavive	Dipyridamole and prednisolone	Synavive is intended for the treatment of rheumatoid arthritis.	Dissociated glucocorticoid	United States	Zalicus Inc.
Synavive	Dipyridamole and prednisolone	Synavive is intended for the treatment of rheumatoid arthritis.	Dissociated glucocorticoid	European Union	Zalicus Inc.
TAK-390MR	Dexlansoprazole	TAK-390MR is intended for healing and mantenance treatment of erosive esophagitis.	Proton pump inhibitor	Japan	Takeda Pharmaceutical Co.
TAK-390MR	Dexlansoprazole	TAK-390MR is intended for the treatment of non-erosive gastroesophageal reflux disease.	Proton pump inhibitor	Japan	Takeda Pharmaceutical Co.
Talactoferrin	Talactoferrin alfa	Talactoferrin is intended for the treatment of diabetic ulcers.	—	United States	Agennix Inc.
Topical Interferon Alpha-2b	-	Topical Interferon Alpha-2b is intended for the treatment of low-grade cervical dysplasia.	Antiviral	United States	Helix BioPharma Corp.
Topical Interferon Alpha-2b	-	Topical Interferon Alpha-2b is intended for the treatment of low-grade cervical dysplasia.	Antiviral	Germany	Helix BioPharma Corp.
TPIM-02/Insulin	-	TPM-02/Insulin is intended for the treatment of type 1 diabetes.	Insulin	United States	Phosphagenics Ltd.
Transdur	Sufentanil	Transdur is intended for the treatment of chronic pain.	Narcotic analgesic	United States	Durect Corp.
Transdur	Sufentanil	Transdur is intended for the treatment of chronic pain.	Narcotic analgesic	European Union	Durect Corp.
Π-063	S-flurbiprofen	TT-063 is intended for the treatment of myalgia.	_	Japan	Developer: Taisho Pharmaceutical Co. and Tokuhon Corp.; Marketer: Taisho Pharmaceutical Co.
Π-063	S-flurbiprofen	TT-063 is intended for the treatment of osteoarthritis pain.	_	Japan	Developer: Taisho Pharmaceutical Co. and Tokuhon Corp.; Marketer: Taisho Pharmaceutical Co.
Π-063	S-flurbiprofen	TT-063 is intended for the treatment of scapulohumeral periarthritis pain.	_	Japan	Developer: Taisho Pharmaceutical Co. and Tokuhon Corp.; Marketer: Taisho Pharmaceutical Co.
V-101	_	V-101 is intended for the treatment of erythema in patients with rosacea.	_	United States	Vicept Therapeutics Inc.
ViaDerm-hPTH (1-34)	Calcitonin	ViaDerm-hPTH (1-34) is intended for the treatment of osteoporosis.	—	United States	Eli Lilly and Co.
Vicinium	_	Vicinium is intended for the treatment of locally persistent non-invasive bladder cancer.	_	United States	Viventia Biotechnologies Inc.
Vicinium	-	Vicinium is intended for the treatment of locally persistent non-invasive bladder cancer.	-	Canada	Viventia Biotechnologies Inc.
Vismodegib	Vismodegib	Vismodegib is intended for the treatment of basal cell nevus syndrome (Gorlin syndrome).	Hedgehog antagonist	United States	Genentech Inc.
VR496	-	VR496 is intended for the treatment of cystic fibrosis.	-	United States	Vectura Group Plc.
VR496	_	VR496 is intended for the treatment of cystic fibrosis.	_	European Union	Vectura Group Plc.
WBI-1001	-	WBI-1001 is intended for the treatment of atopic dermatitis (type of eczema).	-	Canada	Welichem Biotech Inc.
WBI-1001	—	WBI-1001 is intended for the treatment of psoriasis.	-	Canada	Welichem Biotech Inc.
Xantryl	-	Xantryl is intended for the treatment of atopic dermatitis.	—	United States	Provectus Pharmaceuticals Inc.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Xantryl	-	Xantryl is intended for the treatment of psoriasis.	-	United States	Provectus Pharmaceuticals Inc.
Xaracoll	Bupivacaine	Xaracoll is intended to provide pain control at the surgical site and thus reduce the level of additional analgesia required after surgery.	-	United States	Innocoli Inc.
Xaracoll	Bupivacaine	Xaracoll is intended to provide pain control at the surgical site and thus reduce the level of additional analgesia required after surgery.	_	European Union	Innocoll Inc.
XEN402	-	XEN402 is intended for the treatment of post herpetic neuralgia.	-	Canada	Xenon Pharmaceuticals Inc.
XP21279	_	XP21279 is intended for the treatment of Parkinson's disease patients with motor fluctuations.	_	United States	XenoPort Inc.
Zaltrap	Aflibercept	Zaltrap, in combination with 5-fluorouracil, leucovorin and oxaliplatin, is intended as first- line treatment for metastatic colorectal cancer.	Vascular endothelial growth factor	United States	Developer/ Marketer: Regeneron Pharmaceuticals Inc. and Sanofi
Zoraxel	-	Zoraxel is intended for the treatment of erectile dysfunction.	-	United States	Rexahn Pharmaceuticals Inc.
ZP-PTH	Teriparatide	ZP-PTH is intended for the treatment of osteoporosis.	-	United States	Zosano Pharma Inc.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
ARG101	Testosterone	ARG101 is intended for the treatment of dry eye syndrome in menopausal women.	-	United States	arGentis Pharmaceuticals Inc.
BC-819	—	BC-819 is intended for the treatment of ovarian cancer.	_	United States	BioCancell Therapeutics Inc.
Civamide	Civamide	Civamide is intended for the treatment of chronic post- herpetic neuralgia.	TRPV-1 receptor modulator	United States	Winston Pharmaceuticals Inc.
HGT-2310	Idursulfase-IT	HGT-2310 is intended for the treatment of Hunter syndrome patients with significant central nervous system symptoms.	Human iduronate-2- sulfatase	United States	Shire US Inc.
IBI-20089	Triamcinolone acetonide	IBI-20089 is intended for the treatment of cystoid macular edema.	-	United States	Icon Bioscience Inc. (IBI)
MP0112	_	MP0112 is intended for the treatment of diabetic macular edema.	_	Switzerland	Allergan Inc.
MP0112	_	MP0112 is intended for the treatment of wet age-related macular degeneration.	_	Switzerland	Allergan Inc.
ND0611	—	ND0611 is intended for the treatment of Parkinson's disease.	—	Israel	NeuroDerm Ltd.
OPB-2045G	Gluconate olanexidin	OPB-2045G is intended as antiseptic in preoperative patients.	-	Japan	Otsuka Pharmaceutical Co.
RPL554	_	RPL554 is intended for the treatment of allergic rhinitis.	phosphodiesterase 3 and phosphodiesterase 4 enzyme inhibitors	Netherlands	Verona Pharma Plc.
RT001	Botulinum toxin type A	RT001 is intended for the treatment of hyperhidrosis (excessive sweating).	_	United States	Revance Therapeutics Inc.
ThermoDox	Doxorubicin	ThermoDox, in combination with hyperthermia (heat), is intended for the treatment of recurrent chest wall breast cancer.	_	United States	Celsion Corp.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
610677	_	610677 is intended for the treatment of chronic obstructive pulmonary disease.	p38 kinase inhibitor	United States	GlaxoSmithKline Inc.
705498	-	705498 is intended for the treatment of pruritis.	Transient receptor potential vanilloid (TRPV1) antagonist	United States	GlaxoSmithKline Inc.
ALKS 9070	Aripiprazole	ALKS 9070 is intended for the treatment of schizophrenia.	Dopamine receptor agonist and dopamine receptor antagonist	United States	Alkermes plc.
Alocrest	Vinorelbine tartrate	Alocrest is intended for the treatment of advanced solid tumors.	Semi-synthetic vinca alkaloid	United States	Talon Therapeutics Inc.
AN2718	-	AN2718 is intended for the treatment of skin and onychomycosis fungal infections.	Antifungal	United States	Anacor Pharmaceuticals Inc.
AN2728	_	AN2728 is intended for the treatment of atopic dermatitis.	Phosphodiesterase 4 enzyme inhibitor	United States	Anacor Pharmaceuticals Inc.
AN2898	-	AN2898 is intended for the treatment of atopic dermatitis.	Anti-inflammatory	United States	Anacor Pharmaceuticals Inc.
AN2898	-	AN2898 is intended for the treatment of psoriasis.	Anti-inflammatory	United States	Anacor Pharmaceuticals Inc.
AP301	-	AP301 is intended for the treatment of oedematous respiratory failure in patients suffering from lung infection, lung injury and lung transplantation.	Synthetic peptide	Austria	Apeptico GmbH
APD515	_	APD515 is intended for the treatment of xerostomia (dry mouth) in advanced cancer patients.	_	United Kingdom	Acacia Pharma Ltd.
ARD-1600	Nicotine	ARD-1600 is intended as an aid to smoking-cessation treatment.	Nicotinic agonist	United States	Aradigm Corp.
ATI355	_	ATI355 is intended for the treatment of spinal cord injury.	Anti NOGO-A mAb	United States	Novartis Pharmaceuticals Corp.
AZ-003	Fentanyl	AZ-003 is intended for the treatment of acute pain.	Analgesic	United States	Alexza Pharmaceuticals Inc.
BEMA Buprenorphine	Buprenorphine	BEMA Buprenorphine, in combination with nalaxone, is intended for the treatment of opioid dependence.	Partial mu-opiate receptor agonist	United States	BioDelivery Sciences International Inc.
BEMA Granisetron	Granisetron	BEMA Granisetron is intended for the prevention of nausea and vomiting associated with cancer therapy.	5-HT3 receptor antagonist	United States	BioDelivery Sciences International Inc.
Bepotastine Nasal	Bepotastine Besilate	Bepotastine Nasal, in combination with Antihistamine and Steroid, is intended for the treatment of allergic rhinitis.	Histamine H1 receptor antagonist	United States	Ista Pharmaceuticals Inc.
Brakiva	Topotecan	Brakiva is intended for the treatment of ovarian cancer.	—	United States	Talon Therapeutics Inc.
Brakiva	Topotecan	Brakiva is intended for the treatment of small cell lung cancer.	_	United States	Talon Therapeutics Inc.
DermX	_	DermX is intended for the prevention of radiodermatitis in post-surgical breast cancer.	_	United States	ProCertus BioPharm Inc.
Diazepam	Diazepam	Diazepam is intended for the management of patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity.	_	United States	Neurelis Inc.
Dipraglurant	Dipraglurant	Dipraglurant is intended for the treatment of dystonia.	Metabotropic glutamate receptor 5 negative allosteric modulator	European Union	Addex Pharmaceuticals SA
DM-1992	Levodopa and carbidopa	DM-1992 is intended for the treatment of Parkinson's disease.	_	Russia	Depomed Inc.
EGP-437	Dexamethasone phosphate	EGP-437 is intended for the treatment of scleritis.	_	United States	EyeGate Pharmaceuticals Inc.

Exenatide Nasal Spray	Exenatide	Exenatide Nasal Spray is			
		intended for the treatment of type 2 diabetes.	Glucagon-like peptide-1 receptor agonist	United States	Developer: Amylin Pharmaceuticals Inc. and MDRNA Inc.; Marketer: Amylin Pharmaceuticals Inc.
Exenatide Transdermal Patch	Exenatide	Exenatide Transdermal Patch is intended for the treatment of type 2 diabetes.	Glucagon-like peptide-1 receptor agonist	United States	Developer/Marketer: Eli Lilly and Co. and Amylin Pharmaceuticals Inc.
Extended-Release Formulation of Interferon Beta 1a	_	Extended-Release Formulation of Interferon Beta 1a is intended for the treatment of multiple sclerosis.	Interferon beta 1a	European Union	Merck Serono SA
GelVac Influenza Vaccine	_	GelVac Influenza Vaccine is intended for the prevention of influenza.	Preventive vaccine	United States	Nanotherapeutics Inc.
Hydromorphone (PF329)	Hydromorphone	Hydromorphone (PF329) is intended for the treatment of pain.	Narcotic analgesic	United States	PharmacoFore Inc.
iCo-007	_	iCo-007 is intended for the treatment of diabetic macular edema.	c-Raf Kinase	United States	iCo Therapeutics Inc.
IDP 113	_	IDP 113 is intended for the treatment of fungal infection.	_	United States	Valeant Pharmaceuticals International Inc.
IFNbeta-1a Extended Release	_	IFNbeta-1 a Extended Release for the treatment of relapsing forms of multiple sclerosis.	IFNbeta-1a	United States	EMD Serono Inc.
INT0010	Dronabinol	INT0010 is intended for the treatment of multiple sclerosis induced neuropathic pain.	_	Canada	IntelGenx Corp.
ISIS-SOD1	_	ISIS-SOD1 is intended for the treatment of amyotrophic lateral sclerosis.	Antisense	United States	Isis Pharmaceuticals Inc.
ПСА 638		ITCA 638 is intended for the treatment of chronic hepatitis C.	Th1 cytokine	United States	Intarcia Therapeutics Inc.
ITCA 880	_	ITCA 880 is intended for the treatment of obesity.	Endocrine peptide	United States	Intarcia Therapeutics Inc.
ITCA 884	—	ITCA 884 is intended for the treatment of obesity.	Endocrine peptide	United States	Intarcia Therapeutics Inc.
Lemuteporfin	Lemuteporfin	Lemuteporfin is intended for the treatment of acne.	—	Canada	Valocor Therapeutics Inc.
Liris	Lidocaine	LiRIS (Lidocaine Releasing Intravesical System) is intended for the treatment of interstitial cystitis.	_	United States	Taris Biomedical Inc.
Marqibo	Vincristine sulfate	Marqibo is intended for the treatment of cancer in children.	Vinca alkaloid	United States	Talon Therapeutics Inc.
MDT-637	_	MDT-637 is intended for the treatment of respiratory syncytial virus.	Small molecule fusion inhibitor	United States	Developer/Marketer: MicroDose Therapeutx Inc. and Gilead Sciences Inc.
MEDI-534	_	MEDI-534 is intended for the prevention of parainfluenzavirus type 3 infection in young infants.	Preventive vaccine	United States	Medimmune Inc.
Menadione Topical Lotion	Menadione	Menadione is intended for the treatment and prevention of skin rash associated with the use of epidermal growth factor receptor (EGFR) inhibitors in the treatment of certain cancers.	_	United States	Talon Therapeutics Inc.
	Morphine and oxycodone	MoxDuo CR is intended for the treatment of chronic pain.	Opioid analgesic	United States	QR Pharma Inc.
	Buprenorphine and naloxone	NanoBUP is intended for the treatment of opiate addiction.	_	United States	Nanotherapeutics Inc.
NanoDOX	Doxycycline	NanoDOX is intended for the treatment of trauma wounds.	_	United States	Nanotherapeutics Inc.

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
NB-1008	—	NB-1008 is intended for the treatment of influenza.	Therapeutic vaccine	United States	NanoBio Corp.
NRI-ANA	Lidocaine	NRI-ANA is intended for the treatment of acute neuropathic pain.	_	United States	Nuvo Research Inc.
OTO-104	Dexamethasone	OTO-104 is intended for the treatment of Meniere's disease.	Steroid	United States	Otonomy Inc.
Probuphine	Buprenorphine and ethylene vinyl acetate	Probuphine is intended for the treatment of chronic pain.	—	United States	Titan Pharmaceuticals Inc.
Probuphine	Buprenorphine and ethylene vinyl acetate	Probuphine is intended for the treatment of chronic pain.	—	United States	Titan Pharmaceuticals Inc.
Prochieve 2nd Generation	Progesterone	Prochieve 2nd Generation is intended for the treatment of infertile women with progesterone deficiency.	Progestin	United States	Watson Pharmaceuticals Inc.
PUR118	-	PUR118 is intended for the treatment of chronic obstructive pulmonary disease.	-	United States	Pulmatrix Inc.
PUR118	-	PUR118 is intended for the treatment of cystic fibrosis.	_	United States	Pulmatrix Inc.
R343	-	R343 is intended for the treatment of allergic asthma.	Syk kinase inhibitor	United States	Rigel Pharmaceuticals Inc.
Retinoic acid	Retinoic acid	Retinoic acid is intended for the treatment of acne.	Vitamin A derivative	United States	Phosphagenics Ltd.
S-524101	_	S-524101 is intended for the treatment of allergies rhinitis caused by house dust mite allergen.	Therapeutic vaccine	Japan	Shionogi & Co.
Sancuso	Granisetron	Sancuso is intended for the prevention of chemotherapy-induced nausea and vomiting.	5-HT3 receptor antagonist	Japan	Solasia Pharma KK
TPM/Oxycodone	Oxycodone	TPM/Oxycodone is intended for the treatment of pain.	Narcotic analgesic	United States	Phosphagenics Ltd.
Transmucosal Film	Oxybutinin	Transmucosal Film is intended for the treatment of overactive bladder.	_	United States	Auxilium Pharmaceuticals Inc.
UX001	Sialic acid	UX001 is intended for the treatment of hereditary inclusion body myopathy (HIBM).	-	United States	Ultragenyx Pharmaceutical Inc.
Vabicaserin	Vabicaserin hydrochloride	Vabicaserin is intended for the treatment of schizophrenia.	_	United States	Pfizer Inc.
VIAtab	Insulin	VIAtab is intended as an insulin supplement for the treatment of early-stage type 2 diabetes.	-	United States	Biodel Inc.
Vicodin 10/650	Hydrocodone bitartrate and acetaminophen	Vicodin 10/650 is intended for the treatment of moderate-to-severe chronic and acute pain.	Narcotic analgesic and antitussive	United States	Abbott Laboratories
Zoenasa	-	Zoenasa is intended for the treatment of adult patients with left-sided, or distal, ulcerative colitis.	_	United States	Altheus Therapeutics Inc.
ZT-031	_	ZT-031 is intended for the treatment of osteoporosis.	Parathyroid hormone analog	United States	Developer: Azelon Pharmaceuticals Inc. and Aegis Therapeutics LLC; Marketer: Azelon Pharmaceuticals Inc.
ZT-034	Teriparatide	ZT-034 is intended for the treatment of osteoporosis.	Parathyroid hormone analog	United States	Azelon Pharmaceuticals Inc.

Preclinical Development — Drug-Delivery Prescription Products

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
ALKS 7921	-	ALKS 7921 is intended for the treatment of schizophrenia.	_	United States	Alkermes plc.
Alpha-1 Protease Inhibitor Aerosol	_	Alpha-1 Protease Inhibitor Aerosol is intended for the treatment of chronic obstructive pulmonary disease.	Alpha-1 proteinase inhibitor	United States	Grifols Inc.
Alpha-1 Protease Inhibitor Aerosol	_	Alpha-1 Protease Inhibitor Aerosol is intended for the treatment of congenital alpha1 antitrypsin deficiency.	Alpha-1 proteinase inhibitor	United States	Grifols Inc.
Alpha-1 Protease Inhibitor Aerosol	-	Alpha-1 Protease Inhibitor Aerosol is intended for the treatment of cystic fibrosis.	Alpha-1 proteinase inhibitor	United States	Grifols Inc.
Alpha-1 Protease Inhibitor I.V.	_	Alpha-1 Protease Inhibitor I.V. is intended for the treatment of chronic obstructive pulmonary disease.	Alpha-1 proteinase inhibitor	United States	Grifols Inc.
Alpha-1 Protease Inhibitor I.V.	-	Alpha-1 Protease Inhibitor I.V. is intended for the treatment of congenital alpha1 antitrypsin deficiency.	Alpha-1 proteinase inhibitor	United States	Grifols Inc.
Alpha-1 Protease Inhibitor I.V.	-	Alpha-1 Protease Inhibitor I.V. is intended for the treatment of cystic fibrosis.	Alpha-1 proteinase inhibitor	United States	Grifols Inc.
AP301	-	AP301 is intended for the prevention of Ischemia reperfusion injury in the lung during lung transplantation.	Synthetic peptide	United States	Apeptico GmbH
AP301	-	AP301 is intended for the treatment of acute lung injury.	Synthetic peptide	Austria	Apeptico GmbH
ARD-1100	Ciprofloxacin	ARD-1100 is intended for the prevention of pulmonary anthrax infection.	_	United States	Aradigm Corp.
ARD-1100	Ciprofloxacin	ARD-1100 is intended for the treatment of pulmonary anthrax infection.	-	United States	Aradigm Corp.
ARG102	Progesterone	ARG102 is intended for the treatment of dry eye syndrome.	_	United States	arGentis Pharmaceuticals Inc.
Aricept	Donepezil hydrochloride	Aricept is intended for the treatment of Alzheimer's disease.	Acetylcholinesterase inhibitor	Japan	Developer: Teikoku Seiyaku Co. and Eisai Co.; Marketer: Eisai Co.
ATL1102	-	ATL1102 is intended for the treatment of asthma.	-	United States	Antisense Therapeutics Ltd.
ATS907	-	ATS907 is intended for the treatment of glaucoma.	Rho kinase inhibitor	United States	Altheos Inc.
BEMA Triptan	-	BEMA Triptan is intended for the treatment of migraine.	_	United States	BioDelivery Sciences International Inc.
COL-172	-	COL-172 is intended for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy for an extended period of time.	Opioid analgesic	United States	Collegium Pharmaceutical Inc.
CollaGuard	Collagen	CollaGuard is intended for the prevention of postoperative adhesions following abdominal and pelvic surgery.	_	Canada	Merus Labs International Inc.
Cutasil	-	Cutasil is intended for skin scarless wound healing.	-	United States	Simaomics Inc.
Duromist	Sildenafil	Duromist is intended for the treatment of erectile dysfunction.	_	United States	NovaDel Pharma Inc.
ETX1153a	_	ETX1153a is intended for the treatment of hospital acquired resistant infections.	-	United Kingdom	e-Therapeutics Plc.
EV-086	_	EV-086 is intended for the treatment of invasive and topical fungal infections.	Antifungal	Switzerland	Evolva Holding SA
GelVac Typhoid Vaccine	-	GelVac Typhoid Vaccine is intended for the prevention of norovirus infection.	Preventive vaccine	United States	Nanotherapeutics Inc.

Preclinical Development — Drug-Delivery Prescription Products

Dreduct name	Chemical	Indiagtion		Dogion	Doveloper /Marketer
Product name	Cnemical	Indication	Class of drug	Region	Developer/Marketer
GelVac Typhoid Vaccine	_	GelVac Typhoid Vaccine is intended for the prevention of typhoid fever.	Preventive vacciné	United States	Nanotherapeutics Inc.
HB1345	-	HB1345 is intended for the treatment of acne.	Lipohexapeptide	United States	Helix BioMedix Inc.
HB1345	-	HB1345 is intended for the treatment of dermatological infections.	Lipohexapeptide	United States	Helix BioMedix Inc.
HBV Vaccine	_	HBV Vaccine is intended for the treatment of hepatitis B virus infection.	Therapeutic vaccine	United States	NanoBio Corp.
IXS312	_	IXS312 is intended for the treatment of age-related macular degeneration.	Antibody	United States	InNexus Biotechnology Inc.
KRP-AB1102	Aclidinium bromide	KRP-AB1102 is intended for the treatment of chronic obstructive pulmonary disease.	Long acting muscarinic antagonist	Japan	Kyorin Pharmaceutical Co.
LAS190792	_	LAS190792 is intended for the treatment of chronic obstructive pulmonary disease.	Muscarinic antagonist	Spain	Laboratorios Almirall S.A.
Marqibo	Vincristine sulfate	Marqibo is intended for the treatment of multiple melanoma.	Vinca alkaloid	United States	Talon Therapeutics Inc.
MCD-386CR	_	MCD-386CR is intended for the treatment of progressive supranuclear palsy.	M1 selective muscarinic agonist	United States	Mithridion Inc.
N6022 Inhaled	-	N6022 Inhaled is intended for the treatment of asthma.	-	United States	N30 Pharma Inc.
N6022 Inhaled	_	N6022 Inhaled is intended for the treatment of chronic obstructive pulmonary disease.	_	United States	N30 Pharma Inc.
NanoFOVIR	Cidofovir	NanoFOVIR is intended for the treatment of respiratory infection.	-	United States	Nanotherapeutics Inc.
NanoGENT	Gentamicin	NanoGENT is intended to provide early treatment for exposure to biological warfare agents, as well as tuberculosis and other respiratory infections.	Antibiotic	United States	Nanotherapeutics Inc.
NVX-207	-	NVX-207 is intended for the treatment of actinic keratosis.	Small molecule sterol analog	United States	Novelix Pharmaceuticals Inc.
OTO-201	-	OTO-201 is intended for the treatment of otitis media.	Antibiotic	United States	Otonomy Inc.
PeptiClere	-	PeptiClere is intended for the treatment of Alzheimer's disease.	-	United States	ProteoTech Inc.
PT010	Glycopyrrolate, formoterol fumarate and an inhaled corticosteroid	PT010 is intended for the treatment of severe chronic obstructive pulmonary disease.	_	United States	Pearl Therapeutics Inc.
Pulmaquin	Ciprofloxacin	Ciprofloxacin is intended for the management of bronchiectasis.	-	United States	Aradigm Corp.
Relday	Risperidone	Relday is intended for the treatment of schizophrenia.	-	United States	Zogenix Inc.
RTOO1	Botulinum toxin type A	RT001 is intended for the treatment of acne.	-	United States	Revance Therapeutics Inc.
Seala	-	Seala is intended for the treatment of postmenopausal vaginal atrophy.	Estrogen receptor-beta agonist	United States	BioNovo Inc.
Seala	-	Seala is intended for the treatment of vaginal dryness.	Estrogen receptor-beta agonist	United States	BioNovo Inc.
SGX203	-	SGX203 is intended for the treatment of pediatric Crohn's disease.	Corticosteroid	United States	Soligenix Inc.
Simplivir	-	Simplivir is intended for the treatment of gerpes simplex virus.	-	United States	CytoGenix Inc.
Teribone	Teriparatide acetate	Teribone is intended for the treatment of osteoporosis.	Synthetic human parathyroid hormone	Japan	Asahi Kasei Corp.
Topiramate	Topiramate	Topiramate is intended for the treatment of epilepsy.	-	United States	Supernus Pharmaceuticals Inc.

Preclinical Development — Drug-Delivery Prescription Products

Product name	Chemical	Indication	Class of drug	Region	Developer/Marketer
Transmucosal Film	Oxybutinin	Transmucosal Film is intended for the treatment of pain.	-	United States	Auxilium Pharmaceuticals Inc.
Veregen	Polyphenol	Veregen is intended for the treatment of genital warts.	Antiviral	Canada	Developer: MediGene AG; Marketer: Triton Pharma Inc.
Xerclear	Chlorhexidine	Xerclear is intended for the treatment of labial herpes (cold sores).	Antiviral	China	Developer: Medivir AB; Marketer: Daewoong Pharmaceutical Co.
Xerclear	Chlorhexidine	Xerclear is intended for the treatment of labial herpes (cold sores).	Antiviral	Hong Kong	Developer: Medivir AB; Marketer: Daewoong Pharmaceutical Co.
Xerese	Acyclovir and hydrocortisone	Xerese is intended for the treatment of genital herpes.	Purine nucleoside analog	United States	Meda Pharmaceuticals Inc.
Zenpep	Pancrelipase	Zenpep is intended for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis and other conditions.	Pancreatic enzyme product	Russia	Developer: Aptalis Pharma Inc.; Marketer: Nycomed Group
Zolpimist	Zolpidem tartrate	Zolpimist is intended for the treatment of insomnia.	Imidazopyridine	European Union	Rechon Life Science AB
Zybrestat	Fosbretabulin	Zybrestat is intended for the treatment of age-related macular degeneration.	Combretastatin-A4 phosphate	United States	Oxigene Inc.

Drug-Delivery Prescription-Product Companies

A.P. Pharma Inc.

123 Saginaw Dr. Redwood City, CA 94063, United States Phone: 650-366-2626 Fax: 650-365-6490 Website: www.appharma.com

Abbott Laboratories

100 Abbott Park Rd. Abbott Park, IL 60064-6400, United States Phone: 847-937-6100 Fax: 847-937-1511 Email: customerservice@abbott.com Website: www.abbott.com Year established: 1888

Acacia Pharma Ltd.

Harston Mill Cambridge, CB22 7GG, United Kingdom Phone: +44 1223 875130 Fax: +44 1223 875131 Website: www.acaciapharma.com

Access Pharmaceuticals Inc.

2600 Stemmons Freeway, Suite 176 Dallas, TX 75207-2107, United States Phone: 214-905-5100 Fax: 214-905-5101 Email: akc@accesspharma.com Website: www.accesspharma.com Year established: 1974

AcelRx Pharmaceuticals Inc.

575 Chesapeake Dr. Redwood City, CA 94063, United States Phone: 650-216-3500 Fax: 650-216-6500 Email: info@acelrx.com Website: www.acelrx.com Year established: 2005

Adamas Pharmaceuticals Inc.

1900 Powell St., Suite 1050 Emeryville, CA 94608, United States Phone: 510-450-3500 Fax: 510-428-0519 Email: info@adamaspharma.com Website: www.adamaspharma.com Year established: 2002

Addex Pharmaceuticals SA

12, chemin des Aulx Geneva, Plan-les-Ouates 1228, Switzerland Phone: +41 22 884 15 55 Fax: +41 22 884 15 56 Email: info@addexpharma.com Website: www.addexpharma.com

Adeona Pharmaceuticals Inc.

3995 Research Park Drive, Suite 200 Ann Arbor, MI 48108, United States Phone: 734-332-7800 Fax: 734-332-7878 Email: info@adeonapharma.com Website: www.adeonapharma.com Year established: 2001

Aegis Therapeutics LLC

16870 West Bernardo Dr., Suite 390 San Diego, CA 92127, United States Phone: 858-618-1400 Fax: 858-618-1441 Email: info@aegisthera.com Website: www.aegisthera.com

Aerovance Inc.

2929 Seventh St., Suite 120 Berkeley, CA 94710, United States Phone: 510-549-5500 Fax: 510-549-5501 Email: info@aerovance.com Website: www.aerovance.com Year established: 2004

Agennix Inc.

8 Greenway Plaza, Suite 910 Houston, TX 77046, United States Phone: 713-552-1091 Fax: 713-552-0795 Email: info@agennix.com Website: www.agennix.com Year established: 1993

Agile Therapeutics Inc.

306 Wall St., Princeton, NJ 08540, United States Phone: 609-683-1880 Fax: 609-683-1855 Email: info@agiletherapeutics.com Website: www.agiletherapeutics.com Year established: 1997

Akela Pharma Inc.

11501 Domain Drive, Suite 130 Austin, TX 78758, United States Phone: 512-834-0449 Fax: 512-834-2105 Website: www.akelapharma.com Year established: 1998

Alcobra Ltd.

53 Hashalom Rd. Givatayim, Israel *Phone: +972 3 7326616* Year established: 2008

Alexza Pharmaceuticals Inc.

2091 Stierlin Court Mountain View, CA 94043, United States Phone: 650-944-7000 Fax: 650-944-7999 Email: info@alexza.com Website: www.alexza.com Year established: 2000

Alimera Sciences Inc.

6120 Windward Pkwy., Suite 290 Alpharetta, GA 30005, United States Phone: 678-990-5740 Fax: 678-990-5744 Website: www.alimerasciences.com Year established: 2003

Alkermes plc.

852 Winter St. Waltham, MA 02451, United States Phone: 781-609-6000 Email: mediainfo@alkermes.com Website: www.alkermes.com Year established: 1987

Allergan Inc.

2525 DuPont Dr., PO Box 19534 Irvine, CA 92612, United States Phone: 714-246-4500 Fax: 714-246-6987 Email: corpinfo@allergan.com Website: www.allergan.com Year established: 1950

Allon Therapeutics Inc. 1168 Hamilton St., Suite 506 Vancouver, BC V6B 2S2, Canada Phone: 604-736-0634 Fax: 604-736-1616 Email: info@allontherapeutics.com Website: www.allontherapeutics.com

Alnylam Pharmaceuticals Inc.

300 Third St., 3rd Floor Cambridge, MA 02142, United States Phone: 617-551-8200 Fax: 617-551-8101 Website: www.alnylam.com Year established: 2002

Altheos Inc.

601 Gateway Blvd., Suite 250 South San Francisco, CA 94080, United States Phone: 650-989-8570 Fax: 650-745-0676 Email: info@altheos.com Website: altheos.net Year established: 2009

Altheus Therapeutics Inc.

755 Research Pkwy., Suite 435 Oklahoma City, OK 73104, United States Phone: 405-319-8180 Fax: 408-319-8178 Email: info@altheustherapeutics.com Website: altheustherapeutics.com

Amylin Pharmaceuticals Inc.

9360 Towne Centre Dr., Suite 110 San Diego, CA 92121, United States Phone: 858-552-2200 Fax: 858-552-2212 Email: ir@amylin.com Website: www.amylin.com Year established: 1987

Anacor Pharmaceuticals Inc.

1020 E. Meadow Cir. Palo Alto, CA 94303, United States Phone: 650-543-7500 Fax: 650-543-7660 Email: info@anacor.com Website: www.anacor.com Year established: 2002

AndroScience Corp.

11175 Flintkote Ave., Suite F San Diego, CA 92121, United States Phone: 858-638-7230 Email: info88@androscience.com Website: www.androscience.com Year established: 2000

Antares Pharma Inc.

250 Phillips Blvd., Suite 290, Princeton Crossroads Corporate Center Ewing, NJ 08618, United States Phone: 609-359-3020 Fax: 609-359-3015 Email: info@antarespharma.com Website: www.antarespharma.com Year established: 2001

Antisense Therapeutics Ltd.

Level 1, 10 Wallace Ave. Toorak, Victoria 3142, Australia Phone: +61 3 9827 8999 Fax: +61 3 9827 1166 Website: www.antisense.com.au

Apeptico GmbH

Mariahilferstraße 136 Top 1.15 Vienna, A-1150, Austria Phone: +43 664 1432919 Fax: +43 664 1477280 Email: office@apeptico.com Website: www.apeptico.com

Apricus Biosciences Inc.

6330 Nancy Ridge Drive, Suite 103 San Diego, CA 92121, United States Phone: 858-222-8041 Fax: 858-866-0482 Email: nexmedla@aol.com Website: www.apricusbio.com Year established: 1987

Aptalis Pharma Inc.

597 Laurier Blvd. Mont-Saint-Hilaire, QC J3H 6C4, Canada Phone: 450-467-5138 Fax: 450-464-9979 Email: axcan@axcan.com Website: www.aptalispharma.com Year established: 1982

Aradigm Corp.

3929 Point Eden Way Hayward, CA 94545, United States Phone: 510-265-9000 Fax: 510-265-0277 Email: investor@aradigm.com Website: www.aradigm.com Year established: 1991

Arcion Therapeutics Inc.

2400 Boston St., Suite 330 Baltimore, MD 21224, United States Phone: 410-522-8701 Email: info@arciontherapeutics.com Website: www.arciontherapeutics.com

arGentis Pharmaceuticals Inc.

1661 International Drive, Suite 400 Memphis, TN 38120, United States Phone: 901-818-3262 Fax: 866-460-8790 Email: info@argentisrx.com Website: www.argentisrx.com Year established: 2005

Asahi Kasei Corp.

1-105 Kanda Jinbocho, Chiyoda-ku Tokyo, Chiyoda-ku 101-8101, Japan Phone: +81 3 3507 2060 Fax: +81 3 3507 2495 Email: asahi@ml.asahi-kasei.co.jp Website: www.asahi-kasei.co.jp Year established: 1931

Ascend Therapeutics Inc.

607 Herndon Parkway, Suite 110 Herndon, VA 20170, United States Phone: 703-471-4744 Fax: 703-478-0959 Email: info@ascendtherapeutics.com Website: www.ascendtherapeutics.com Year established: 2001

Asmacure Ltee

2600 Blvd. Laurier, Suite 880 Quebec, QUG1V4W2, Canada Phone: 418-780-4255 Fax: 418-781-0216 Website: www.asmacure.com

AstraZeneca Pharmaceuticals LP

1800 Concord Pike, PO Box 15437 Wilmington, DE 19850-5437, United States Phone: 302-886-3000 Website: www.astrazeneca-us.com

AstraZeneca Pic.

2 Kingdom Street, Paddington London, W2 6BD, United Kingdom Phone: +44 20 7604 8000 Fax: +44 20 7604 8270 Email: investor-relations@astrazeneca.com Website: www.astrazeneca.com Year established: 1999

Auxilium Pharmaceuticals Inc.

40 Valley Stream Pkwy. Malvern, PA 19355, United States Phone: 484-321-5900 Fax: 484-321-5999 Website: www.auxilium.com Year established: 1999

Azelon Pharmaceuticals Inc. Four Tower Bridge, 200 Barr Harbor Dr. Suite 400 West Conshohocken, PA 19428, United States Phone: 610-260-6045 Website: www.azelon.com Year established: 2001

Baxter Healthcare Corp.

One Baxter Pkwy. Deerfield, IL 60015, United States Phone: 847-948-2000 Fax: 847-948-3642 Website: www.baxter.com

Bayer HealthCare Pharmaceuticals

Mueller Strasse 178 Berlin, Mitte 13353, Germany Phone: +49 3 04 681 111 Fax: +49 3 04 681 5305 Email: investor.relations@schering.de Website: www.bayerscheringpharma.de Year established: 2006

Bayer HealthCare Pharmaceuticals Inc.

6 West Belt Rd. Wayne, NJ 07470, United States Phone: 973-694-4100 Website: www.bayerhealthcare.com Year established: 2007

BHR Pharma LLC

607 Herndon Pkwy., Suite 110 Herndon, VA 20170, United States Phone: 703-964-3033 Fax: 703-964-3044 Email: info@bhr-pharma.com Website: www.bhr-pharma.com Year established: 2008

BioAlliance Pharma SA

49 Boulevard du General Martial Valin, 4th Floor Paris, 75015, France Phone: +33 1 45 58 76 00 Fax: +33 1 45 58 08 81 Email: bioalliance@bioalliancepharma.com Website: www.bioalliancepharma.com

BioCancell Therapeutics Inc.

8 Hartom St. Jerusalem, 97775, Israel Phone: +972 2 548 6555 Fax: +972 2 548 6550 Email: info@biocancell.com Website: www.biocancell.com Year established: 2004

Biodel Inc.

100 Saw Mill Rd. Danbury, CT 06810-7352, United States Phone: 203-796-5000 Fax: 203-796-5001 Email: media@biodel.com Website: www.biodel.com

BioDelivery Sciences International Inc.

801 Corporate Center Drive, Suite 210 Raleigh, NC 27607, United States Phone: 919-582-9050 Fax: 919-582-9051 Email: bdsi-info@bdsinternational.com Website: www.bdsi.com Year established: 1997

Biolex Therapeutics Inc.

158 Credle St Pittsboro, NC 27312, United States Phone: 919-542-9901 Fax: 919-542-9910 Email: info@biolex.com Website: www.biolex.com Year established: 1997

BioMarck Pharmaceuticals Ltd.

Westpark Corporate Center, 4364 South Alston Avenue Durham, NC 27713, United States Email: info@biomarck.com Website: www.biomarck.com

BioNovo Inc.

5858 Horton St., Suite 400 Emeryville, CA 94608, United States Phone: 510-601-2000 Fax: 510-601-5050 Email: business@bionovo.com Website: www.bionovo.com Year established: 1998

Biopartners GmbH

Sihlbruggstrasse 3 Baar, 6340, Switzerland Phone: +41 41 766 20 80 Fax: +41 41 766 20 81 Email: info@biopartners.ch Website: www.biopartners.ch Year established: 2000

BioSante Pharmaceuticals Inc.

111 Barclay Blvd. Lincolnshire, IL 60069, United States Phone: 847-478-0500 Fax: 847-478-9152 Email: info@biosantepharma.com Website: www.biosantepharma.com

Boehringer Ingelheim GmbH

Binger Strasse 173 Ingelheim, 55216, Germany Phone: +49 6 13 277 0 Fax: +49 6 13 272 3000 Website: www.boehringer-ingelheim.com Year established: 1885

Bristol-Myers Squibb Co.

345 Park Ave. New York, NY 10154-0037, United States Phone: 212-546-4000 Fax: 212-546-4020 Website: www.bms.com Year established: 1989

BTG International Inc.

Five Tower Bridge Suite 800, 300 Barr Harbor Dr. West Conshohocken, PA 19428-2998, United States Phone: 610-278-1660 Fax: 610-278-1605 Email: info@btgplc.com Website: www.btgplc.com

CardioVascular BioTherapeutics Inc.

9500 Hillwood Drive, Suite 200 Las Vegas, NV 89134, United States Phone: 702-839-7200 Email: pr@cvbt.com Website: www.CVBT.com

Celator Pharmaceuticals Inc.

303B College Rd. East Princeton, NJ 08540, United States Phone: 609-243-0123 Fax: 609-243-0202 Email: info@celatorpharma.com Website: www.celatorpharma.com

Celsion Corp.

10220-I Old Columbia Rd. Columbia, MD 21046-1705, United States Phone: 410-290-5390 Fax: 410-290-5394 Fmail: celsion@celsion.com Website: www.celsion.com

Celtic Pharmaceutical Holdings L.P.

1 Victoria Street, 4th Floor Hamilton, HM 11, Bermuda Phone: +1 441 299 7440 Email: info@celticpharma.com Website: www.celticpharma.com

Celtic Therapeutics LLLC

34-35 Dronningens Gade, Hibsicus Alley St. Thomas, 00802, U.S. Virgin Islands Phone: 340-779-6908 Fax: 340-714-5192 Email: info@celtictherapeutics.com Website: www.celtictherapeutics.com Year established: 2007

Cerulean Pharma Inc.

840 Memorial Drive, 5th Floor Cambridge, MA 02139, United States Phone: 617-551-9600 Fax: 617-494-1544 Email: info@Ceruleanrx.com Website: www.ceruleanrx.com

Clinuvel Pharmaceuticals Ltd.

330 Collins St., Level 11 Melbourne, Victoria VIC 3000, Australia Phone: +61 3 9660 4900 Fax: +61 3 9660 4999 Email: mail@clinuvel.com Website: www.clinuvel.com Year established: 1999

CoDa Therapeutics Inc.

10505 Sorrento Valley Rd., Suite 395 San Diego, CA 92121, United States Phone: 858-677-0474 Fax: 858-677-0475 Email: info@codatherapeutics.com Website: www.codatherapeutics.com

Collegium Pharmaceutical Inc.

400 Highland Corporate Dr. Cumberland, RI 02864, United States Phone: 401-762-2000 Email: info@collegiumpharma.com Website: www.collegiumpharma.com Year established: 2002

Cosmo Pharmaceuticals SpA

Via C. Colombo 1 Lainate, I-20020, Italy Phone: +39 2 9333 7614 Fax: +39 2 9333 7663 Email: info@cosmopharmaceuticals.com Website: www.cosmopharmaceuticals.com Year established: 1996

Creabilis SA

15 Rue Edward Steichen L-2540, Luxembourg Email: info@creabilis-sa.com Website: www.creabilis-sa.com Year established: 2003

Cubist Pharmaceuticals Inc.

65 Hayden Ave. Lexington, MA 02421, United States Phone: 781-860-8660 Fax: 781-240-0256 Email: ir@cubist.com Website: www.cubist.com Year established: 1992

CytoGenix Inc.

New York, NY 77042, United States Phone: 830-632-5944 Fax: 830-632-5944 Email: info@cytogenix.com Website: www.cytogenix.com

Cytokine PharmaSciences Inc.

Walnut Hill Plaza, 150 S. Warner Rd., Suite 420 King of Prussia, PA 19406, United States Phone: 610-687-1776 Fax: 610-687-4340 Email: info@cytokinepharmasciences.com Website: www.cytokinepharmasciences.com Year established: 1993

Daewoong Pharmaceutical Co.

163-3 Samsung-dong, Kangnam-gu Seoul, Korea Phone: +82 2 550 8259 Fax: +82 2 550 8249 Email: global@daewoong.co.kr Website: www.daewoong.com

Daiichi Sankyo Co.

3-5-1 Nihombashi-honcho Tokyo, Chuo-ku 103-8426, Japan Phone: +81 3 6225 1111 Website: www.daiichisankyo.co.jp Year established: 2005

Daiichi Sankyo Inc.

Two Hilton Ct. Parsippany, NJ 07054, United States Phone: 973-359-2600 Fax: 973-359-2645 Website: www.daiichisankyo-us.com Year established: 2006

Delcath Systems Inc. 810 Seventh Avenue, Suite 3505 New York, NY 10019, United States Phone: 212-489-2100 Fax: 212-498-2102 Email: info@delcath.com Website: www.delcath.com

Depomed Inc.

1360 O'Brien Dr. Menlo Park, CA 94025-1436, United States Phone: 650-462-5900 Fax: 650-462-9993 Email: media@depomedinc.com Website: www.depomedinc.com Year established: 1995

Diamyd Inc.

2100 Wharton Street, Suite 701 Pittsburgh, PA 15203, United States Phone: 412-488-0348 Fax: 412-488-0349 Email: info@diamyd.com Website: www.diamyd.com Year established: 2005

Digestive Care Inc.

1120 Win Dr. Bethlehem, PA 18017-7059, United States Phone: 610-882-5950 Fax: 610-882-0349 Email: digestivecare@fast.net Website: www.digestivecare.com Year established: 1990

Dipexium Pharmaceuticals LLC

22 Camelot Ct. White Plains, NY 10603-1552, United States Phone: 917-533-1469 Website: www.dipexiumpharmaceuticals.com

Durect Corp.

2 Results Way Cupertino, CA 95014-5962, United States Phone: 408-777-1417 Fax: 408-777-3577 Email: ir@durect.com Website: www.durect.com Year established: 1998

Dyax Corp.

300 Technology Sq. Cambridge, MA 02139, United States Phone: 617-225-2500 Fax: 617-225-2501 Email: ir@dyax.com Website: www.dyax.com Year established: 1989

Eisai Co.

4-6-10 Koishikawa Tokyo, Bunkyo-ku 112-8088, Japan Phone: +81 3 3817 3700 Fax: +81 3 3811 3305 Website: www.eisai.co.jp Year established: 1941

Eisai Inc.

100 Tice Blvd. Woodcliff, NJ 07666, United States Phone: 201-692-1100 Fax: 201-692-1804 Website: www.elsai.com Year established: 1995

Eli Lilly and Co.

Lilly Corporate Center Indianapolis, IN 46285, United States Phone: 317-276-2000 Fax: 317-277-6429 Website: www.lilly.com Year established: 1876

Elite Pharmaceuticals Inc.

165 Ludlow Ave. Northvale, NJ 07647, United States Phone: 201-750-2646 Fax: 201-750-2755 Email: info@elitepharma.com Website: www.elitepharma.com Year established: 1990

EMD Serono Inc.

One Technology PI. Rockland, MA 02370, United States Phone: 781-681-2340 Email: us.mediarelations@serono.com Website: www.emdserono.com Year established: 2007

Endo Pharmaceuticals Inc.

100 Endo Blvd. Chadds Ford, PA 19317, United States Phone: 610-558-9800 Fax: 610-558-8979 Website: www.endo.com

EpiCept Corp.

777 Old Saw Mill River Rd. Tarrytown, NY 10591, United States Phone: 914-606-3500 Fax: 914-606-3501 Email: mail@epicept.com Website: www.epicept.com

e-Therapeutics Plc.

Holland Park, Holland Dr. New Castle-upon-Tyne, NE2 4LZ, United Kingdom *Website: www.etherapeutics.co.uk* Year established: 2001

Evolva Holding SA

Duggingerstrasse 23 Reinach, CH-4153, Switzerland Phone: +41 61 485 2000 Fax: +41 61 485 2001 Email: info@evolva.com Website: www.evolva.com

EyeGate Pharmaceuticals Inc.

100 Beaver St. Waltham, MA 02453, United States Phone: 781-788-8869 Email: info@eyegatepharma.com Website: www.eyegatepharma.com Year established: 1998

FemmePharma Global Healthcare Inc.

37 West Ave., Second Floor Wayne, PA 19087, United States Phone: 610-995-0801 Fax: 610-995-0825 Email: info@fpghc.com Website: www.fpghc.com Year established: 2005

Forest Laboratories Inc.

909 Third Ave. New York, NY 10022-4731, United States Phone: 212-421-7850 Email: InvestorRelations@fx.com Website: www.fx.com Year established: 1956

Galderma Laboratories LP

14501 N. Freeway Fort Worth, TX 76177, United States Phone: 817-961-5000 Website: www.galdermausa.com Year established: 1961

Genentech Inc.

One DNA Way South San Francisco, CA 94080-4990, United States Phone: 650-225-1000 Fax: 650-225-6000 Email: investor.relations@gene.com Website: www.gene.com Year established: 1976

Generex Biotechnology Corp.

33 Harbour Square, Suite 202 Toronto, ON M5J 2G2, Canada Phone: 416-364-2551 Fax: 416-364-9363 Email: info@generex.com Website: www.generex.com Year established: 1983

Gilead Sciences Inc.

333 Lakeside Dr. Foster City, CA 94404, United States Phone: 650-574-3000 Fax: 650-578-9264 Email: public_offairs@gileaal.com Website: www.gileaal.com Year established: 1987

GlaxoSmithKline Inc.

5 Moore Dr., PO Box 13398 Research Triangle Park, NC 27709-0000, United States Phone: 888-825-5249 Fax: 919-248-2381 Email: corporate.media@gsk.com Website: us.gsk.com

GlaxoSmithKline Plc.

980 Great West Rd. Brentford, Middlesex TW8 9GS, United Kingdom Phone: +44 208 047 5000 Fax: +44 208 047 7897 Email: corporate.media@gsk.com Website: www.gsk.com Year established: 2000

Grifols Inc.

4101 Research Commons, 79 T. W. Alexander Dr., PO Box 110526 Research Triangle Park, NC 27709, United States Phone: 919-316-6300 Website: www.talecris.com Year established: 2005

Grunenthal GmbH

Pascalstrabe 6 Aachen-Oberforstbach, 52076, Germany Phone: +49 2 41 569 1111 Fax: +49 2 41 569 1112 Email: info@grunenthal.com Website: www.grunenthal.com Year established: 1946

HAL Allergy Group

J.H. Oortweg 15-17 Leiden, 2333 CH, Netherlands *Website: www.hal-allergy.com* Year established: 1959

Hameln rds GmbH

Langes Feld 13 Hameln, 31789, Germany Phone: +49 5151 581 208 Website: www.hameln-rds.com

Hatchtech Pty Ltd

Level 9, 278 Collins Street Victoria, 3000, Australia Phone: +61 400 673 938 Email: vbowles@hatchtech.com.au Website: hatchtech.com.au

Healthpoint Ltd.

3909 Hulen St. Ft. Worth, TX 76107, United States Phone: 800-441-8227 Fax: 817-900-4100 Website: www.healthpoint.com Year established: 1992

Helix BioMedix Inc.

22118 20th Ave. SE, Suite 204 Bothell, WA 98021, United States Phone: 425-402-8400 Fax: 425-806-2999 Website: www.helixbiomedix.com

Helix BioPharma Corp.

305 Industrial Pkwy. S., Unit 3 Aurora, ON L4G 6X7, Canada Phone: 905-841-2300 Fax: 905-841-2244 Email: helix@helixbiopharma.com Website: www.helixbiopharma.com Year established: 1995

Hisamitsu Pharmaceutical Inc.

408 Tashireo Daikan-machi Saga, Tosu-shi 841-0017, Japan Phone: +81 3 5293 1720 Fax: +81 3 5293 1724 Website: www.hisamitsu.co.jp/english/index.html Year established: 1847

Horizon Pharma Inc.

1033 Skokie Blvd., Suite 355 Northbrook, IL 60062, United States Phone: 224-383-3000 Fax: 224-383-3001 Website: www.horizonpharma.com Year established: 2010

iCo Therapeutics Inc.

760-777 Hornby St. Vancouver, BC V6Z 154, Canada Phone: 604-602-9414 Fax: 604-602-9699 Email: info@icotherapeutics.com Website: www.icotherapeutics.com Year established: 2005

Icon Bioscience Inc. (IBI)

1253 Reamwood Ave. Sunnyvale, CA 94089, United States Website: www.iconbioscience.com

Impax Laboratories Inc.

30831 Huntwood Ave. Hayward, CA 94544, United States Phone: 510-476-2000 Fax: 510-471-3200 Email: info@impaxlabs.com Website: www.inpaxlabs.com Year established: 1997

Incyte Corp.

Rt. 141 & Henry Clay Rd., Building E336 Wilmington, DE 19880, United States Phone: 302-498-6700 Fax: 302-425-2750 Email: info@incyte.com Website: www.incyte.com Year established: 1991

InNexus Biotechnology Inc.

1055 West Hastings St., Suite 2200 Vancouver, BC V6E 2E9, Canada Phone: 480-862-7500 Fax: 480-657-8919 Email: info@ixsbio.com Website: www.ixsbio.com Year established: 2001

Innocoll Inc.

42662 Kitchen Prim Ct. Ashburn, VA 20148, United States Email: customerservice@innocollinc.com Website: www.innocollinc.com

Inotek Pharmaceuticals Corp.

100 Cummings Center, 4th Floor Beverly, MA 01915, United States Phone: 978-232-9660 Fax: 978-232-8975 Email: info@inotekcorp.com Website: www.inotekcorp.com Year established: 1996

InSite Vision Inc.

965 Atlantic Ave. Alameda, CA 94501, United States Phone: 510-865-8800 Fax: 510-865-5700 Website: www.insitevision.com Year established: 1986

Insmed Inc.

8720 Stony Point Pkwy., Suite 200 Richmond, VA 23235, United States Phone: 804-565-3000 Fax: 804-565-3500 Email: investor@insmed.com Website: www.insmed.com

Insys Therapeutics Inc. 10220 South 51st Street, Suite 2 Phoenix, AZ 85044, United States Phone: 602-910-2617 Fax: 602-910-2627 Email: info@insysrx.com Website: www.insysrx.com

Intarcia Therapeutics Inc.

24650 Industrial Blvd. Hayward, CA 94545, United States Phone: 510-782-7800 Fax: 510-782-7801 Website: www.intarcia.com Year established: 1997

IntelGenx Corp.

6425 Abrams Ville St-Laurent, QC H4S 1X9, Canada Phone: 514-331-7440 Fax: 514-331-0436 Email: info@intelgenx.com Website: www.intelgenx.com

Intendis GmbH

Max-Dohrn-StraBe 10 Berlin, Mitte 10589, Germany Phone: +49 30 520075 660 Email: media@intendis.com Website: www.intendis.com Year established: 2005

Intercell AG

Campus Vienna Biocenter 3 Vienna, 1030, Austria Phone: +43 1 20620 Fax: +43 1 20620-800 Email: info@intercell.com Website: www.intercell.com Year established: 1998

Ipsen Inc.

27 Maple St. Milford, MA 01757-3650, United States Phone: 774-396-6800 Fax: 508-473-3531 Email: contact.presse@ipsen.com Website: www.ipsen.com Year established: 1986

Isis Pharmaceuticals Inc.

1896 Rutherford Rd. Carlsbad, CA 92008, United States Phone: 760-931-9200 Fax: 760-603-2700 Email: info@isisph.com Website: www.isispharm.com Year established: 1989

Ista Pharmaceuticals Inc. 15295 Alton Pkwy., Irvine, CA 92618, United States *Phone: 949-788-6000* Fax: 949-788-6010 Email: info@istavision.com Website: www.istavision.com

Source: eKnowledgeBase.com

Janssen Pharmaceuticals Inc.

Titusville, NJ, United States Website: www.janssenpharmaceuticalsinc.com

Johnson & Johnson Pharmaceutical Research &

Development 920 Route 202, PO Box 300 Raritan, NJ 08869, United States Phone: 908-704-4000 Fax: 908-722-5867 Email: GlblPharmaRDCom@prdus.jnj.com Website: www.jnjpharmarnd.com

Kamada Ltd.

Year established: 1988

Kiryat Weizmann, Science Park, 7 Sapir St., PO Box 4081 Ness Ziona, 74140, Israel Phone: +972 8 940 6472 Fax: +972 8 940 6473 Email: invest@kamada.com Website: www.kamada.com Year established: 1990

Kyorin Pharmaceutical Co.

5, Kanda Surugadai 2-chome Tokyo, Chiyoda-ku 101-8311, Japan *Phone: +81 3 3293 3451* Email: homepage@kyorin-gr.co.jp Website: www.kyorin-gr.co.jp/e/index.html

Kyowa Hakko Kirin Co.

Otemachi Building 5F 1-6-1 Tokyo, Chiyoda-ku 100-8185, Japan Phone: +81 3 3282 0007 Fax: +81 3 3284 1968 Website: www.kyowa-kirin.co.jp Year established: 2008

Kyowa Hakko Kirin Pharma Inc.

212 Carnegie Center, Suite 101 Princeton, NJ 08540, United States Phone: 609-919-1100 Website: www.kyowa-kirin-pharma.com

Laboratorios Almirall S.A.

General Mitre 151 Barcelona, 08022, Spain Phone: +34 93 291 30 00 Fax: +34 93 291 31 80 Email: info@almirallprodesfarma.com Website: www.almirall.es Year established: 1943

Labtec GmbH

Ralifeisenstrasse 4 Langenfeld, 40764, Germany Phone: +49 2173 9735 0 Fax: +49 2173 9735 35 Email: info@labtec-pharma.com Website: www.labtec-pharma.com Year established: 1990

Leo Pharma Inc.

1 Sylvan Way Parsippany, NJ 07054, United States Phone: 973-637-1690 Fax: 973-637-1682 Website: www.leo-pharma.com

LG Life Sciences Ltd.

LG Twin Tower, 20, Youido-dong Seoul, Yongdungpo-gu 150-721, Korea Phone: +82 23 773 1114 Fax: +82 23 773 7012 Website: www.lgls.co.kr/eng Year established: 2002

Lightlake Therapeutics Inc.

54 Baker Street London, W1U 7BU, United Kingdom Website: www.lightlaketherapeutics.com

LigoCyte Pharmaceuticals Inc.

2155 Analysis Dr. Bozeman, MT 59718, United States Phone: 406-585-2733 Fax: 406-585-2766 Email: ligocyte@ligocyte.com Website: www.ligocyte.com Year established: 1998

Lipid Therapeutics GmbH

Alte Glockengiesserei 9 Heidelberg, 69115, Germany Phone: +49 6221 33 50 58 0 Fax: +49 6221 33 50 58 9 Email: info@lipid-therapeutics.com Website: www.lipid-therapeutics.com Year established: 2008

Living Cell Technologies Ltd

70 Pitt St., Level 3, Suite 302, Sydney, NSW 2000, Australia Phone: +61 3 0013 5875 Email: info@lctglobal.com Website: www.lctglobal.com Year established: 1987

Mallinckrodt Pharmaceuticals

675 McDonnell Blvd., PO Box 5840 St. Louis, MO 63134, United States Phone: 800-325-8888 Website: www.mallinckrodt.com

MannKind Corp. 28903 N. Ave. Paine Valencia, CA 91355, United States Phone: 661-775-5300 Fax: 661-775-2081 Website: www.mannkindcorp.com Year established: 1991

MAP Pharmaceuticals Inc.

2400 Bayshore Pkwy., Suite 200 Mountain View, CA 94043, United States Phone: 650-386-3100 Fax: 650-386-3101 Website: www.mappharma.com Year established: 2003

McNeil Pediatrics

Boston, MA, United States Website: www.mcneilpediatrics.net

MDRNA Inc.

3830 Monte Villa Pkwy. Bothell, WA 98021, United States Phone: 425-908-3600 Fax: 425-908-3650 Email: ir@marinabio.com Website: www.mdrnainc.com Year established: 1993

Meda AB

Pipers vag 2 A, Box 906, Solna, SE-170 09, Sweden Phone: +46 8 630 19 00 Fax: +46 8 630 1 9 50 Email: info@meda.se Website: www.meda.se

Meda Pharmaceuticals Inc.

265 Davidson Ave., Suite 300 Somerset, NJ 08873, United States Phone: 732-564-2200 Website: www.medpointepharma.com Year established: 2001

MediGene AG

Lochhamer Strasse 11, Martinsried, 82152, Germany Phone: +49 89 85 65 29 00 Fax: +49 89 85 65 29 20 Email: medigene@medigene.de Website: www.medigene.com Year established: 1994

MedImmune Inc.

One MedImmune Way Gaithersburg, MD 20878, United States Phone: 301-398-0000 Email: info@medimmune.com Website: www.medimmune.com Year established: 1988

MediQuest Therapeutics Inc.

22322 20th Ave. SE, Suite 100 Bothell, WA 98021, United States Phone: 425-398-9580 Fax: 425-398-9590 Email: info@mqti.com Website: www.mqti.com Year established: 1994

Medivir AB

Lunastigen 7, PO Box 1086 Huddinge, SE-141 22, Sweden Phone: +46 85 46 83 10 0 Fax: +46 85 46 83 19 9 Email: medivir@medivir.se Website: www.medivir.se Year established: 1988

Merck & Co.

One Merck Dr., PO Box 100 Whitehouse Station, NJ 08889-0100, United States Phone: 908-423-1000 Website: www.merck.com Year established: 1891

Merck Serono SA

9 Chemin des Mines Geneva, CH-1211, Switzerland Phone: +41 22 739 30 00 Fax: +41 22 739 21 79 Email: media.relations@serono.com Website: www.merckserono.net Year established: 1906

Merus Labs International Inc. 1177 W. Hastings St., Suite 2007 Vancouver, BC V6E 2K3, Canada Phone: 604-221-0595 Fax: 604-225-0588 Email: info@meruslabs.com Website: www.meruslabs.com

MicroDose Therapeutx Inc.

4262 U.S. Route 1 Monmouth Junction, NJ 08852, United States Phone: 732-355-2100 Fax: 732-355-2101 Website: mdtx.com Year established: 1998

Milestone Biosciences LLC

200 Via De Lago, Suite B Altamonte Springs, FL 32701, United States Fax: 407-977-2247 Email: info@milestonebio.com Website: www.milestonebio.com Year established: 2007

Mithridion Inc.

505 Science Dr., Suite C Madison, WI 53711, United States Phone: 608-443-2432 Fax: 608-443-2434 Email: info@mithridion.com Website: www.mithridion.com Year established: 2006

Mochida Pharmaceutical Co.

7, Yotsuya 1-chome Tokyo, Shinjuku-ku 160-8515, Japan Phone: +81 3 3358 7211 Fax: +81 3 3358 7887 Website: www.mochida.co.jp Year established: 1913

Morria Biopharmaceuticals Plc.

53 Davies St. London, Mayfair W1K5JH, United Kingdom Phone: +44 207 152 6341 Fax: +44 207 152 6342 Email: info@morria.com Website: www.morria.com

Mpex Pharmaceuticals Inc.

11535 Sorrento Valley Rd. San Diego, CA 92109, United States Phone: 858-875-2840 Fax: 858-875-2851 Email: info@mpexpharma.com Website: www.mpexpharma.com

Mundipharma International Ltd.

Milton Rd., Cambridge Science Park, Unit 220 Cambridge, CB4 0GW, United Kingdom Phone: +44 1223 424 211 Fax: +44 1223 426 626 Website: www.mundipharma.co.uk

N30 Pharma Inc.

885 Arapahoe Ave. Boulder, CO 80302, United States Phone: 720-565-4079 Website: www.n30pharma.com

NanoBio Corp. 2311 Green Rd., Suite A Ann Arbor, MI 48105, United States Phone: 734-302-4000 Fax: 734-302-9150 Email: info@nanobio.com Website: www.nanobio.com Year established: 2000

Nanotherapeutics Inc.

13859 Progress Blvd., Suite 300 Alachua, FL 32615, United States Phone: 386-462-9663 Fax: 386-462-2087 Email: info@nanotherapeutics.com Website: www.nanotherapeutics.com

Nektar Therapeutics

455 Mission Bay Boulevard South San Francisco, CA 94158, United States Phone: 415-482-5300 Fax: 415-339-5300 Email: nektarSF@nektar.com Website: www.nektar.com Year established: 1990

Neurelis Inc.

San Diego, CA, United States Website: www.neurelis.com

NeuroDerm Ltd.

Weizmann Science Park Ness Ziona, Israel Email: info@neuroderm.com Website: www.neuroderm.com

NeurogesX Inc.

2215 Bridgepointe Parkway, Suite 200 San Mateo, CA 94404, United States Phone: 650-358-3300 Fax: 650-649-1798 Email: info@neurogesx.com Website: www.neurogesx.com Year established: 2000

NeuroHealing Pharmaceuticals Inc. 50 Undine Rd., Unit #1

Newton, MA 02135, United States Phone: 617-331-4111 Email: info@NeuroHealing.com Website: www.NeuroHealing.com

Neurotech USA Inc.

701 George Washington Hwy. Lincoln, RI 02865, United States Phone: 401-333-3880 Fax: 401-495-2420 Email: contact@neurotechusa.com Website: www.neurotechusa.com

NewBridge Pharmaceuticals

Business Čentral Tower A, Office #2405, Dubai Internet City, PO Box 500618 Dubai, United Arab Emirates Phone: +971 4 429 8700 Fax: +971 4 429 8676 Email: info@nbpharma.com Website: www.nbpharma.com

Nippon Kayaku Co.

Tokyo Fujimi Building,11-2, Fujimi 1-Chome Chiyoda-ku, Tokyo, Chiyoda-ku 102-8172, Japan Phone: +81 3 3237 5046 Website: www.nipponkayaku.co.jp Year established: 1916

Nippon Shinyaku Co.

14, Kisshoin Nishinosho-Monguchicho Kisshoin, Minami-ku Kyoto, Minami-ku 601-8550, Japan Phone: +81 7 5321 1111 Fax: +81 7 5321 0678 Email: pr@mb.nippon-shinyaku.co.jp Website: www.nippon-shinyaku.co.jp Year established: 1919

NovaBay Pharmaceuticals Inc.

5980 Horton St., Suite 550 Emeryville, CA 94608, United States Phone: 510-899-8800 Fax: 510-291-8811 Email: info@novabaypharma.com Website: www.novabaypharma.com

NovaBiotics Ltd.

Cruickshank Bldg., Craibstone Aberdeen, AB21 9TR, United Kingdom Phone: +44 1224 711377 Fax: +44 1224 711370 Email: info@novabiotics.co.uk Website: www.novabiotics.co.uk Year established: 2004

NovaDel Pharma Inc.

1200 Route 22 East, Suite 2000 Bridgewater, NJ 08807, United States Phone: 908-203-4640 Fax: 908-203-4744 Email: Info@novadel.com Website: www.novadel.com Year established: 1982

Novagali Pharma

1 rue Pierre Fontaine, Genavenir IV Evry, Cedex F-91058, France Phone: +33 1 69 87 40 20 Fax: +33 1 69 87 40 30 Email: contact@novagali.com Website: www.novagali.com Year established: 2000

Novartis Ophthalmics Inc.

Basel, CH 4002, Switzerland Phone: +41 61 324 1111 Fax: +41 61 324 8001 Website: www.novartisophthalmics.com Year established: 1996

Novartis Pharma AG

Forum 1, Novartis Campus Basel, CH-4056, Switzerland Phone: +41 61 324 11 11 Fax: +41 61 324 80 01 Website: www.novartis.com Year established: 1996

Novartis Pharmaceuticals Corp.

One Health Plaza, 59 Route 10 East Hanover, NJ 07936-1080, United States Phone: 862-778-8300 Fax: 888-644-8585 Email: investor.relations@novartis.com Website: www.pharma.us.novartis.com

Novelix Pharmaceuticals Inc.

8008 Girard Avenue, Suite 330 La Jolla, CA 92037, United States Phone: 858-454-3245 Fax: 858-729-0465 Email: jansen@novelix.com Website: www.novelix.com

Novo Nordisk AS

Novo Alle, Krogshoe JVEJ41 Bagsvaerd, DK-2880, Denmark Phone: +45 44 44 88 88 Fax: +45 44 49 05 55 Website: www.novonordisk.com Year established: 1989

NuPathe Inc.

375 East Elm St., Suite 110 Conshohocken, PA 19428, United States Phone: 484-567-0130 Fax: 484-567-0136 Email: info@nupathe.com Website: www.nupathe.com

Nuvo Research Inc.

7560 Airport Rd., Unit 10 Mississauga, ON L4T 4H4, Canada Phone: 905-673-6980 Fax: 905-673-1842 Email: info@nuvoresearch.com Website: www.nuvoresearch.com Year established: 1990

Nycomed Group

Thurgauerstrasse 130, PO Box 88 Zurich, 8152, Switzerland Phone: +41 44 555 10 00 Fax: +41 44 555 10 01 Email: companymail@nycomed.com Website: www.nycomed.com Year established: 1874

Nymox Pharmaceutical Corp.

9900 Cavendish Blvd., Suite 306 Saint-Laurent, QC H4M 2V2, Canada Phone: 800-936-9669 Fax: 514-332-2227 Email: info@nymox.com Website: www.nymox.com Year established: 1989

Oakwood Laboratories LLC

7670 First Place, Suite A Oakwood Village, OH 44146, United States Phone: 440-359-0000 Fax: 440-359-0001 Email: info@oakwoodlabs.com Website: www.oakwoodlabs.com Year established: 1997

Oncolytics Biotech Inc.

1167 Kensington Crescent NW, Suite 210 Calgary, AB 12N 1X7, Canada Phone: 403-670-7377 Fax: 403-283-0858 Email: info@oncolyticsbiotech.com Website: www.oncolyticsbiotech.com Year established: 1998

Ono Pharmaceutical Co.

8-2 Kyutaromachi, 1-chome Osaka, Chuo-ku 541-8526, Japan Phone: +81 6 6263 5670 Website: www.ono.co.jp Year established: 1717

Orexigen Therapeutics Inc.

3344 N. Torrey Pines Court, Suite 200 La Jolla, CA 92037, United States Phone: 858-875-8600 Fax: 858-875-8650 Email: info@orexigen.com Website: www.orexigen.com Year established: 2002

Orient Europharma Co.

7F No. 368, SEC 1, Fu Hsing S. Rd. Taipei, Taiwan Phone: +886 2 2755 4881 Fax: +886 2 2702 4324 Email: oep@mail.oep.com.tw Website: www.oep.com.tw Year established: 1982

Otonomy Inc.

5626 Oberlin Dr., Suite 100 San Diego, CA 92121, United States Phone: 858-768-7823 Fax: 858-200-0821 Website: www.otonomy.com

Otsuka America Pharmaceutical Inc.

2440 Research Blvd. Rockville, MD 20850, United States Phone: 301-990-0030 Fax: 301-212-8647 Website: www.otsuka-us.com Year established: 1989

Otsuka Pharmaceutical Co.

2-9 Kanda-Tsukasamachi Tokyo, Chiyoda-ku 101-8535, Japan Phone: +81 3 3292 0021 Fax: +81 3 3295 2058 Website: www.otsuka.com/en Year established: 1964

Oxigene Inc.

701 Gateway Blvd., Suite 210 South San Francisco, CA 94080, United States Phone: 650-635-7000 Fax: 650-635-7001 Website: www.oxigene.com

Palatin Technologies Inc.

4-C Cedar Brook Dr., Cedar Brook Corporate Center Cranbury, NJ 08512, United States Phone: 609-495-2200 Fax: 609-495-2201 Email: info@palatin.com Website: www.palatin.com Year established: 1986

Pearl Therapeutics Inc.

200 Saginaw Dr. Redwood City, CA 94063, United States Phone: 650-305-2600 Fax: 650-568-1804 Email: info@pearltherapeutics.com Website: www.pearttherapeutics.com Year established: 2006

Pergamun AB

Banvaktsvagen 12 Solna, SE-171 48, Sweden Phone: +468 470 37 40 Website: www.pergamum.com Year established: 2005

Pfizer Inc.

235 East 42nd St. New York, NY 10017-5755, United States Phone: 212-733-2323 Fax: 212-733-7851 Email: pfizermedia@pfizer.com Website: www.pfizer.com Year established: 1849

PharmacoFore Inc.

75 Shoreway Rd., Suite D San Carlos, CA 94070, United States Phone: 650-331-4000 Fax: 650-331-4050 Email: info@pfore.com Website: www.pharmacofore.com

PharmaEngine Inc.

16F, 237 Sung-Chiang Rd. Taipei, 104, Taiwan Phone: +886 2 25158228 Fax: +886 2 25157558 Email: info@pharmaenaine.com Website: www.pharmaengine.com Year established: 2003

Pharmaxis Ltd.

20 Rodborough Rd. Frenchs Forest, New South Wales 2086, Australia Phone: +61 2 9454 7200 Fax: +61 2 9451 3622 Email: info@pharmaxis.com.au Website: www.pharmaxis.com.au Year established: 1998

Pherin Pharmaceuticals Inc.

4962 El Camino Real, Suite 223 Los Altos, CA 94022, United States Phone: 650-961-2703 Fax: 650-568-1671 Website: www.pherin.com Year established: 1991

Phosphagenics Ltd.

2/90 William St. Melbourne, VIC 3000, Australia Phone: +61 3 9605 5916 Fax: +61 3 9605 5999 Email: info@phosphagenics.com Website: www.phosphagenics.com Year established: 1999

PhotoCure ASA

Hoffsveien 48 Oslo, NO-0377, Norway Phone: +47 22 06 2210 Fax: +47 22 06 2218 Email: info@photocure.no Website: www.photocure.com Year established: 1993

Plethora Solutions Holdings Plc.

233 High Holborn, 4th Floor London, Covent Garden WC1V 7DN, United Kingdom Phone: +44 20 3077 5400 Fax: +44 20 3077 5440 Email: mail@plethorasolutions.co.uk Website: www.plethorasolutions.co.uk Year established: 2003

Pozen Inc.

1414 Raleigh Rd., Suite 400 Chapel Hill, NC 27517, United States Phone: 919-913-1030 Fax: 919-913-1039 Email: investors@pozen.com Website: www.pozen.com

ProCertus BioPharm Inc. 510 Charmany Dr., Suite 175 B Madison, WI 53719, United States Phone: 608-277-7950 Fridrie. 000-2777, 7,000 Fax: 608-277-8041 Website: www.procertus.com Year established: 1997

ProStrakan Group Plc.

Galabank Business Park Galashiels, Scotland TD1 1QH, United Kingdom Phone: +44 189 666 4000 Fax: +44 189 666 4001 Email: pr@prostrakan.com Website: www.prostrakan.com Year established: 1995

ProteoTech Inc.

12040 115th N.E. Ave. Kirkland, WA 98034, United States Phone: 425-825-0400 Fax: 425-823-8505 Email: info@proteotech.com Website: www.proteotech.com Year established: 1996

Provectus Pharmaceuticals Inc.

7327 Oak Ridge Hwy., Suite A Knoxville, TN 37931, United States Phone: 866-594-5999 Fax: 866-998-0005 Email: info@pvct.com Website: www.pvct.com

pSivida Ltd.

400 Pleasant Street Watertown, 02472, United States Phone: 617-926-5000 Fax: 617-926-5050 Website: www.psivida.com

Pulmatrix Inc.

99 Hayden Ave., Suite 390 Lexington, MA 02421, United States Phone: 781-357-2333 Fax: 781-357-2399 Email: info@pulmatrix.com Website: www.pulmatrix.com Year established: 2003

Purdue Pharma LP

One Stamford Forum, 201 Tresser Blvd. Stamford, CT 06901-3431, United States Phone: 203-588-8000 Fax: 203-588-8850 Website: www.purduepharma.com Year established: 1892

QR Pharma Inc.

259 Radnor Chester Rd., Suite 205 Radnor, PA 19087, United States Phone: 484-253-2296 Fax: 484-253-2288 Email: info@QRPharma.com Website: www.grpharma.com

QRxPharma Pty Ltd.

1/194 Miller Street North Sydney, NSW 2060, Australia Phone: +61 2 9492 8021 Fax: +61 2 8920 0314 Website: www.qrxpharma.com Year established: 2002

Quintiles Laboratories Ltd.

610 Oakmont Ln. Westmont, IL 60559, United States Phone: 630-789-1233 Website: www.quintiles.com

Raptor Pharmaceutical Corp.

9 Commercial Blvd., Suite 200 Novato, CA 94949, United States Phone: 415-382-8111 Fax: 415-382-1368 Email: info@raptorpharma.com Website: www.raptorpharma.com Year established: 2006

Rechon Life Science AB

Soldattorpsvägen 5 Limhamn, Sweden Phone: +46 40 36 10 10 Email: info@rechon.se Website: www.rechon.com

Recordati SpA

Via Matteo Čivitali, 1 Milan, 20148, Italy Phone: +39 2 4878 71 Fax: +39 2 4007 3747 Email: inver@recordati.it Website: www.recordati.com Year established: 1926

Regeneron Pharmaceuticals Inc.

777 Old Saw Mill River Rd. Tarrytown, NY 10591-6707, United States Phone: 914-345-7400 Email: info@regeneron.com Website: www.regeneron.com Year established: 1988

RegeneRx Biopharmaceuticals Inc.

15245 Shady Grove Rd., Suite 470 Rockville, MD 20850, United States Phone: 301-208-9191 Email: info@regeneRx.com Website: www.regenerx.com Year established: 1982

Revance Therapeutics Inc.

2400 Bayshore Pkwy., Suite 100 Mountain View, CA 94043, United States Phone: 650-230-4500 Fax: 650-230-4501 Email: info@revance.com Website: www.revance.com

Revotar Biopharmaceuticals AG

Neuendorfstrasse 24a Hennigsdorf, 16761, Germany Phone: +49 3 30 2202 5010 Fax: +49 3 30 2202 5011 Email: info@revotar-ag.de Website: www.revotar.de

Rexahn Pharmaceuticals Inc.

15245 Shady Grove Rd., Suite 455 Rockville, MD 20850, United States Phone: 240-268-5300 Fax: 240-268-5310 Email: info@rexahn.com Website: www.rexahn.com Year established: 2001

Rigel Pharmaceuticals Inc.

1180 Veterans Blvd. South San Francisco, CA 94080, United States Phone: 650-624-1100 Fax: 650-624-1101 Email: communications@rigel.com Website: www.rigel.com

Sanofi

55 Corporate Dr., PO Box 6800 Bridgewater, NJ 08807-2854, United States Phone: 800-981-2491 Email: media-relations@sanofi-aventis.com Website: en.sanofi.com

Sanofi SA

174 Avenue de France Paris, Cedex 13 75635, France Phone: +33 1 53 77 40 00 Fax: +33 1 53 77 42 96 Email: media-relations@sanofi.com Website: www.sanofi.com Year established: 2004

Santen Pharmaceutical Co.

9-19, Shimoshinjo 3-chome Osaka, Higashiyodogawa-ku 533-8651, Japan Phone: +81 6 6321 7000 Fax: +81 6 6328 5082 Email: info@santen.co.ip

ir@santen.co.jp

Website: www.santen.co.jp Year established: 1890

SARcode Corp. 343 Sansome St., Suite 505 San Francisco, CA 94104-5622, United States Email: SARcode@sarcode.com Website: www.sarcode.com Year established: 2006

SciClone Pharmaceuticals Inc.

950 Tower Lane, Suite 900 Foster City, CA 94404-2125, United States Phone: 650-358-3456 Fax: 650-358-3469 Email: investorrelations@sciclone.com Website: www.sciclone.com Year established: 1989

Shionogi & Co.

1-8, Doshomachi 3-chome Osaka, Chuo-Ku 541-0045, Japan Phone: +81 6 6202 2161 Fax: +81 6 6229 9596 Website: www.shionogi.co.jp Year established: 1878

Shionogi Inc.

100 Campus Dr. Florham Park, NJ 07932, United States Phone: 973-966-6900 Email: info@shionogi-usa.com Website: www.shionogiusa.com Year established: 2001

Shire Plc.

5 Riverwalk, Citywest Business Campus Dublin, Hampshire 24, Ireland Phone: +44 125 689 4000 Fax: +44 125 689 4708 Email: investorrelations@uk.shire.com Website: www.shire.com Year established: 1986

Shire US Inc.

725 Chesterbrook Blvd., Wayne, PA 19087, United States Phone: 484-595-8800 Fax: 484-595-8200 Website: www.shire.com

Sirnaomics Inc.

401 Professional Dr., Suite 130 Gaithersburg, MD 20879, United States Phone: 301-740-1730 Email: info-office@sirnaomics.com Website: www.sirnaomics.com Year established: 2007

SkyePharma Plc.

46-48 Grosvenor Gardens London, SW1W 0EB, United Kingdom Phone: +44 207 881 0524 Fax: +44 207 881 1199 Website: www.skyepharma.com Year established: 1996

Solasia Pharma KK

3F Shiodome Bldg., 1-2-20 Kaigan, Minato-ku Tokyo, 105-0022, Japan *Phone: +81 3 6721 8332* Fax: +81 3 6721 2020 Website: www.solasia.co.jp/en Year established: 2006

Soligenix Inc.

29 Emmons Drive, Suite C-10 Princeton, NJ 08540, United States Phone: 609-538-8200 Fax: 609-452-6467 Email: info@soligenix.com Website: www.soligenix.com Year established: 1985

Somnus Therapeutics Inc.

135 Route 202/206, Suite 4 Bedminster, NJ 07921, United States Phone: 908-901-0300 Website: www.somnusthera.com Year established: 2007

Stallergenes 6, rue Alexis de Tocqueville Antony Cedex, 92183, France Phone: +33 1 55 59 20 00 Fax: +33 1 55 59 20 02 Website: www.stallergenes.com

Stiefel

20 T.W. Alexander Drive Research Triangle Park, NC 27709-4910, United States Phone: 919-990-6000 Website: www.stiefel.com Year established: 1847

Sunovion Pharmaceuticals Inc.

84 Waterford Dr. Marlborough, MA 01752-7010, United States Phone: 508-481-6700 Fax: 508-357-7499 Email: info@sunovion.com Website: www.sunovion.com Year established: 1984

Supernus Pharmaceuticals Inc.

1550 East Gude Dr., Rockville, MD 20850, United States Phone: 301-838-2500 Fax: 301-838-2501 Website: www.supernuspharma.com

Taiho Pharmaceutical Co.

1-27, Kanda danishiki-cho Tokyo, Chiyoda-ku 101-8444, Japan Phone: +81 3 3294 4527 Fax: +81 3 3233 4057 Website: www.taiho.co.jp/english/index.html Year established: 1963

Taisho Pharmaceutical Co.

3-24-1, Takada, Toshima-ku 5 24-г., тыкшаа, тояпіта-ки Tokyo, Toshima-ku 170-8633, Japan Phone: +81 3 3985 1111 Fax: +81 3 3985 0716 Website: www.taisho.co.jp Year established: 1912

Takeda Pharmaceutical Co.

1-1, Doshomachi 4-chome Osaka, Chuo-ku 540-8645, Japan Phone: +81 6 6204 2111 Fax: +81 6 6204 2880 Website: www.takeda.com Year established: 1781

Takeda Pharmaceuticals North America Inc.

One Takeda Pkwy., Deerfield, IL 60015, United States Phone: 224-554-6500 Website: www.tpna.com Year established: 1998

Talon Therapeutics Inc.

400 Oyster Point Blvd., Suite 215 South San Francisco, CA 94080, United States Phone: 650-588-6404 Fax: 650-588-2787 Email: info@hanabiosciences.com Website: www.talontx.com

Taris Biomedical Inc.

Parts Biomedical Inc. 99 Hayden Ave., Suite 100 Lexington, MA 02421, United States Phone: 781-676-7750 Fax: 781-676-778 Email: info@TARISbio.com Website: www.tarisbiomedical.com

Teijin Ltd.

6-7, Minami-hommachi, 1-chome Osaka, Chuo-ku 541-8587, Japan Phone: +81 6 6268 21312 Website: www.teijin.co.jp Year established: 1918

Teikoku Seiyaku Co.

567 Sanbonmatsu, Higashikagawa Kagawa, 769-2695, Japan Phone: +81 879 25 2221 Fax: +81 879 24 1555 Website: www.teikoku.co.jp/english_v/e_index.html Year established: 1848

Tercica Inc.

2000 Sierra Point Pkwy., Suite 400 Brisbane, CA 94005, United States Phone: 650-624-4900 Fax: 650-243-5111 Email: info@tercica.com Website: www.tercica.com Year established: 2001

Teva Pharmaceutical Industries Ltd.

5 Basel St. Petach Tikva, 49131, Israel Phone: +972 3 926 72 67 Fax: +972 3 923 40 50 Website: www.tevapharm.com Year established: 1901

Teva Pharmaceuticals USA Inc.

1090 Horsham Rd., PO Box 1090 North Wales, PA 19454-1090, United States Phone: 215-591-3000 Fax: 215-591-8600 Email: info@tevausa.com Website: www.tevapharmusa.com Year established: 1996

Theravance Inc.

901 Gateway Blvd. South San Francisco, CA 94080, United States Phone: 650-808-6000 Email: corpcomm@theravance.com Website: www.theravance.com Year established: 1996

ThromboGenics Ltd.

14 Bridgecourt Office Park, Walkinstown Ave. Dublin, 12, Ireland Phone: +353 1 409 7757 Frione: +303 1 407 77.07 Fax: +353 1 409 8180 Emcili: info@thrombogenics.com Website: www.thrombogenics.com Year established: 1998

Tissue Repair Co.

6740 Top Gun St San Diego, CA 92121, United States Phone: 858-793-6641 Fax: 858-793-7243 Email: info@t-r-co.com Website: www.t-r-co.com

Titan Pharmaceuticals Inc.

400 Oyster Point Blvd., Suite 505 South San Francisco, CA 94080, United States Phone: 650-244-4990 Fax: 650-244-4956 Email: info@titanpharm.com Website: www.titanpharm.com Year established: 1992

Tokuhon Corp.

Shiba 2 Chome Bldg. 13F, 2-28-8 Chiba Tokyo, Minato-ku 105-0014, Japan Phone: +81 3 5439 2100 Fax: +81 3 5439 2500 Email: intl.sales@tokuhom.co.ip Website: www.tokuhon.co.jp/english Year established: 1901

Topaz Pharmaceuticals LLC

500 Office Center Dr., Suite 400 Fort Washington, PA 19034, United States Website: www.topazpharma.com

Topica Pharmaceuticals Inc.

435 Tasso St., Suite 325 Palo Alto, CA 94301, United States Phone: 650-473-3800 Fax: 650-473-3805 Website: www.topicapharma.com

Transcept Pharmaceuticals Inc.

1003 W. Cutting Blvd., Suite 110 Pt. Richmond, CA 94804, United States Phone: 510-215-3500 Fax: 510-215-3535 Email: info@transcept-pharma.com Website: www.transcept-pharma.com

Transdel Pharmaceuticals Inc.

4225 Executive Square, Suite 485 La Jolla, CA 92037, United States Phone: 858-457-5300 Email: info@transdelpharma.com Website: www.transdelpharma.com

Tris Pharma

2033 Route 130, Brunswick Business Park, Suite D Monmouth Junction, NJ 08852, United States Phone: 732-940-2800 Fax: 732-940-2855 Website: www.trispharma.com

Triton Pharma Inc.

665 Milway Ave., Suite 31B Concord, ON L4K 3T8, Canada Phone: 866-429-9707 Email: feedback@tritonpharma.ca Website: www.tritonpharma.ca Year established: 2005

UCB Inc.

1950 Lake Park Dr. Smyrna, GA 30080, United States Phone: 770-970-7500 Fax: 770-970-8917 Website: www.ucb-group.com

Ultragenyx Pharmaceutical Inc.

77 Digital Dr., Suite 210 Novato, CA 94949, United States Phone: 415-884-0223 Fax: 415-884-0562 Email: info@ultragenyx.com Website: www.ultragenyx.com Year established: 2010

United Therapeutics Corp.

1110 Spring St. Silver Spring, MD 20910, United States Phone: 301-608-9292 Fax: 301-608-9291 Email: ir@unither.com Website: www.unither.com Year established: 1996

Upsher-Smith Laboratories Inc.

6701 Evenstad Dr. Maple Grove, MN 55369, United States Phone: 763-315-2000 Email: uslinfo@upsher-smith.com Website: www.upsher-smith.com Year established: 1919

Valeant Pharmaceuticals International Inc.

7150 Mississauga Rd. Mississauga, ON L5N 8M5, Canada Phone: 905-286-3000 Fax: 905-286-3050 Website: www.valeant.com Year established: 1994

Valocor Therapeutics Inc.

777 Dunsmuir St., Suite 1300 Vancouver, BC V7Y 1K2, Canada Website: www.valocor.com

Vectura Group Plc.

One Prospect W. Chippenham, SN14 6FH, United Kingdom Phone: +44 124 966 7700 Fax: +44 124 966 7701 Website: www.vectura.com Year established: 1997

Verona Pharma Plc.

100 Borough High St., Suite 21 - Alpha House London, SE1 1LB, United Kingdom Phone: +44 20 7863 3300 Fax: +44 20 7863 3314 Email: info@veronapharma.com Website: www.veronapharma.com

Vical Inc.

10390 Pacific Center Ct. San Diego, CA 92121-4340, United States Phone: 858-646-1100 Fax: 858-646-1150 Email: info@vical.com Website: www.vical.com Year established: 1987

Vicept Therapeutics Inc. 101 Lindenwood Drive, Suite 430 Malvern, PA 19355, United States Phone: 484-324-2930 Fax: 484-324-2988 Email: info@vicepttx.com Website: www.vicepttx.com Year established: 2009

ViroXis Corp.

12621 Silicon Dr., Suite 100 San Antonio, TX 78249, United States Phone: 210-558-8896 Fax: 210-694-9466 Email: info@viroxis.com Website: www.viroxis.com Year established: 2006

Viventia Biotechnologies Inc.

7895 Tranmere Drive, Suite 204 Mississauga, ON L5S 1V9, Canada Phone: 905-362-2973 Fax: 905-362-2981 Email: info@viventia.com Website: www.viventia.com Year established: 1983

Vivus Inc.

1172 Castro St. Mountain View, CA 94040, United States Phone: 650-934-5200 Fax: 650-934-5357 Email: ir@vivus.com Website: www.vivus.com Year established: 1991

Watson Pharmaceuticals Inc.

Morris Corporate Center III, 400 Interpace Pkwy. Parsippany, NJ 07054, United States Phone: 862-261-7000 Website: www.watson.com Year established: 1985

Welichem Biotech Inc.

316-4475 Wayburne Dr. Burnaby, BC V5G 3L1, Canada Phone: 604-432-1703 Fax: 604-432-1704 Email: info@welichem.com Website: www.welichem.com

Winston Pharmaceuticals Inc.

100 North Fairway Dr., Suite 134 Vernon Hills, IL 60061, United States Phone: 847-362-8200 Fax: 847-362-8394 Email: info@winstonlaboratories.com Website: www.winstonlabs.com

Xenon Pharmaceuticals Inc.

3650 Gilmore Way, Burnaby, BC V5G 4W8, Canada Phone: 604-484-3300 Fax: 604-484-3450 Email: info@xenon-pharma.com Website: www.xenon-pharma.com

XenoPort Inc.

3410 Central Expressway Santa Clara, CA 95051, United States Phone: 408-616-7200 Fax: 408-616-7210 Email: info@xenoport.com Website: www.xenoport.com Year established: 1999

Yakult Honsha Co.

1-19 Higashi-Shinbashi 1-Chome Minato-Ku Tokyo, 105-8660, Japan *Phone: +81 3 3574 8960 Website: www.yakult.co.jp* Year established: 1935

Yaupon Therapeutics Inc.

259 North Radnor-Chester Rd. Radnor, PA 19087, United States Phone: 610-975-9290 Fax: 610-975-9012 Website: www.yaupontherapeutics.com

Source: eKnowledgeBase.com

Zalicus Inc.

245 First St., Third Floor Cambridge, MA 02142, United States Phone: 617-301-7000 Fax: 617-301-7010 Email: info@combinatorx.com Website: www.zalicus.com Year established: 2000

Zeria Pharmaceutical Co.

10-11 Nihonbashi- Kobuna-cho Tokyo, Chuo-ku 103-8351, Japan Phone: +81 3 3663 2351 Website: www.zeria.co.jp/english/index.html Year established: 1955 Zogenix Inc.

11682 El Camino Real, Suite 320 San Diego, CA 92130, United States Phone: 858-259-1165 Fax: 858-259-1166 Email: info@zogenix.com Website: www.zogenix.com

Zosano Pharma Inc.

34790 Ardentech Ct. Fremont, CA 94555, United States Phone: 510-745-1200 Website: www.zosanopharma.com Year established: 2006

Product name	Product code	Product description	Regulation number	Company name
Board, Arm (With Cover), Sterile	BTX		878.3910	Alimed, Inc.
Board, Arm (With Cover), Sterile	BTX	Arm boards for a variety of surgical procedures.	878.3910	Bryton Corp.
Board, Arm (With Cover), Sterile	BTX	Neonatal limb board immobilizes I.V. site.	878.3910	Cas Medical Systems, Inc.
Board, Arm (With Cover), Sterile	BTX	DALE Bendable Armboard. Large #650 fits most adults. Medium #651 fits pediatrics. Small # 652 fits infant.	878.3910	Dale Medical Products, Inc.
Board, Arm (With Cover), Sterile	BTX	Reusable armboard strap.	878.3910	Fpp, Inc.
Board, Arm (With Cover), Sterile	BTX		878.3910	Hausmann Industries, Inc.
Board, Arm (With Cover), Sterile	BTX	TKO Multi-Position Armboard, used with virtually any rail clamp; when used with the Midkiff GEOSTATIC Clamp, greater positioning flexibility and allocation is achieved.	878.3910	Health Supply Company Inc., The
Board, Arm (With Cover), Sterile	BTX		878.3910	J. T. Posey Co.
Board, Arm (With Cover), Sterile	BTX	Ameritus Neonatal and Pediatric limb boards designed to stabilize the hand and foot for IV securement and other applications.	878.3910	Kentec Medical Inc.
Board, Arm (With Cover), Sterile	BTX	Arm board.	878.3910	Kentron Health Care, Inc.
Board, Arm (With Cover), Sterile	BTX	Vinyl covered foam. Disposable/reusable. Item no. 1012.	878.3910	Lundy Medical Product, Llc
Board, Arm (With Cover), Sterile	BTX		878.3910	Medrecon, Inc.
Board, Arm (With Cover), Sterile	BTX	Lateral, pivoting & surgical (radiolucent).	878.3910	Mizuho Osi
Board, Arm (With Cover), Sterile	BTX	Premie, newborn, neonatal to adult models, disposable or reusable: 1x4, 1.5x3, 2x4, 2x6, 2x9, 3x6, 3x9, 3x12, 3x18, 4x9, & 4x18in.	878.3910	Morrison Medical
Board, Arm (With Cover), Sterile	BTX	Arm rest boards	878.3910	Peaktop Ltd.
Board, Arm (With Cover), Sterile	BTX	PEDI-BOARD \$2.52 to \$6.90 for 3, 4, 6, 8, and 15 in. sizes.	878.3910	Pedicraft, Inc.
Board, Arm (With Cover), Sterile	BTX		878.3910	Philips Medical Systems North America
Board, Arm (With Cover), Sterile	BTX	(wtih cover), non-sterile - TARRY ARM BOARD; TARRY ARM BOARD SLEEVES; TARRY BOARD	878.3910	Tarry Manufacturing
Board, Arm (With Cover), Sterile	BTX	TELOS anesthesia/general purpose radiolucent arm board. Fits any Clark Socket and may be used for hand and shoulder surgery.	878.3910	Telos Medical Equipment (Austin & Assoc., Inc.)
Stand, Infusion	FOX	Infusion stand.	880.6990	Ac Healthcare Supply, Inc.
Stand, Infusion	FOX	SAF-T-POLE I.V., pole and irrigation tower for arthroscopy, TURP and hysteroscopy. Saves money and the practitioner's back.	880.6990	Advanced Medical Innovations, Inc.
Stand, Infusion	FOX		880.6990	Alimed, Inc.
Stand, Infusion	FOX	Easy Irrigation Tower - Four independently adjustable hooks each safely support up to 10,000cc of fluid. Comfortable, quick-release knobs permit vertical adjustment of hangers from 51⁄2 to 81⁄2. (167.5 cm x 259 cm) This nurse- friendly design m	880.6990	Allen Medical Systems, Inc.

Product name	Product code	Product description	Regulation number	Company name
Stand, Infusion	FOX		880.6990	American Medical Mfg., Inc.
Stand, Infusion	FOX		880.6990	Armstrong Medical Industries, Inc.
Stand, Infusion	FOX		880.6990	Atd-American Co.
Stand, Infusion	FOX		880.6990	B. Braun Medical, Inc.
Stand, Infusion	FOX	Stainless steel and chrome IV Stands with four, five and six leg bases. Five different height adjustment mechanisms- foot- operated, twist lock, friction knob, thumb control, trigger lock.	880.6990	Blickman
Stand, Infusion	FOX	IV poles, many varieties.	880.6990	Brandt Industries, Inc.
Stand, Infusion	FOX		880.6990	Brenner Metal Products
Stand, Infusion	FOX		880.6990	Brewer Company, The
Stand, Infusion	FOX		880.6990	Cameron-Miller, Inc.
Stand, Infusion	FOX	Stand infusion, intravenous.	880.6990	Camtec
Stand, Infusion	FOX		880.6990	Cardinal Health 200, Inc
Stand, Infusion	FOX		880.6990	Clinimed, Incorporated
Stand, Infusion	FOX	Various configurations of iv poles.	880.6990	Conmed Integrated Systems (Cmis)
Stand, Infusion	FOX	Various styles & sizes of wall brackets, dispensers, etc.	880.6990	Covidien Lp, Formerly Registered As Kendall
Stand, Infusion	FOX		880.6990	Covidien Lp, Formerly Registered As Kendall
Stand, Infusion	FOX	I.V. stands and accessories.	880.6990	Crest Healthcare Supply
Stand, Infusion	FOX		880.6990	Depuy Mitek, Inc.
Stand, Infusion	FOX	Infusion stand.	880.6990	Ekos Corp.
Stand, Infusion	FOX		880.6990	Ethicon, Inc.
Stand, Infusion	FOX	\$50.00 for aluminum I.V. pole for ambulance gurney.	880.6990	Farley Inc., W.T.
Stand, Infusion	FOX		880.6990	Galaxy Medical Manufacturing Co.
Stand, Infusion	FOX	IV securement device. IV Protector is an FDA - Class 1 excemst infusion set accessory device -(Anchor joint)- disposable for IV line safety so as to avoid strain, disconnection from patient while in transport.	880.6990	Glo Touch Corporation
Stand, Infusion	FOX	Various.	880.6990	Health Care Logistics, Inc.
Stand, Infusion	FOX		880.6990	Hill-Rom Holdings, Inc.
Stand, Infusion	FOX	Infusion stands and accessories.	880.6990	Hill-Rom, Inc.
Stand, Infusion	FOX		880.6990	Homak Manufacturing Company Inc.
Stand, Infusion	FOX	Hospira IV stand	880.6990	Hospira Inc.
Stand, Infusion	FOX	I.v. stand.	880.6990	I.V. League Medical
Stand, Infusion	FOX	I.v. stand and accessories.	880.6990	Icu Medical (Ut), Inc
Stand, Infusion	FOX	Infusion stand.	880.6990	Innovative Medical Designs
Stand, Infusion	FOX		880.6990	Instrument Specialists, Inc.
Stand, Infusion	FOX		880.6990	Integra Lifesciences Of Ohio
Stand, Infusion	FOX	Infusion pump stand i.v. pole.	880.6990	Iradimed Corporation
Stand, Infusion	FOX		880.6990	Jedmed Instruments Co.
Stand, Infusion	FOX	Cart, walker.	880.6990	Livengood Engineering Inc.
Stand, Infusion	FOX		880.6990	Maquet, Inc.
Stand, Infusion	FOX	Various models of infusion stands and poles.	880.6990	Maquet, Inc.
Stand, Infusion	FOX	ly pole.	880.6990	Medical Depot
Stand, Infusion	FOX		880.6990	Medi-Crush Company
Stand, Infusion	FOX		880.6990	Medtronic Navigation, Inc.
Stand, Infusion	FOX	Heavy duty, stainless steel IV poles and accessories.	880.6990	Medved Products, Inc.
Stand, Infusion	FOX	"The Messerii Connection" Adjustable connector for IV poles and adjustable receiver for wheelchairs, beds, and gurneys. Takes 3-5 seconds to make the switch.	880.6990	MEI Corporation

Product name	Product code	Product description	Regulation number	Company name
Stand, Infusion	FOX	Infusion pump stands.	880.6990	Modular Services Company
Stand, Infusion	FOX		880.6990	Ohmeda Medical
Stand, Infusion	FOX		880.6990	Omni Medical Supply Inc.
Stand, Infusion	FOX	Stainless steel or chrome: pump, gravity feed, hand or foot operated.	880.6990	Pedigo Products
Stand, Infusion	FOX	\$190.00 per IV floor stand.	880.6990	Phelan Manufacturing Corp.
Stand, Infusion	FOX	Infusion stand	880.6990	Provita Gmbh Medizintechnik
Stand, Infusion	FOX	A broad and deep variety of standard and custom IV stands are available. These products are designed to work safely and effectively in their intended patinet care areas.	880.6990	Pryor Products
Stand, Infusion	FOX	I.v. stand, i.v. pole.	880.6990	Quality Control Corp.
Stand, Infusion	FOX		880.6990	Quest Medical, Inc.
Stand, Infusion	FOX		880.6990	Radiation Products Design, Inc.
Stand, Infusion	FOX		880.6990	Sharps Compliance Corp.
Stand, Infusion	FOX		880.6990	Steelcraft, Inc.
Stand, Infusion	FOX		880.6990	The After Market Group
Stand, Infusion	FOX	INFUSION CART	880.6990	Wells Johnson Co.
Stand, Infusion	FOX	No common name listed	880.6990	Wisap Gesellschaft Fur Wissenschaftl. App. Bau Mbh
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	(including sunlamp protective eyewear and post-mydriatic eyewear) - CLEAR EYE SHIELD	886.4750	Alcon Research, Ltd.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	Alimed, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	Alphaprotech, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	Altomed Opthalmic Products Ltd.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Opthalmic eye shield	886.4750	Amann Medizintechnik
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Various models of shield, eye, ophthalmic	886.4750	Amarco Medizintechnik Gmbh
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Ophthalmic eye shield. To be used primarily by children with lazy eye, or to conceal the eye after surgery, etc. for adults as well as children.	886.4750	Anissa's Fun Patches
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Architectures	886.4750	Architectures
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Shield, eye, ophthalmic (including sunlamp protective eye).	886.4750	Astron International Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	INCLUDING SUNLAMP PROTECTIVE EYEWEAR AND POST- MYDRIATIC EYEWEAR) - VIbex	886.4750	Avedro, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Various types of shields.	886.4750	B. Graczyk, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Eye shield	886.4750	Baur Und Haselbarth-Chirurg Gmbh
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	Bausch & Lomb Surgical
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Anti-fog coated shields for surgical and face masks.	886.4750	Brady Precision Converting, Lic

	Product		Regulation	
Product name	code	Product description	number	Company name
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Various types of safety shields and spectacle frame mounted occulars.	886.4750	Ctp Coil Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	Eagle Laboratories
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Edge i-wear corp.	886.4750	Edge I-Wear Corp.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	Ferguson Production, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Ophthalmic eye shield.	886.4750	Fresnel Prism & Lens Co.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Spectacle frames and sunglasses	886.4750	Fukui Koki Co. Ltd.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	Gargoyles Eyewear
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	НОҮ		886.4750	General Scientific Safety Equipment Co.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	Genesis Biosystems, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	George Tiemann & Co.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Safety glasses	886.4750	Greattec Vision S.A. De C.V.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	Gulden Ophthalmics
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Eye protector convex/flat	886.4750	Gustav Ehinger Gmbh & Co.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Eye shield, light shield.	886.4750	Hurricane Medical
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Eye shield	886.4750	Indo German Surgical Corp.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Sun goggles	886.4750	Intercos Gmbh
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Sunglasses	886.4750	Izumi Optical Co.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Eye mask	886.4750	J.E.M. Sales Ltd.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	Jardon Eye Prosthetics, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	Jedmed Instruments Co.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	K Medical
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	(INCLUDING SUNLAMP PROTECTIVE EYEWEAR AND POST- MYDRIATIC EYEWEAR)	886.4750	Kod, Inc.

	Product		Regulation	
Product name	code	Product description	number	Company name
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	No common name listed	886.4750	Leonids Traders Pvt. Ltd.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Tanning booth eyewear.	886.4750	Lt Acquisition, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Ablatable mask.	886.4750	Maverick Technologies, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	SAFE-CHOICE Disposable.	886.4750	Medegen Medical Products, Llc
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Various.	886.4750	Medone Surgical, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	E-Z CLEAN eye shield.	886.4750	Megadyne Medical Products, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Various	886.4750	Model Eye Industry
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	NEOSHADES: Phototherapy Eye Shields. Cute phototherapy mask with sunglasses printed on one side. Fun for parents, patients and staff.	886.4750	Neotech Products, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Spectacle frame, sunglassess	886.4750	One Optical Co., Ltd.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Eye shield	886.4750	Paul Instruments (India)
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Safety shields.	886.4750	Perioptix, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	\$47.30 per box of 50 pcs. of PRO-SHIELDS.	886.4750	Pro-Optics, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Radiation filtering glasses.	886.4750	Protech Leaded Eyewear
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Hematocrit control.	886.4750	Richmond Products, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Eye shield, ophthalmic	886.4750	Rz Medizintechnik Gmbh
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	Sharn, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Various	886.4750	Sofard Co., Ltd.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	Sperian Eye & Face Protection Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Eye protector.	886.4750	Sun-Med
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Pediatric & Adult Eye Shields.	886.4750	Total Molding Services, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	SAFE-EDGE malleable ophthalmic aluminum eyeshield and Universal Polycarbonate plastic eyeshield with U.V. additive.	886.4750	Trident Medical Products
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY		886.4750	U.V. Vision Corp.

Product name	Product code	Product description	Regulation number	Company name
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	ULTRACELL PVA corneal light shields and LASIK shields.	886.4750	Ultracell Medical Technologies, Inc.
Shield, Eye, Ophthalmic (Including Sunlamp Protective Eyewear and Post-mydriatic Eyewear)	HOY	Various	886.4750	Woosung Industry Co.
Infusor, Pressure, For IV Bags	KZD		880.5420	Armstrong Medical Industries, Inc.
Infusor, Pressure, For IV Bags	KZD	Various pressure infusors and accessories.	880.5420	Baxter Healthcare Corp., Renal Division
Infusor, Pressure, For IV Bags	KZD	Pressure infusor.	880.5420	Circulatory Technology, Inc.
Infusor, Pressure, For IV Bags	KZD	\$65.00 to \$68.00 each; volumes: 500mL and 1000mL (units used to administer fluids under pressure).	880.5420	Clark Company Inc., David
Infusor, Pressure, For IV Bags	KZD	Pressure Infusor Irrigator	880.5420	Covidien
Infusor, Pressure, For IV Bags	KZD	BLOOD TRANSFUSION PRESSURE BAG; I.V. FLUID	880.5420	Cw Medical, Inc.
Infusor, Pressure, For IV Bags	KZD	Pressure infusor.	880.5420	David Clark Company, Inc.
Infusor, Pressure, For IV Bags	KZD	Infuser bag.	880.5420	Ethox International
Infusor, Pressure, For IV Bags	KZD	Pressure infusor for use with BLOOD PACK units and transfer packs.	880.5420	Fenwal Inc.
Infusor, Pressure, For IV Bags	KZD	Pressure infusor	880.5420	Fujinomiya Factory Of Terumo Corporation
Infusor, Pressure, For IV Bags	KZD	Infusion device for IV fluid administration.	880.5420	Health Care Logistics, Inc.
Infusor, Pressure, For IV Bags	KZD	Various types.	880.5420	Icu Medical (Ut), Inc
Infusor, Pressure, For IV Bags	KZD	Piv system, various models.	880.5420	Mfg One, Llc
Infusor, Pressure, For IV Bags	KZD	Pressure infusor/irrigator	880.5420	Mmj S.A. De C.V.
Infusor, Pressure, For IV Bags	KZD		880.5420	Mobile I.V. Systems, LIC
Infusor, Pressure, For IV Bags	KZD	I.V.; MULTIPLE MODELS; REPROCESSED PRESSURE INFUSER	880.5420	ReNu Medical Inc.
Infusor, Pressure, For IV Bags	KZD	Automated pressure infusor for I.V. fluid therapy.	880.5420	Smiths Medical Asd, Inc.
Infusor, Pressure, For IV Bags	KZD	INFU-SURG	880.5420	Sts Division Of Ethox International
Infusor, Pressure, For IV Bags	KZD	Pressure infusion bag.	880.5420	Ventlab Corp.
Infusor, Pressure, For IV Bags	KZD	Infusor inflating device.	880.5420	Vital Signs Mn, Inc.
Infusor, Pressure, For IV Bags	KZD		880.5420	Vital Signs, Inc.
Infusor, Pressure, For IV Bags	KZD		880.5420	Zoll Medical Corp.

Product name	Product code	Product description	Regulation number	Company name
Flowmeter, Blood, Cardiovascular	DPW	Hemosonic 100 non-invasive transesophageal hemodynamic monitor.	870.2100	Arrow International, Inc.
Flowmeter, Blood, Cardiovascular	DPW	Vascular probe.	870.2100	Cardinal Healthcare 209, Inc.
Flowmeter, Blood, Cardiovascular	DPW	\$6,900.00 for FM501D electromagnetic flowmeter for research use. \$7,595.00 for FM701D CLINIFLOW II for operating room use.	870.2100	Carolina Medical, Inc.
Flowmeter, Blood, Cardiovascular	DPW	Doppler vascular access monitor.	870.2100	Escalon Trek Medical
Flowmeter, Blood, Cardiovascular	DPW	Tissue perfusion monitoring system	870.2100	Hemedex Incorporated
Flowmeter, Blood, Cardiovascular	DPW		870.2100	Koven Technology, Inc.
Flowmeter, Blood, Cardiovascular	DPW	Laser doppler perfusion imager	870.2100	Lisca Ab
Flowmeter, Blood, Cardiovascular	DPW	Medical blood volume flowmeter	870.2100	Medi-Stim A/S
Flowmeter, Blood, Cardiovascular	DPW		870.2100	Terumo Cardiovascular Systems, Corp
Flowmeter, Blood, Cardiovascular	DPW	Doppler, instrument monitor.	870.2100	Volcano Corporation
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ		870.3470	Bard Peripheral Vascular, Inc.

Product name	Product code	Product description	Regulation number	Company name
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	Fabrics,grafts,pledgets.	870.3470	Bard Shannon Limited
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	Cardiovascular patch.	870.3470	Bridger Biomed, Inc.
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	Cardiovascular patch kit (sterile).	870.3470	Chase Medical, Lp
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	CorMatrix ECM for Pericardial Closure; CorMatrix ECM for Cardiac Tissue Repair	870.3470	CorMatrix Cardiovascular Inc.
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	Ptfe pledget.	870.3470	Covidien Lp, Formerly Registered As United States Surgical
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	CryoPatch SG Pulm. Human Cardia	870.3470	Cryolife, Inc.
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	Various, cardiovascular patch.	870.3470	Deroyal Surgical - Rose Hill
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ		870.3470	Ethicon, Inc
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ		870.3470	Ethicon, Inc.
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	Sterile teflon pledgets.	870.3470	Ethicon, Llc.
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	HEMASHIELD	870.3470	Maquet Cardiovascular LLC
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	Intracardiac patch or pledget.	870.3470	Mast Biosurgery Usa Inc.
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	Patch.	870.3470	Shelhigh, Inc.
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	CorRestore(TM) System; Bovine pericardial patch system uniquely designed for cardiac repair and reconstruction and especially well-suited for Surgical Ventricular Restoration (SVR).	870.3470	Somanetics Corp.
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	Peri-Guard Cardiovascular Patch; Supple Peri-Guard; Vascu- Guard	870.3470	Synovis Life Technologies, Inc
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ		870.3470	Tuzik Boston
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	Teflon pledget	870.3470	Tyco Healthcare Uk Ltd.
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ		870.3470	Ussc Puerto Rico, Inc.
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	Cardiovascular patch.	870.3470	W.L. Gore & Associates,Inc
Patch, Pledget And Intracardiac, PETP, PTFE, Polypropylene	DXZ	Patch "sterile".	870.3470	Yama, Inc.
System, Dialysate Delivery, Sealed	FII		876.5860	Fresenius Usa, Inc.
System, Dialysate Delivery, Single Pass	FIL		876.5820	Fresenius Usa, Inc.
System, Dialysate Delivery, Single Patient	FKP		876.5820	B. Braun Medical Inc., Renal Therapies Div.
System, Dialysate Delivery, Single Patient	FKP	Sps single patient system.	876.5820	Baxter Healthcare Corp., Renal Division
System, Dialysate Delivery, Single Patient	FKP	Chf systems 100.	876.5820	Chf Solutions, Inc.
System, Dialysate Delivery, Single Patient	FKP		876.5820	Fresenius Usa, Inc.
System, Dialysate Delivery, Single Patient	FKP	No common name listed	876.5820	Fuji Medical Instr Mfg., Co. Ltd.
System, Dialysate Delivery, Single Patient	FKP	Sodium bicarbonate mixing & delivery system, mixes and monitors sodium bicarbonate solution and delivers it to the dialysis patients.	876.5820	G.E.M. Water Systems, Int'L., LIC
System, Dialysate Delivery, Single Patient	FKP	Watercheck 2 reagent strip, chloramine test strips.	876.5820	Integrated Biomedical Technology, Inc.
System, Dialysate Delivery, Single Patient	FKP	No common name listed	876.5820	Nikkiso Co. Ltd.

Product name	Product code	Product description	Regulation number	Company name
System, Dialysate Delivery, Single Patient	FKP	Hemodialysis accessory.	876.5820	Nxstage Medical, Inc.
System, Dialysate Delivery, Central Multiple Patient	FKQ	Diacide.	876.5820	Alden Medical LIC
System, Dialysate Delivery, Central Multiple Patient	FKQ	CONCENTRATE FOR HEMODIALYSIS (LIQUID OR POWDER)	876.5820	Fresenius Medical Care North America
System, Dialysate Delivery, Central Multiple Patient	FKQ	CONCENTRATE FOR HEMODIALYSIS (LIQUID OR POWDER)	876.5820	Fresenius Medical Care North America
System, Dialysate Delivery, Central Multiple Patient	FKQ	CONCENTRATE FOR HEMODIALYSIS (LIQUID OR POWDER)	876.5820	Fresenius Medical Care North America
System, Dialysate Delivery, Central Multiple Patient	FKQ	CONCENTRATE FOR HEMODIALYSIS (LIQUID OR POWDER)	876.5820	Fresenius Medical Care North America
System, Dialysate Delivery, Central Multiple Patient	FKQ	CONCENTRATE FOR HEMODIALYSIS (LIQUID OR POWDER)	876.5820	Fresenius Medical Care North America
System, Dialysate Delivery, Central Multiple Patient	FKQ	O3Z OZONE SYSTEM	876.5820	Mar Cor Purification
System, Dialysate Delivery, Central Multiple Patient	FKQ	RENAPAK.; Acetate Concentrate; Acid Concentrate; Bicarbonate Concentrate; Conductivity Meter;; Conductivity Meter	876.5820	Minntech Corporation
System, Dialysate Delivery, Central Multiple Patient	FKQ	Dialysate delivery systems, sigle and multi stations	876.5820	Rismed Oncology Systems
System, Dialysate Delivery, Sorbent Regenerated	FKT	Model 1000; Allient Sorbent Hemodialysis System; Model 1500; 2008 Hemodialysis Sorbent System	876.5600	Renal Solutions Inc.
System, Dialysate Delivery, Sorbent Regenerated	FKT	Sorbent cartridges.	876.5600	Sorb Technology, Inc.
Stopcock, I.V. Set	FMG	Plastic disposable non-sterile stop cock.	880.5440	Ac Healthcare Supply, Inc.
Stopcock, I.V. Set	FMG	multiple	880.5440	Arrow International, Inc.
Stopcock, I.V. Set	FMG	Similar models of stopcocks	880.5440	B. Braun Medical Ag
Stopcock, I.V. Set	FMG	OTHER; DISCOFIX	880.5440	B. Braun Medical, Inc.
Stopcock, I.V. Set	FMG		880.5440	B. Braun Oem Division, B. Braun Medical Inc.
Stopcock, I.V. Set	FMG	lv set stopcock.	880.5440	B. Braun Of Puerto Rico, Inc.
Stopcock, I.V. Set	FMG	Stopcock, various types	880.5440	Baur Und Haselbarth-Chirurg Gmbh
Stopcock, I.V. Set	FMG	I.V. SET - Multi-Port Manifold; Stopcock Manifold Gangs;	880.5440	Baxter Healthcare Corporation, Medication Delivery
Stopcock, I.V. Set	FMG		880.5440	Baxter Healthcare Corporporation, Alternate Care And Channel Team
Stopcock, I.V. Set	FMG	Various stopcocks.	880.5440	Baxter Healthcare S.A.
Stopcock, I.V. Set	FMG	Various designs & combinations of plastic stopcocks	880.5440	Baxter Productos Medicos, Ltda.
Stopcock, I.V. Set	FMG	PTFs, various types & sizes	880.5440	Berghof/America
Stopcock, I.V. Set	FMG	Metal stopcocks in 30 sizes.	880.5440	Cadence Science Inc.
Stopcock, I.V. Set	FMG	i.v. set - Various	880.5440	Cardinal Health 303,Inc.
Stopcock, I.V. Set	FMG		880.5440	Churchill Medical Systems, Inc.
Stopcock, I.V. Set	FMG		880.5440	Cook Inc.
Stopcock, I.V. Set	FMG	I.V. SET - Plas. Stck. w/extension tube/steril; MULTIPLE	880.5440	Covidien
Stopcock, I.V. Set	FMG		880.5440	Covidien Lp
Stopcock, I.V. Set	FMG		880.5440	David Scott Company
Stopcock, I.V. Set	FMG		880.5440	Directmed, Inc.
Stopcock, I.V. Set	FMG	Stopcock, i.v. set.	880.5440	Edwards Lifesciences Technology Sarl
Stopcock, I.V. Set	FMG		880.5440	Elcam Medical, Inc.
Stopcock, I.V. Set	FMG		880.5440	Ernst Flow Industries
Stopcock, I.V. Set	FMG	No common name listed	880.5440	Farmatap S.A. De C.V.
Stopcock, I.V. Set	FMG	i.v. set - Robertsite 4 Way Stopcock	880.5440	Halkey-Roberts Corp.
· · · · · · · · · · · · · · · · · · ·				

Product name	Product code	Product description	Regulation number	Company name
Stopcock, I.V. Set	FMG	INTRALOCK disposable stopcock.	880.5440	Hospira, Inc.
Stopcock, I.V. Set	FMG	Intravascular administrtion set.	880.5440	Icu Medical (Ut), Inc
Stopcock, I.V. Set	FMG	Intravascular administration set.	880.5440	Icu Medical, Inc.
Stopcock, I.V. Set	FMG	Ultraconcentrator manifold with extension set. Graft delivery syringe. Disposable system for intraoperative collection of autologous growth factors.	880.5440	Interpore Cross International
Stopcock, I.V. Set	FMG	Stopcocks and iv sets.	880.5440	Kentron Health Care, Inc.
Stopcock, I.V. Set	FMG		880.5440	Kontes Glass Co.
Stopcock, I.V. Set	FMG	Various types of stopcocks with luer lock adapters.	880.5440	Merit Medical Systems, Inc.
Stopcock, I.V. Set	FMG		880.5440	Microgroup
Stopcock, I.V. Set	FMG		880.5440	Mps Acacia
Stopcock, I.V. Set	FMG		880.5440	Novosci Corp.
Stopcock, I.V. Set	FMG		880.5440	S4j Manufacturing Services, Inc.
Stopcock, I.V. Set	FMG	No common name listed	880.5440	Schad Medical Instruments Gmbh
Stopcock, I.V. Set	FMG	HYPERAL stopcock, extension sets and T-connector.	880.5440	Smiths Medical OEM
Stopcock, I.V. Set	FMG		880.5440	Sorin Group Usa
Stopcock, I.V. Set	FMG	Three way stopcock.	880.5440	Terumo Medical Corporation
Stopcock, I.V. Set	FMG	Stopcock and stopcock adapter.	880.5440	Unimed S.A.
Stopcock, I.V. Set	FMG	Disposable stopcocks.	880.5440	Vygon Corp.
Stopcock, I.V. Set	FMG	Sterile stopcocks	880.5440	Vygon S A
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Various models of orthodontic products.	880.5200	All Star Orthodontics, Llc
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Various central lines sterile.	880.5200	Alsius Corp.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Flush syringes.	880.5200	Amsino Medical Usa
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Central catheter, central venous catheter, kit & tray.	880.5200	Argon Medical Devices Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Intravascular catheter.	880.5200	Arkray Factory Usa, Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Various intravascular catheters	880.5200	Arrow Internacional De Mexico, S.A. De C.V.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	multiple	880.5200	Arrow International, Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Various	880.5200	As Advanced Medical Systems
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ		880.5200	B. Braun Medical Inc., Renal Therapies Div.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	MULTIPLE	880.5200	Bard Access Systems, Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Various	880.5200	Bard Reynosa S.A. De C.V.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	0.9% SODIUM CHLORIDE INJECTION ; BD Posifiush Saline	880.5200	Becton Dickinson And Co.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	0.9% SODIUM CHLORIDE INJECTION ; BD Posifiush Saline	880.5200	Becton Dickinson And Company
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ		880.5200	Becton Dickinson And Company
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	multiple	880.5200	Becton Dickinson Infusion Therapy Systems, Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Catheter, intravascular, short term.; BD Preefil Flush Syringe; BD Posiflush Heparin	880.5200	Becton Dickinson Medical Systems
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Infusion catheter.	880.5200	Bentec Medical, Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Multiple	880.5200	Catalent Pharma Solutions

Product name	Product code	Product description	Regulation number	Company name
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ		880.5200	Catheter Research, Inc. (Cri)
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ		880.5200	Centurion Medical Products Corp.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ		880.5200	Centurion Medical Products Corporation
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ		880.5200	Cook Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ		880.5200	Covidien Lp
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	SUNDER CENTRAL VENOUS CATHETER KIT	880.5200	Cw Medical, Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Custom design and manufacturing of catheters and specialty guidewires. Guiding catheters; stent delivery and drug delivery systems.	880.5200	Diablo Sales & Marketing, Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Central venous catheter kit.	880.5200	Edwards Lifesciences Technology Sarl
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Therapeutic, short-term (less than 30 days).; MULTIPLE	880.5200	Edwards Lifesciences, Llc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Various types of sterile infusion catheter & accessories.	880.5200	Ev3 Neurovascular
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Pre-filled saline flush syringe.	880.5200	Excelsior Medical Corp.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Needle	880.5200	Haemonetics Corp.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Multiple	880.5200	Hospira Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ		880.5200	Hospira, Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Various	880.5200	Johnson & Johnson De Monterrey, Sa De Cv
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Various	880.5200	Kofu Factory Of Terumo Corp.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Catheter, iv, therapeutic, short-term less than 30 days.	880.5200	Kollsut Scientific Corporation
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Normal Saline & Heparin I. V. Flush Syringe (in diff. volumes) - prefilled syringe for single use	880.5200	Medefil, Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ		880.5200	Millar Instruments, Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Peripherally inserted central catheters and placement kits.	880.5200	Navilyst Medical
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Intravenous silicone catheter.	880.5200	Neo Medical Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Neonatal, dual lumen umbilical catheter; pediatric PICC and umbilical catheterization kit.	880.5200	Neo-Care Arrow International
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ		880.5200	Patton Medical Devices
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Vents (self sealing) for IV Cathether	880.5200	Porex Technologies Gmbh
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	VANISHPOINT I.V. CATHETER	880.5200	Retractable Technologies, Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Jelco; Optiva	880.5200	Smiths Medical Asd, Inc.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Introducer needle.	880.5200	Stryker Instruments, Instruments Div.
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Intravascular catheter.	880.5200	Terumo Medical Corporation
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ		880.5200	Tfx Medical Oem
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Over-the-needle catheter.	880.5200	Thomas Medical Products, Inc.

Product name	Product code	Product description	Regulation number	Company name
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Mudicut intrvenous cannula, (various sizes)	880.5200	Tyco Healthcare Ireland Limited
Catheter, Intravascular, Therapeutic, Short-term Less Than 30 Days	FOZ	Sterile short iv cannula	880.5200	Vygon S A
Set, Administration, Intravenous	FPA	Various sizes of IV administration sets (sterile).	880.5440	Abbott Diagnostics Intl, Biotechnology Ltd
Set, Administration, Intravenous	FPA	Complete line of IV administration sets.	880.5440	Accellent El Paso
Set, Administration, Intravenous	FPA	AMSINO I.V. administration set is available in a variety of spikes, chambers, tubing lengths, and diameters.	880.5440	Amsino International, Inc.
Set, Administration, Intravenous	FPA	Convenience kit.	880.5440	Aplicare, Inc.
Set, Administration, Intravenous	FPA	IV Transfer Spike	880.5440	App Pharmaceuticals, Llc
Set, Administration, Intravenous	FPA	Hyperbaric kit.	880.5440	Argon Medical Devices Inc.
Set, Administration, Intravenous	FPA	Sterile subcutaneous infusion set.	880.5440	Arkray Factory Usa, Inc.
Set, Administration, Intravenous	FPA	Multiple	880.5440	Arrow Internacional De Mexico, S.A. De C.V.
Set, Administration, Intravenous	FPA	High flow solution administration set.	880.5440	Arrow International, Inc.
Set, Administration, Intravenous	FPA	Solution administration set	880.5440	Ashitaka Factory Of Terumo Corporation
Set, Administration, Intravenous	FPA	No common name listed	880.5440	B. Braun Celsa
Set, Administration, Intravenous	FPA		880.5440	B. Braun Oem Division, B. Braun Medical Inc.
Set, Administration, Intravenous	FPA	Iv administration set.	880.5440	B. Braun Of Puerto Rico, Inc.
Set, Administration, Intravenous	FPA	Various	880.5440	Bard Reynosa S.A. De C.V.
Set, Administration, Intravenous	FPA	Various sterile sets with/without filters.	880.5440	Baxter Healthcare Corp., Renal Division
Set, Administration, Intravenous	FPA	Basic solution, Blood sets, Interlink Access System.	880.5440	Baxter Healthcare Corporporation, Alternate Care And Channel Team
Set, Administration, Intravenous	FPA	Various sterile sets with/without filters.	880.5440	Baxter Healthcare S.A.
Set, Administration, Intravenous	FPA	Various sterile sets with and without filters	880.5440	Baxter Productos Medicos, Ltda.
Set, Administration, Intravenous	FPA	I.V. start kits and accessories.	880.5440	Becton Dickinson Infusion Therapy Systems, Inc.
Set, Administration, Intravenous	FPA	Infusion sets.	880.5440	Becton, Dickinson & Co., (Bd) Preanalytical System
Set, Administration, Intravenous	FPA	Shielded needle connector assembly.	880.5440	Beech Medical Products, Inc.
Set, Administration, Intravenous	FPA	SELEC-3 is a multi-drip I.V. administration set. Choose between a 10, 15, or 60-drop/cc-volume setting without breaking the line. Each set has two "Y" port connections and a built-in extension set, with a backflow prevention device. Custom sets availab	880.5440	Biomedix, Inc.
Set, Administration, Intravenous	FPA	Iv administration set	880.5440	Block Medical De Mexico S.A. De C.V.
Set, Administration, Intravenous	FPA	Scalp vein set	880.5440	Boin Medica Co. Ltd.
Set, Administration, Intravenous	FPA	multiple	880.5440	Cardinal Health 200, Inc
Set, Administration, Intravenous	FPA	Various administration sets & accessories.	880.5440	Cardinal Health 303,Inc.
Set, Administration, Intravenous	FPA	Intravascular fluid transfer & administration set	880.5440	Carmel Pharma Ab.
Set, Administration, Intravenous	FPA	Needle-free valved connector and cap.	880.5440	Catheter Innovations, Inc.
Set, Administration, Intravenous	FPA		880.5440	Centurion Medical Products Corp.
Set, Administration, Intravenous	FPA		880.5440	Centurion Medical Products Corporation
Set, Administration, Intravenous	FPA	Various sizes of i.v. administration set, infusion set	880.5440	Changchun Kangda Medical Supply Co., Ltd.
Set, Administration, Intravenous	FPA	Administration sets.	880.5440	Clinical Pharmacies, Inc.
Set, Administration, Intravenous	FPA		880.5440	Codan Us Corporation
Set, Administration, Intravenous	FPA		880.5440	Coeur Inc., Sheboygan
Set, Administration, Intravenous	FPA	MASTERFLOW IV rate controller which controls rate of solution flow economically.	880.5440	Conmed Corporation

	Product		Regulation	
Product name	code	Product description	number	Company name
Set, Administration, Intravenous	FPA		880.5440	Csl Behring
Set, Administration, Intravenous	FPA		880.5440	Custom Healthcare Systems, Inc.
Set, Administration, Intravenous	FPA	VARIOUS MODELS OF INFUSION SET	880.5440	Cw Medical, Inc.
Set, Administration, Intravenous	FPA	Various intravascular administration sets, sterile and non-sterile.	880.5440	Deroyal Surgical - Rose Hill
Set, Administration, Intravenous	FPA	Decanting devices.	880.5440	Deuteronomy Management Services, Inc.
Set, Administration, Intravenous	FPA		880.5440	Directmed, Inc.
Set, Administration, Intravenous	FPA	Fluid transfer spike, i.v. administration.	880.5440	Edwards Lifesciences Research Medical
Set, Administration, Intravenous	FPA	Set, administration, intravascular.	880.5440	Edwards Lifesciences Technology Sarl
Set, Administration, Intravenous	FPA	Extension sets.	880.5440	Entracare, LIC
Set, Administration, Intravenous	FPA	I.v. administration	880.5440	Erika De Reynosa, S.A. De C.V.
Set, Administration, Intravenous	FPA	Infusion set (winged).	880.5440	Evans Medical Inc.
Set, Administration, Intravenous	FPA	Microbore extension set.	880.5440	Excelsior Medical Corp.
Set, Administration, Intravenous	FPA	Huber infusion sets. EXEL I.V. Administration Set.	880.5440	Exelint International Co.
Set, Administration, Intravenous	FPA		880.5440	Filtrona Extrusion, Inc./Pexco®
				Medical Products Div.
Set, Administration, Intravenous	FPA	Lure lock, luer slip; with/without needle; various sizes;also include injection site and burette	880.5440	Global Healthcare
Set, Administration, Intravenous	FPA	I.V. administration sets, available with y-injection sites and flashback bulbs.	880.5440	Globe Medical Tech, Inc.
Set, Administration, Intravenous	FPA	Blood collection needle	880.5440	Greiner Bio-One Gmbh
Set, Administration, Intravenous	FPA	No common name listed	880.5440	Haemotronic, S.P.A. Advanced Medical Technologies
Set, Administration, Intravenous	FPA	Infusion set	880.5440	Halex Istar Industria Farmaceutica Ltda.
Set, Administration, Intravenous	FPA	OEM and private-labeled infusion disposables, including infusion bags and sets, extension sets, heparin traps, T-connectors, roller clamps, latex-free injection sites, and infusion components.	880.5440	Harmac Medical Products, Inc.
Set, Administration, Intravenous	FPA	Icoset i.v. solution administration set, disposable	880.5440	Hatu'- Ico S.P.A.
Set, Administration, Intravenous	FPA	Various leukocyte reduction filters sets.	880.5440	Hemerus Medical, Llc.
Set, Administration, Intravenous	FPA		880.5440	Hospira, Inc.
Set, Administration, Intravenous	FPA	Various sizes of iv administration sets (sterile).	880.5440	Hospira, Inc.
Set, Administration, Intravenous	FPA	Various.	880.5440	Icu Medical (Ut), Inc
Set, Administration, Intravenous	FPA	Intravascular administration set.	880.5440	Icu Medical, Inc.
Set, Administration, Intravenous	FPA	Set, administration, intravascular	880.5440	Imp Group Ltd.
Set, Administration, Intravenous	FPA		880.5440	Integra Biotechnical Llc
Set, Administration, Intravenous	FPA		880.5440	International Medical Industries
Set, Administration, Intravenous	FPA	Infusion pump administration sets.	880.5440	Iradimed Corporation
Set, Administration, Intravenous	FPA	Cardioplegia cooling/administration set.	880.5440	Jostra Bentley, Inc.
Set, Administration, Intravenous	FPA		880.5440	Kawasumi Laboratories America, Inc.
Set, Administration, Intravenous	FPA	Infusion plug w/wo filter needle	880.5440	Kelsar, S.A.
Set, Administration, Intravenous	FPA	Infusion set	880.5440	Kofu Factory Of Terumo Corp.
Set, Administration, Intravenous	FPA	Various types of i.v. solution administration sets	880.5440	Labomed Sre
	FPA FPA	Various types on v. solution daministration sets	880.5440	Laborned sie
Set, Administration, Intravenous				
Set, Administration, Intravenous	FPA FDA	IV Set, Buret Set, Extension Set; Lifeline IV & Buret Sets; disposable.	880.5440	Lifemed Of California
Set, Administration, Intravenous	FPA		880.5440	Lucomed Inc.
Set, Administration, Intravenous	FPA	Dual flow divider	880.5440	Macosta S.N.C.
Set, Administration, Intravenous	FPA	Various	880.5440	Medex Medical Ltd.
Set, Administration, Intravenous	FPA	I.V. line securing device.	880.5440	Medical Action Industries, Inc.
Set, Administration, Intravenous	FPA	Multi lumen extension set.	880.5440	Medical Technologies Of Georgia, Inc.

Product name	Product code	Product description	Regulation number	Company name
Set, Administration, Intravenous	FPA	Tubing clamp	880.5440	Medivice Systems, Ltd.
Set, Administration, Intravenous	FPA	Injection cap.	880.5440	Medron, Inc.
Set, Administration, Intravenous	FPA		880.5440	Medtronic Minimed
Set, Administration, Intravenous	FPA		880.5440	Merit Medical Systems Inc.
Set, Administration, Intravenous	FPA	Fluid administration sets.	880.5440	Merit Medical Systems, Inc.
Set, Administration, Intravenous	FPA	Various types of angiography kits eg digital subtraction.	880.5440	Merit Medical Systems, Inc.
Set, Administration, Intravenous	FPA		880.5440	Merlyn Pharmaceuticals, Inc.
Set, Administration, Intravenous	FPA	Safety blood collection and infusion sets. IV administration sets. Specialty anesthesia trays and kits.	880.5440	Myco Medical
Set, Administration, Intravenous	FPA	Fluid delivery sets.	880.5440	Navilyst Medical
Set, Administration, Intravenous	FPA	Various macro and microbore, extension sets, filter sets, sterile.	880.5440	Nexus Medical, Llc
Set, Administration, Intravenous	FPA	Infusion set.	880.5440	Nipro Diabetes Systems, Inc.
Set, Administration, Intravenous	FPA	Plastic IV check valves, plastic IV hooks, custom plastic set components.	880.5440	Np Medical, Inc.
Set, Administration, Intravenous	FPA		880.5440	Omni Medical Supply Inc.
Set, Administration, Intravenous	FPA		880.5440	Primrose Medical, Inc.
Set, Administration, Intravenous	FPA	I.V. administration sets, infusion set, I.V. tubing.	880.5440	Prizm Medical, Inc.
Set, Administration, Intravenous	FPA	Various sterile sets with and without filters.	880.5440	Rd Medical Mfg. Inc.
Set, Administration, Intravenous	FPA	Various.	880.5440	Rymed Technologies, Inc.
Set, Administration, Intravenous	FPA		880.5440	Smiths Medical OEM
Set, Administration, Intravenous	FPA	LiftLoc Safety Infusion Set. LiftLoc is a safety Huber needle designed to reduce the risk of accidental needlesticks by shielding the needle after use. LiftLoc's low profile and small footprint make dressing the site easy.	880.5440	Specialized Health Products International, Inc.
Set, Administration, Intravenous	FPA		880.5440	State Trading Corporation Of India, Ltd.
Set, Administration, Intravenous	FPA	Iv administration set.	880.5440	Terumo Cardiovascular Systems (Tcvs)
Set, Administration, Intravenous	FPA	Intravascular administration set.	880.5440	Terumo Medical Corporation
Set, Administration, Intravenous	FPA	Various sizes of infusion set	880.5440	Tianjin Hanaco Medical Co.,Ltd.
Set, Administration, Intravenous	FPA	Various.	880.5440	Venetec International., Inc.
Set, Administration, Intravenous	FPA	Technegas patient administration set	880.5440	Vita Medical Ltd.
Set, Administration, Intravenous	FPA	Set, administration, intravascular.	880.5440	Vital Signs Mn, Inc.
Set, Administration, Intravenous	FPA	Shielded needle connector.	880.5440	VIv Associates, Inc.
Set, Administration, Intravenous	FPA	Intravenous accessories.	880.5440	Vygon Corp.
Set, Administration, Intravenous	FPA	Various types of sterile infusion tubing sets.	880.5440	Walkmed Infusion LIc
Set, Administration, Intravenous	FPA	Various configurations of amsino i.v. sets	880.5440	Zhejiang Kindly Medical Devices And Plastics Co.,
Tubing, Fluid Delivery	FPK	ACE Extension Tubes ; with and without Medication Sites	880.5440	Ace Surgical Supply Co., Inc.
Tubing, Fluid Delivery	FPK	Empower Transfer Set	880.5440	Acist Medical Systems, Inc.
Tubing, Fluid Delivery	FPK		880.5440	Apothecary Products, Inc.
Tubing, Fluid Delivery	FPK		880.5440	B. Braun Oem Division, B. Braun Medical Inc.
Tubing, Fluid Delivery	FPK	Liquid delivery systems and oral liquid tube sets.	880.5440	Baxa Corporation
Tubing, Fluid Delivery	FPK	MICRO-VOLUME Infusion Sets, Solution Sets, Extension Sets, IV Filtration Sets.	880.5440	Baxter Healthcare Corporporation, Alternate Care And Channel Team
Tubing, Fluid Delivery	FPK	Filtration sets.	880.5440	Codan Us Corporation
Tubing, Fluid Delivery	FPK	Tubing, fluid delivery.	880.5440	Edwards Lifesciences Technology Sarl
Tubing, Fluid Delivery	FPK		880.5440	Filtrona Extrusion, Inc./Pexco® Medical Products Div.
Tubing, Fluid Delivery	FPK	Various accessories for fluid delivery tubing.	880.5440	Health Care Logistics, Inc.
Tubing, Fluid Delivery	FPK	Multiple	880.5440	Hospira Inc.
Tubing, Fluid Delivery	FPK	Tubing, extension set.	880.5440	Hurricane Medical

Product name	Product code	Product description	Regulation number	Company name
Tubing, Fluid Delivery	FPK	Various types of arterial pressure tubing.	880.5440	Icu Medical (Ut), Inc
Tubing, Fluid Delivery	FPK	Fluid transfer set.	880.5440	Integra Lifesciences Corp.
Tubing, Fluid Delivery	FPK	I.V. extension sets.	880.5440	Marquette Medical, Inc.
Tubing, Fluid Delivery	FPK	Sof-set Micro QR MMT-324; Sof-set Micro QR MMT-325	880.5440	Medtronic Minimed
Tubing, Fluid Delivery	FPK	High-pressure tubing with SHERLOCK connectors.	880.5440	Merit Medical Systems, Inc.
Tubing, Fluid Delivery	FPK	Cytostraw.	880.5440	Monogen, Inc.
Tubing, Fluid Delivery	FPK		880.5440	Mps Acacia
Tubing, Fluid Delivery	FPK	NALGENE clear PVC, low-density polyethylene, polyproplylene, FEP, PFA, PVDF, PUR and platinum-cured silicone available.	880.5440	Nalge Nunc International
Tubing, Fluid Delivery	FPK	Drug delivery catheter system i.v.	880.5440	Norfolk Medical Products, Inc.
Tubing, Fluid Delivery	FPK		880.5440	Quest Medical, Inc.
Tubing, Fluid Delivery	FPK	TYGON tubing represents a broad range of materials and formulations to meet specific application requirements.	880.5440	Saint-Gobain Performance Plastics–Akron
Tubing, Fluid Delivery	FPK		880.5440	Spectra Medical Devices, Inc.
Tubing, Fluid Delivery	FPK	Irrigation tubing.	880.5440	Stryker Puerto Rico, Ltd.
Tubing, Fluid Delivery	FPK	Funneled, co-extrusion, multi-lumen, striped, radiopaque, coiled and cut-to-length. PVC, polyetheylene, nylon and other thermoplastics. Custom and standard tubing.	880.5440	Sunlite Plastics, Inc.
Tubing, Fluid Delivery	FPK		880.5440	Tfx Medical Oem
Tubing, Fluid Delivery	FPK	Custom contract manufacturer.	880.5440	The Metrix Co.
Tubing, Fluid Delivery	FPK	Tubing set.	880.5440	Thomas Medical Products, Inc.
Tubing, Fluid Delivery	FPK	Silicone rubber tubing & molded components.	880.5440	Tss Hudson
Pump, Infusion	FRN		880.5700	3m Co.
Pump, Infusion	FRN	Volumetric pump features selection dial that simplifies the user interface and a mode button for switching from primary to secondary fluid administration.	880.5700	Abbott Laboratories
Pump, Infusion	FRN	Quantum Enteral Nutrition Pump	880.5700	Abbott Laboratories
Pump, Infusion	FRN	Infusion pump.	880.5700	Acist Medical Systems, Inc.
Pump, Infusion	FRN	Specialized repair services for leading infusion pumps. AC Adapters, batteries, power cords and other service parts also available for sale.	880.5700	Aiv, Inc. (Formerly American Iv)
Pump, Infusion	FRN	ENTERAL -	880.5700	Altron, Inc.
Pump, Infusion	FRN	The pneumo-hydraulic capillary infusion system.	880.5700	Arndorfer Medical Specialties
Pump, Infusion	FRN	Arthroscopy pump and various types of tubing (sterile).	880.5700	Arthrex, Inc.
Pump, Infusion	FRN	Multipurpose wound drain, multilumen drain allowing lavage and topical applications while continuing evacuation. Relocation/repositioning made easy. Multiple sizes.	880.5700	Axiom Medical, Inc.
Pump, Infusion	FRN	MULTIPLE	880.5700	B. Braun Medical, Inc.
Pump, Infusion	FRN		880.5700	B. Braun Oem Division, B. Braun Medical Inc.
Pump, Infusion	FRN	Syringe pump for microfilter/min perfusions. For use with research animals only– not for for humans.	880.5700	Basi (Bioanalytical Systems, Inc.)
Pump, Infusion	FRN	MICRO FUSE, Dual Rate Infuser: 13-oz, portable, battery- operated syringe infuser with two selectable rates of flow. Custom infusers are available.; InFuse T10	880.5700	Baxa Corporation
Pump, Infusion	FRN	Various infusion pumps,	880.5700	Baxter Healthcare Corporation
Pump, Infusion	FRN	APII. INFUSO.R. INTERMATE system. INFUS.O.R.	880.5700	Baxter Healthcare Corporporation, Alternate Care And Channel Team
Pump, Infusion	FRN	Infusion pump with Warmer FMS 2000 fluid-management system for rapid infusion of warmed fluid, including blood products, up to 750 ml/min, with monitoring for air bubbles, line pressure, temperature, and volume infused.	880.5700	Belmont Instrument Corp.
Pump, Infusion	FRN	Ambulatory infusion pump.	880.5700	Bionica, Inc.
Pump, Infusion	FRN	Infusion pump	880.5700	Block Medical De Mexico S.A. De C.V.
Pump, Infusion	FRN		880.5700	Braemar, Inc.
Pump, Infusion	FRN		880.5700	Brandel

Pump, Infusion	FRN	Mutti-infusion. Infiltration system - automatic and syringe delivery. AUTOFUSE 10c multiple injection system. Also available, BIG BAG 3000 and PSI-TEC syringe pump. Finesse Insulin Delivery System Navigator Delivery System Influsion pump Design and development of fluid management systems. Influsion pump V EXPRES, CHRONOPUMP influsion pump for hospital and ambulatory use, multi mode (PCA, TPN, DOSE, Continuous, Secondary)	880.5700 880.5700 880.5700 880.5700 880.5700 880.5700 880.5700 880.5700 880.5700 880.5700 880.5700 880.5700 880.5700 880.5700 880.5700 880.5700 880.5700 880.5700	Breg, Inc., An Orthofix Company Byron Medical Calibra Medical Inc. Carticept Medical, Inc Changchun Kangda Medical Supply Co., Ltd. Cmrt, Inc. Conmed Linvatec Corpak Medsystems, Inc. Covidien Lp, Formerly Registered As Kendall
Pump, Infusion	FRN FRN FRN FRN FRN FRN FRN FRN FRN	10c multiple injection system. Also available, BIG BAG 3000 and PSI-TEC syringe pump. Finesse Insulin Delivery System Navigator Delivery System Infusion pump Design and development of fluid management systems. Infusion pump Vextor Vextor Infusion pump Design and development of fluid management systems. Infusion pump Design and development of fluid management systems.	880.5700 880.5700 880.5700 880.5700 880.5700 880.5700 880.5700	 Calibra Medical Inc. Carticept Medical, Inc Changchun Kangda Medical Supply Co., Ltd. Cmt, Inc. Conmed Linvatec Corpak Medsystems, Inc. Covidien Lp, Formerty Registered
Pump, Infusion	FRN FRN FRN FRN FRN FRN FRN FRN	Navigator Delivery System Infusion pump Design and development of fluid management systems. Infusion pump VEXPRES, CHRONOPUMP Infusion pump for hospital and ambulatory use, multi mode (PCA, TPN, DOSE, Continuous,	880.5700 880.5700 880.5700 880.5700 880.5700 880.5700 880.5700	Carticept Medical, Inc Changchun Kangda Medical Supply Co., Ltd. Cmt, Inc. Conmed Linvatec Corpak Medsystems, Inc. Covidien Lp, Formerly Registered
Pump, Infusion	FRN FRN FRN FRN FRN FRN FRN FRN	Infusion pump Design and development of fluid management systems. IV EXPRES, CHRONOPUMP infusion pump for hospital and ambulatory use, multi mode (PCA, TPN, DOSE, Continuous,	880.5700 880.5700 880.5700 880.5700 880.5700	Changchun Kangda Medical Supply Co., Ltd. Cmt, Inc. Conmed Linvatec Corpak Medsystems, Inc. Covidien Lp, Formerly Registered
Pump, Infusion Pump, Infusion	FRN FRN FRN FRN FRN FRN FRN	Design and development of fluid management systems. Image: Comparison of the system of the	880.5700 880.5700 880.5700 880.5700	Supply Co., Ltd. Cmt, Inc. Conmed Linvatec Corpak Medsystems, Inc. Covidien Lp, Formerly Registered
Pump, Infusion	FRN FRN FRN FRN FRN FRN	IV EXPRES, CHRONOPUMP Infusion pump for hospital and ambulatory use, multi mode (PCA, TPN, DOSE, Continuous,	880.5700 880.5700 880.5700	Conmed Linvatec Corpak Medsystems, Inc. Covidien Lp, Formerly Registered
Pump, Infusion	FRN FRN FRN FRN FRN	ambulatory use, multi mode (PCA, TPN, DOSE, Continuous,	880.5700 880.5700	Corpak Medsystems, Inc. Covidien Lp, Formerly Registered
Pump, Infusion Image: Pump, Infusion	FRN FRN FRN FRN	ambulatory use, multi mode (PCA, TPN, DOSE, Continuous,	880.5700	Covidien Lp, Formerly Registered
Pump, Infusion	FRN FRN FRN	ambulatory use, multi mode (PCA, TPN, DOSE, Continuous,		
Pump, Infusion	FRN FRN	ambulatory use, multi mode (PCA, TPN, DOSE, Continuous,	880.5700	
Pump, Infusion Pump,	FRN			Debiotech Sa
Pump, Infusion Pump,			880.5700	Dma Med-Chem Corporation
Pump, Infusion Pump, Infusion Pump, Infusion Pump, Infusion Pump, Infusion Pump, Infusion	FRN	Mechanical infusion pump.	880.5700	Ethox International
Pump, Infusion Pump, Infusion Pump, Infusion Pump, Infusion		Syringe pump.	880.5700	Excelsior Medical Corp.
Pump, Infusion Pump, Infusion Pump, Infusion	FRN	Centrifuge and Diaphragm Pumps.	880.5700	Graymills Corp.
Pump, Infusion Pump, Infusion	FRN	Peristattic.	880.5700	Greylor Co.
Pump, Infusion	FRN	OEM and private-labeled infusion bags and administration sets. Contract manufacturer of custom infusion disposables.	880.5700	Harmac Medical Products, Inc.
	FRN	Microprocessor controlled.	880.5700	Harvard Apparatus, Inc.
	FRN	Multiple	880.5700	Hospira Inc.
Pump, Infusion	FRN	MULTIPLE	880.5700	Hospira, Inc.
Pump, Infusion	FRN	Various types of infusion pumps (non-sterile).	880.5700	Icu Medical (Ut), Inc
Pump, Infusion	FRN	Pargwtaral infusor pump	880.5700	Infusion Medix, Ltd.
Pump, Infusion	FRN	Sterile empty pca syringe.	880.5700	International Medication Systems, Ltd.
Pump, Infusion	FRN	Infusion pump and accessories.	880.5700	Iradimed Corporation
Pump, Infusion	FRN	Enteral feeding pumps and accessories	880.5700	Kelsar, S.A.
Pump, Infusion	FRN	Infusion pump.	880.5700	Kmi Kolster Methods, Inc.
Pump, Infusion	FRN	INSULIN - Symphony Meter Remote	880.5700	Lifescan, Inc.
Pump, Infusion	FRN	MTP 1001 \$2,375 for general use peristattic infusion pump.	880.5700	Medical Technology Products, Inc.
Pump, Infusion	FRN		880.5700	Mediq/Prn
Pump, Infusion	FRN	Various models of portable infusion pumps	880.5700	Medis S.R.L.
Pump, Infusion	FRN	MicroMed MIMT-407C; Paradigm Reservoir; MIMT-103 Reservoir; MIMT-326 Paradigm Reservoir	880.5700	Medtronic Minimed
Pump, Infusion	FRN		880.5700	Mentor Texas, Inc.
Pump, Infusion	FRN	SILBERG TISSUE PREPARATION SYSTEM: consists of a peristaltic pump to infuse saline subcutaneously and disperse the saline into deeper tissues using ultrasound, \$15,000.	880.5700	Mettler Electronics Corp.
Pump, Infusion	FRN	COMPUFLO	880.5700	Milestone Scientific Inc.
Pump, Infusion	FRN	MULTIPLE	880.5700	Moog Inc.
Pump, Infusion	FRN	No common name listed	880.5700	Nikkiso Co. Ltd.
Pump, Infusion	FRN	Rental of equipment.	880.5700	Omni Medical Supply Inc.
Pump, Infusion	FRN	\$207.00 for pole mounted drug pump; \$444.00 for ICU pump; also, oxytocin flow rate chart optional.	880.5700	Razel Scientific Instruments, Inc.
Pump, Infusion	FRN	CardioGen-82 Infusion System	880.5700	Rbm Services, Llc.
Pump, Infusion	FRN		000 5700	
Pump, Infusion	FIXIN		880.5700	Sigma International, Llc.

P roduct name	Product code	Product description	Regulation number	Company name
Pump, Infusion	FRN	Infusion pump and accessories.	880.5700	Smith & Nephew Inc., Endoscopy Div.
Pump, Infusion	FRN		880.5700	Smith & Nephew, Inc., Endoscopy Division
Pump, Infusion	FRN		880.5700	Smith & Nephew, Inc., Endoscopy Division
Pump, Infusion	FRN		880.5700	Sparton Corporation
Pump, Infusion	FRN	Peristaltic.	880.5700	Specialty Manufacturing Co., The
Pump, Infusion	FRN	Peristaltic pumps: routine lab use and chromatography applications.	880.5700	Spectrum Laboratories, Inc.
Pump, Infusion	FRN		880.5700	Spencer Italia S.R.L.
Pump, Infusion	FRN	Various models of infusion pumps and accessories.	880.5700	Stryker Instruments, Instruments Div.
Pump, Infusion	FRN	Infusion pump.	880.5700	Stryker Puerto Rico, Ltd.
Pump, Infusion	FRN	SURGI-PRESS PRESSURE INFUSION; MULTIPLE	880.5700	Sts Division Of Ethox International
Pump, Infusion	FRN	SMART peristattic pump, non influsion. 1,2,3 or 4 channel with 8 rollers.	880.5700	Tecan Systems
Pump, Infusion	FRN		880.5700	Terumo Cardiovascular Systems, Corp
Pump, Infusion	FRN	Ambulatory infusion pump.	880.5700	Universal Medical Technologies
Pump, Infusion	FRN	Infusion pump.	880.5700	Valeritas, LIC
Pump, Infusion	FRN	Various models of infusion pumps.	880.5700	Walkmed Infusion LIc
Pump, Infusion	FRN		880.5700	Wells Johnson Co.
Pump, Infusion	FRN		880.5700	World Precision Instruments (W.P.I.), Inc.
Container, IV	KPE		880.5000	Advance Medical Designs, Inc.
Container, IV	KPE	Tamper evident seal.	880.5000	App Pharmaceuticals, Llc
Container, IV	KPE		880.5000	App Pharmaceuticals, Llc
Container, IV	KPE		880.5000	App Pharmaceuticals, Llc
Container, IV	KPE	Vitalmix plus empty i.v. container.	880.5000	Avail Medical Products
Container, IV	KPE	Dual-chambered container to store both drug and diluent.	880.5000	B. Braun Oem Division, B. Braun Medical Inc.
Container, IV	KPE	Various types of sterile iv mixing containers/bags and accessories.	880.5000	B. Braun Of Puerto Rico, Inc.
Container, IV	KPE	QUICK MIX Container.	880.5000	Baxter Healthcare Corporation
Container, IV	KPE	Large and small volume parenterals, premix medications, VIAFLEX containers, evacuated glass containers.	880.5000	Baxter Healthcare Corporation, Global Drug Delivery
Container, IV	KPE	Evacuated Container; I.V. GENERAL HOSPITAL; Vialfex Container; Additive Cap; IntraVia Container Empty; AlHn-One Container;	880.5000	Baxter Healthcare Corporation, Medication Delivery
Container, IV	KPE	Various sterile empty solution containers.	880.5000	Baxter Healthcare S.A.
Container, IV	KPE	Iva seal ii.	880.5000	Covidien Lp, Formerly Registered As Ludlow
Container, IV	KPE	Iva seal ii.	880.5000	Covidien Lp, Formerly Registered As Tyco Healthcare
Container, IV	KPE	Tamper evident seal.	880.5000	Custom Tape Company
Container, IV	KPE	Decanting device.	880.5000	Deuteronomy Management Services, Inc.
Container, IV	KPE	STERI-SPOUTS	880.5000	Durden Enterprises
Container, IV	KPE	Mix container with attached transfer set.	880.5000	Entracare, LIC
Container, IV	KPE	Various.	880.5000	Health Care Logistics, Inc.
Container, IV	KPE	Multiple	880.5000	Hospira Inc.
Container, IV	KPE	multiple	880.5000	Hospira, Inc.
Container, IV	KPE		880.5000	Jorgensen Laboratories
Container, IV	KPE		880.5000	Lucomed Inc.

Product name	Product code	Product description	Regulation number	Company name
Container, IV	KPE		880.5000	Medi-Dose, Inc.
Container, IV	KPE	INFUSIO JUTURUM 2000 Wide range of IV bags for infusion, irrigation, blood collection, etc.	880.5000	Medistad Medical Bv
Container, IV	KPE	Intravenous solution bags.	880.5000	Millipore Corporation
Container, IV	KPE	Empty solution transfer container for total parenteral nutrition	880.5000	Plasco, Inc.
Container, IV	KPE	SECURE Total parenteral nutrition bags, 250ml. through 4000ml. (available in plastic also).	880.5000	The Metrix Co.
Container, IV	KPE	Calibrated cylinders used as I.V. chambers.	880.5000	Tulox Plastics Corp.
Container, IV	KPE	Various types of sterile reservoir bags.	880.5000	Walkmed Infusion LIC
Container, IV	KPE	Pharmaceutical containers.	880.5000	West Pharmaceutical Services, Inc.
System, Dialysate Delivery, Semi- Automatic, Peritoneal	KPF	Renal therapy clinical data management software.	876.5630	Baxter Healthcare Corp., Renal Division
System, Dialysate Delivery, Semi- Automatic, Peritoneal	KPF		876.5630	Fresenius Usa, Inc.
Set, IV Fluid Transfer	LHI	Fluid transfer sets and spikes.	880.5440	Accellent El Paso
Set, IV Fluid Transfer	LHI	Maxifill Transfer Set	880.5440	App Pharmaceuticals, Llc
Set, IV Fluid Transfer	LHI		880.5440	App Pharmaceuticals, Llc
Set, IV Fluid Transfer	LHI	Transfer set.	880.5440	Avail Medical Products
Set, IV Fluid Transfer	LHI	HYPERFORMER COMPOUNDER	880.5440	B. Braun Medical, Inc.
Set, IV Fluid Transfer	LHI		880.5440	B. Braun Oem Division, B. Braun Medical Inc.
Set, IV Fluid Transfer	LHI	lv sets	880.5440	B. Braun Of Dominican Republic
Set, IV Fluid Transfer	LHI	Various dispensing pins/connectors and fluid transfer sets.	880.5440	B. Braun Of Puerto Rico, Inc.
Set, IV Fluid Transfer	LHI		880.5440	Baxa Corporation
Set, IV Fluid Transfer	LHI	Solution transfer sets.	880.5440	Baxter Healthcare Corporation Nutrition
Set, IV Fluid Transfer	LHI	CHEMO-AIDE DISPENSING PIN; VIAL-MATE RECONSTITUTION DEVICE;	880.5440	Baxter Healthcare Corporation, Medication Delivery
Set, IV Fluid Transfer	LHI	Solution transfer sets.	880.5440	Baxter Healthcare Corporporation, Alternate Care And Channel Team
Set, IV Fluid Transfer	LHI	Chemotherapy dispensing pin.	880.5440	Baxter Healthcare S.A.
Set, IV Fluid Transfer	LHI	Single dose dispensing pin.	880.5440	Cardinal Health 303,Inc.
Set, IV Fluid Transfer	LHI		880.5440	Churchill Medical Systems, Inc.
Set, IV Fluid Transfer	LHI	Pharmacy compounding systems.	880.5440	Covidien Lp, Formerly Registered As Ludlow
Set, IV Fluid Transfer	LHI	Various contrast saver sets, intravascular administration sets.	880.5440	Deroyal Surgical - Rose Hill
Set, IV Fluid Transfer	LHI	I.v.sets.	880.5440	Deroyal Wound Care
Set, IV Fluid Transfer	LHI		880.5440	Directmed, Inc.
Set, IV Fluid Transfer	LHI	Emergency infusion.	880.5440	Ethox International
Set, IV Fluid Transfer	LHI	Set in fluid transfer	880.5440	Eurospital S.P.A.
Set, IV Fluid Transfer	LHI	Dispensing pump tubing.	880.5440	Excelsior Medical Corp.
Set, IV Fluid Transfer	LHI	Various.	880.5440	Health Care Logistics, Inc.
Set, IV Fluid Transfer	LHI	Multiple	880.5440	Hospira Inc.
Set, IV Fluid Transfer	LHI	I.v. decanter-flexible.	880.5440	Inrad
Set, IV Fluid Transfer	LHI	Tubing set for therapeutic phlebotomy.	880.5440	Kawasumi Laboratories America, Inc.
Set, IV Fluid Transfer	LHI	INSTAFIL, Transfer unit, high flow or gravity.	880.5440	Lifemed Of California
Set, IV Fluid Transfer	LHI	I.V. extension sets.	880.5440	Medikmark Inc.
Set, IV Fluid Transfer	LHI		880.5440	Mps Acacia
Set, IV Fluid Transfer	LHI	Vial Adapter	880.5440	Novo Nordisk Pharmaceuticals, Inc.
Set, IV Fluid Transfer	LHI	QTMicro System; SafeFill Vial Adaptors; QTJunior System; QuickTest System	880.5440	Q.I. Medical, Inc.

Product Regulation					
Product name	code	Product description	Regulation number	Company name	
Set, IV Fluid Transfer	LHI		880.5440	Smiths Medical OEM	
Set, IV Fluid Transfer	LHI	I.V. safety connector.	880.5440	Venetec International., Inc.	
Set, IV Fluid Transfer	LHI	Fluid transfer set.	880.5440	West Pharmaceutical Services, Inc.	
Set, IV Fluid Transfer	LHI	multiple	880.5440	West Pharmaceutical Services, Inc Lititz, Pa	
Pump, Infusion, PCA	MEA		880.5700	Abbott Laboratories	
Pump, Infusion, PCA	MEA	Specialized repair services for leading PCA pumps. AC Adapters available for sale as well.	880.5700	Aiv, Inc. (Formerly American Iv)	
Pump, Infusion, PCA	MEA		880.5700	Ardus Medical, Inc.	
Pump, Infusion, PCA	MEA	Pca infusor, basal-bolus, pca infusor.; MULTIPLE	880.5700	Baxter Healthcare Corporation, Medication Delivery	
Pump, Infusion, PCA	MEA		880.5700	Hospira, Inc.	
Pump, Infusion, PCA	MEA	Verifuse.	880.5700	Integra Lifesciences Corp.	
Pump, Infusion, PCA	MEA		880.5700	Mps Acacia	
Pump, Infusion, PCA	MEA		880.5700	Smiths Medical Asd, Inc.	
Pump, Infusion, PCA	MEA	Infusion pump.	880.5700	Stryker Instruments, Instruments Div.	
Pump, Infusion, PCA	MEA	Various models of PCA infusion pumps.	880.5700	Walkmed Infusion LIc	
Pump, Infusion, Elastomeric	MEB	Elastomeric infusion pump.	880.5700	Advanced Infusion, Inc.	
Pump, Infusion, Elastomeric	MEB	Solace Post-Operative Pain Relief Infusion System	880.5700	Apex Medical Technologies, Inc.	
Pump, Infusion, Elastomeric	MEB	Infusor, elastomeric infusion pump.	880.5700	Baxter Healthcare Corporation, Medication Delivery	
Pump, Infusion, Elastomeric	MEB	Various types of infusion pumps.	880.5700	Biomet, Inc.	
Pump, Infusion, Elastomeric	MEB	Various	880.5700	Block Medical De Mexico S.A. De C.V.	
Pump, Infusion, Elastomeric	MEB	Pain care 2000.	880.5700	Breg, Inc., An Orthofix Company	
Pump, Infusion, Elastomeric	MEB	Multiple	880.5700	I-Flow Corporation	
Pump, Infusion, Elastomeric	MEB	Various models of infusion pumps, and accessories.	880.5700	Stryker Instruments, Instruments Div.	
Pump, Infusion, Elastomeric	MEB	Disposable infusion pump kit.	880.5700	Symbios Medical Products, Llc	
Pump, Infusion, Elastomeric	MEB	Innsion pump, various sterile disposables and non-sterile non- disposables.	880.5700	Tandem Medical, Inc.	
Pump, Infusion, Elastomeric	MEB	Disposable ambulatory infuser.	880.5700	Walkmed Infusion LIc	
Pump, Infusion, Elastomeric	MEB	MULTIPLE	880.5700	Zevex Incorporated	
Vessel Guard or Cover, To facilitate revision surgeries	MFX	Patch, cardiovascular.	870.3470	Medtronic Cardiovascular Surgery, The Heart Valve Div.	
Vessel Guard or Cover, To facilitate revision surgeries	MFX	Patch cardiovascular.	870.3470	Medtronic Heart Valves	
Vessel Guard or Cover, To facilitate revision surgeries	MFX	Surgical membrane.	870.3470	W.L. Gore & Associates,Inc	

Product name	Product code	Product description	Regulation number	Company name
Silicone, Liquid, Injectable	KGM	Sterile silicone oil for use as a prolonged retinal tamponade.		Therapeutic Silicone Technologies, Inc.
Agent, Bulking, Injectable For Gastro-Urology Use	LNM	Uretheral bulking agent.		Bioform Medical, Inc.
Agent, Bulking, Injectable For Gastro-Urology Use	LNM	MACROPLASTIQUE IMPLANTS		Uroplasty, Inc.
Agent, Injectable, Embolic	MFE	Injectable bulking agent.		Carbon Medical Technologies, Inc.
Agent, Injectable, Embolic	MFE	Liquid embolic agent.		Cordis Neurovascular, Inc.

Product name	Product code	Product description	Regulation number	Company name
Agent, Injectable, Embolic	MFE	Injectable embolic agent.		Ev3 Neurovascular
Intravascular Radiation Delivery System	MOU	Various types of vascular brachytherapy systems including sterile catheters and.		Best Vascular, Inc.
Intravascular Radiation Delivery System	MOU	Source delivery unit.		Guidant Corporation

Drug-Delivery Unclassified Devices - 510(k)

Product name	Product code	Product description	Regulation number	Company name
System, Delivery, Allergen And Vaccine	LDH	Allergy prick test needle.		Alkaline Corp.
System, Delivery, Allergen And Vaccine	LDH	ASTRAL Inoculation System–1- and 10-uL inoculation loop system; streaking needles; Clone-Piks.		Bio Plas, Inc.
System, Delivery, Allergen And Vaccine	LDH	Hill top chamber r.		Hill Top Research Corp
System, Delivery, Allergen And Vaccine	LDH	QUINTEST and QUINTIP skin test devices (sterile)for allergy testing.		Hollister-Stier Laboratories, Llc
System, Delivery, Allergen And Vaccine	LDH	Injectable vaccines and Medical Supply		Insource, Inc.
System, Delivery, Allergen And Vaccine	LDH	Skin prick test.		Panatrex, Inc.
System, Delivery, Allergen And Vaccine	LDH	Allergy skin test device-sterile.		Q.T.I. Corp.
Controller, Infusion, Intravascular	LDR			Csl Behring
Controller, Infusion, Intravascular	LDR			Deka Research & Development Corp.
Kit, IV Start	LRS			Audina Hearing Instruments, Inc.
Kit, IV Start	LRS			Becton Dickinson Infusion Therapy Systems, Inc.
Kit, IV Start	LRS			Centurion Medical Products Corp.
Kit, IV Start	LRS			Centurion Medical Products Corporation
Kit, IV Start	LRS			Cotran Corp.
Kit, IV Start	LRS			Crest Healthcare Supply
Kit, IV Start	LRS	I.v. prep kit ryder.		Customed, Inc.
Kit, IV Start	LRS	Features include tourniquet, alcohol prep pad, PVP ointment, PVP prep pad or ampule swab, 2x2 gauze sponges, 3/4in. surgical tape and patient ID label. Other components available.		Cypress Medical Products
Kit, IV Start	LRS	Primary gravity IV sets (84-120") for use in oncology centers and ambulatory surgical suite.		Kawasumi Laboratories America, Inc.
Kit, IV Start	LRS	Various Types & Configurations including Chloraprep. Price Range mostly \$50 to \$147		Lsl Industries, Inc.
Kit, IV Start	LRS	ChloraPrep		Medikmark Inc.
Kit, IV Start	LRS	nfusion Kit for NovoSeven RT; Test Medium Reconstitution Kit for Training		Novo Nordisk Pharmaceuticals, Inc.
Kit, IV Start	LRS	I.v. set		Nypro Singapore Pte. Ltd.
Kit, IV Start	LRS	Various types of iv start kits.		Rd Medical Mfg. Inc.
Kit, IV Start	LRS	Various		Servo-Med Industries Pvt. Ltd.
Labor and Delivery Kit	MLS			Armstrong Medical Industries, Inc.
Labor and Delivery Kit	MLS	The Placental Triage Kit (PTK). The PTK is designed to help improve how placentas are handled in the birthing room. It standardizes placental triage, making it quicker, more efficient and low cost while optimizing documentation and information on placen		Bio-Logics Products, Inc.

Drug-Delivery Unclassified Devices - 510(k)

Product name	Product code	Product description	Regulation number	Company name
Labor and Delivery Kit	MLS			Centurion Medical Products Corp.
Labor and Delivery Kit	MLS			Centurion Medical Products Corporation
Labor and Delivery Kit	MLS	OB KITS, Kit obstetrical, disposable for birthing and delivery of babies in emergency situations. Available with many various components to meet your expectations or regulations.		Morrison Medical
Labor and Delivery Kit	MLS			Rockford Medical & Safety Co.
Labor and Delivery Kit	MLS			Utah Medical Products, Inc.

Drug-Delivery Medical-Device Companies

Abbott Diagnostics Intl, Biotechnology Ltd

Road #2 KN. 58.0, PO Box 278, Cruce Ďavila Barceloneta, PR 00617, United States Phone: 787-846-3500 Email: globalcitizenship@abbott.com Website: www.abbott.com

Abbott Laboratories

100 Abbott Park Rd. Abbott Park, IL 60064-3500, United States Phone: 847-937-6100 Fax: 847-935-3969 Email: globalcitizenship@abbott.com Website: www.abbott.com Year established: 1888

Abbott Laboratories

1033 Kingsmill Pkwy., Columbus, OH 43229, United States Phone: 614-624-7677 Fax: 614-227-3244 Website: www.ross.com

Ac Healthcare Supply, Inc.

116-51 230th St. Cambria Heights, NY 11411, United States Phone: 905-448-4706

Accellent El Paso

31C Butterfield Trail El Paso, TX 79906, United States Phone: 915-771-9112 Fax: 915-771-907 Email: info@accellent.com Website: www.accellent.com

Ace Surgical Supply Co., Inc.

1034 Pearl St. Brockton, MA 02301, United States Phone: 508-588-3100 Fax: 508-583-3140 Email: info@acesurgical.com Website: www.acesurgical.com

Acist Medical Systems, Inc.

7905 Fuller Road Eden Prairie, MN 55344, United States Phone: 952-995-9300 Fax: 952-941-4648

Advance Medical Designs, Inc.

1241 Atlanta Industrial Drive Marietta, GA 30066, United States Phone: 770-422-3125 Fax: 770-429-2471 Email: sales@a-m-d-inc.com Website: www.advancemedicaldesigns.com Year established: 1984

Advanced Infusion, Inc.

466 West Arrow Hwy, Unit H San Dimas, CA 91773, United States Phone: 909-305-9857

Advanced Medical Innovations, Inc.

9410 De Soto Avenue,, Building J Chatsworth, CA 91311, CA 91311, United States Phone: 818-701-7180 Fax: 818-701-9708 Email: sales@amiwelisten.com Website: www.amiwelisten.com Year established: 1995

Aiv, Inc. (Formerly American Iv)

7485 Shipley Avenue Harmans, MD 21077, United States Phone: 410-787-1300 Fax: 410-787-1337 Email: aivsales@aiv-inc.com Website: www.aiv-inc.com

Alcon Research, Ltd.

6201 South Fwy. Fort Worth, TX 76134-2001, United States Phone: 817-293-0450 Fax: 800-241-0677 Email: mary.dulle@alconlabs.com Website: www.alconlabs.com Year established: 1945

Alden Medical Llc

360 Cold Spring Ave. West Springfield, MA 01089, United States *Phone: 413-747-9717*

Alimed, Inc.

297 High St. Dedham, MA 02026-2844, United States Phone: 781-329-2900 Fax: 781-329-8392 Email: info@alimed.com Website: www.alimed.com Year established: 1970

Alkaline Corp.

20 Meridian Road #9 Eatontown, NJ 07724, United States Phone: 732-531-7830 Fax: 732-531-7830 Email: alkaline@allergyhelp.com Website: www.allergyhelp.com

All Star Orthodontics, Llc

4570 Progress Dr. Columbus, IN 47201, United States Phone: 812-314-0804

Allen Medical Systems, Inc.

1 Post Office Square Acton, MA 01720, United States Phone: 978-263-5401 Fax: 978-263-8846 Email: customerservice@allenmedical.com Website: www.allenmedical.com

Alphaprotech, Inc.

1287 West Fairway Dr. Nogales, AZ 85621, United States Phone: 229-242-1931

Alsius Corp.

15770 Laguna Canyon, Suite 150 Irvine, CA 92618, United States Phone: 949-453-0150 Fax: 949-453-9702 Email: info@alsius.com Website: www.alsius.com

Altomed Opthalmic Products Ltd.

2 Witney Way, Boldon Business Park Boldon Colliery, NE35 9PE, United Kingdom Phone: 191/519-0111 Fax: 191/519-0283 Email: admin@altomed.com Website: www.altomed.com Year established: 1976

Altron, Inc.

6700 Bunker Lake Blvd. N.W. Minneapolis, MIN 55303-5852, United States Phone: 763-427-7735 Fax: 763-427-3773 Email: sales@altronmfg.com Website: www.altronmfg.com Year established: 1974

Amann Medizintechnik

Neuhauser Str. 43 Emmingen-Liptingen, 78576, Germany *Phone: 49-746-59267*

Amarco Medizintechnik Gmbh

Finkenstr. 8 Tuttlingen, 78532, Germany *Phone: 74-61-9 21 1*

American Medical Mfg., Inc.

9410 Desoto Ave., Unit J Chatsworth, CA 91311, United States Phone: 818-701-7171 Fax: 818-701-9708 Email: sales@amiwelisten.com Website: www.amiwelisten.com Year established: 1990

Amsino International, Inc.

855 Towne Center Drive, Pomona, CA 91767, United States Phone: 909-626-5888 Fax: 909-626-5888 Email: info@amsino.com Website: www.amsino.com Year established: 1993

Amsino Medical Usa

5209 Linbar Dr., Suite 640 Nashville, TN 37211, United States *Phone: 615-332-9959*

Anissa's Fun Patches

P.O. Box 455 Chuckey, TN 37641, United States Phone: 423-234-3404 Fax: 423-234-3404 Email: anissasfunpatch@mounet.com Website: www.anissasfunpatches.com Year established: 2002

Apex Medical Technologies, Inc.

10064 Mesa Ridge Ct., Suite 202 San Diego, CA 92121-2948, United States Phone: 858-535-0012 Fax: 858-535-9715 Email: adepaul@apexmedtech.com Website: www.apexmedtech.com Year established: 1985

Aplicare, Inc.

550 Research Parkway Meriden, CT 06450, United States Phone: 203-630-0500 Fax: 203-630-4876 Email: customerservice@aplicare.com Website: www.aplicare.com Year established: 1983

Apothecary Products, Inc. 11750 12th Avenue S. Burnsville, MN 55337-1295, United States Phone: 888-770-8767 Fax: 800-328-1584 Email: customerservice@apothecaryproducts.com Website: www.apothecaryproducts.com Year established: 1975

App Pharmaceuticals, Llc

3159 Staley Rd. Grand Island, NY 14072, United States Phone: 847-330-3953 Email: contactus@APPpharma.com Website: www.apppharma.com

App Pharmaceuticals, Llc

2020 N. Ruby St. Melrose Park, IL 60160, United States Phone: (708) 345-6170 Fax: (708) 450-7563

App Pharmaceuticals, Llc

1501 E. Woodfield Rd., Suite 300e Schaumburg, IL 60173, United States Phone: 847-330-3953

Architectures

26 Rue Poncelet Paris, 75017, France Phone: 1-563-33-34

Ardus Medical, Inc.

11297 Grooms Rd. Cincinnati, OH 45242, United States Phone: 513-469-7867 Fax: 513-469-2329 Email: sales@ardusmedical.com Website: www.ardusmedical.com Year established: 1994

Argon Medical Devices Inc.

1445 Flat Creek Rd. Athens, TX 75751, United States Phone: 903-675-9321 Fax: 903-677-9396 Website: www.argonmedical.com

Arkray Factory Usa, Inc.

5182 West 76th St Minneapolis, MN 55439, United States Phone: 952-646-3168

Armstrong Medical Industries, Inc.

575 Knightsbridge Pkwy. Lincolnshire, IL 60069-3616, United States Phone: 847-913-0101 Fax: 847-913-0138 Email: csr@armstrongmedical.com Website: www.armstrongmedical.com Year established: 1957

Arndorfer Medical Specialties

5656 Grove Terrace Greendale, WI 53129, United States Phone: 414-425-1661

Arrow Internacional De Mexico, S.A. De C.V.

Modulo 1, Circuito 5, Parque Industrias De America Col. Panamericana, Chihuahua, Mexico Phone: 610-378-0131

Arrow International, Inc.

9 Plymouth St. Everett, MA 02149, United States Phone: 610-655-8522 Website: www.arrowintl.com Year established: 1975

Arrow International, Inc.

2 Berry Dr Mount Holly, NJ 08060, United States Phone: 610-655-8522 Website: www.arrowintl.com Year established: 1975

Arthrex, Inc.

1370 Creekside Blvd. Naples, FL 34108, United States Phone: 239-643-5553 Fax: 800-643-9310 Website: www.arthrex.com Year established: 1984

As Advanced Medical Systems

Werdauer Str. 51 Fraureuth, 8427, Germany Phone: 614-889-2220

Ashitaka Factory Of Terumo Corporation

150 Maimaiki-Cho Fujinomiya, 418-0015, Japan Phone: 011-81-33374

Astron International Inc.

3410 Westview Dr. Naples, FL 34104, United States Phone: 239-435-0136

Atd-American Co.

135 Greenwood Ave. Wyncote, PA 19095-1337, United States Phone: 215-576-1000 Fax: 215-576-1827 Email: website@atd.com Website: www.atd.com

Audina Hearing Instruments, Inc.

165 E. Wildmere Ave. Longwood, FL 32750, United States Phone: 800-223-7700 Website: www.audina.net Year established: 1990

Avail Medical Products

5950 Nancy Ridge Dr, Ste 500 San Diego, CA 92121, United States Phone: 858-635-2206

Avedro, Inc.

230 Third Avenue Waltham, MA 02451, United States Phone: 781-768-3400 Fax: 781-768-3401 Website: www.avedro.com

Axiom Medical, Inc.

19320 Van Ness Ave. Torrance, CA 90501, United States Phone: 310-533-9020 Fax: 310-533-8127 Email: Sales@AxiomMed.com Website: www.AxiomMed.com Year established: 1976

B. Braun Celsa

Avenue Des Temps Modernes Chassenevil, Cedex, France Phone: 610-266-0500

B. Braun Medical Ag

Postfach 176 Escholzmatt, 6182, Switzerland Phone: 495-661-710

B. Braun Medical Inc., Renal Therapies Div.

824 Twelfth Avenue Bethlehem, PA 18018, United States Phone: 610-691-5400 Fax: 610-691-1547 Email: safetyexpert@bbraun.com Website: www.bbraunusa.com Year established: 1979

B. Braun Medical, Inc.

901 Marcon Blvd. Allentown, PA 18109, United States Phone: 610-596-2536 Website: www.bbraunusa.com

B. Braun Medical, Inc.

1601 Wallace Dr., Suite 150 Carrollton, TX 75006, United States Phone: 610-596-2536

B. Braun Oem Division, B. Braun Medical Inc.

824 Twelfth Avenue Bethlehem, PA 18018-3524, United States Phone: 610-691-6785 Fax: 610-691-1785 Email: contact-usa@bbraunoem.com Website: www.bbraunoem.com Year established: 1979

B. Braun Of Dominican Republic

Km No. 22, Las Americas Hwy. Parque Las Americas, Dominican Republic Phone: 610-691-5400

B. Braun Of Puerto Rico, Inc.

215.7 Insular Rd. Sabana Grande, PR 00637, United States Phone: 610-691-5400

B. Graczyk, Inc.

27826 Burmax Court Dowagiac, MI 49047, United States Phone: 269-782-2100

Bard Access Systems, Inc.

605 N. 5600 West Salt Lake City, UT 84116, United States Phone: 801-522-5000 Fax: 801-522-49485 Email: slc.cs@crbard.com Website: www.bardaccess.com

Bard Peripheral Vascular, Inc.

1625 West Third Street Tempe, AZ 85281, United States Phone: 480-894-9515 Fax: 480-303-2767 Email: bpv.products@crbard.com Website: www.bardpv.com

Bard Reynosa S.A. De C.V.

Blvd. Montebello #1, Parque Industrial Colonial Reynosa, Tamaulipas, Mexico Phone: 908-277-8000

Bard Shannon Limited

San Geronimo Industrial Park, Lot # 1, Road # 3, Km 79.7 Humacao, PR 00791, United States Phone: 908-277-8000

Basi (Bioanalytical Systems, Inc.)

2701 Kent Avenue West Lafayette, IN 47906-1382, United States Phone: 765-463-4527 Fax: 765-497-1102 Email: basi@bioanalytical.com Website: www.bioanalytical.com Year established: 1974

Baur Und Haselbarth-Chirurg Gmbh

Sauerbruchstr. 7 Ellerau, 25479, Germany Phone: 041-067-2091

Bausch & Lomb Surgical

3365 Tree Ct. Indust. Blvd. St. Louis, MO 63122-6615, United States Phone: 636-255-5051 Fax: 909-399-1422 Website: www.bausch.com

Baxa Corporation

9540 S Maroon Circle, Suite 400 Englewood, CO 80112, United States Phone: 303-690-4204 Fax: 303-690-4804 Email: baxamail@baxa.com Website: www.baxa.com Year established: 1975

Baxter Healthcare Corp., Renal Division

7511 114th Avenue North Largo, FL 33777, United States Phone: 847-948-2000 Fax: 800-756-4952 Email: onebaxter@baxter.com

Baxter Healthcare Corporation

900 Corporate Grove Drive Buffalo Grove, IL 60089, United States Phone: 847-473-6141

Baxter Healthcare Corporation Nutrition

One Baxter Pkwy. Deerfield, IL 60015, United States Phone: 847-948-2000 Fax: 888-229-0020 Email: onebaxter@baxter.com Website: www.baxter.com Year established: 1931

Baxter Healthcare Corporation, Global Drug Delivery

One Baxter Parkway Deerfield, IL 60015-4625, United States Phone: 800-422-9837 Fax: 800-568-5020 Email: onebaxter@baxter.com Website: www.baxter.com Year established: 1931

Baxter Healthcare Corporation, Medication Deliverv

17511 Armstrong Ave Irvine, CA 92614, United States Phone: 949-851-9066 Fax: 800-756-4952 Email: onebaxter@baxter.com Website: www.baxter.com Year established: 1931

Baxter Healthcare Corporation, Medication

Delivery 25212 W. Illinois Route 120 Round Lake, IL 60073, United States Phone: 847-948-4770 Fax: 888-229-0020 Email: onebaxter@baxter.com Website: www.baxter.com Year established: 1931

Baxter Healthcare Corporporation, Alternate Care

And Channel Team

One Baxter Parkway Deerfield, IL 60015-4625, United States Phone: 847-948-2000 Fax: 800-568-5020 Email: onebaxter@baxter.com Website: www.baxter.com Year established: 1931

Baxter Healthcare S.A.

Rd. 721, Km. 0.3 Aibonito, PR 00609, United States Phone: 847-948-2000 Fax: 800-756-4952 Email: onebaxter@baxter.com

Baxter Productos Medicos, Ltda.

Parque Industrial De Cartago Cartago, 7050, Costa Rica Phone: 847-948-2000

Becton Dickinson And Co.

1 Becton Drive Franklin Lakes, NJ 07417, United States Phone: 201-847-6800

Becton Dickinson And Company

1 Becton Dr. Franklin Lakes, NJ 07417, United States Phone: 201-847-6800 Fax: 201-847-6475 Email: customer_support@bd.com Website: www.bd.com Year established: 1897

Becton Dickinson And Company

2153 12th Ave. Columbus, NE 68601, United States Phone: 201-847-4570

Becton Dickinson Infusion Therapy Systems, Inc.

9450 S. State St Sandy, UT 84070, United States Phone: 888-237-2762 Fax: 800-847-2220 Email: infusion_marketing@bd.com Website: www.bd.com/infusion

Becton Dickinson Medical Systems

9630 South 54th St. Franklin, WI 53132, United States Phone: 201-847-6800

Becton, Dickinson & Co., (Bd) Preanalytical System

1575 Airport Rd. Sumter, SC 29153, United States Phone: 201-847-6280

Beech Medical Products, Inc.

2 South Winchester St. West Swanzey, NH 03469, United States

Belmont Instrument Corp.

780 Boston Road Billerica, MA 01821-5925, United States Phone: 978-663-0212 Fax: 978-663-0214 Email: sales@belmontinstrument.com Website: www.belmontinstrument.com Year established: 1980

Bentec Medical, Inc.

1380 East Beamer St. Woodland, CA 95776, United States Phone: 757-224-0177

Berghof/America

3773 NW 126th Avenue, Building 1 Coral Springs, FL 33065, United States Phone: 954-344-2554 Fax: 954-344-2008 Email: berghof@berfhofusa.com Website: www.berghofusa.com Year established: 1992

Best Vascular, Inc.

4350 International Blvd. Norcross, GA 30093, United States Phone: 770-717-0904

Bio Plas, Inc.

4340 Redwood Highway, Suite A15 San Rafael, CA 94903, United States Phone: 415-472-3777 Fax: 415-472-3758 Email: info@bioplas.com Website: www.bioplas.com Year established: 1976

Bioform Medical, Inc.

4133 Courtney Road, #10 Franksville, WI 53126, United States Phone: 262-835-3323

Bio-Logics Products, Inc. PO Box 505, West Jordan, UT 84084, United States Phone: 801-561-9208 Fax: 801-561-9208 Email: sales@biologicsinc.com Website: www.biologicsinc.com Year established: 1972

Biomedix, Inc.

3895 W. Vernal Pike Bloomington, IN 47404, United States Phone: 812-355-7000 Fax: 812-355-7001 Email: biomedix@biomedix-inc.com Website: www.biomedix-inc.com Year established: 1992

Biomet, Inc.

56 E. Bell Dr., PO Box 587 Warsaw, IN 46581, United States Phone: 574-267-6639 Fax: 574-267-8137 Email: biomet@biomet.com Website: www.biomet.com Year established: 1977

Bionica, Inc.

5112 Bailey Loop Mcclellan, CA 95652, United States Phone: 916-643-2222

Blickman

39 Robinson Road Lodi, NJ 07644, United States Phone: 201-909-0807 Fax: 201-909-0832 Email: info@blickman.com Website: www.blickman.com Year established: 1975

Block Medical De Mexico S.A. De C.V.

La Mesa Parque Industrial, Paseo Reforma S/n, Fracc. Tijuana, Bc, Mexico Phone: 949-206-2700

Boin Medica Co. Ltd.

106-9 Cho-Dong 5f Dong, Chon Bldg. Seoul, Chung-Ku, Republic of Korea Phone: 11-54-646155

Brady Precision Converting, Llc

1801 Big Town Blvd., Suite 100 Mesquite, TX 75149, United States Phone: 214-275-9595 Fax: 214-275-6748 Email: bdavies@pcitechnology.com Website: www.pcitechnology.com Year established: 1995

Braemar, Inc.

1285 Corporate Center Dr., Suite 150 Eagan, MN 55121, United States Phone: 651-286-8620 Fax: 651-286-8630 Email: info@braemarinc.com Website: www.braemarinc.com Year established: 1998

Brandel

8561 Atlas Dr. Gaithersburg, MD 20877-4135, United States Phone: 301-948-6506 Fax: 301-869-5570 Email: sales@brandel.com Website: www.brandel.com

Brandt Industries, Inc.

4461 Bronx Blvd. Bronx, NY 10470-1496, United States Phone: 718-994-0800 Fax: 718-325-7995 Email: info@brandtind.com Website: www.brandtind.com Year established: 1930

Breg, Inc., An Orthofix Company

2611 Commerce Way, Vista, CA 92081, United States Phone: 760-599-3000 Fax: 800-329-2734 Email: info@breg.com Website: www.breg.com Year established: 1989

Brenner Metal Products

16 Main Ave. Wallington, NJ 07057, United States Phone: (973) 778-0084 Fax: 973-778-2466

Brewer Company, The

N88 W13901 Main St. Menomonee Falls, WI 53051, United States Phone: 262-251-9530 Fax: 262-251-2332 Email: sales@brewercompany.com Website: www.brewercompany.com Year established: 1947

Bridger Biomed, Inc.

2430 North 7th Ave. Bozeman, MT 59715, United States Phone: 908-277-8000

Bryton Corp.

4310 Guion Rd. Indianapolis, IN 46254-3111, United States Phone: 317-334-8700 Fax: 317-334-8787 Email: info@brytoncorp.com Website: www.brytoncorp.com Year established: 1981

Byron Medical

602 W. Rillito Tucson, AZ 85705, United States Phone: 520-573-0857 Fax: 520-746-1757 Email: bleavenworth@byronmedical.com Website: www.byronmedical.com Year established: 2002

Cadence Science Inc.

1979 Marcus Ave, Suite 215 Lake Success, NY 11042, United States Phone: 516-248-0300 Fax: 516-747-1188 Email: sales@cadencescience.com Website: www.cadencescience.com Year established: 1922

Calibra Medical Inc.

220 saginaw drive Redwood City, CA 94063, United States Phone: 650-298-4710 Email: abasu@calibra.com Website: www.myfinesse.com

Cameron-Miller, Inc.

5410 West Roosevelt, Road #241 Chicago, IL 60644, United States Phone: 773-379-2624 Fax: 773-379-2686 Email: info@cameron-miller.com Website: cameron-miller.com Year established: 1915

Camtec

1959 Church Creek Rd. Cambridge, MD 21613, United States Phone: 410-228-1156

Carbon Medical Technologies, Inc.

1290 Hammond Road Saint Paul, MN 55110, United States Phone: 651-653-8512 Fax: 651-407-1975 Email: info@carbonmed.com Website: www.carbonmed.com Year established: 1994

Cardinal Health 200, Inc

200 Mcknight St Jacksonville, TX 75766, United States Phone: 847-785-3323 Website: www.cardinal.com

Cardinal Health 200, Inc

One Butterfield Trail El Paso, TX 79906, United States Phone: 847-785-3323 Website: www.cardinal.com

Cardinal Health 303, Inc.

1515 Ivac Way Creedmoor, NC 27522, United States Phone: 858-458-7830 Website: www.cardinal.com

Cardinal Healthcare 209, Inc.

5225 Verona Rd. Madison, WI 53711-4495, United States Phone: 610-862-0800

Carmel Pharma Ab.

16-B Flojelbergsgatan Molndál, Sweden Phone: 46-31-703040

Carolina Medical, Inc.

157 Industrial Dr., King, NC 27021-0307, United States Phone: 336-983-5132 Fax: 336-983-8992 Email: info@caromed.com Website: www.caromed.com

Carticept Medical, Inc

6120 Windward Parkway, Suite 220 Alpharetta, GA 30005, United States Phone: (770) 754-3800 Fax: (770) 754-3808

Cas Medical Systems, Inc. 44 E. Industrial Rd., Branford, CT 06405, United States Phone: 203-488-6056 Fax: 203-488-9438 Email: custsrv@casmed.com Website: www.casmed.com Year established: 1984

Catalent Pharma Solutions

2200 Lake Shore Dr. Woodstock, IL 60098, United States Phone: 815-338-9500 Fax: 815-206-1335 Email: patricia.mcgee@catalent.com Website: www.catalent.com.

Catheter Innovations, Inc.

3598 West 1820 South Salt Lake City, UT 84104-4859, United States Phone: 801-954-8444 Fax: 801-954-8484 Website: www.bostonscientific.com

Catheter Research, Inc. (Cri)

5610 W. 82nd St. Indianapolis, IN 46278, United States Phone: 317-872-0074 Fax: 317-872-0169 Email: info@catheterresearch.com Website: www.catheterresearch.com Year established: 1987

Centurion Medical Products Corp.

3310 South Main St. Salisbury, NC 28147, United States Phone: 517-545-1135 Website: www.tristate.com

Centurion Medical Products Corporation

3173 East 43rd St., Yuma, AZ 85365, United States Phone: 517-546-5400 Fax: 517-546-1195 Email: info@tshsc.com

Changchun Kangda Medical Supply Co., Ltd.

4 Huo Ju Rd. Changchun, China Phone: 86-431-51797

Chase Medical, Lp

1876 Firman Dr. Richardson, TX 75081, United States Phone: 972-783-0644

Chf Solutions, Inc.

7601 Northland Dr. Ste. 170 Brooklyn Center, MN 55428, United States Phone: 763-463-4600

Churchill Medical Systems, Inc.

103a Park Drive Montgomeryville, PA 19044, United States Phone: 215-956-0585 Fax: 215-672-6740 Email: CMS935@aol.com Website: www.ChurchillMedicalSystems.com Year established: 1987

Circulatory Technology, Inc.

21 Singworth St. Oyster Bay, NY 11771, United States Phone: 516-624-2424

Clark Company Inc., David

360 Franklin St Worcester, MA 01615-0054, United States Phone: 508-756-6216 Fax: 508-753-5827 Email: sales@davidclark.com Website: www.davidclark.com

Clinical Pharmacies, Inc.

21622 Surveyor Circle, #8-C Huntington Beach, CA 92646, United States Phone: 714-969-6818 Fax: 714-969-2320 Email: carl@cpmednet.com Website: www.cpmednet.com Year established: 1981

Clinimed, Incorporated

303 Markus Court, Sandy Brae Industrial Park Newark, DE 19713-1187, United States Phone: 302-454-8400 Fax: 302-737-8900 Email: info@clinimed.us Website: www.clinimed.us Year established: 1978

Cmt, Inc.

Post Office Box 297 Hamilton, MA 01936-0297, United States Phone: 978-768-2555 Fax: 978-768-2555 Email: info@habitatmonitor.com Website: www.habitatmonitor.com Year established: 1984

Codan Us Corporation

3511 W. Sunflower Avenue Santa Ana, CA 92704-6944, United States Phone: 714-545-2111 Fax: 714-545-9111 Email: info@codanus.com Website: www.codanus.com

Coeur Inc., Sheboygan

3411 Behrens Pkwy. Sheboygan, WI 53081, United States Phone: 920-458-4664 Fax: 920-458-1368 Website: www.vpicorp.com Year established: 1951

Conmed Corporation

310 Broad Street Utica, NY 13501, United States Phone: 800-448-6506 Fax: 800-438-3051 Email: customer_service@mail.conmed.com Website: www.conmed.com Year established: 1970

Conmed Integrated Systems (Cmis)

1815 NW 169th Place, Suite 4020 Beaverton, OR 97006, United States Phone: 800-448-6506 Fax: 800-438-3051 Email: customer_service@mail.conmed.com Website: www.conmed.com

Conmed Linvatec

11311 Concept Blvd Largo, FL 33773-4908, United States Phone: 800-448-6506 Fax: 800-438-3051 Email: customer service@mail.conmed.com Website: www.conmed.com Year established: 1963

Cook Inc.

PO Box 489 Bloomington, IN 47402-0489, United States Phone: 812-339-2235 Fax: 812-339-5369 Email: info@cook-inc.com *Website: www.cookgroup.com* Year established: 1963

Cordis Neurovascular, Inc.

14201 NW 60 Avenue Miami Lakes, FL 33014, United States Phone: 786-313-6550 Website: www.cordis.com Year established: 1959

CorMatrix Cardiovascular Inc.

155-a moffett park drive, Suite 240 Sunnyvale, CA 94089, United States Phone: 408-734-2628 Fax: 408-734-2629 Email: ecm@cormatrix.com Website: www.cormatrix.com Year established: 2001

Corpak Medsystems, Inc.

100 Chaddick Dr. Wheeling, IL 60090, United States Phone: 847-403-3400 Fax: 847-541-9526 Email: questions@corpakmedsystems.com Website: www.corpakmedsystems.com Year established: 1979

Cotran Corp.

574 Park Avenue, PO Box 130 Portsmouth, RI 02871, United States Phone: 401-682-1555 Fax: 401-682-1775 Email: info@cotrancorp.com Website: www.cotrancorp.com Year established: 1986

Covidien

5870 Stoneridge Drive, Suite 6 Pleasanton, CA 94588, United States Phone: 303-305-2382 Website: www.covidien.com

Covidien Lp

15 Hampshire St. Mansfield, MA 02048, United States Phone: 508-261-8000 Email: todd.carpenter@covidien.com Website: www.covidien.com

Covidien Lp, Formerly Registered As Kendall

986 Faichney Dr Watertown, NY 13601, United States Phone: 315-788-0301 Email: customersupport@covidien.com Website: www.covidien.com

Covidien Lp, Formerly Registered As Kendall

444 Mcdonnell Blvd. Hazelwood, MO 63042, United States Phone: 800-962-9888 Email: customersupport@covidien.com Website: www.covidien.com

Covidien Lp, Formerly Registered As Kendall

815 Tek Dr. Crystal Lake, IL 60039, United States Phone: 815-444-2500 Email: customersupport@covidien.com Website: www.covidien.com

Covidien Lp, Formerly Registered As Ludlow

Two Ludlow Park Dr. Chicopee, MA 01022, United States Phone: 413-593-6400 Email: customersupport@covidien.com Website: www.covidien.com

Covidien Lp, Formerly Registered As Tyco Healthcare

15 Hampshire Street Mansfield, MA 02048, United States Phone: 508-261-8000 Email: customersupport@covidien.com Website: www.covidien.com

Covidien Lp, Formerly Registered As United States Surgical

195 Mcdermott Road North Haven, CT 06473, United States Phone: 203-492-5000 Website: www.covidien.com

Crest Healthcare Supply

195 Third Street South, Dassel, MN 55325, United States Phone: 320-275-3382 Fax: 320-275-2306 Email: customerservice@cresthealthcare.com Website: www.cresthealthcare.com Year established: 1968

Cryolife, Inc.

1655 Roberts Blvd. NW. Kennesaw, GA 30144, United States Phone: 770-419-3355 Fax: 770-426-0031 Email: info@cryolife.com Website: www.cryolife.com Year established: 1984

Csl Behring 1020 First Ave., P.O. Box 61501 King of Prussia, PA 19406-0901, United States Phone: 610-878-4000 Fax: 610-878-4009 Website: www.cslbehring.com

Ctp Coil Inc.

1801-D Howard Street Elk Grove Village, IL 60007, United States Phone: 847-228-8818 Fax: 847-593-3930 Email: jpope@iwic.net Website: www.ctpcoil.co.uk Year established: 1994

Custom Healthcare Systems, Inc.

4205 Eubank Rd. Richmond, VA 23231, United States Phone: 804-421-5959

Custom Tape Company

6270 Claude Way East Inver Grove Heights, MN 55076, United States Phone: 651-228-7044

Customed, Inc.

Calle Igualdad #7 Fajardo, PR 00738, United States Phone: 787-801-0101

Cw Medical, Inc.

5595 Daniels St, Suite E, Chino, CA 91710, United States Phone: 909-591-5220 Fax: 909-591-5769 Email: customerservice@cwmedical.us Website: www.cwmedical.us Year established: 1994

Cypress Medical Products

202 S. Rte. 31 MCHenry, IL 60050, United States Fax: 815-385-0114 Email: info@cypressmed.com Website: www.cypressmed.com Year established: 1988

Dale Medical Products, Inc.

7 Cross St. Plainville, MA 02762-0556, United States Phone: 508-695-9316 Fax: 508-695-6587 Email: info@dalemed.net Website: www.dalemed.com Year established: 1961

David Clark Company, Inc.

360 Franklin St. Worcester, MA 01604, United States Phone: 508-751-5800 Fax: 508-753-5827 Email: sales@davidclark.com Website: www.davidclark.com Year established: 1935

David Scott Company

59 Fountain St. Framingham, MA 01702, United States Phone: 508-875-3333 Fax: 508-875-3375 Email: sales@davidscottco.com Website: www.davidscottco.com Year established: 1972

Debiotech Sa

Le Portique, Avenue de Sévelin 28 Lausanne, CH 1004, Switzerland Phone: +41 21 623-6000 Fax: +41 21 623-6001 Email: debiotech@debiotech.com Website: www.debiotech.com Year established: 1990

Deka Research & Development Corp.

340 Commercial St. Manchester, NH 03101-1121, United States Phone: 603-669-5139 Fax: 603-624-0573 Email: contactdeka@dekaresearch.com Website: www.dekaresearch.com

Depuy Mitek, Inc. 325 Paramount Dr.

Raynham, MA 02767, United States Phone: 508-880-8100 Fax: 508-880-8122 Email: DePuySpine@dpyus.jnj.com Website: www.depuyspine.com Year established: 1895

Deroyal Surgical - Rose Hill

100 Rose Hill Industrial Park Rose Hill, VA 24281, United States Phone: 865-362-6022 Email: customerservice@deroyal.com Website: www.deroyal.com Year established: 1973

Deroyal Wound Care

164 giles hollow road, P.O. Box 309 Rose Hill, VA 24281, United States Phone: 865-362-6022 Email: customerservice@deroyal.com Website: www.deroyal.com Year established: 1973

Deuteronomy Management Services, Inc.

1439 Live Oak St., Suite A Niceville, FL 32578-8829, United States Phone: 850-897-3321

Diablo Sales & Marketing, Inc.

PO Box 408 Diablo, CA 94526, United States Phone: 925-648-1611 Fax: 925-648-1711 Email: info@diablosales.com Website: www.diablosales.com Year established: 1987

Directmed, Inc. 150 Pratt Oval, Glen Cove, NY 11542, United States Phone: 516-656-3377 Fax: 516-656-5574 Email: cs@directmed.com Website: www.directmed.com Year established: 1997

Dma Med-Chem Corporation

49 Water Mill Lane Great Neck, NY 11021-4234, United States Phone: 516-829-1200 Fax: 516-487-1239 Email: info@dmamed.com Website: www.dmamed.com Year established: 1982

Durden Enterprises

1317 4th Ave., P.O. Box 909 Auburn, GA 30011, United States Phone: 770-963-0637 Fax: 770-995-7067 Email: steriorders@durdene.com Website: www.sterisystems.com Year established: 1971

Eagle Laboratories 10201-A. Trademark Street Rancho Cucamonga, CA 91730-5850, United States Phone: 909-481-0011 Fax: 909-481-4481 Email: rdecamp@eaglelabs.com Website: www.eaglelabs.com Year established: 1988

Edge I-Wear Corp.

1775 Curtiss Ct La Verne, CA 91750, United States Phone: 909-598-7679

Edwards Lifesciences Research Medical

6864 South 300 West Midvale, UT 84047, United States Phone: 949-250-2500

Edwards Lifesciences Technology Sarl

State Rd. 402 N.km 1.4 Anasco, PR 00610-1577, United States Phone: 949-250-2500

Edwards Lifesciences, Llc.

One Edwards Way Irvine, CA 92614, United States Phone: 949-250-2500 Fax: 949-250-2525 Website: www.edwards.com Year established: 1958

Ekos Corp.

11911 N Creek Parkway South Bothell, WA 98011, United States Phone: 425-415-3100 Fax: 425-415-3102 Email: Ekosmarketing@ekoscorp.com Website: www.ekoscorp.com Year established: 1995

Elcam Medical, Inc.

2 University Plaza, suite 620 Hackensack, NJ 07601, United States Phone: 201-457-1120 Fax: 201-457-1125 Email: info@elcam-medical.com Website: www.elcam-medical.com Year established: 1970

Entracare, Lic

11315 Strang Line Rd. Lenexa, KS 66215, United States Phone: 913-451-2234

Erika De Reynosa, S.A. De C.V.

Brecha E99 Sur; Paraue, Industrial Revnos, Blda, li Cd, Reynosa, Tamps, Mexico Phone: 781-402-9068

Ernst Flow Industries

116 Main St. Farmingdale, NJ 07727-1495, United States Phone: 732-938-5641 Fax: 888-992-2843 Fmail: info@ernstflow.com Website: www.ernstflow.com Year established: 1962

Escalon Trek Medical

2440 S. 179th St. New Berlin, WI 53146, United States Phone: 262-821-9182 Fax: 262-821-9927 Email: sales@escalonmed.com Website: www.escalonmed.com

Ethicon, Inc

3348 Pulliam St. San Angelo, TX 76905, United States Phone: 908-218-2996 Website: www.ethicon.com

Ethicon, Inc.

Route 22 West, p.o. box 151 Somerville, NJ 08876, United States Phone: 908-218-0707 Fax: 908-218-2471 Website: www.ethicon.com

Ethicon, Llc.

Rd. 183, Km. 8.3,, Industrial Area Hato San Lorenzo, PR 00754, United States Phone: 908-218-2887 Website: www.ethicon.com

Ethox International

251 Seneca St. Buffalo, NY 14204, United States Phone: 716-842-4000 Fax: 716-842-4040 Email: mpd@ethoxint.com Website: www.ethoxint.com Year established: 1966

Eurospital S.P.A.

Via Flavia 122 Trieste, 34147, Italy Phone: 003-904-0899

Ev3 Neurovascular 9775 Toledo Way

Irvine, CA 92618, United States Phone: 949-837-3700 Fax: 949-837-2044 Email: webmaster@ev3.net Website: www.ev3.net Year established: 2000

Evans Medical Inc.

1529 Terracina Drive El Dorado Hills, CA 95762, United States Phone: 916-939-2451

Excelsior Medical Corp.

1933 Heck Ave. Neptune, NJ 07753, United States Phone: 732-776-7525 Fax: 732-776-7600 Website: www.excelsiormedical.com

Exelint International Co.

5840 W. Centinela Ave. Los Angeles, CA 90045, United States Phone: 727-827-1922 Fax: 727-827-1635 Email: info@exelint.com Website: www.exelint.com

Farley Inc., W.T.

931 Via Alondra Camarillo, CA 93012, United States Phone: 805-437-7090 Fax: 805-437-7098 Email: heather@wtfarley.com Website: www.wtfarley.com Year established: 1968

Farmatap S.A. De C.V.

117 Alfonso Esparza Oteo Mexico Df 01020, Mexico

Fenwal Inc.

Three Corporate Drive Lake Zurich, IL 60073, United States Phone: 847-550-2300 Fax: 847-550-5788 Email: info@fenwalinc.com Website: www.fenwalinc.com Year established: 1949

Ferguson Production, Inc.

2130 Industrial Drive Conway, KS 67460, United States Phone: (620) 241-2400 Fax: (620) 241-2084 Email: info@fergusonproduction.com Website: www.fergusonproduction.com

Filtrona Extrusion, Inc./Pexco® Medical Products Div.

764 south athol road Athol, MA 01331, United States Phone: 404-564-8560 Fax: 404-584-8579 Website: www.filtronaextrusion.com Year established: 1949

Fpp, Inc. 6800 S.W. 66th St. Ocala, FL 34476-5526, United States Phone: 352-622-4595 Fax: 352-237-4855 Email: bpetti5570@aol.com

Fresenius Medical Care North America

920 Winter Street Waltham, MA 02451, United States Phone: 781-699-9000 Website: www.fmcna.com

Fresenius Medical Care North America

420 Industrial Dr Livingston, CA 95334, United States Phone: 781-699-9068 Website: www.fmcna.com

Fresenius Medical Care North America

750 North Lallendorf Rd Oregon, OH 43616, United States Phone: 781-699-9068 Website: www.fmcna.com

Fresenius Medical Care North America

5201 Regent Blvd Irving, TX 75063, United States Phone: 781-699-9068 Website: www.fmcna.com

Fresenius Medical Care North America

475 West 13th St Ogden, UT 84404, United States Phone: 781-699-9068 Website: www.fmcna.com

Fresenius Usa, Inc.

920 Winter Street Waltham, MA 02451-1457, United States Phone: 781-699-900 Website: www.fmc-ag.com

Fresnel Prism & Lens Co.

6824 Washington Avenue Eden Prairie, MN 55344, United States Phone: 952-496-0432

Fuji Medical Instr Mfg., Co. Ltd.

5-5-21 Nipponbashi, Naniwa-Ku Osaka, 556-0005, Japan Phone: 310-978-3897

Fujinomiya Factory Of Terumo Corporation

818 Misono-Daira Fujinomiya, 418-0004, Japan Phone: 011-81-33374

Fukui Koki Co. Ltd.

1-1-40 Sanroku-Cho Sabae, 916-0021, Japan Phone: 077-851-2833

G.E.M. Water Systems, Int'L., Lic

6351 Orangethorpe Avenue Buena Park, CA 90620, United States Phone: 714-736-9990 Fax: 714-736-9402 Email: jack@gemwater.com Website: www.gemwater.com Year established: 1981

Galaxy Medical Manufacturing Co.

5411 Sheila Street Commerce, CA 90040-2103, United States Phone: 323-728-3980 Fax: 323-728-5971 Email: sales@galaxymfg.com Website: www.galaxymfg.com Year established: 1949

Gargoyles Eyewear

500 George Washington Hwy Smithfield, RI 02917, United States Phone: 800-426-6396 Website: gargoyleseyewear.com

General Scientific Safety Equipment Co. 2553 E Somerset St. 1st Floor Philadelphia, PA 19134-4742, United States Phone: 215-739-7559 Fax: 215-739-7441 Year established: 1988

Genesis Biosystems, Inc.

1500 Eagle Court, Lewisville, TX 75057, United States Phone: 972-315-7888 Fax: 972-315-7818 Email: info@genesisbiosystems.com Website: www.genesisbiosystems.com Year established: 2001

George Tiemann & Co.

25 Plant Ave. Hauppauge, NY 11788-3804, United States Phone: 631-273-6199 Fax: 631-273-6199 Email: richard@georgetiemann.com Website: www.georgetiemann.com

Glo Touch Corporation

3075 Judd Rd. Milan, MI 48160, United States Phone: 734-439-8248 Email: glotouch2002@hotmail.com Year established: 2000

Global Healthcare

1495 Hembree Rd., Ste. 700 Roswell, GA 30076, United States Phone: 770-522-7520 Fax: 770-522-7518 Email: info@globalhealthcare.net Website: www.globalhealthcare.net Year established: 1993

Globe Medical Tech, Inc.

1766 W. Sam Houston Pkwy N. Houston, TX 77043, United States Phone: 713-365-9595 Fax: 713-365-9935 Email: sales@globemedtech.com Website: www.globemedtech.com

Graymills Corp.

3705 N. Lincoln Avenue Chicago, IL 60613-3517, United States Phone: 773-477-4100 Fax: 773-477-4133 Email: info@graymills.com Website: www.graymills.com Year established: 1939

Greattec Vision S.A. De C.V.

Circuito De La Amistad #2700 Mexicali B.c., Mexico

Greiner Bio-One Gmbh

Bad Haller Straße 32 Kremsmünster, 4550, Austria Phone: 43-0-7583679

Greylor Co.

2340 Andalusia Blvd. Cape Coral, FL 33909, United States Phone: (239) 574-2011 Fax: (239) 574-2036 Email: sales@greylor.com Website: www.greylor.com

Guidant Corporation

8934 Kirby Drive, Houston, TX 77054, United States Phone: 408-845-3995 Website: www.bostonscientific.com

Gulden Ophthalmics

225 Cadwalader Avenue Elkins Park, PA 19027-0154, United States Phone: 215-884-8105 Fax: 215-884-0418 Email: info@guldenindustries.com Website: www.guldenindustries.com Year established: 1938

Gustav Ehinger Gmbh & Co.

Erlaheimer Str. 3 Balingen, 72336, Germany Phone: 004-974-3321

Haemonetics Corp. 400 Wood Road, P.O. Box 9114 Braintree, MA 02184, United States Phone: 800-225-5242 Website: www.haemonetics.com

Source: MDRWeb.com

Haemotronic, S.P.A. Advanced Medical Technologies Via Morandi 12 Mirandola, 41037, Italy

Halex Istar Industria Farmaceutica Ltda.

Br 153 Conjunto Caicara Goiania, Go, Brazil Phone: 305-477-4069

Phone: 011-39-535-6

Halkey-Roberts Corp.

2700 Halkey-Roberts Place North St. Petersburg, FL 33716, United States Phone: 727-471-4200 Fax: 727-578-0450 Email: sales@halkeyroberts.com Website: www.halkeyroberts.com Year established: 1941

Harmac Medical Products, Inc.

2201 Bailey Avenue Buffalo, NY 14211-1797, United States Phone: 716-897-4500 Fax: 716-897-0016 Email: info@harmac.com Website: www.harmac.com

Harvard Apparatus, Inc.

84 October Hill Road, Holliston, MA 01746, United States Phone: 508-893-8999 Fax: 508-429-5732 Email: bioscience@harvardapparatus.com Website: www.harvardapparatus.com Year established: 1901

Hatu'- Ico S.P.A.

Via Andrea Costa 160 Bologna, 40134, Italy

Hausmann Industries, Inc.

130 Union St. Northvale, NJ 07647-2207, United States Phone: 201-767-0255 Fax: 201-767-1369 Email: info@hausmann.com Website: www.hausmann.com

Health Care Logistics, Inc. 450 East Town St., PO Box 25

Circleville, OH 43113, United States Phone: 740-477-1686 Fax: 800-447-2923 Email: hcl@healthcarelogistics.com Website: www.healthcarelogistics.com Year established: 1978

Health Supply Company Inc., The

2902 Marlin Cir. Atlanta, GA 30341-5118, United States Phone: 770-452-0090 Email: healthsupplyco@yahoo.com Website: www.hsc-usa.com

Hemedex Incorporated

222 Third Street, Suite 0123 Cambridge, MA 02142, United States Phone: 617-577-1759 Fax: 617-577-9328 Email: info@hemedex.com Website: www.hemedex.com Year established: 2000

Hemerus Medical, Llc.

5000 Township Parkway St. Paul, MN 55110, United States Phone: 651-635-0070

Hill Top Research Corp

P.o. Box 138, 6088 Main & Mill Streets Miamiville, OH 45147, United States Phone: 513-831-3114

Hill-Rom Holdings, Inc. 1069 State Route 46 East

Batesville, IN 47006, United States Phone: 812-934-7777 Fax: 812-934-8189 Website: www.hill-rom.com Year established: 1929

Hill-Rom, Inc.

4115 Dorchester Rd., Unit 600 North Charleston, SC 29405, United States Phone: 812-934-7777 Website: www.hill-rom.com

Hollister-Stier Laboratories, Llc

3525 North Regal St. Spokane, WA 99207-5788, United States Phone: 509-489-5656 Fax: 509-484-4320 Email: fill@hollister-stier.com Website: www.Hollister-Stier.com Year established: 1921

Homak Manufacturing Company Inc.

1605 Old Route 18, Suite 4-36 Wampum, PA 16157, United States Phone: 724-535-1080 Fax: 724-535-1081 Email: bmiller@homakmfg.com Website: www.homakmfg.com

Hospira Inc. 275 N. Field Drive Lake forest, IL 60045, United States Phone: 224-212-2000 Website: www.hospira.com

Hospira, Inc.

Hwy. 301 North Rocky Mount, NC 27801, United States Phone: 224-212-2000 Website: www.hospira.com

Hospira, Inc.

755 Jarvis Drive Morgan Hill, CA 95037, United States Phone: 877-946-7747 Website: www.hospira.com

Hurricane Medical

5315 Lena Road Bradenton, FL 34211, United States Phone: 941-751-0588

I.V. League Medical

460 S. Lombard St. Oxnard, CA 93030, United States Phone: 805-988-1010

Icu Medical (Ut), Inc

4455 Atherton Dr. Salt Lake City, UT 84123, United States Phone: 949-366-2183

Icu Medical, Inc. 951 Calle Amanecer San Clemente, CA 92673-6212, United States Phone: 949-366-2183 Fax: 949-366-8368 Website: www.icumed.com Year established: 1984

I-Flow Corporation

20202 Windrow Dr. Lake Forest, CA 92630, United States Phone: 949-206-2700 Fax: 949-206-2600 Email: info@l-flowcorp.com Website: www.l-flowcorp.com Year established: 1985

Imp Group Ltd.

400-2651 Dutch Village Rd Halifax, B3L 4T1, Canada Phone: 902-453-2400

Indo German Surgical Corp.

151 Kaliandas Udyog Bhavan, Near Century Bazar, Prabhadevi Bombay, India Phone: 800-354-7848

Infusion Medix, Ltd.

5 Rakefet St. Ceasaria, Israel Phone: 001-972-6326

Innovative Medical Designs

130 West Rampart Rd. Shelbyville, IN 46176, United States Phone: 317-421-0308

Inrad

4375 Donker Court S.E. Kentwood, MI 49512, United States Phone: 616-301-7800 Fax: 616-301-7799 Email: inrad-inc@inrad-inc.com Website: inrad-inc.com Year established: 1981

Insource, Inc.

PO Box 9 Bastian, VA 24314, United States Phone: 540-688-4121 Fax: 800-869-8895 Email: customersfirst@insourceonline.com Website: www.insourceonline.com Year established: 1991

Instrument Specialists, Inc.

Instrument spectrumsts, inc. 32390 IH-10 West Boerne, TX 78006, United States Phone: 800-537-1945 Fax: 830-249-9433 Email: is@issurgery.com Website: www.isisurgery.com Year established: 1978

Integra Biotechnical Llc

2755 Dos Aarons Way, Suite B Vista, CA 92081, United States Phone: 760-597-9878 Fax: 760-597-9879 Website: www.integrabio.com

Integra Lifesciences Corp.

311 Enterprise Drive Plainsboro, NJ 08536, United States Phone: 609-275-0500 Fax: 609-275-5363 Email: custsvcnj@integra-ls.com Website: www.integra-ls.com

Integra Lifesciences Of Ohio

4900 Charlemar Drive, Building A Cincinnati, OH 45227, United States Phone: 800-654-2873 Email: ohiohr@integra-ls.com

Integrated Biomedical Technology, Inc.

2931 Moose Trail Elkhart, IN 46514, United States Phone: 574-264-0025

Intercos Gmbh

Klosterweg 25 Fernwald, 35463, Germany Phone: 011-49-64042

International Medical Industries

2881 West McNab Road Pompano Beach, FL 33069, United States Phone: 954-917-9570 Fax: 954-917-9244 Email: sales@imiweb.com Website: www.imiweb.com

International Medication Systems, Ltd.

1886 Santa Anita Ave. South El Monte, CA 91733, United States Phone: 800-423-4136 Fax: 909-909-5726 Email: info@ims-limited.com Website: www.ims-limited.com

Interpore Cross International

181 Technology Dr., Irvine, CA 92618, United States Phone: 949-453-3200 Fax: 949-453-3225 Website: www.interpore.com Year established: 1975

Iradimed Corporation

7457 Aloma Ave., Suite 201 Winter Park, FL 32792, United States Phone: 407-677-8022

Source: MDRWeb.com

Izumi Optical Co. 2-21 Shinmachi, Sakai Osaka, 590, Japan Phone: 072-2324267

J. T. Posey Co.

5635 Peck Rd. Arcadia, CA 91006-5851, United States Phone: 626-443-3143 Fax: 626-443-5014 Website: www.posey.com Year established: 1937

J.E.M. Sales Ltd.

6-110 Norfinch Dr Toronto, M3N 1X1, Canada Phone: 416-663-7313

Jardon Eye Prosthetics, Inc.

15920 W 12 Mile Road Southfield, MI 48076-2115, United States Phone: 248-424-8560 Fax: 248-424-8561 Email: jardoneye@aol.com Website: jardoneye.com

Jedmed Instruments Co.

5416 Jedmed Ct. St. Louis, MO 63129-2221, United States Phone: 314-845-3770 Fax: 314-845-3771 Email: info@jedmed.com Website: www.jedmed.com

Johnson & Johnson De Monterrey, Sa De Cv

Carretera Miguel Aleman, km21.7 Apodaca, Monterrey, Mexico Phone: 817-262-5211

Jorgensen Laboratories

1450 N. Van Buren Avenue Loveland, CO 80538-3683, United States Phone: 970-669-2500 Fax: 970-663-5042 Email: info@jorvet.com Website: www.jorvet.com Year established: 1965

Jostra Bentley, Inc. Rd. 402 N. Km 1.4, Industrial Park Anasco, PR 00610-1577, United States Phone: 302-454-9959

K Medical

PO Box 5224 Fort Lauderdale, FL 33310, United States Phone: 954-974-3078 Fax: 954-974-7437 Email: kmed@hotmail.com Website: www.Face-Shields.com

Kawasumi Laboratories America, Inc.

4723 Oakfair Blvd Tampa, FL 33610, United States *Phone: 813-630-5554* Fax: 813-630-5033 Email: info@kawasumiamerica.com Website: www.kawasumiamerica.com Year established: 1991

Kbd, Inc.

2550 American Ct Crescent Springs, KY 41017, United States Phone: 859-331-0800 Fax: 859-331-0802 Email: sales@sperti.com Website: www.sperti.com

Kelsar, S.A.

Blvd. Insurgentes, Libriamento a La Tijuana, 22450, Mexico Phone: 508-261-8000

Kentec Medical Inc. 17871 Fitch, Irvine, CA 92614, United States Phone: 949-863-0810 Fax: 949-833-9730 Email: sales@kentecmedical.com Website: www.kentecmedical.com Year established: 1975

Kentron Health Care, Inc. 3604 Kelton Jackson Road, P.o. Box 120 Springfield, TN 37172, United States Phone: 615-384-0573

Kmi Kolster Methods, Inc.

3185 Palisades Dr. Corona, CA 92880, United States Phone: 909-737-5476

Kofu Factory Of Terumo Corp.

1727-1 Tsuijiarai, Showa-Cho Nakakoma-Gun, Japan Phone: 011-81-33374

Kollsut Scientific Corporation

3286 North 29th Court Hollywood, FL 33020, United States Phone: 630-290-5746

Kontes Glass Co.

Vineland, NJ 08360-2841, United States Phone: 856-692-8500 Fax: 856-794-9762 Email: cs@kimkon.com Website: www.kontes.com Year established: 1993

Koven Technology, Inc.

12125 Woodcrest Executive Dr., Suite 320 St. Louis, MO 63141, United States Phone: 314-542-2101 Fax: 314-542-6020 Email: info@koven.com Website: www.koven.com

Labomed Sre

3, Via Partigiani Ripalta Cremasca Cr, Italy

Leonids Traders Pvt. Ltd.

36 Lenin Sarani Calcutta, 700001, India Phone: 800-354-7848

Lexamed

705 Front St. Northwood, OH 43605, United States Phone: 419-693-5307

Lifemed Of California

1216 So. Allec St. Anaheim, CA 92805-6301, United States Phone: 714-517-6900 Fax: 714-517-6911 Email: info@lifemedofcalifornia.com Website: www.lifemedofcalifornia.com

Lifescan, Inc.

1000 Gibraltar Dr Milpitas, CA 95035-6314, United States Phone: 408-263-9789 Fax: 408-942-6070 Email: CustomerService@LifeScan.com Website: www.lifescan.com

Lisca Ab

Berzelius Science Park LinkÃping, 582 25, Sweden Phone: +46 13 473

Livengood Engineering Inc.

1112 Oakridge Dr., #104 Pmb 51 Fort Collins, ČO 80525, United States Phone: 970-493-2569

Lsl Industries, Inc.

5535 N. Wolcott Avenue Chicago, IL 60640, United States Phone: 773-878-1100 Fax: 773-878-9100 Email: sales@LSLIND.com Website: www.LSLIND.com Year established: 1981

Lt Acquisition, Inc.

4489 East Paris Ave. Grand Rapids, MI 49512, United States Phone: 616-698-1830

Lucomed Inc.

45 Kulick Rd. Fairfield, NJ 07004, United States Phone: 973-575-0614 Fax: 973-227-0151 Email: wghelfi@lucomedinc.com Website: www.lucomedinc.com Year established: 1991

Lundy Medical Product, Llc

9376 East Bahia, Suite D-101 Scottsdale, AZ 85260, United States Phone: 480-473-7330 Fax: 480-315-1790 Email: sschramm@lundymedical.com Website: www.lundymedical.com Year established: 1978

Macosta S.N.C.

Via Volta 36 Mirandola, 41037, Italy Phone: 201-760-9550

Maguet Cardiovascular LLC

45 Barbour Pond Dr. Wayne, NJ 07470, United States Phone: 888-880-2874 Fax: 973-709-7699 Email: info@maquet.com Website: www.maquet.com Year established: 2003

Maquet, Inc.

45 Barbour Pond Drive Wayne, NJ 07470, United States Phone: 1-888-MAQUET3 Email: info@maquet-inc.com Website: www.maquet.com

Maquet, Inc.

7371 Spartan Blvd. East N Charleston, SC 29418, United States Phone: 843-552-8652 Website: www.maquet.com

Mar Cor Purification

4450 Township Line Road Skippack, PA 19474-1429, United States Phone: 484-991-0220 Fax: 484-991-0230 Email: info@mcpur.com Website: www.mcpur.com Year established: 1970

Marquette Medical, Inc. 2600 Cabover Drive, Suite J

Hanover, MD 21076, United States Phone: 800-296-2134 Fax: 410-987-2998 Email: marquette@toad.net Website: www.pilotmedicalproducts.com Year established: 1985

Mast Biosurgery Usa Inc.

6749 Top Gun St., Suite 108 San Diego, CA 92121, United States Phone: 858-550-8050

Maverick Technologies, Inc.

1754 Grove Drive Clearwater, FL 33759, United States Phone: 727-791-6151

Medefil, Inc.

250 Windy Point Drive Glendale Heights, IL 60139, United States Phone: 630-682-4600 Fax: 630-681-9100 Email: info@medefil.com Website: www.medefil.com Year established: 1998

Medegen Medical Products, Llc

209 Medegen Drive Gallaway, TN 38036-0228, United States Phone: 901-867-2951 Fax: 901-867-8954 Email: email@medegen.com Website: www.medegen.com Year established: 1874

Medex Medical Ltd.

St. Crispin Way, Haslingden Rossendale, Lancashier, United Kingdom Phone: 614-889-2220

Medical Action Industries, Inc.

25 Heywood Rd Arden, NC 28704, United States Phone: 800-645-7042 Fax: 631-231-3075 Website: www.medical-action.com Year established: 1977

Medical Depot

99 Seaview Blvd. Port Washington, NY 11050, United States Phone: 516-998-4600

Medical Technologies Of Georgia, Inc.

15151 Prater Drive Covington, GA 30014, United States Phone: 404-394-2478

Medical Technology Products, Inc. 2221-16 5th Avenue Ronkonkoma, NY 11779, United States Phone: 631-285-6640 Fax: 631-285-6641 Email: Service@Medtechproducts.Com Website: www.medtechproducts.com Year established: 1982

Medi-Crush Company

P.O. BOX 321381 Flowood, MS 39232, United States Phone: 800-262-6334 Fax: 601-898-3249 Email: medicrush@c-gate.net

Medi-Dose, Inc.

70 Industrial Drive Ivyland, PA 18974, United States Phone: 215-396-8600 Fax: 800-323-8966 Email: info@medi-dose.com Website: www.medi-dose.com Year established: 1971

Medikmark Inc.

3600 Bur Wood Waukegan, IL 60085-8399, United States Phone: 847-887-8400 Fax: 847-887-0766 Email: sales@medikmark.com Website: www.medikmark.com Year established: 1987

Mediq/Prn

1 Medig Plaza Pennsauken, NJ 08110, United States Phone: 609-662-3200 Fax: 856-661-0223 Email: contactus@medig.net Website: www.mediq.net

Medis S.R.L.

Viale Dei Mille 5 Milano, 20129, Italy Phone: 02-718-672

Medistad Medical Bv

Nijverheidsweg 1, PO Box 99 Medemblik, NOORD HOLLAND 1670 AB, Netherlands Phone: +31 227 546600 Fax: +31 227 542230 Email: sales.nl@medistad.com Website: www.medistad.com Year established: 1979

Medi-Stim A/S

Sandakerveien 110 Oslo, 483, Norway Phone: 47-23-05 96

Medivice Systems, Ltd. Harton 9, Har Hahozvim Jerusalem, 91999, Israel Phone: 972 2 540

Medone Surgical, Inc. 670 Tallevast Road Sarasota, FL 34243, United States Phone: 941-359-3129

Medrecon, Inc.

257 South Avenue Garwood, NJ 07027-1341, United States Phone: 908-789-2050 Fax: 908-789-3275 Email: ortables@medrecon.com Website: www.medrecon.com Year established: 1972

Medron, Inc.

1518 S. Gladiola St. Salt Lake City, UT 84104, United States Phone: 801-974-3010 Fax: 801-974-3063 Email: medron@medroninc.com Website: www.medroninc.com Year established: 1994

Medtronic Cardiovascular Surgery, The Heart Valve Div.

1851 East Deere Ave. Santa Ana, CA 92705, United States Phone: 800-328-2518 Website: www.medtronic.com

Medtronic Heart Valves

8299 Central Ave., N.e. Spring Lake Park, MN 55432-3576, United States Phone: 800-227-3191 Website: www.medtronic.com

Medtronic Minimed

18000 Devonshire Northridge, CA 91325, United States Phone: 818-362-5958 Fax: 818-576-6534 Website: www.minimed.com Year established: 1983

Medtronic Navigation, Inc.

826 Coal Creek Cir. Louisville, CO 80027, United States Phone: 720-890-3200 Fax: 720-890-3500 Email: rs.navceiregistrar@medtronic.com Website: www.medtronicnavigation.com

Medved Products, Inc. P.O. Box 120883 St. Paul, MN 55112-0883, United States Phone: 651-482-8413 Fax: 651-482-8413 Email: mdr@medvedproducts.com Website: www.medvedproducts.com Year established: 1989

Megadyne Medical Products, Inc.

11506 S. State St. Draper, UT 84020, United States Phone: 801-576-9669 Fax: 801-576-9698 Email: mhintze@megadyne.com Website: www.megadyne.com Year established: 1985

MEI Corporation

4907 South 90th St., Omaha, NE 68127, United States Phone: 402-339-3300 Fax: 402-339-1333 Email: meicorp@cox.net Website: www.meicorp.net

Mentor Texas, Inc.

3041 Skyway Circle North, Irving, TX 75038, United States Phone: 972-252-6060 Website: www.mentorcorp.com Year established: 1969

Merit Medical Systems Inc.

12701 Kingston Ave Chesterfield, VA 23837, United States Phone: 804-416-1030 Fax: 804-416-1031 Website: www.merit.com Year established: 1997

Merit Medical Systems, Inc.

1600 W. Merit Pkwy. South Jordan, UT 84095, United States Phone: 801-253-1600 Fax: 801-253-1652 Email: awright@merit.com Website: www.merit.com Year established: 1987

Merit Medical Systems, Inc. 1111 South Velasco

Angleton, TX 77515, United States Phone: 801-253-1600 Fax: 1-801-253-1652

Merlyn Pharmaceuticals, Inc.

8175 Kroger Farm Rd. Cincinnati, OH 45243-1639, United States Phone: 513-831-3005 Fax: 513-831-5237 Email: merlynp@yahoo.com Website: merlynp.homestead.com

Mettler Electronics Corp.

1333 S. Claudina Street Anaheim, CA 92805-6235, United States Phone: 714-533-2221 Fax: 714-635-7539 Email: mail@mettlerelectronics.com Website: www.mettlerelectronics.com Year established: 1957

Mfg One, Llc

3900 Skyhawk Dr. Chantilly, VA 20151, United States Phone: 703-437-9838

Microgroup

7 Industrial Park Road Medway, MA 02053, United States Phone: 508-533-4925 Fax: 508-533-5691 Email: info@microgroup.com Website: www.microgroup.com Year established: 1971

Milestone Scientific Inc.

220 South Orange Ave. Livingston, NJ 07039, United States Phone: 800-862-1125 Website: www.milestonescientific.com

Millar Instruments, Inc.

6001-A Gulf Freeway Houston, TX 77023-5417, United States *Phone: 832-667-7000* Fax: 832-667-7001 Email: info@millarmail.com Website: www.millarinstruments.com Year established: 1971

Millipore Corporation

290 Concord Road Billerica, MA 01821, United States Phone: 978-715-4321 Fax: 800-645-5439 Email: biobagsales@shasta.com Website: www.millipore.com Year established: 1954

Minntech Corporation

14605 28th Avenue N. Minneapolis, MN 55447, United States Phone: 763-553-3300 Fax: 763-553-3387 Email: info@minntech.com Website: www.minntech.com Year established: 1974

Mizuho Osi

30031 Ahern Avenue Union City, CA 94587-1234, United States Phone: 510-429-1500 Fax: 510-429-8500 Email: CustSvc@mizuhosi.com Website: www.osiosi.com Year established: 1978

Mmj S.A. De C.V.

716 Ponciano Arriaga Cd. Juarez, Chih., Mexico Phone: 314-654-2000

Mobile I.V. Systems, Llc

23630 N. 35th Dr Glendale, AZ 85310, United States Phone: 623-434-3136

Model Eye Industry

2nd Fl. 807-52 Sankyuk, 1-Dong Buk-Gu Daegu, Republic of Korea Phone: 82-53-941050

Modular Services Company

109 N.e. 38th St. Oklahoma City, OK 73105, United States Phone: 405-521-9923

Monogen, Inc.

3630 Bur Wood Dr. Waukegan, IL 60085, United States Phone: 847-573-6700 Fax: 847-758-4273 Email: info@monogen.com Website: www.monogen.com Year established: 1996

Moog Inc.

Jamison Rd. East Aurora, NY 14052, United States Phone: 716-652-2000 Fax: 716-687-4457 Email: info.usa@moog.com Website: www.moog.com Year established: 1951

Morrison Medical

3735 Paragon Drive Columbus, OH 43228, United States Phone: 614-461-4400 Fax: 614-469-9696 Email: morr@morrisonmed.com Website: www.morrisonmed.com Year established: 1970

Mps Acacia

785 Challenger St. Brea, CA 92821, United States Phone: 714-257-0470 Fax: 714-257-0513 Email: info@mpsacacia.com Website: www.mpsacacia.com Year established: 1990

Myco Medical

158 Towerview Court Cary, NC 27513, United States Phone: 919-460-2535 Fax: 919-460-2536 Email: sales@mycomedical.com Website: www.mycomedical.com Year established: 1993

Nalge Nunc International

75 Panorama Creek Drive Rochester, NY 14625-2303, United States Phone: 585-586-8800 Fax: 585-586-3294 Email: nnitech@nalgenunc.com Website: www.NALGENE.com Year established: 1949

Navilyst Medical

26 Forest Street Marlborough, MA 01752, United States Phone: 508.658.7990 Website: www.navilystmedical.com Year established: 2008

Neo Medical Inc.

42514 Albrea Street Fremont, CA 94538, United States Phone: 888-450-3334

Neo-Care Arrow International

5714 Epsilon Rd. San Antonio, TX 78249-3407, United States Phone: 210-696-4061 Fax: 210-696-1305 Email: neocarekb@aol.com Website: www.neocare.com Year established: 1994

Neotech Products, Inc.

27822 Fremont Ct Valencia, CA 91355, United States Phone: 661-775-7466 Fax: 800-966-0585 Email: info@neotechproducts.com Website: www.neotechproducts.com Year established: 1986

Nexus Medical, Llc

11315 Strang Line Road Lenexa, KS 66215, United States Phone: 913-451-2234

Nikkiso Co. Ltd.

498/1 Shizutani, Haibara-Gun Haibara, 421-0404, Japan Phone: 3-3443-3711

Nipro Diabetes Systems, Inc.

3361 Enterprise Way Miramar, FL 33025, United States Phone: 816-637-2233 Fax: 954-435-9295 Website: www.nipro.com

Norfolk Medical Products, Inc.

7350 North Ridgeway Skokie, IL 60076, United States Phone: 847-674-7075

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West Princeton, NJ 08540-7810, United States Phone: 609-987-5800 Fax: 609-921-8082 Email: sspv@novonordisk.com Website: www.novonordisk-us.com Year established: 1950

Novosci Corp. 2828 N. Crescent Ridge Drive The Woodlands, TX 77381, United States Phone: 281-363-4949 Fax: 888-570-4009 Email: Info@novosci.us Website: www.novosci.us Year established: 2003

Np Medical, Inc.

Di Union St. Clinton, MA 01510, United States Phone: 978-368-4514 Fax: 978-365-4025 Email: sales@npmedical.com Website: www.npmedical.com Year established: 1955

Nxstage Medical, Inc.

439 South Union St., 5th Floor Lawrence, MA 01843, United States Phone: 978-687-4700 Fax: 978-687-4809 Website: www.nxstage.com

Nypro Singapore Pte. Ltd.

29 Joo Koon Circle Singapore, 629058, Singapore Phone: 978-365-9721

Ohmeda Medical

8880 Gorman Road Laurel, MD 20723, United States Phone: 410-888-5200 Fax: 301-483-8340 Email: icss@ohmedamedical.com Website: www.gehealthcare.com

Omni Medical Supply Inc.

4153 Pioneer Drive Walled Lake, MI 48390, United States Phone: 248-360-8000 Fax: 248-360-9375 Email: omni@omnimedicalsupply.com Website: www.omnimedicalsupply.com Year established: 1992

One Optical Co., Ltd.

644-2, Chimsan-3dong, Buk-Ku Taegu, Republic of Korea Phone: 053-357-2470

Panatrex, Inc.

1648 Sierra Madre Cir. Placentia, CA 92870-6626, United States Phone: 714-630-5582

Patton Medical Devices

31058 N. Lamar Blvd., Austin, TX 78705, United States Phone: 512-279-4545 Year established: 2004

Paul Instruments (India)

11/2 Tamer Ln. Calcutta, 700001, India Phone: 606-259-4924

Peaktop Ltd.

Changzhen Village, Gongming, Town, Baoan, Qu District Shenzhen City, Guangdong Prov., China Phone: 714-639-6590

Pedicraft, Inc.

4134 St. Augustine Road Jacksonville, FL 32247, United States Phone: 904-396-9627 Fax: 904-346-3947 Email: info@pedicraft.com Website: www.pedicraft.com Year established: 1966

Pedigo Products 4000 S.E. Columbia Way Vancouver, WA 98661, United States Phone: 360-695-3500 Fax: 360-696-1700 Email: custserv@pedigo.usa.com Website: www.pedigo-usa.com Year established: 1947

Perioptix, Inc. 1001 Avenida Pico, #C62 San Clemente, CA 92763, United States *Phone: 949-366-3333* Email: customerservice@perioptix.com Website: www.perioptix.com

Phelan Manufacturing Corp.

2523 Minnehaha Ave. Minneapolis, MN 55404-4119, United States Phone: 612-724-3677

Philips Medical Systems North America

2301 Fifth Ave.,, Ste. 200 Seattle, WA 98121, United States Phone: 800-934-7372 Website: www.medical.philips.com

Plasco, Inc.

Carretera Presta La Amistad, Km.19 Acuna, Coahila, Mexico Phone: 847-662-4400

Porex Technologies Gmbh

Industriestrasse Singwitz/Bautzen, SAXONIA 2692, Germany Phone: +49 3591/37220 Fax: +49 3591/44531 Email: hotmail@porex.de Website: www.porex.de Year established: 1990

Primrose Medical, Inc.

478 High Plain St., Walpole, MA 02081, United States Phone: 508-660-8688 Fax: 508-660-8699 Email: fletcher@primrosemedical.com Website: www.primrosemedical.com

Prizm Medical, Inc.

P.O.Box 40 Oakwood, GA 30566, United States Phone: 770-622-0933 Fax: 678-714-7243

Pro-Optics, Inc.

317 Woodwork Lane Palatine, IL 60067-4993, United States Fax: 847-991-9696 Email: jb@proopticsinc.com Website: www.proopticsinc.com

Protech Leaded Eyewear

10415 riverside drive Palm Beach Gardens, FL 33410, United States Phone: 561-627-9769 Fax: 561-627-0923 Email: info@protecheyewear.com Website: www.protecheyewear.com

Provita Gmbh Medizintechnik

Wermelskirchener Str. 20 Wermelskirchen, 42929, Germany Phone: 49-219-35105

Pryor Products

1819 Peacock Blvd. Oceanside, CA 92056-3578, United States Phone: 619-724-8244 Fax: 619-724-0944 Email: pryorproducts@pryorproducts.com Website: www.pryorproducts.com Year established: 1972

Q.I. Medical, Inc.

440-C Lower Grass Valley Road Nevada City, CA 95959, United States Phone: 530-265-4820 Fax: 530-265-9416 Email: info@qimedical.com Website: www.gimedical.com Year established: 1992

Q.T.I. Corp.

879 Del Valle Drive Fallbrook, CA 92028, United States Phone: 760-723-9825

Quality Control Corp.

7315 W. Wilson Ave. Harwood Heights, IL 60706, United States Phone: 708-887-5400

Quest Medical, Inc.

1 Allentown Pkwy Allen, TX 75002-4211, United States Phone: 972-390-9800 Fax: 972-390-7173 Email: custserveweb@questmedical.com Website: www.questmedical.com Year established: 1994

Radiation Products Design, Inc.

5218 Barthel Industrial Dr. Albertville, MN 55301, United States Phone: 763-497-2071 Fax: 763-497-2295 Email: sales@rpdinc.com Website: www.rpdinc.com

Razel Scientific Instruments, Inc.

PO Box 111 St. Albans, VT 05478, United States Phone: 203-324-9914 Fax: 802-527-5095 Email: info@razelscientific.com Website: www.razelscientific.com Year established: 1968

Rbm Services, Llc.

101-b Valley Court Oak Ridge, TN 37830, United States Phone: 865-483-0067 Email: Contact@rbm-services.com

Rd Medical Mfg. Inc. Road 183, Km 21.6, Las Piedras Industrial Park Las Piedras, PR 00771, United States Phone: 787-716-6363

Renal Solutions Inc.

770 Commonwealth Drive, Suite 101 Warrendale, PA 15086, United States Phone: 724-772-6900 Fax: (724) 772-6925 Website: www.renalsolutionsinc.com

ReNu Medical Inc.

9800 Evergreen Way Everett, WA 98204, United States Phone: 877-252-1110 Fax: 425-353-9116 Email: sales@renumedical.com Website: www.renumedical.com Year established: 2000

Retractable Technologies, Inc.

511 Lobo Lane Little Elm, TX 75068, United States Phone: 972-294-1010 Fax: 972-292-3600 Email: rti@vanishpoint.com Website: www.vanishpoint.com Year established: 1994

Richmond Products, Inc.

4400 Silver Se Albuquerque, NM 87108, United States Phone: 505-275-2406

Rismed Oncology Systems

2494 Washington Street Huntsville, AL 35811-1663, United States Phone: 256-534-6993 Fax: 256-534-6996 Email: info@rismed.com Website: www.rismed.com Year established: 1977

Rockford Medical & Safety Co.

2420 Harrison Avenue, PO Box 5646 Rockford, IL 61125-0646, United States Phone: 815-394-4809 Fax: 800-368-7891 Email: firensafety@msn.com Website: www.r-m-s-c.com Year established: 1976

Rymed Technologies, Inc.

137 Third Avenue North Franklin, TN 37064, United States Phone: 615-790-8093 Fax: 615-790-8984 Email: info@rymedtech.com Website: www.rymedtech.com

Rz Medizintechnik Gmbh

Zollernstr. 4 Tuttlingen, 78532, Germany Phone: 497-461-9331

S4j Manufacturing Services, Inc.

2685 N.E. 9th Avenue Cape Coral, FL 33909, United States Phone: 239-574-9400 Fax: 239-574-9567 Email: sales@s4jluer.com Website: www.s4jluer.com Year established: 1964

Saint-Gobain Performance Plastics-Akron

2664 Gilchrist Rd. Akron, OH 44305, United States Phone: 330-798-9240 Fax: 330-798-6968 Email: bradley.e.hanson@saint-gobain.com Website: www.medical.saint-gobain.com

Schad Medical Instruments Gmbh

Hegaustrasse 9 Neuhausen 1, Germanv Phone: 074-67-94610

Servo-Med Industries Pvt. Ltd.

8-30 Veera Desai Rd. Andheri, mumbai, Bombay, India Phone: 011-912-2 63

Sharn, Inc.

4517 George Road Suite 200 Tampa, FL 33634-6236, United States Phone: 813-889-9614 Fax: 813-886-2701 Email: mailbox@sharn.com Website: www.sharn.com Year established: 1983

Sharps Compliance Corp.

9220 Kirby Drive, Suite 500 Houston, TX 77054, United States Phone: 713-432-0300 Fax: 713-838-0508 Email: sharps@sharpsinc.com Website: www.sharpsinc.com Year established: 1992

Shelhigh, Inc.

650 Liberty Ave. Union, NJ 07083, United States Phone: 908-206-8706

Sigma International, Llc.

711 Park Avenue Medina, NY 14103-0756, United States Phone: 585-798-3901 Fax: 585-798-3909 Email: customersupport@sigmapumps.com Website: www.sigmapumps.com Year established: 1992

Smisson-Cartledge Biomedical

487 Cherry St, Third Street Tower Macon, GA 31201, United States Phone: 1-866-944-9992 Fax: 478-744-9996 Email: billy@t3med.com

Smith & Nephew Inc., Endoscopy Div.

76 S. Meridian Ave. Oklahoma City, OK 73107-6512, United States Phone: 978-749-1000 Website: www.endo.smith-nephew.com

Smith & Nephew, Inc., Endoscopy Division

150 Minuteman Road Andover, MA 01810-1031, United States Phone: 978-749-1000 Fax: 978-749-1599 Email: endo.inquiry@smith-nephew.com Website: www.endo.smith-nephew.com

Smith & Nephew, Inc., Endoscopy Division

130 Forbes Blvd. Mansfield, MA 02048, United States Phone: 978-749-1000 Fax: 978-748-1599 Website: www.endo.smith-nephew.com

Smiths Medical Asd, Inc.

1265 Grey Fox Road St. Paul, MN 55112, United States Phone: 651-633-2556 Fax: 651-628-7459 Email: info.md@smiths-medical.com Website: www.smiths-medical.com Year established: 1983

Smiths Medical Asd, Inc.

5200 Upper Metro Place, Suite 200 Dublin, OH 43017, United States Phone: 214-618-0218 Fax: 614-734-0254 Email: info.asd@smiths-medical.com Website: www.smiths-medical.com

Smiths Medical Asd, Inc.

201 West Queen St. Southington, CT 06489, United States Phone: 614-791-5568

Smiths Medical OEM

5200 Upper Metro Place, Suite 200 Dublin, OH 43017, United States Phone: 614-210-7300 Fax: 614-889-2651 Email: OEM.Inquiries@smiths-medical.com Website: www.smiths-medical.com

Sofard Co., Ltd. 82/31 Shino-Cho

Fukui, 910-2148, Japan Phone: 81-776-41722

Somanetics Corp.

2600 Troy Center Drive Troy, MI 48084, United States Phone: 248-244-1400 Fax: 248-244-0978 Email: customerservice@somanetics.com Website: www.somanetics.com

Sorb Technology, Inc.

3631 S.w. 54th St Oklahoma City, OK 73119, United States Phone: 405-682-1993

Sorin Group Usa

14401 W. 65th Wav Arvada, CO 80004-3599, United States Phone: 303-425-5508 Fax: 303-467-6584 Email: customerservice@sorin.com Website: www.soringroup-usa.com Year established: 1999

Sparton Corporation

22740 Lunn Road Strongsville, OH 44149, United States Phone: 440-878-4630 Website: sparton.com

Specialized Health Products International, Inc.

585 W. 500 S. Bountiful, UT 84010, United States Phone: 801-298-3360 Fax: 801-298-1759 Email: pevans@shpi.com Website: www.shpi.com Year established: 1993

Specialty Manufacturing Co., The

5858 Centerville Rd. St. Paul, MN 55127-6804, United States Phone: 651-653-0599 Fax: 651-653-0989 Email: info@specialtymfg.com Website: www.specialtymfg.com Year established: 1901

Spectra Medical Devices, Inc.

4C Henshaw St Woburn, MA 01801, United States Phone: 781-938-8649 Fax: 781-938-0357 Email: rduffett95@aol.com Year established: 1995

Spectrum Laboratories, Inc.

18617 Broadwick St. Rancho Dominguez, CA 90220, United States Phone: 310-885-4600 Fax: 310-885-4666 Email: customerservice@spectrapor.com Website: www.spectrumlabs.com Year established: 1970

Spencer Italia S.R.L.

Strada Cavi, 7 Collecchio, PR 43034, Italy Phone: 0521/5411 Fax: 0521/541222 Email: quality@spencer.it Website: www.spencer.it

Sperian Eye & Face Protection Inc.

10 Thurber Blvd. Smithfield, RI 02917, United States Phone: 401-232-1200

State Trading Corporation Of India, Ltd. 350 5th Ave., Ste. 1124, 11th Fl. New York, NY 10118, United States Phone: 212-244-3317 Fax: 212-244-3319 Email: stcnewyork@aol.com

Steelcraft, Inc.

115 W. Main St. Millbury, MA 01527, United States Phone: 508-865-4445 Fax: 508-865-4600 Email: djb@steelcraft-inc.com

Stryker Instruments, Instruments Div.

4100 East Milham Ave. Kalamazoo, MI 49001, United States Phone: 800-253-3210 Fax: 800-999-3811 Email: Custsvc@Strykerinc.com Website: www.instrumedinc.com

Stryker Puerto Rico, Ltd.

Hwy. 3, Km. 131.2, Las Guasimas Ind. Park Arroyo, PR 00714, United States Phone: 939-307-2500 Fax: 939-307-2501

Sts Division Of Ethox International

7500 West Henrietta Rd. Rush, NY 14543, United States *Phone: 585.533.1672* Fax: 585.533.1796 Email: info@ethoxsts.com Website: www.ethoxsts.com

Sunlite Plastics, Inc.

W194 N11340 McCormick Dr. Germantown, WI 53022, United States Phone: 262-253-0600 Fax: 262-253-0601 Email: info@sunliteplastics.com Website: www.sunliteplastics.com Year established: 1946

Sun-Med

12393 Belcher Road, Suite #450 Largo, FL 33773, United States Phone: 727-530-7099 Fax: 727-531-3991 Email: info@sun-med.com Website: www.sunmedusa.com

Symbios Medical Products, Llc

7301 Georgetown Rd, Suite 150 Indianapolis, IN 46268, United States Phone: 317-225-4447

Synovis Life Technologies, Inc

2575 University Ave. W St. Paul, MN 55114, United States Phone: 651-796-7300 Fax: 651-642-9018 Website: www.synovislife.com

Tandem Medical, Inc.

535 Encinitas Blvd, Suite 109 Encinitas, CA 92024, United States Phone: 760-943-0100 Fax: 760-943-0143 Email: jdhaldeman@tanmed.com Website: www.autodose.com Year established: 1997

Tarry Manufacturing

22 Shelter Rock Lane Danbury, CT 06810-8156, United States Phone: 203-794-1438 Fax: 203-792-5581 Email: customerservice@tarrymfg.com Website: www.tarrymfg.com Year established: 1982

Tecan Systems

2450 Zanker Rd., San Jose, CA 95131, United States Phone: 408-953-3100 Fax: 408-953-3101 Email: helpdesk-sv@tecan.com Website: www.tecan.com

Telos Medical Equipment (Austin & Assoc., Inc.)

1109 Sturbridge Road Fallston, MD 21047-1905, United States Phone: 410-877-3029 Fax: 410-877-0544 Email: telosusa@aol.com Website: www.telosmedical.com

Terumo Cardiovascular Systems (Tcvs)

28 Howe St Ashland, MA 01721, United States Phone: 508-881-4858 Fax: 508-231-5210 Website: www.terumo-cvs.com Year established: 1921

Terumo Cardiovascular Systems, Corp

6200 Jackson Rd. Ann Arbor, MI 48103-9300, United States Phone: 734-663-4145 Fax: 734-741-6079 Website: www.terumo-cvs.com Year established: 1921

Terumo Medical Corporation

950 Elkton Blvd., P.O.Box 605 Elkton, MD 21921, United States Phone: 410-392-8500 Fax: 410-392-7218 Website: www.terumomedical.com Year established: 1921

Tfx Medical Oem

50 Plantation Drive Jaffrey, NH 03452, United States Phone: 603-532-7706 Fax: 603-532-6108 Email: sales@tfx.com Website: www.tfx.com Year established: 1981

The After Market Group

39400 Taylor Parkway N. Ridgeville, OH 44039, United States Phone: 888-824-8200 Fax: 800-468-0033 Website: www.aftermarketgroup.com

The Metrix Co.

4400 Chavenelle Road Dubuque, IA 52002-2655, United States Phone: 563-556-8800 Fax: 563-556-4704 Email: info@metrixco.com Website: www.metrixco.com Year established: 1964

Therapeutic Silicone Technologies, Inc.

909 Fifth Avenue New York, NY 10021, United States Phone: 212-606-0830

Thomas Medical Products, Inc. 65 Great Valley Pkwy. Malvern, PA 19355, United States *Phone: 610-296-3000* Fax: 610-296-4591 Email: info@thomas-medical.com Year established: 1990

Tianjin Hanaco Medical Co.,Ltd.

7 Dong Ting Street, Econ. & Tech. Devel. Zone Tianjin, 300061, China Phone: 86-22-988729

Total Molding Services, Inc.

354 East Broad St. Trumbauersville, PA 18970, United States Phone: 215-538-9613 Fax: 215-538-2519 Email: info@totalmoldingservices.com Website: www.totalmoldingservices.com Year established: 1985

Trident Medical Products

1201 Summit Avenue Fort Worth, TX 76102, United States Phone: 817-335-4031 Fax: 817-820-0241 Email: trident@flash.net Year established: 1986

Tss Hudson

19 Brent Dr Hudson, MA 01749, United States

Tulox Plastics Corp. 401 S. Miller Ave., P.O. Box 984 Marion, IN 46952-0984, United States Phone: 765-664-5155 Fax: 765-664-0257 Email: sales@tulox.com Website: www.tulox.com Year established: 1983

Tuzik Boston

104 Longwater Dr., Assinippi Park Norwell, MA 02061, United States Phone: 781-878-6363 Fax: 781-878-6938 Email: info@tuzikboston.com Website: www.tuzikboston.com

Tyco Healthcare Ireland Limited Sragh Industrial Estate

Tullamore, Ireland Phone: 508-261-8000

Tyco Healthcare Uk Ltd.

Fareham Rd Gosport, Hants, United Kingdom Phone: 203-845-1000

U.V. Vision Corp.

7702 e. doubletree ranch road, suite 300 Scottsdale, AZ 85258, United States Phone: 480-948-5350

Ultracell Medical Technologies, Inc.

183 Providence New London Tpke. North Stonington, CT 06359, United States Phone: 860-599-4883 Fax: 860-599-4193 Email: sales@ultracell.com Website: www.ultracell.com Year established: 1991

Unimed S.A.

Grand Pre 10 Lausanne, CH 1002, Switzerland Phone: 21/624-2151 Fax: 21/624-5332 Email: info@unimed.ch Website: www.unimed.ch Year established: 1958

Universal Medical Technologies 15720 N. Greenway Hayden Loop, Suite 8 Scottsdale, AZ 85260, United States Phone: 415-924-1133

Uroplasty, Inc.

5420 Fetti Road Minnetonka, MN 55343, United States Phone: 952-426-6140 Fax: 952-426-6199 Email: info.usa@uroplasty.com Website: uroplasty.com Year established: 1992

Ussc Puerto Rico, Inc.

Building 911-67, Sabanetas Industrial Park Ponce, PR 00731, United States Phone: 203-845-1000 Website: www.covidien.com

Utah Medical Products, Inc.

7043 S. 300 W. Midvale, UT 84047, United States Phone: 801-566-1200 Fax: 801-566-2062 Email: info@utahmed.com Website: www.utahmed.com Year established: 1978

Valeritas, Llc 800 Boston Turnpike

Shrewsbury, MA 01545, United States Phone: 508-845-1177 Email: gjenkins@valeritas.com Website: www.valeritas.com

Venetec International., Inc.

12555 High Bluff Drive,, Suite 100 San Diego, CA 92130, United States Phone: 858-509-2400 Fax: 858-350-7899 Email: cservice@venetec.com Website: www.venetec.com

Ventlab Corp.

155 Boyce Drive Mocksville, NC 27028, United States Phone: 336-753-5000

Vita Medical Ltd.

75 Business & Technology Park,, New Illawarra Rd.lucas Heights Sydney, Australia Phone: 02-525-5700

Vital Signs Mn, Inc. 12250 Nicollet Ave. Burnsville, MN 55337, United States Phone: 973-790-1330 Email: Customer Service@Vital-Signs.com Website: www.vital-signs.com

Vital Signs, Inc.

20 Campus Road Totowa, NJ 07512, United States Phone: 973-790-1330 Email: Customer Service@Vital-Signs.com Website: www.vital-signs.com Year established: 1972

VIv Associates, Inc.

30-C Ridgedale Ave. East Hanover, NJ 07936, United States Phone: 973-428-2884 Fax: 973-428-2877 Email: mv@vlvassociates.com Website: www.vlvassociates.com Year established: 1982

Volcano Corporation

3661 Valley Centre Drive, Suite 200 Rancho Cordova, CA 92130, United States Phone: 916-638-8008 Fax: 916-638-8812 Email: info@volcanocorp.com Website: www.volcanocorp.com Year established: 2001

Vygon Corp. 103a Park Drive

Montgomeryville, PA 18936, United States Phone: 800-473-5414 Fax: 215-672-6740 Email: ileaity@vygonusa.com Website: www.vygonusa.com Year established: 1962

Vygon S A

5-11 Rue Adeline Ecouen, 95440, France Phone: 331-39-92636

W.L. Gore & Associates, Inc

1505 North Fourth St. Flagstaff, AZ 86004, United States Phone: 928-526-3030

Walkmed Infusion Llc

4080 Youngfield St. Wheat Ridge, CO 80033-3862, United States Phone: 303-420-9569 Fax: 303-420-4545 Email: info@mckinleymed.com Website: www.mckinleymed.com Year established: 1995

Wells Johnson Co.

8000 South Kolb Road Tucson, AZ 85706, United States Phone: 520-298-6069 Fax: 520-885-1189 Email: sales@wellsgrp.com Website: www.wellsgrp.com Year established: 1980

West Pharmaceutical Services, Inc.

101 Gordon Dr. Lionville, PA 19341, United States Phone: 610-594-2900 Fax: 610-594-3000 Email: webmaster@westpharma.com Website: www.westpharma.com Year established: 1923

West Pharmaceutical Services, Inc.

6453 US Highway 15 Montgomery, PA 17752, United States Phone: 610-594-3105 Website: www.westpharma.com Year established: 1923

West Pharmaceutical Services, Inc. - Lititz, Pa

179 W. Airport Road brickerville, PA 17543, United States Phone: 717-560-8460 Fax: 717-560-8468 Website: www.westpharma.com

Wisap Gesellschaft Fur Wissenschaftl. App. Bau Mbh

Rudolf-Diesel-Ring 20 Sauerlach, 82054, Germany

Woosung Industry Co.

862-3 Yongsan-Dong Dalseo-Gu Daegu, Republic of Korea Phone: 82-53-555565

World Precision Instruments (W.P.I.), Inc.

175 Sarasota Center Blvd. Sarasota, FL 34240-9258, United States Phone: 941-371-1003 Fax: 941-377-5428 Email: wpi@wpiinc.com Website: www.wpiinc.com Year established: 1967

Yama, Inc. 650 Liberty Ave. Union, NJ 07083, United States Phone: 908-206-8706

Zevex Incorporated

4314 ZEVEX Park Lane Salt Lake City, UT 84123-4650, United States Phone: 801-264-1001 Fax: 801-264-1051 Email: sales@zevex.com Website: www.zevex.com Year established: 1986

Zhejiang Kindly Medical Devices And Plastics Co.,

252 Yongqiang Rd. Yongzhong, Wenzhou, China Phone: 086-577-6372

Zoll Medical Corp.

269 Mill Road Chelmsford, MA 01824, United States Phone: 978-421-9655 Fax: 978-421-0025 Email: info@zoll.com Website: www.zoll.com Year established: 1980